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NOMENCLATURE 
IUPAC nomenclature does not allow rapid visualization of carbohydrate and 
nucleoside structures. Hence, in this thesis compound names are derived from the 
parent sugar molecule and nucleobase, the use of which is accepted in this field of 
study (Figure 1). For instance the IUPAC name for compound 3.25 would be 1-
((2R,4R)-4-hydroxytetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione, 
while we prefer to denote it as 1ʹ-(thymin-1-yl)-2ʹ-deoxy-α-L-threofuranose. 
However, in Chapter 6, which comprises nucleosides with many different 
functionalities and protecting groups, IUPAC nomenclature proved more practical. 
 
Apiose is a C-branched natural carbohydrate that has one asymmetric center in the 
open form but has an extra asymmetric carbon at position 3 in the cyclic furanose 
form (in addition to the anomeric center) (Figure 2). 
 
Unconventially, the nomenclature of the cyclic forms of apiose therefore requires the 
use of two chirality designations (D, L) to distinguish between the two possible C3-
 xiv 
epimers. Alternatively, the prefixes threo and erythro may be used. D-Apio-D-
furanose then corresponds with 3-C-(hydroxymethyl)-D-erythrofuranose. In literature, 
the natural D-apio-D-furanose is referred to as simply ‘D-apiose’. In this manuscript 
the terms ‘D/L-furano’ is used to unambiguously specify the configuration at C-3.  
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PREFACE 
The chemical modification of nucleosides has been and will continue to remain a 
valuable strategy towards antiviral and anticancer drugs. Also other applications of 
nucleoside analogues, for instance to modulate purinergic G-protein coupled receptors 
(e.g., A3 adenosine receptor) prove promising with several compounds under clinical 
investigation. Nucleoside analogues are also being developed as inhibitors of enzymes 
that play a crucial role in bacteria responsible for emerging infectious diseases (e.g., 
thymidylate kinase of M. tuberculosis).  
Nucleosides and especially their phosphorylated analogues are polar chemical entities, 
which hampers passive diffusion into the cells. Prodrug strategies may overcome this 
problem. In antiviral research, phosphoramidates are dual purpose prodrugs, which 
not only enhance the bio-availability but also bypass the first phosphorylation step 
(Figure 1). 
 
Nucleoside and nucleotide mimics, including acyclic analogues are successful as 
antivirals. The literature precedents and recent advances in the 1ʹ/4ʹ-CH2 type 
 xvi 
nucleosides were pivotal to the inception of this thesis, in which we will focus on 4ʹ-
hydroxymethyl deleted and transposed nucleosides (Figure 1). The rationale to 
undertake this work is described in Chapter 2. 
Chapter 3 will describe the synthesis and biological evaluation of analogues I, while 
that of D-apio nucleosides II will be discussed in Chapter 4. 
The new synthetic route developed to gain access to nucleosides II, will be employed 
to synthesize unprecedented apionucleosides as A3 adenosine receptor ligands 
(Chapter 5). 
Our group has reported some of the most potent inhibitors of this thymidine 
monophosphate kinase of M. tuberculosis (TMPKmt) (Chapter 1, sec 1.5). From an in 
silico quantitative structure activity relationship (QSAR) analysis, compound IIIa 
emerged as promising TMPKmt inhibitor (Figure 2). This led us to synthesized IIIb,c 
to test the effect of 5ʹ and 5-CH2OH modifications on inhibitory potency (Chapter 6). 
 
 
 
  
  
  
 
 
  
 
 
 
 
 
 
 
 
CHAPTER – 1 
INTRODUCTION 
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1.1. Definition and Structure of Nucleosides 
Nucleosides consist of a heterocycle (often called a nucleobase) attached to a sugar 
moiety through a glycosidic bond (Figure 1.1). When a nucleoside contains a 
phosphate residue at any oxygen of the sugar, it is termed a nucleotide. Many types of 
carbohydrates and bases exist but endogenous nucleosides generally contain one of 
the five bases bound to a D-ribofuranose or D-2ʹ-deoxyribofuranose sugar to form 
RNA and DNA building blocks, respectively. These molecules are synthesized via 
two pathways. In the de novo pathway nucleosides are built up from basic small 
molecules. Purine nucleosides are constructed from activated carbohydrates, amino 
acids, N
10
-formyl-THF (as a formate source) and carbonic acid. Pyrimidines are made 
from carbamoyl phosphate, amino acids, activated carbohydrate and N
10
-formyl-THF 
(as 5-methyl donor). The major difference between the purine and pyrimidine 
pathways is that the former are built on the sugar moiety, while the pyrimidine core 
structure is built first and later attached to sugar, to form different pyrimidine 
nucleosides. In the salvage pathway, nucleosides are recovered from degradation 
products. Comparatively, the latter is less energy demanding. Nucleosides are the 
basis of genetic material, play an important role in signaling pathways and are also 
involved in energy transfer and storage. 
 
Figure 1.1. Structure of nucleos(t)ides 
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1.2. Conformations of the Nucleoside 
The conformation of a nucleoside can be defined by three parameters: the glycosyl 
torsion angle (χ), the torsion angle (γ) between 5ʹ-OH and 3ʹ-C, and the furanose ring 
puckering, known as pseudorotation (P). The structural change in nucleosides caused 
by pseudorotation is highlighted in Figure 1.2.
1
 In solution nucleosides are in dynamic 
equilibrium between Northern (N, 3ʹ-endo-2ʹ-exo, 2E, 
3
T2, 
3
E) and Southern (S, 3ʹ-exo-
2ʹ-endo, 2E, 2T3, 3E) type conformations but often preferentially adopt one of these two 
conformations. In addition, the orientation of the nucleobase (syn/anti) and 5ʹ-
hydroxyl group influence the overall conformation in solution. Notably, the 
conformation in solid state (crystals) may be different from the conformation in 
solution. Even though the energy difference between conformations is relatively small, 
enzymes may have outspoken preferences for typical nucleoside conformers and 
conformationally non-adaptive molecules may be differently recognized by enzymes 
in a given biological sequence.  
 
Figure 1.2. Pseudorotational cycle of nucleosides (left), torsion angle γ (top right) and 
χ (bottom right). 
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The crucial importance of the conformation or conformational flexibility for the 
biological activity of nucleosides was nicely demonstrated by Marquez et al. using 
nucleoside analogues that are locked in one conformation.
2
 From these and other 
studies
3
 it became clear that nucleoside kinases readily phosphorylate S-conformers, 
while HIV-1 RT preferably binds nucleoside triphosphates (such as AZT-TP) in an N-
type conformation.
4
 The unambiguous proof comes from the study of locked 
nucleosides. The triphosphates of bicyclic nucleoside mimics (N)-methano-carba-AZT 
(Figure 1.3, 1.1) and (S)-methano-carba-AZT (1.2) were investigated as inhibitors for 
HIV RT (recombinant and wild type), showing that inhibition of RT occurred only 
with the conformationally locked (N)-methano-carba-AZT 5ʹ-triphosphate. The 
inhibition was equipotent to and kinetically indistinguishable from that produced by 
AZT 5ʹ-triphosphate. The 5ʹ-triphosphate of (S)-methano-carba-AZT, by contrast, did 
not inhibit RT. 
 
Figure 1.3. Conformation of locked nucleosides methano-carba-AZT. 
 
1.3. Nucleosides as Antivirals
5 
Modified nucleosides were first used in cancer chemotherapy and are still being 
investigated for therapeutic use in oncology (e.g., citarabine, one of the nucleoside 
still in use was approved by the FDA in 1969). The use of nucleosides as antivirals 
became widespread only after the discovery of the human immunodeficiency virus 
(HIV) and which fueled antiviral drug development.
6
 3ʹ-Azidothymidine (AZT), 
whose synthesis was reported already in 1964,
7
 was the first drug licensed for HIV 
treatment, thereby becoming the first approved nucleoside analogue for antiviral 
Chapter 1 
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therapy.
8
 Even after three decades of research, treatment of chronic infections caused 
by HIV, HCV, HBV and acute infections (e.g. influenza, SARS, etc.) is proving 
difficult. In the absence of effective vaccines against these viruses, common problems 
in antiviral chemotherapy involve toxicity, adverse effects, drug-drug interactions, 
emergence of new viruses and, last but not least, the development of drug resistance. 
1.3.1. Mechanism of action of nucleosides/ nucleoside phosphonates as antivirals 
In a strict sense most nucleoside drugs are prodrugs. They are metabolized by cellular 
or viral kinases to their corresponding 5ʹ-nucleoside triphosphates (NTP), which are 
the actual inhibitors of DNA or RNA polymerases (Figure 1.4). Structural 
requirements for antiviral activity include:  
- Sterically non-crowded hydroxyl group for phosphorylation (so far only 
primary hydroxyls have been demonstrated to be effectively triphosporylated) 
and a nucleobase (mimic).  
- Orientation of the nucleobase and the primary hydroxyl group on the same side 
of the ring.  
- Ring systems should be sufficiently flexible to adapt the conflicting 
conformations for kinase activation and polymerase binding. 
A nucleoside first undergoes phosphorylation by nucleoside kinases to its 5ʹ-
monophosphate (NMP). Very often, this is the rate-determining step in the activation 
process (AZT, is a well-known exception
9
). Nucleoside phosphonates have been 
developed to bypass this first phosphorylation step. The NMP is converted to the NDP 
(or nucleoside phosphonate to NP-MP) by the action of NMPKs. Subsequent 
phosphorylation by NDPKs yields the NTP (or NP-DP). The triphosphate analogue 
interacts with viral DNA/RNA polymerase either as a competitive inhibitor or as a 
substrate. Since antiviral nucleosides often lack a 3ʹ-hydroxyl group, their 
incorporation eventually leads to DNA/RNA chain termination.  
Due to the close structural similarity of the triphosphorylated antiviral nucleosides and 
the natural NTPs, the former may also interact with host cell DNA/RNA polymerases 
Introduction 
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resulting in toxicity. This is the main cause for mitochondrial toxicity. The toxicity 
may be diminished to a large extent in the case the virus produces its own kinases, 
making it possible to design viral kinase/ polymerase specific nucleosides. Non-
natural L-nucleoside analogues have also proven successful in lowering mitochondrial 
toxicity due to differential uptake by mitochondrial transporter proteins. 
 
Figure 1.4. General mode of action of nucleosides/ phosphonates. 
 
In recent years, nucleoside analogs have also been found useful to inhibit crucial 
enzymes such as S-adenosyl homocystine (SAH) hydrolase, viral/cellular RNA 
helicase and inosine monophosphate dehydrogenase.  
Chapter 1 
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Figure 1.5. Nucleoside/ nucleotide analogs approved for therapeutic use. 
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At present, there are 25 approved nucleoside/nucleotide analogs in use as antivirals 
(Figure 1.5). Generally, these nucleos(t)ides closely resemble natural nucleosides and 
are characterized by slightly modified bases, non-natural L-sugars, carbocyclic rings, 
bis-hetero-sugar moieties, acyclic nucleosides and nucleoside phosphonates. The only 
drug featuring with an intensively modified base moiety is ribavirin (Figure 1.5, 26). 
 
1.3.2. The 4ʹ-hydroxymethyl/ base transposed nucleosides/ nucleoside 
phosphonates 
1.3.2.1. Apionucleosides 
 
D-apio-D-furanose (1.3) is a branched natural carbohydrate. Apiose derivatives, 
including nucleosides such as β-D-apio-D-furanoadenosine (1.4) are mostly found in 
plants.
10
 The presence of the D-apio-D-furanose form in all naturally occurring 
apiosides is explained by the fact that the transferases catalyze the transfer of the 
erythro- but not the threo-furanose from UDP-D-apiose to the various acceptors.
11
 The 
first syntheses of apionucleosides were reported by Riest et al.
12
 and Carey et al.
13
 
Detailed studies on the chemistry, physical properties and evaluation of 
apionucleosides were carried out in the laboratory of J. Tronchet. It was demonstrated 
that the apionucleosides exist mainly in the E3ʹ (S-type) conformation and that β-D-
apio-D-furanoadenosine nucleoside 1.4 is resistant to adenosine deaminase, while its 
α-L-furano counterpart 1.5a is a substrate.14  Medicinal chemistry aspects of these 
molecules were first explored by Watson et al. who evaluated them against T-
lymphocyte proliferation and HSV.
15
 Compound 1.5a significantly reduced HSV-2 
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plaque formation in BHK cells (42% reduction at 4 µM), while 1.4 did not and all the 
α-L-nucleosides (1.5a-e) inhibited rat T-lymphocytes/ human MGL8 lymphoblasts. 
Initially, the adenine analogue of 1.6 (L-ddAA) was reported to show weak anti-HIV 
activity in MT-4 cells (data not provided)
16
, but subsequently it is found that series 1.6, 
1.7 and 1.8 are neither cytotoxic nor active.
17
 The homologated dideoxyapioadenosine 
1.9 and its enantiomer were found inactive too, although they were shown to be 
resistant to adenosine deaminase and to be hydrolytically more stable than ddA.
18
 
 
The bioisosteric thioapio dideoxynucleosides 1.10 and their anomers 1.11 (both tested 
as enantiomeric mixtures) were tested against HIV-1, but did not afford any promising 
compounds due to cytotoxicity. In particular the 6-Cl-purines 1.10 and 1.11 showed 
cytotoxicity in MT4-cells (CC50 <8.5 and <5 µM respectively). This prompted the 
authors to assess the potential of 6-Cl-purine 1.11 in colon-2 cancer cells (IC50: 10.3 
µM).
19
 Most apio-dideoxydidehydro nucleosides 1.12 showed moderate to potent anti-
HCMV activity without cytotoxicity, the 5-fluorouracil derivative being the most 
potent (EC50: 30.2 µM in AD-169 cells and 12.3 µM in Davis cells). However, the 
corresponding thioapio analogues did not exhibit any significant anti-HCMV 
activities.
20
 
 
A series of N-type apionucleosides was synthesized, which are somewhat related to 
(N) methanocarba-T (1.15), a potent anti-HSV agent. 1.13T demonstrated toxicity 
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dependent anti-HIV-1/2 activity (EC50: 190.6 µM).
21
 2ʹ,3ʹ-Cyclopropyl fused α-
nucleosides 1.16 were devoid of antitumor activity, but no antiviral data have been 
reported.
22
 
 
The pyrimidine apionucleosides 1.17 and their corresponding 2ʹ-deoxy congeners 1.18 
were reported to be inactive against a panel of viruses (HIV-1/2, HSV-1/2, VV, VSV, 
etc), while the later series 1.18 was found slightly toxic for Vero cells. The 
enantiomeric 2ʹ-deoxy compounds 1.19 and anomers 1.20 were also found inactive.23 
 
The D- and L-3ʹ-deoxynucleosides 1.21 and 1.22 failed to inhibit DNA or RNA viruses 
(HIV-1/2, HSV-1/2, VV, VSV, etc.) and, unlike their 2ʹ-deoxy regiomers 1.18, 
showed no cytotoxicity.
24
 The triphosphates of 1.21 and natural nucleic acids were 
found to form chimeric oligomers by many DNA polymerases.
25
 The cytidine 
congener 1.23 was also shown to be inactive against HIV.
26
 Jung et al. found 2ʹ- azido 
and fluoro analogs 1.24 inactive against a panel of viruses, but found the thymidine 
analogue of 1.21 active against HSV-1(KOS) (MIC50: 39.6 µM), and the guanine 
analogue active against HSV-1 in two different cell lines i.e. KOS and 2(G) (MIC50: 
7.1 and 35.9 µM, respectively).
27
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The ring expanded oxetanocin analogues 1.25, 1.26 and an unusual azasugar 
nucleoside 1.27 were inactive against HIV-1, HSV-1/2.
28
 Antiviral assays against 
HIV-1, HSV-1/2, HCMV involving the racemate of 1.28 and its anomer did not yield 
encouraging results.
29
 No biological data have been reported for compounds 1.29 and 
their enantiomers.
30
 
 
The 3ʹ-F-2ʹ,3ʹ-dideoxyapionucleosides 1.30 and 1.31 are amongst the most promising 
in the apionucleoside class. These compounds are highly active against HBV. The 3ʹ-
methoxy analogs 1.32 and 1.33 are claimed equally effective against this virus. In 
vitro activity data are reported for selected compounds only (T, C, 5-F-C, and 5-I-U). 
Among these the cytosine analogue 1.30 is the most potent (EC50: 0.011 µM) with 
a >10,000 fold selectivity index.
31
 Notably, enantiomers of 1.30 and 1.31 (A and C 
analogs) do not show significant activity against HIV, HSV-1/2 and poliovirus, but 
their ability to inhibit HBV is not reported.
32
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The racemic mixture of 1.35 (B = A) was found to be active against HBV (EC50: 3.5 
µM). The (R,R) isomer was synthesized stereoselectively and found inactive, hence it 
was inferred that the active compound is (S,S) isomer. No other analogues of this type 
showed antiviral activity against HBV, HIV-1, HSV-1/2, HCMV and poliovirus, nor 
cytotoxic activity.
33
 Compound 1.38 showed moderate activity against HIV (EC50: 
2.55 µM). Interestingly, compound 1.39 showed much better activity, but also 
significant toxicity (EC50: 0.073 µM, IC50: 1.0 µM in PBM cells). However, none of 
these compounds showed any significant anti-HBV activity up to 100 mM.
34
 
Biological data for their 4ʹ-thio congeners are not presented.35  
 
The 2ʹ-deoxy-3ʹ-hydroxymethyl apioside 1.40 demonstrated weak anti HIV-1 activity 
(EC50: 75.8 µM), while its thymine congener is still weaker (EC50: 199 µM). Upon 
replacement of the oxygen by sulphur, the adenine derivative lost its activity 
completely, while cytidine 1.41 gained activity against HIV-1 (EC50: 74.7 µM) and 
HCMV (EC50: 133.2 µM).
36
 When the hydroxymethyl group anti to the base was 
replaced by a vinyl group, the resulting compound 1.42 (B = U) proved active against 
HIV-1 (EC50: 72.6 µM) and HCMV (EC50: 187.6 µM). Substituting the syn 
hydroxymethyl to a vinyl led to some activity loss (B = T; 238.6 µM, B = U; 331.2 
µM).
37
 Replacing the vinyl moiety in 1.42 by phenyl rendered the molecule inactive.
38
 
If we take into account the data from compounds 1.30 to 1.39, it is evident that the 3ʹ-
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substitution is very important for activity, possibly by imposing a favorable 
conformation/ molecular orientation. 
 
Compound 1.44A was moderately potent against HIV-1 (EC50: 36.1 µM) and also 
showed moderate HSV-1 (EC50: 116.7 µM) and HCMV activity (EC50: 148.9 µM). 
The antiviral activity of 1.45A is 2-fold weaker compared to 1.44A against all viruses. 
Amongst the pyrimidine analogues only analogues 1.44 showed anti-HCMV activity, 
1.44U and 1.42U,T showed anti-HSV-1 activity, while 1.44T,C showed anti-HSV-2 
activity.
39
 Compound 1.46A inhibited the replication of HCV (IC50: 19 µM).
40
 
 
 
1.3.2.2. Apionucleoside phosphonates 
Herdewijn et al. reported the synthesis and anti-HIV properties of the first 
apionucleoside monophosphate bioisosteres, namely the threosylphosphonate 
compound series 1.48.
41
 The adenine and thymine derivatives showed promising anti 
HIV-1/2 activity (EC50: 2.36 µM and 6.59 µM, respectively) without significant 
toxicity (>320 µM). The diphosphate of phosphonomethoxydeoxythreosyladenine 
(PMDTA, 1.48A) was incorporated by hDNApol-α only at enzyme concentration that 
are 100 times higher than those required for the dATP substrate. On the other hand 
HIV RT accepts this diphospophosphonate readily with only 2.5 times slower kinetics 
compared to dATP. This makes it a promising candidate for development as a 
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potential anti-HIV drug. Interestingly, substituting the 3ʹ-oxygen with a methylene 
decreases the efficacy (1.50: EC50: 12.6 µM), while increasing toxicity (30.4 µM in 
CEM cells).
42
 Although, the 2ʹ-hydroxy series 1.49 is inactive against HIV replication, 
these molecules are readily accepted by the therminator polymerase to form 
oligophosphonates.
43
  
 
Further modifications to 1.48A led to compounds 1.51-56, which all were inactive 
against HIV. The triphosphate of the locked phosphonate 1.53 was ineffectively 
incorporated by HIV RT. Only at very high substrate and enzyme concentrations (400 
µM and 1.44U/µL) 18% of the template was elongated.
44
 
 
Recently, more modified PMDTA analogues were reported, such as the spacer 
elongated variants 1.57 and 1.58, the 3ʹ-thio congeners 1.59 and 1.60, the unsaturated 
phosphonates 1.61 and 1.62, the all carbon 3ʹ- elongated 1.63 and the cyclic apiosyl 
phosphonate 1.64.
45
 None of these exhibited anti-HIV, HCV, RSV or cytotoxic 
properties. 
Chapter 1 
16 
 
Similar to compound 1.50, 1.66G combined significant anti-HIV-1 activity (EC50: 
10.2 µM) with cellular cytotoxicity (IC50: 45.5 µM in PMB, and 32.0 µM in CEM 
cells). Other phosphonates (1.65 and 1.66A) exhibited weak anti-HIV-1 activity (EC50: 
45-80 µM) without cytotoxicity (>100 µM). A similar trend was followed by 1.67 and 
1.68. 1.68A was moderately active against HIV-1 (22.2 µM) with cytotoxicity in PMB 
(42.4 µM) and CEM cells (30.4 µM) and the EC50 of the other analogues was in the 
range 50-85 µM. A modelling study pointed towards a shift of the phosphonate 
moiety of 1.66G compared to that in PMDTA, while 1.68A also showed a slight shift 
of base.
46
 
 
 
1.3.2.3. Isonucleosides 
In an effort to discover nucleosides that can withstand chemical and enzymatic 
glycosidic cleavage, Montgomery and Thomas synthesized the first isonucleosides 
1.69a and 1.69b.
47
 These were found inactive against leukemic 1210 cells. Later 
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studies showed that compound 1.69a demonstrates reasonable anti-HSV1/2 (EC50: 
78.8, 93.9 µM, respectively) and HCMV (EC50: 76.4 µM) activity, in addition to 
toxicity in L1210 cells (IC50: 71.6 µM). The guanine analogue 1.69d proved four 
times more potent than 1.69a against HSV1/2 (EC50: 15.3 and 22.8 µM, respectively) 
without noticeable cytotoxicity, while other bases were inactive.
48
 The 4ʹ-thio 
congeners 1.70 were found inactive against all tested viruses (HIV, HSV-1/2, VZV, 
and HCMV) and demonstrated no cytotoxicity.
49
 
 
Ten years after the first synthesis of isonucleoside 1.69a, its 3ʹ-deoxy-enantiomer 
(R,R)-isoddA 1.71 was reported to possess potent anti-HIV activity (ED50: 5-20 µM in 
different cells).
50
 The guanine counterpart was less active than 1.71, while other base 
variations did not show any anti-HIV activity. Compound 1.71 is highly resistant to 
adenosine deaminase and intracellular activation to its triphosphate occurs better than 
for the ddA isomer.
51 
Phosphoramidate and SATE prodrugs of 1.71 increased the anti-
HIV activity almost 400 fold.
52
 In fact the ProTide of 1.71 is as effective as AZT 
(EC50: 0.04 µM, MT-4 cells) against HIV-2. However this ProTide also possesses 
considerable toxicity with a selectivity index of only 65.
53
 Compound 1.71 also 
displayed weak binding affinity to A2A and A3 receptors while it was found inactive at 
A1 receptor.
54
 The 4ʹ-thio derivative 1.72 and other base analogues were inactive 
against HIV.
55
  
Interestingly, the triphosphate of the 8-azaadenine congener 1.73 inhibits recombinant 
RT almost eight times more effectively (IC50: 4.3 µM) than the triphosphate of 1.71 
(IC50: 35 µM), while 1.71 is much more potent in acutely infected cells. This anomaly 
could be due to a different uptake of the two compounds by infected cells.
53
 The 
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dideoxyisoguanine 1.74 was marginally active against HSV-1/2 (MIC: 8-16 µM) and 
virtually inactive against vaccinia virus and TK
 
deficient mutants of HSV-1, a trend 
that is similar to that of acyclovir.
56 
 
Nair and co-workers reported that (S,S)-isoddA (1.76) displayed twenty times better 
anti-HIV-1 (IC50: 0.67 µM) activity than its enantiomer 1.71.
57
 The inhibition of HIV-
1 RT by the triphosphate of 1.76 (Ki: 16 nM) is comparable to that caused by AZT-TP 
(Ki: 4 nM). IsoddATP and ddATP, exhibit complimentary results for human DNA 
polymerases. ddATP is a strong inhibitor of DNA polymerase β and γ (Ki: 1.1 and 
0.018 µM, respectively), while isoddATP effectively inhibits DNA polymerase α (Ki: 
0.63 µM). (S,S)-IsoddA is insensitive to deaminases and even acts as a weak inhibitor 
of this enzyme. However, isoddA was found to inhibit the growth of human bone 
marrow progenitor cells. Compound 1.76 also exhibited HBV activity in vitro (IC50: 
3.3 µM; CC50: ~140 µM) but showed in vivo toxicity.
58
 Compound 1.76 
predominantly adopts a northern conformation in solution (58%), while it appeared in 
the southern conformation in the crystal structure.
59
 In solution, the nucleosides with 
anti-HIV activity typically adapt the southern conformation.
60
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Stereochemical modifications at the 2ʹ and 4ʹ-carbon and various base modifications, 
as in 1.78, yielded inactive or marginally active compounds.
61
 Isonucleosides with 
tricyclic bases caused inhibition of HIV integrase, a viral enzyme responsible for 
incorporating viral double stranded DNA in to host chromosomal DNA genome. The 
integrase enzyme recognizes the specific sequence (5ʹ-ACTG…CAGT-3ʹ) in viral 
DNA and removes the 3ʹ-CA dinucleotide (called 3ʹ-processing step), before 
transferring the viral DNA into host DNA by creating a specific incision to host 
chromosomal DNA (called strand-transfer step). The monophosphate 1.79 inhibited 
this strand transfer step (IC50: 68 µM) and 1.81 inhibited both the 3ʹ-processing and 
strand transfer steps (IC50: 75 µM and 53 µM, respectively).
62
 
 
BVisoddU 1.82 inhibited HSV-1 replication at concentrations between 6 and 30.3 µM, 
which is almost 100 times higher than BVDU. Like BVDU, 1.82 is not active against 
HSV-2 strains, VV, VZV, VSV and CMV. Since BVDU and BVisoddU express 
relatively similar binding strengths to thymidine kinase, it is inferred that the 
difference in activity is probably related to different effects on HSV-1 DNA 
polymerase.
63
 Nair and co-workers described the synthesis of enantiomeric 
compounds 1.83 and 1.84,
64
 as well as a homologue of the potent anti-HIV compound 
isoddA 1.85 
65
 and 2ʹ,3ʹ-vinylic 1.86 66. None of these significantly inhibited HIV. 
Inhibition of HSV-1 by 1.87a and 1.87b was weak (IC50: 124 and 68.5 µM, 
respectively), while 1.87b also exhibited weak anti-HSV-2 activity (IC50: 137 µM). 
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Interesting results were obtained for anti-proliferative effect on human promyelocytic 
leukemia (HL-60) cells (ED50: 5.08, 1.6, 8.06 µM for 1.87a, 1.87b and 1.87c, 
respectively). Also the corresponding monophophates displayed anti-leukemia activity: 
1.88a and 1.88c were weak inhibitors (190, 170 µM) while 1.88b and 1.88d displayed 
ED50 values of 4.5 and 9.3 µM, respectively. Based on the 
1
H-
1
H coupling constant it 
was inferred that these compounds adopt a S-type conformation (in DMSO).
67
 The 
triphosphates of 1.87 were readily accepted by many polymerases (thermostable) and 
acted as chain terminators.
68
 
 
The isonucleoside 5ʹ-homologue 1.89, and its enantiomer 1.90 69 and the AZT mimic 
1.91 
70
 failed to show promising anti-HIV activity. 
 
The 3ʹ-F-4ʹ-thio, isonucleosides 1.92 did not exhibit anti-HIV/HSV/EMCV activity. 
The cytidine anlaogue exhibited anti-VSV actitivity (EC50: 38.5 μM) but this was 
combined with high cytotoxicity (CC50: 59.3 μM) in HeLa cell. The activity profile of 
this compound is interesting since it inhibited the RNA virus VSV, but unlike 
lamivudine from which it was structurally derived, failed to inhibit HIV.
71
 For 
compound 1.93 an isostere of 3TC no biological activity could be found.
72
 The locked 
nucleosides 1.94, designed as S-Type conformers of lamivudine, did not show anti-
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HIV-1 or HSV-1 activity.
73
 The synthesis of diastereomers 1.95 is reported without 
biological evaluation.
74
 
 
Interesting results were obtained with the ring expanded oxetanocin analogues 
1.96.
75 ,48 
The adenine congener 1.96a displayed potent broad spectrum antiviral 
activity, comparable with ganciclovir, HCMV (EC50: 4.4 µM), HSV-1/2 (EC50: 33.9, 
37.7 µM), HBV (EC50: 2.6 µM), and against cancer cell lines (L1210, IC50: 10.2 µM; 
KB cells, IC50: 196 µM). The guanine analogue 1.96c showed selective inhibition 
towards HSV-1/2 (EC50: 7.8-10 µM). Compounds 1.96b and 1.96d displayed EC50 
values against HSV1/2 and HCMV in the 50-120 µM range, while 1.96b also showed 
anti-HBV activity (EC50: 23.5 µM). 
 
The bromovinyluridine analogue 1.97 displayed very potent and selective inhibition of 
different strains of HSV and VZV (submicromolar to double digit nanomolar 
concentrations) without cytostatic effect, thereby being more effective than acyclovir 
against VZV. Because of its activity against simian varicella virus, extensive animal 
studies were carried out in African green monkeys, but further development was 
apparently stopped.
76
 The 4ʹ-thio counterpart of 1.96 was evaluated as an epimeric 
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mixture (1.98) for anti-HIV activity and found inactive.
77
 Only the L-thymine 
analogue 1.99 exhibited moderate anti-HIV activity (IC50: > 200 µM, EC50: 0.8 µM, 
TI50: > 250).
78
 
 
In general exocyclic methylene compounds (1.100-1.102) and spiro-cyclopropyl 1.103 
lack anti-HIV activity. Since these molecules are more rigid, diminished anti-HIV 
activity is not surprising. The compound series 1.100 are inactive against HIV-1 and 
HSV-1/2, but showed good activity against HCMV and surprisingly, also against 
HBV. The uracil derivative of 1.100 was more than 10-fold less activite against 
HCMV (EC50: 47.3 µM) than ganciclovir in AD-169 cells. The adenine derivative of 
1.100 expressed moderate activity against HCMV (EC50: 134.7 µM) in addition to 
anti-HBV activity (EC50: 1.5 µM). Their enantiomer series 1.101 did not display any 
activity.
79
 The thio-sugar with 6-chloropurine base 1.102 exhibited very weak anti-
HCV activity. All other nucleosides of the series were inactive against HIV-1, HBV, 
HCV, and HCMV.
80
 Likewise, the spironucleoside 1.103 and 3ʹ-α-methyl 
isonucleoside 1.104 lacked activity against HIV-1, HSV, VZV and CMV.
81
 
 
Antiviral evaluation of a series of 3ʹ-carbon substituted isonucleosides 1.105-1.108 
indicated that they were marginally active or inactive against HIV-1, HSV, VZV and 
CMV.
82
 For the thio-compound 1.109 no biological data have been reported.
83
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The dinucleotide 1.110, composed of a natural nucleoside and an isonucleoside 
(pIsodApC), is reported to inhibit HIV integrase. It curtailed both 3ʹ-processing and 
strand transfer steps (IC50: 19 and 25 µM, respectively) in comparison to known 
natural dinucleotide pdApdC (IC50: 6 and 3 µM, respectively). Interestingly, 
pdApIsodA 1.111 reduced the efficiency of the integrase enzyme only in the strand 
transfer step (IC50: 41 µM).
84
 
The synthesis of 3ʹ-isonucleoside of adenine 1.112 and its enantiomer 1.113 is 
reported, but no biological activity data.
85  
The anti-HIV activity of homologated 
nucleosides of the structure 1.114 is not significant,
86
 while no biological data have 
been released for 1.115.
87
 
 
Also, antiviral data of the base transposed furanose and pyranose nucleosides 1.116 
and 1.117 are awaited,
88
 while compound 1.118 did not display anti-HCV activity.
89
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1.3.2.4. Isonucleoside phosphonates 
 
The isodideoxyadenosinephosphonate (isoddAP, 1.119) demonstrated relatively 
potent anti-HIV activity, though its EC50 (9.5 µM) is almost two and half times higher 
than that of tenofovir, which is attributed to poorer activation to the triphosphate. This 
phosphonate possessed a rather attractive profile towards mutant strains. The activity 
dropped by a factor eleven in M184V RT, and a factor of 3.2 and 2.2 against 6TAMs 
(thymidine analogue mutation) and K65R mutant strains, respectively. This is in sharp 
contrast to tenofovir but in line with abacavir. The extrusion of pyrimidine based 
nucleosides by thymidine analogue mutation is well documented with adenine based 
acyclic nucleosides being most vulnerable to these mutations.
90
 Phosphonate 1.120 
showed much lower activity compared to the parent compound (S,S)-isoddA.
91
 
Derivatives 1.121 did not show in vitro antiviral activity.
92
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Compounds 1.122–24 were only screened against HCMV, but only 1.124 proved 
active (IC50: 15.2 µM; CC50: 507.1 µM).
93
 The carbocyclic guanine phosphonate 
1.125 showed reasonable activity against HIV in CEM cells (IC50: 20 µM).
94
 
 
1.3.2.5. Homonucleosides and homonucleoside phosphonates 
 
Idenix Pharma reported the synthesis of 2ʹ-C branched nucleosides 1.126,95 but these 
were inactive against HCV, HIV and other viruses and not cytotoxic. The lack of 
activity was explained as, the entropy price paid by the addition of rotational 
flexibility between the sugar and the nucleobase or the change in spatial distance 
between the base and the primary alcohol of these isohomonucleosides. The locked 
AZT mimic 1.127 lacked anti-HIV-1 activity as well as toxicity in MT-4 cells.
96
 The 
1,2-disubstituted carbocyles 1.128 
97
 showed antitumor activity (IC50: 52.1, 24.3, 59.5 
mM against cell lines L1210/0, Molt4/C8, CEM/0, respectively) and its pyrimidine 
analogues exhibited marginal anti-HIV-1/2 activity (<285 µM). Compound 1.129 is 
reported to be potent inhibitor of human purine nucleoside phosphorylase (PNP), but 
no antiviral activity data have been reported.
98
 
 
1.3.2.6. C-nucleosides and extremely modified non-natural bases 
The L-apio C-nucleosides 1.130 and 1.131 revealed moderate antiviral profiles.
99
 
Compound 1.131 (EC50: 20.5 µM) performed somewhat better than 1.130 (EC50: 35.2 
µM) against HIV-1. Both exhibited moderate to poor activity against HSV-1/2 and 
HCMV (EC50: 94.6 - 190 µM). Compound 1.132 and 1.133 showed moderate activity 
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against HIV-1 (EC50: 25.1 and 14.7 µM, respectively) in MT-4 cells without any 
cytotoxicity up to 100 µM.
100
  
 
Kim et al. synthesized the ribavirin type apionucleosides 1.134 and its thiazole 
analogue 1.135. Both compounds were screened against a panel of viral strains 
without notable activity.
 
Compound 1.136, its enantiomer and diasteriomers are 
claimed to be a potent anti-HBV agents but no exact data are available.
101
 The 
isonucleosides featuring modified bases such as triazolyl-4,5-dicarboxamide 
(1.137),
102
 and imidazolyl-4-carboxamide 1.138 were inactive or showed very low 
potency against HIV.
61
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1.4. Nucleosides as A3 Adenosine Receptor (AR) Ligands
103
 
Transmembrane receptors coupled to G-proteins (heterotrimeric guanine nucleotide 
binding proteins) constitute a large receptor family, often referred to as G-protein 
coupled receptors (GPCRs) or seven-transmembrane domain (7TM) receptors. The 
amino terminal part of these receptors is located extracellularly and these receptors 
pass 7 times through the cell membrane, thereby forming seven transmembrane 
helices, three or four intracellular loops (ILs), three extracellular loops (ELs) and an 
intracellular C-terminus.
104
 
Triggered by messenger molecules or signals outside the cell, GPCRs activate 
different signal transduction pathways inside the cell and, ultimately, cellular 
responses. The extracellular messengers range from photons over aminergic 
neurotransmitters to proteins. GPCRs are ubiquitous and involved in processes 
varying from directed chemotaxis
105
 of small organisms (e.g. searching food for 
survival) to triggering apoptosis (cell death) in large animals. They are the targets of 
almost 50% of marketed active pharmaceutical ingredients.
106
 
GPCRs activated by extracellular adenosine are classified as adenosine receptors 
(ARs), which are divided in four different subtypes, i.e. A1, A2A, A2B and A3 
adenosine receptors.
107,108
 The amino acid sequence similarity between the human (h) 
A3AR and hA1, hA2A, hA2BAR is 54 %, 48 % and 44 %, respectively.
103b
 The ARs use 
different signaling pathways. The A1AR and A3AR are coupled to Gi-proteins, and 
upon activation lead to adenylate cyclase inhibition, while the A2AAR and A2BAR are 
coupled to Gs-proteins and lead to adenylate cyclase activation. In some cells (e.g., 
mast cells), the A2BAR is dually coupled to Gs and Gq and consequently also elevates 
phosphoinositides, mobilizes calcium and activates phospholipase C and MAPK.
107,109
 
Besides adenosine 1.139 itself, which is used clinically for the treatment of 
supraventricular tachycardia, 
110
 only one adenosine receptor-specific agent – the 
A2AAR agonist regedenoson (1.140) – has so far been approved by the FDA. However, 
a relatively large group of AR ligands are currently under clinical evaluation (table 
1.1).
111
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Table 1.1. Adenosine receptor ligands in clinical use or trails (Figure 1.6). 
 
Ligand, Subtype and action Application Phase Company 
Adenosine 1.139 (Adenocard)  
A1 agonist 
Paroxysmal supraventricular 
tachycardia 
Approved Astellas 
INO-8875 Glaucoma I–II Inotek 
Capadenoson 1.140, Bay-68-4986 Atrial fibrillation II Bayer-Schering 
Adenosine 1.139 (Adenoscan)  
 
A2A agonist 
Myocardial perfusion imaging Approved Astellas 
Apadenoson 1.141, ATL146e 
(Stedivaze) 
Myocardial perfusion imaging III Forest Laboratories 
Regadenoson 1.142, CV-3146 
(Lexiscan) 
Myocardial perfusion imaging Approved Astellas/Gilead 
Regadenoson 1.142, CV-3146 
(Lexiscan) 
Sickle cell disease I Dana-Farber Cancer Institute 
IB-MECA 1.143, CF101  
A3 agonist 
Rheumatoid arthritis, psoriasis, 
dry eye, glaucoma 
II/III Can-Fite 
Cl-IB-MECA 1.144, CF102 Hepatocellular carcinoma, 
chronic hepatitis C (genotype 1) 
II Can-Fite 
Caffeine 1.145  
AR 
antagonist 
Sleep apnea, cancer pain, PD II/III Univ. of Texas, McMaster Univ., 
Nobelpharma, Korea Research, 
McGill University 
Theophylline 1.146 Asthma, COPD Approved – 
Istradefylline 1.147, KW-6002  
 
 
A2A 
antagonist 
PD III Kyowa Hakko 
KW-6356 PD  Kyowa Hakko (in Asia), Lundbeck 
Preladenant 1.148, SCH-420814 PD III Schering 
Tozadenant 1.149, SYN-115 PD, cocaine dependence IIB Biotie, NIDA (Synosia Therapeutics) 
ST-1535 1.150 PD I Sigma-Tau 
V81444 PD I Vernalis 
[
11
C]-SCH442416 1.151 PET imaging of PD I Institute for Neurodegenerative 
Disorders 
 
[
123
I]MNI-420 1.152 SPECT imaging of PD, 
Huntington’s disease 
I 
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Figure 1.6. Structure of adenosine receptor ligands in clinical use or in trails.
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The A3AR agonists are found effective against inflammatory conditions such as 
rheumatoid arthritis, psoriasis, keratoconjuctivitis sicca (dry eye syndrome), and 
glaucoma, while antagonists are potentially useful for the treatment of asthma. The 
detection of A3AR expression in cancer cells suggests a potential use of turning 
selective ligands in to diagnostic tools, while a number of recent studies have shown 
that activation of this receptor attenuates proliferation of melanoma, colon, and 
prostate cancer cells and may also inhibit cancer metastasis. The observation that the 
upregulation of ADORA3 mRNA expression in PBM cells from patients with 
hepatocellular carcinoma compared to healthy individuals could lead to its use as 
potential biomarker for the detection of disease progression.
112
 
Surprisingly, knockout of the A3 receptor in mice resulted in marked phenotypes even 
at locations where the receptors are very sparse (e.g., brain). A possible explanation 
for this is that A3ARs may have a role in development.
113
  
 
1.4.1. Substitution patterns on adenosine and their effect on A3AR modulation 
Previous medicinal chemistry studies demonstrated that an adenosine derivative’s 
ability to activate the A3AR is more structure sensitive than at other AR subtypes.
114
 
While a number of changes in various regions of the adenosine molecule have been 
shown to enhance binding to the A3AR, these usually tend to reduce A3AR efficacy, 
leading to nucleoside analogues that are partial agonists or antagonists. 
Structure-affinity and structure-efficacy relationships at this subtype, showed that N
6 
substitution with selected benzyl groups, introduction of a 2-chloro substituent and 
conformational constraints of the ribose moiety of adenosine all contribute to affinity 
enhancement but at the expense of efficacy. In most cases the lost efficacy may be 
regained by substituting the 4ʹ-hydroxymethyl group to a 4ʹ-N-methyl or ethyl 
carboxamide. 
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1.4.1.1. Modification to adenine base 
The N
6
 and C2 modifications in combination with sugar variations are the most 
explored in search of potent and selective AR ligands. The presence of a hydrogen on 
N
6
 is generally essential for high affinity agonists, but a C6-CF3 antagonist is 
known.
115
 Likewise, C8-substitution (as in 8-alkynylated derivatives) generally leads 
to antagonists.
116
 Many A3AR ligands feature a large substituent at N
6
 and a small 
group on C2 (H, Cl, CN, N3, etc.), or vice versa, a small substituent at N
6
 (CH3, OCH3, 
Et, etc.) and a large group at C2. A notable exception is N
6
-methyl-2-cyanoadenosine 
with two relatively small substituents at N
6
 and C2, a potent agonist for the human 
A3AR (Ki: 3.4 nM) that is inactive at rat A3AR.
117
 Well-known N
6
-phenethyl 
substituents are found in compounds 1.153 and 1.154,
118
 which are potent but non-
selective (A1AR) A3AR agonists. Small substituents at C2 (Cl, CN, N3) generally 
increase A3AR selectivity at the expanse of affinity (and/ or efficacy) as exemplified 
by the couples 1.143 and 1.144 and analogues 1.155-1.157 from our laboratory.
117,119
  
 
Various 2-ethynyl modifications produce potent A3AR ligands (e.g., compound 
1.158),
120
 whose A3 selectivity may be increased by alterations at 5ʹ-position.
121
 C2-
heterocycle substituted analogues form an interesting class of potent A3AR ligands. 
The C2-pyrazol-4-yl analogue 1.159 is the most selective agonist of this class,
122
 4-
substituted triazol-1-yl analogue 1.160, synthesized in our lab, turned out to be a 
potent antagonist.
119
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While previously regarded as incompatible, in recent years a number of highly potent 
and selective A3AR modulators have been described that combine two bulky moieties 
at N
6
 and C2. By structure-based design, Tosh et al., for example, discovered 
compound 1.161 as a potent and selective A3AR agonist. The C2 substituent is 
predicted to penetrate deeply into the TM2 region and to act as a firm anchor.
123
 
 
 
1.4.1.2. Sugar and sugar attachments 
Most interactions with the sugar are believed to be indispensable for high affinity. For 
hA3AR agonistic activity, a 4ʹ-N-methylcarboxamide is the most popular sugar 
modification, known to increase affinity and efficacy. Replacing the 4ʹ-oxygen by 
sulfur increases the affinity and selectivity. It has become increasingly evident that 
A3ARs prefer slightly rigid substrates with directed interactions. For example, the 
northern conformation locked (N)-methanocarba adenine 1.162 (Ki: 404 nM) is 150 
times more potent than its southern conformer 1.163.
124
 It is observed that these N-
locked compounds tend to show low efficacy but altering 5ʹ- hydroxyl to uronamide 
allows regaining efficacy as demonstrated for 1.164
125
 compared to 1.143 or 1.144.
126
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The similar behavior of compounds 1.165 and IB-MECA (1.143) as A3AR agonists 
suggests that the 2ʹ-OH group in 1.143 probably acts as a hydrogen bond acceptor and 
that only one hydroxyl may suffice provided the sugar is in correct conformation.
127
 
The 3ʹ-amino compound 1.166, a potent agonist with an ideal pharmacological profile, 
high selectivity, and acceptable aqueous solubility, suggests that the 3ʹ-substituent acts 
as hydrogen bond donor.
128
 The 2ʹ-deoxy-2ʹ-fluoro compound 1.167 is an antagonist, 
with moderate affinity.
129
 
 
In the context of the envisaged analogues it is noteworthy that the 5ʹ-CH2OH-deleted 
compounds 1.168 and 1.169
130 , 131
 exhibit potent and A3AR selective antagonistic 
properties. 
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1.4.2. A3AR homology modelling 
The development of ligands for the A3AR has been directed mainly by traditional 
medicinal chemistry, but the influence of structure-based approaches is increasing. 
Rhodopsin-based homology modelling had been used for many years to obtain three-
dimensional models of the A3AR, and to predict interactions with A3AR ligands with 
different chemical scaffolds. The recently published structure of the human A2AAR 
and other GPCRs provide new templates for creating A3AR homology models, which 
may be helpful in providing structural hypotheses for the design of new ligands.
132
 
Site-directed mutagenesis of the A3AR shows an important role in ligand recognition 
for specific residues in TM3, TM6 and TM7. 
 
 
Figure 1.7. (A) Ligand binding site
133
 (B) Predicted interactions of agonist 1.170 with 
A3AR.
134
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Using homology modelling, the binding mode of compound 1.170 in the A3AR was 
predicted.
134
 The ligand recognition site is in the upper part of the receptor (Figure 1.7 
[A]), between trans-membrane domains (TMs) and the extracellular loops (ELs). TMs 
3, 5, 6, 7 and EL2 are believed to play an important role in ligand recognition. TM4 is 
in direct contact with TM3 but not involved in ligand binding, while TMs 1 and 2 are 
far away from the binding site. In recent studies, however, TM2 was explored in drug-
design efforts, e.g. in the design of compound 1.161. Some of the essential 
interactions of receptor with ligands are listed below (Figure 1.7 [B]): 
- Conserved Asn250 (6.55) makes two important hydrogen bonding interactions, 
one as H-bond acceptor with N
6
 – H and the other H-bond donor to N7. 
- Stacking interaction between conserved Phe168 (EL2) and adenine ring. 
- Thr94 (3.36) interaction via H-bonding to 5ʹ-OH/NH (interaction responsible 
for efficacy). 
- Ser271 (7.42) and His272 (7.43) make crucial H-bonding interactions with the 
3ʹ and 2ʹ substituents (hydroxyls) respectively. 
- Interactions with hydrophobic pockets in the regions involving highly 
conserved Leu90 (3.32), Leu246 (6.51) and Ile268 (7.39). 
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1.5. Nucleosides as Inhibitors of Mycobacterium Tuberculosis Thymidylate 
Kinase
135
 
Nearly two million people die from tuberculosis (TB) every year, and this disease is 
second only to AIDS as the greatest killer worldwide to a single infectious agent. In 
humans is caused by Mycobacterium tuberculosis. The prevalence of TB with HIV, 
multidrug and extreme drug resistance is a major and growing global threat. The 
situation asks for new drugs preferably acting on unaddressed targets
136
 or new 
concepts (e.g. quorum sensing) with short duration of treatment. Thymidine 
monophosphate kinase (TMPK/ ATP-dTMP phosphotransferase) was recently 
introduced as an interesting target enzyme.
137,138
 The TMPK catalyzes the conversion 
of deoxythymidine monophosphate (dTMP) to deoxythymidine diphosphate using 
ATP as a phosphate source. TMPK is situated at the junction of de novo and salvage 
pathways of thymidine triphosphate (dTTP) biosynthesis and is the last specific 
enzyme in these pathways. 
 
1.5.1. Structure of TMPKmt 
The primary sequence similarity between human TMPK (TMPKh) and TMPKmt is 
22%. Despite the fact that the global folding of all TMPKs are similar, their active site 
and their substrate preferences are unique. The monophosphate of AZT, for example, 
is an inhibitor of TMPKmt (Ki: 10 µM), while acts a substrate of its mammalian 
counterpart.
139
 This observation opens opportunities for designing specific inhibitors 
using AZT-MP as a template. The important regions for the catalytic activity of the 
enzyme are revealed by the structure of its complex with the natural substrate 
dTMP.
140
  
The P-loop motif 
141
 (residues 7-14, GlyX1X2X3X4GlyLysX5) is an important segment 
which positions the phosphoryl groups of the phosphate donor through hydrogen 
bonding interations between the α and β ATP phosphate oxygens and amide backbone 
hydrogens. Asp9 (at position X2 of the P-loop motif), a highly conserved amino acid, 
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acts as firm anchor between the P-loop and the phosphoryl acceptor dTMP via a 
hydrogen bonding between its carboxylic acid residue and the 3ʹ-hydroxyl group of 
dTMP. Any mutation to D9 residue (or equivalent in other species, e.g. D15 in 
TMPKh) across all sections of TMPK abolishes the phosphoryl transfer ability.
142
  
The DR(Y/H/F) motif contains the strictly conserved arginine residue and serves as a 
clip that properly aligns the ‘to be transferred’ γ-phosphate of ATP and the acceptor 
phosphate of 5ʹ- dTMP, in such a way that is favorable for interaction with arginine of 
LID region to effect phosphate transfer.  
The LID region (residues 147-159) is like a tethered cap in all nucleotide 
monophosphate kinases. The binding of ATP exerts substantial conformational 
change
143
 and brings the catalytic arginines (of the LID region) to the reaction center. 
Some subtle but important differences between TMPKmt and TMPKh make the 
former an interesting target. 
- The LID region in TMPKh does not contain positively charged amino acids 
like in TMPKmt, which instead reside in the P-loop motif with a single 
mutation to lysine19 and regular conserved argenines. 
- TMPKmt unlike its counterparts has positively charged residues in both LID 
and P-loop (Arg14). 
- The LID closure of TMPKmt is largely due to the binding of a Mg2+ ion in the 
dTMP-binding site and not to the binding of ATP.
144
 
- The difference in affinity of dTMP (Km: 4.5 µM) and ATP (Km: 100 µM) for 
TMPKmt is more than 20 fold, suggesting that initial dTMP binding is largely 
favored.
139
 
- In TMPKmt the magnesium ion lies in the dTMP-binding site, while in its 
human counterpart Mg
2+
 is typically found far away coordinating with 
phosphates of NTP. 
Important interactions between dTMP and the TMPKmt enzyme are
139,145
 (Figure 1.8): 
- A stacking interaction between the pyrimidine nucleobase and Phe70. 
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- A hydrogen bond between O-4 of thymine and the Arg74 side-chain, which 
explains preference to thymidine over cytidine. 
- A hydrogen bond between Asn100 and N-3 of the thymine ring. 
- A network of hydrogen bonds between 3ʹ- hydroxyl of dTMP (responsible for 
positioning the carboxyl of Asp9 to magnesium ion via water9 and the 
phosphate oxygen of dTMP). 
- Hydrogen bonds and ionic interaction between the 5ʹ-O-phosphoryl and Tyr39, 
Phe36, Arg95 and Mg
2+
 respectively. 
- The presence of Tyr103 close to the 2ʹ-position, which confers selectivity 
towards dTMP over its ribose analogue. 
 
Figure 1.8. Schematic drawing of the dTMP (dark lines) binding site of TMPKmt.
139
 
 
TMPKmt has broader substrate specificity for nucleoside triphosphates than other 
NMPKs. The reaction rates with ATP or dATP as phosphate donors are similar. Other 
efficient phosphate donors in order of efficacy are: ITP > GTP > CTP > UTP.
146
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1.5.2. Sugar modified compounds  
Based on AZT-MP as template Vanheusden et al. synthesized a series of 3ʹ-C 
branched chain derivatives.
147
 Among the synthesized compounds 3ʹ-CH2NH2 (1.173), 
3ʹ-CH2N3 (1.172) and 3ʹ-CH2F (1.174) nucleotides exhibited the highest affinities with 
Ki values of 10.5, 12, and 15 µM, respectively. A major limitation of these 
monophsophates is that their charge is expected to impede diffusion through cell 
membranes. Hence, it was interesting to see that the corresponding nucleosides 1.175-
8 exhibited TMPKmt affinities in the same order of magnitude and displayed superior 
selectivity vs. TMPKh. 
 
Also compounds 1.179, 1.180 and 1.181, obtained by serendipity, exhibited 
interesting inhibition constants 3.5, 13.5 and 37 µM, respectively. Modelling studies 
revealed that the second (II) nucleoside residue of 1.181 occupies the position of ATP 
binding site in the enzyme (Figure 1.9).
148
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Figure 1.9. Predicted binding mode of 1.181
148
 
 
 
Based on the dimeric nucleoside 1.181, compound 1.182 was synthesized and found 
to be a potent TMPKmt inhibitor.
149
 Based on the predicted binding mode of 1.181 
(Figure 1.9) 5ʹ-modified α-thymidine analogue 1.183a,b were synthesized, which are 
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the most potent nucleosidic TMPKmt inhibitors reported to date.
150
 Using compound 
1.183 as a starting point, Cui et al. recently designed, synthesized and evaluated a 
number of α-thymidines as Plasmodium falciparum TMPK inhibitors.151 This work 
resulted in a compound 1.184 with potent antimalarial activity (EC50: 28 nM; CC50: 29 
µM), although TMPK inhibition is probably not the only mode of action for this 
analogue. 
Familiar et al. reported the synthesis of acyclic compounds 1.185-8, which were based 
on extensive modelling studies.
152
 Out of 20 different spacers synthesized, a Z-2-
butene as in 1.185, 1.186 was chosen as an ideal linker. The naphtholactam analogue 
1.187 and naphthosultam analogue 1.188 emerged as the most potent TMPKmt 
inhibitors. However, these analogues lacked antimycobacterial activity, probably due 
to poor solubility. 
 
 
1.5.3. Base Modified compounds 
5-MethylisoCMP analogue 1.189 is a weak inhibitor (Ki: 130 µM), dUMP is a poor 
substrate of TMPKmt with 50 fold reduced affinity (Km: 2.1 mM), and a threefold 
lower rate than dTMP. All 5-halogen analogues were poor substrates, except 5-bromo 
dTMP (1.190) which had an affinity (Km: 30 µM) and rate comparable to dTMP.
139
 
Hence, those substituents which can enhance the stacking interaction with Phe36 (i.e., 
5-bromovinyl, 5-furanyl, 5-benzyloxymethyl, 5-thienyl) or hydrogen bonding with 
Arg74 (5-CH2OH-dUMP, 1.191) were synthesized. Compound 1.191 was found to 
possess a Ki value of 110 µM while its α-anomer was fourfold less active.
153
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The crystal structure of 1.191 (Figure 1.10)
153
 shows hydrogen bonds between 
hydroxyl of 5-CH2OH and water molecule (W12). The hydroxyl group may also take 
part in a network of interactions between E6, R95, Y179, and S99. These interactions 
in the dTMP binding site make 5-CH2OH-dUMP a week inhibitor rather than a 
substrate, as was the case for 5-Br-dUMP. 
 
Figure 1.10. Network of interactions of 21 in the active site of TMPKmt.
153
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Prompted by the ability of 5-CH2OH group to convert a substrate (dTMP) to an 
inhibitor and encouraged by recent modelling studies that attributed a pivotal role to 
this 5-CH2OH group in TMPKmt binding,
154
 we decided to investigate possibilities of 
combining this moiety with 5ʹ-substitutions (See Chapter 6). 
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AIM AND RATIONALE OF THIS STUDY 
Modified nucleosides and nucleotides have proven to be therapeutically useful agents. 
They form a substantial core of the clinician’s armamentarium against cancer and viral 
infections. Most nucleosidic anticancer drugs act by inhibiting DNA synthesis by 
some means. Some target DNA synthesis directly, such as the nucleosides cladribine, 
fludarabine and cytarabine. The triphosphate form of these drugs is incorporated into 
the growing DNA and acts as a chain terminator, but probably also interferes with 
other biochemical targets, such as ribonucleotide reductase. Others impede the supply 
of monomers for DNA biosynthesis and so arrest cell division (e.g., the 
antimetabolites fluorouracil, 6-thiopurine and 6-mercaptoguanine).  
The antiviral nucleoside and nucleotide drugs act as prodrugs, which after activation 
to the corresponding triphosphate will interfere with virus-encoded reverse 
transcriptase (RT) or DNA or RNA polymerase enzymes.  
Several nucleoside analogues, which act on different, less established targets, are in 
clinical development. During the past 30 years, a number of selective agonists for 
adenosine receptors, all structurally derived from adenosine, have been developed. 
Several such compounds are undergoing or have undergone clinical trials for the 
treatment of cardiovascular diseases (A1 and A2A), pain (A1), wound healing (A2A), 
diabetic foot ulcers (A2A), colorectal cancer (A3) and rheumatoid arthritis (A3). 
The main goals of this study are: 
- to improve the synthesis of apionucleosides; 
- to construct apio and other nucleosides with potential pharmacological activity 
based on known SAR data; 
- to assess the biological activity of these nucleosides in collaboration with other 
research groups.  
Based on the discovery that the nucleoside phosphonates PMDTA and PMDTT act as 
potent HIV RT inhibitors
41
 and on the observation that threose nucleic acids (TNA) 
are capable of complementary base pairing with DNA and RNA,
155
 we will 
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investigate the antiviral activity of a series of α-L-2ʹ-deoxythreonucleosides Ia (Figure 
2.1). It is noteworthy that a conditio sine qua non for nucleosides Ia to act as RT 
inhibitors/false substrates is their efficient activation by kinases. Since, to the best of 
our knowledge, nucleoside kinase mediated phosphorylation of secondary OH groups 
is unprecedented, we will convert nucleosides Ia to their monophosphate prodrugs Ib.  
 
Figure 2.1. Antiviral compounds in this study. 
 
Even though the 2ʹ,3ʹ-dideoxy-β-D-apio-D-furanonucleosides (ddAN) 1.7, as well as 
their L-enantiomers 1.6 were reported to be inactive against HIV (Figure 2.2), we will 
revisit the synthesis and antiviral evaluation of these compounds, based on the 
observation that: 
- both enantiomers of dideoxyisonucleosides (1.71 and 1.76), structural isomers 
of the envisaged ddANs, and PMDT analogues (A,T), isosteres of the 
monophosphate forms of the proposed ddANs, are potent HIV RT inhibitors; 
- the triphosphate form of the 3ʹ-deoxyANs 1.21, the phosphonomethoxythreosyl 
phosphonate nucleoside diphosphates (1.49) and the isonucleoside 
triphosphates (1.87) are readily accepted by several polymerases. 
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If our studies would confirm that nucleosides IIa (= 1.7) fail to show antiviral activity, 
we will synthesize the corresponding phosphate prodrugs (ProTides IIb) in an effort 
to bypass the first phosphorylation step. 
To further expand our understanding of the influence of the 2ʹ,3ʹ-dideoxy-β-D-apio-D-
furanose modified nucleosides on the orthogonal conformational requirements posed 
by kinases and viral polymerases, we also plan to transform a ddAN to its 
corresponding triphosphate (IIc) to test the effect of the latter on HIV RT. 
 
Figure 2.2. Reported antiviral compounds and compounds that are accepted readily 
by polymerases. 
 
Literature precedents on the synthesis and evaluation of apionucleoside derivatives as 
A3AR modulators are scarce, the recently reported carbocyclic analogue IIIa, a weak 
A3AR agonist, being a notable exception (Figure 2.3; IIIa). Hence, we plan to use the 
synthetic methodology developed for the synthesis of the aforementioned 
apionucleosides to construct suitably modified ANs as possible A3AR modulators. 
Modifications known to favorably influence A3AR modulation (e.g., N
6
-aralkyl and 
4ʹ-carboxamide/carbamate modifications, see Chapter 1, section 1.4) will be 
introduced in the apioadenosine structure (Figure 2.3; IIIb-d). 
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Figure 2.3. A3AR ligands in this study. 
 
Recently, thymidine monophosphate kinase (TMPK) has been validated as a viable 
target for antibacterial drug development. TMPK is an essential enzyme to convert 
dTMP into dTDP in the de novo and salvage DNA biosynthetic pathways. Differences 
in the catalytic site of M. tuberculosis TMPK (TMPKmt) compared to the human 
isozyme have been successfully explored to design selective inhibitors of the former. 
Based on the reported bicyclic TMPKmt inhibitors and other inhibitory data reported 
by our group, Frecer et al. recently applied combinatorial design and structure-based 
in silico screening of a virtual focused library of bicyclic thymidine analogs in an 
effort to identify more potent TMPKmt inhibitors.
154
 In their study they used the three-
dimensional structure of TMPKmt complexed with 5-hydroxymethyl-dUMP to 
develop a QSAR model, to parameterize a target-specific scoring function for 
TMPKmt and to select virtual hits that display the highest predicted binding to the 
target. Compound IV emerged as one of the best analogues (Figure 2.4). Also a 
number of in silico favorable 5ʹ-substituents (a, b, and d) arose from this study. Since 
the 5-CH2OH and 5ʹ-substitutions were described crucial, we aim to prepare a small 
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series of 5ʹ-substituted thymidines with and without 5-methyl modifications (VI and 
Va-e, respectively). In these target analogues the carbocyclic ring, which is mainly 
expected to enhance metabolic stability and the 2ʹ,3ʹ-bicyclic ring proposed in IV, are 
omitted to increase the synthetic feasibility. 
 
Figure 2.4. In silico hit IV and envisaged analogues V and VI as potential inhibitors 
of TMPKmt. 
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3.1. Objectives 
Herdewijn and coworkers showed that selected L-2ʹ-deoxythreose nucleoside 
phosphonates (Figure 3.1) selectively inhibit HIV without affecting human DNA 
synthesis. PMDTA and PMDTT lack a hydroxymethyl group at the 4ʹ-position of the 
furanose ring, but instead have a phosphonomethyl ether moiety at the 3ʹ-position, 
which mimics the monophosphate ester of a 3ʹ-hydroxymethyl substituent. 
Interestingly, Eschenmoser and coworkers showed that α-L- threofuranosyl 
oligonucleotides (TNAs) containing vicinally connected (3ʹ→2ʹ) phosphodiester 
bridges undergo informational base pairing in antiparallel strand orientation and are 
capable of cross-pairing with RNA and DNA.
155
 
Inspired by these findings, we decided to explore the synthesis and the antiviral 
properties of the corresponding non-phosphonylated 2-deoxythreose-based nucleoside 
analogues 3.25-29, characterized by a four-carbon-only carbohydrate part. We 
expected that due to the absence of the 4ʹ-hydroxymethyl group, the secondary 3ʹ-OH 
could become accessible for phosphorylation by cellular nucleoside kinases and 
anticipated 3.25-29 to have a superior bioavailability compared to the phosphonates. 
Remarkably, the synthesis of such α-L-2ʹ-deoxythreofuranosyl analogues (exhibiting 
the 1ʹR, 3ʹR configuration) has not been reported before. Moreover, the thymine 
congener was converted to phosphoramidate prodrug to bypass the first 
phosphorylation step. 
 
Figure 3.1. Structures of active α-L-2ʹ-deoxythreose nucleoside phosphonates and the 
nucleoside surrogates of this study (3.25-27 and 3.29). 
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3.2. Results and Discussion 
3.2.1. Chemistry 
The synthesis of target compounds started from 1,2-O-isopropylidene-α-L-threose 3.1 
(Scheme 3.1), which was synthesized in multi-gram scale following literature 
procedure.
156
 The hydroxyl group of 3.1 was protected using either benzyl bromide or 
4-methoxybenzyl (PMB) chloride to give compounds 3.2 and 3.3 in excellent yields. 
A benzyl group is a safe and versatile protecting group for carbohydrates, but may 
require harsh deprotection conditions. We also explored a more sensitive PMB 
protecting group, which may be removed under alternative conditions. Next, 
deprotection of the isopropylidene group upon treatment with 80% aq. acetic acid 
followed by acetylation afforded the key precursors 3.4 and 3.5 in good yield. 
 
Scheme 3.1. Synthesis of key intermediate 3.4 and 3.5. Reagents and conditions: (a) benzyl 
bromide, NaH, DMF, 0 °C → rt, 4h, 87%; (b) p-methoxybenzyl chloride, NaH, DMF, -20 °C 
→ rt, 4h, 84%; (c) (i) 80% aq. CH3COOH, 80 °C, 8h; (ii) Ac2O, pyridine, rt, 4h, 63-81%. 
 
A Vorbrüggen coupling reaction of 3.4 and 3.5 with the preformed silyl-protected 
nucleobases exclusively gave the α-nucleosides 3.6-11 due to anchimeric assistance 
from the 2-O-acetyl group (Scheme 3.2).
157
 The benzyl-protected thymine- and uracil-
nucleosides 3.6 and 3.7 were isolated in considerably better yields than the PMB 
protected analogues, due to instability of the PMB-protecting group under Vorbrüggen 
conditions. Moreover, the reaction between PMB-protected glycon 3.5 with silylated 
N
6
-benzoyladenine and N
4
-acetylcytosine failed to produce the desired coupling 
products in acceptable yields, which forced us to restrict further investigations to the 
benzyl-protected nucleosides. Under normal coupling conditions, the yield of the 
adenine coupling product 3.10 was also very low, possibly due to the formation of 
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other isomers.
158
 However, prolonged reaction time at elevated temperature (50 °C) 
afforded the thermodynamically favored isomer 3.10 in an acceptable yield of 42%. 
Under the normal coupling conditions the cytidine analogue 3.11 was obtained in 70 % 
yield. 
 
Scheme 3.2. Synthesis of α-L-2ʹ-deoxythreofuranosyl nucleoside analogues 3.25-27 and 3.29. 
Reagents and conditions: (a) (i) nucleobase, pyridine, TMSCl, HMDS, 135 °C, overnight; (ii) 
silylated base, 3.4/5, TMSOTf, 1,2-dichloroethane, 0 °C → rt, 3-5h, 45-87%; (b) (i) 
nucleobase, pyridine, TMSCl, HMDS, 135 °C, overnight; (ii) silylated base, 3.4/5, TMSOTf, 
1,2-dichloroethane, 50 °C, 24h, 42%, for 3.10; (c) 7N NH3-MeOH, rt, 4-48h, 81-95%; (d) 1N 
NH3-MeOH, rt, 5h, 78-90%, for 3.14-15; (e) Ac2O, DMF, rt, 24h, 78%; (f) (i) DMAP, O-p-
tolyl chlorothionoformate, CH3CN, 0 °C → rt, 4h; (ii) Bu3SnH, AIBN, toluene, 100 °C, 2-4h, 
47-86%; (g) Pd-C/H2, MeOH, rt, 3-8h, 40-89%; (h) on 3.21 and 3.22, CAN, CH3CN:H2O, 
0 °C → rt, 1h, 78-84%; (i) DDQ, CH2Cl2, 50 °C, 72h, 11%, for 3.28. 
 
The 2ʹ-O-acetyl group of 3.6 and 3.7 was removed by treatment with 7N ammonia in 
MeOH. Similar treatment of 3.8 and 3.9 led to the formation of small amounts of 2ʹ,3ʹ-
dihydroxy analogues (10-15%). Lowering the ammonia concentration to 1N allowed 
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obtaining the desired compounds 3.14 and 3.15 in high yields. Stirring compound 3.10 
at room temperature in a 7N solution of ammonia in MeOH for 2 days removed both 
the 2ʹ-O-acetyl and the N6-benzoyl group to yield 3.16. Likewise, 3.11 was 
deprotected to the dideacetylated compound 3.17, which was selectively N-acylated to 
3.18 with one equivalent of acetic anhydride in dimethylformamide (DMF).
159
 
Deoxygenation of the 2ʹ-hydroxy group was realized following a two-step Barton-
McCombie procedure.
160
 The xanthate was formed by reacting the 2ʹ-OH group of 
3.12-16 and 3.18 with O-p-tolyl chlorothionocarbonate in the presence of 4-
dimethylaminopyridine (DMAP). The intermediate formed was subjected to heating 
with tributyltinhydride and azoisobisbutyronitrile in toluene to give the 2ʹ-
deoxygenated compounds 3.19-24 in moderate to good yields (47-86%). 
All target compounds were obtained after debenzylation. However, optimal 
debenzylation procedures were distinct for each analogue. The 2ʹ-deoxythreose 
thymine and uracil analogues 3.25 and 3.26 could be obtained by catalytic 
hydrogenation of 3.19 and 3.20 in good albeit variable yields, possibly due to catalyst 
poisoning by the residual sulphur from the previous deoxygenation reaction. 
Desulphurization with hydrogen over Raney-Nickel prior to palladium-catalyzed 
debenzylation improved the reproducibility of this step. Alternatively, CAN-mediated 
deprotection of 3.21 and 3.22 afforded 3.25 and 3.26, respectively.
161
 The adenine 
analogue 3.27 was obtained by a palladium-catalyzed hydrogenation reaction in 
moderate yields.  
 
Scheme 3.3. An improved synthesis of the cytosine analogue 3.29. Reagents and conditions: 
(a) acetic anhydride, DMAP, DMF, rt, 24h, 97%; (b) (i) 1,2,4-triazole, POCl3, pyridine, rt, 4h; 
(ii) NH3, 2h; (iii) NH3-MeOH, rt, 5h, 36%. 
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The cytosine analogue 3.29 was obtained via two different routes. After an 
unsuccessful attempt to hydrogenate 3.24, the benzyl group was removed by treatment 
with excess of 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in 
dichloromethane (CH2Cl2) at 50 °C in a sealed reaction vial for 3 days.
162
 This method 
gave 3.28 in a disappointing yield of 11%. Hence, we also explored the transformation 
of the uridine analogue 3.26 to compound 3.29 (Scheme 3.3).
163
 This was realized by 
protecting the 3ʹ-hydroxy group of 3.26 to the corresponding acetate 3.30, which was 
subsequently treated with phosphorous oxychloride and 1,2,4-triazole, bubbling 
ammonia gas and a 7N solution of ammonia in MeOH. 
 
Scheme 3.4. Synthesis of the ProTide of 3.25. Reagents and conditions: (a) anh. 
triethylamine (TEA), anh. CH2Cl2, -78 °C for 30 min, rt, 2h; (b) 1.0M tert-butylmagnesium 
chloride in THF, anh. THF, rt, 24h, 33%. 
 
The coupling between the phenyldichlorophosphate (3.31) and L-alanine benzyl ester 
tosylate (3.32) has been performed in the presence of Et3N (2 eq) giving the desired 
product (3.33) as an oil, which was used in the following step as a crude (Scheme 3.4). 
The final coupling of the nucleoside 3.25 has been performed using an excess of the 
phosphorochloridate (3.33) (3 eq) in the presence of t-BuMgCl (3eq) following the 
procedure reported by Uchiyama
164
 and extensively used for the synthesis of the 
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ProTides.
165
 The desired compound 3.34 was obtained as a mixture of two 
diastereoisomers confirmed by the presence of two peaks in the 
31P NMR (δ 2.92, 
2.27). 
 
3.2.2. Pharmacological evaluations 
3.2.2.1. Antiviral properties 
None of the final nucleoside analogues showed cytotoxicity at 90 µM. No anti-HIV-1 
and anti-HIV-2 activity was observed in human T-lymphocyte (CEM) cells (EC50 >90 
µM). Furthermore, no significant activity could be detected against the following 
viruses: human Cytomegalovirus (HEL), Varicella-zoster virus (VZV) (HEL); 
Influenza A (H1N1 and H3N2) and B virus (MDCK), Feline Corona and Feline 
Herpes virus (CRFK); Herpes simplex virus type 1 (HSV-1), HSV-2, VSV and 
Vaccinia virus (HEL); Coxsackie virus B4 and Respiratory syncytial virus (HeLa); 
Para-Influenza virus-3, Reovirus-3, Sindbis virus and Punta Toro virus (Vero). Since 
the lack of antiviral activity could be due to the inability of virally-induced and/or 
cellular enzymes to activate the nucleoside analogues, a nucleoside monophosphate 
prodrug was prepared for compound 3.25. Such prodrugs may intracellularly release 
the free monophosphorylated form according to a multistep process lined-out in 
Scheme 3.5. However, also the phosphoramidate 3.34 failed to show activity against 
HIV-1, HIV-2, HSV-1, HSV-2, Vaccinia virus, VSV and HSV-1 (TK
-
). 
 
3.2.2.2. Interaction of test compounds with nucleoside kinases 
Interestingly, upon evaluation of their capacity to inhibit thymidine (1 µM) 
phosphorylation by recombinant purified human cytosolic TK1, human mitochondrial 
TK2, HSV-1 TK, VZV TK, and Drosophila melanogaster (Dm) dNK (Table 3.1), 
compound 3.25 proved inhibitory to TK-2, HSV-1 TK, and VZV TK at an IC50 
ranging between 66 and 429 µM and M. tuberculosis thymidylate kinase with a Ki of 
18 µM. 
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Table 3.1. Nucleoside kinase activity (IC50 in µM) 
 TK-1 TK-2 HSV-1 TK VZV TK Dm dNK 
3.25 >942 429 ± 189 66 ± 14 123 ± 42 ≥ 942 
3.26 >1000 303 ± 207 >1000 >1000 >1000 
3.27 >900 >900 >900 >900 >900 
3.29 >1000 >1000 >1000 >1000 >1000 
 
Therefore, compound 3.25 was investigated more in detail. Whereas 75% of the 
natural substrate thymidine (100 µM) was converted to its 5ʹ-mono- (and 5ʹ-di) 
phosphate within 5 minutes upon exposure to HSV-1 TK, no signs of any conversion 
of compound 3.25 to its phosphorylated derivative was observed after 60 minutes of 
incubation with the enzyme. Therefore, we may assume that these nucleosides purely 
act as enzyme inhibitors, rather than acting as alternative substrates. Lineweaver-Burk 
kinetic analysis revealed a non-competitive mechanism of inhibitory action of 
compound 3.25 against HSV-1 TK using dThd as the natural substrate (Figure 3.2). 
The inhibitory potential of some of the test compounds opens perspectives for using 
this α-L-2ʹ-deoxythreofuranosyl ring as a scaffold for optimizing these enzyme 
inhibitory activities. 
 
Figure 3.2. Lineweaver-Burk plot for compound 3.25. 
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3.2.2.3. Enzymatic study using carboxypeptidase Y enzyme 
The first step of the bioactivation of the phosphoramidate ProTide moiety involves the 
hydrolysis of the ester moiety which is supposed to be mediated by a 
carboxypeptidase type enzyme (Scheme 3.5). An enzymatic study using 
carboxypeptidase Y enzyme has been performed in order to understand if compound 
3.34 may be metabolized under these conditions. The experiment was performed by 
incubating compound 3.34 with carboxypeptidase in acetone-d6 and trizma buffer (pH 
= 7.6) following its conversion by 
31
P NMR. The spectra (Figure 3.3) showed a fast 
conversion of one of the diasteroisomers 3.34 (P = 2.38) to the compound 3.37 (P = 
6.25) through the intermediate 3.35 (P = 3.66). The other diastereoisomer (P = 2.24) 
was slower converted and it was still detectable after 14 h. This experiment showed 
that 3.34 is partially converted to the metabolite 3.37. The last step of the 
phosphoramidate bioactivation pathway involves the cleavage of the P-N bond in 3.37, 
which is considered to be mediated by a phosphoramidase type enzyme called human 
Hint-1 enzyme.
166
 The poor activity found for phosphoramidate prodrug 3.34 may be 
due to the inefficient bio-activation to the monophosphate and/ triphosphate form. 
 
Scheme 3.5. Putative mechanism of bioactivation of the ProTide  
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Figure 3.3. Carboxypeptidase-mediated cleavage of 3.34, monitorated by 
31
P NMR. 
 
3.3. Conclusions 
In conclusion, we have developed a practical and straightforward procedure for the 
synthesis of a series of α-L-2ʹ-deoxythreofuranosyl nucleosides containing four natural 
nucleobases. None of the analogues displayed significant antiviral activity or 
cytotoxicity. In an effort to bypass the often problematic conversion to the 
monophophate a ProTide version of thymine analogue was synthesized, which also 
proved to be inactive. On the other hand, the thymine analogue showed encouraging 
inhibitory activity towards a number of thymidine kinases, which may be a new 
starting point towards more potent and selective inhibitors. 
 
3.34 
3.35 
3.37 
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3.4. Experimental Section 
3.4.1. Chemical synthesis 
All reagents were from standard commercial sources and of analytic grade. Dry 
solvents were obtained directly from commercial sources and stored on molecular 
sieves. Moisture sensitive reactions were carried out under argon atmosphere. 
Precoated Merck silica gel F254 plates were used for TLC, spots were examined 
under ultraviolet light at 254 nm and further visualized by sulphuric acid-anisaldehyde 
spray. Column chromatography was performed on silica gel (63-200 μm, 60 Å, 
Biosolve, Valkenswaard, The Netherlands). NMR spectra were determined using a 
Varian Mercury 300 MHz spectrometer. Chemical shifts are given in ppm (δ) relative 
to the residual solvent signals or TMS as internal standard. Exact mass measurements 
were performed on a Waters LCT PremierXETMTime of flight (TOF) mass 
spectrometer equipped with a standard electrospray ionization (ESI) and modular 
LockSpray TM interface. Samples were infused in a CH3CN/water (1:1) mixture at 10 
μL/min. 
1,2-O-Isopropylidene-3-benzyl-β-L-threofuranose (3.2): To a solution of compound 
3.1 (2.3 g, 14.36 mmol) in dry DMF (50 mL) cooled at 0 °C under inert atmosphere, 
NaH (60% in mineral oil, 0.861 g, 21.54 mmol) was added portionwise and the 
mixture was stirred for 10 minutes. Benzyl bromide (2.56 mL, 21.54 mmol) was 
added dropwise to the above suspension, which was allowed to come to room 
temperature and stirred for an additional 4h. The reaction mixture was quenched by 
addition of MeOH (1 mL) and the volatile solvents were evaporated under reduced 
pressure. The residue was partitioned between water-EtOAc (1:3, 300 mL). The 
organic layer was separated, washed with water, brine and dried over anhydrous 
MgSO4. After evaporation, the crude product was purified by silica-gel 
chromatography (15% EtOAc-hexanes) to afford compound 3.2 (3.1 g, 87%) as a 
colorless oil. 
1
H NMR(CDCl3, 300 MHz) δ ppm 1.32 (s, 3H), 1.47 (s, 3H), 4.01-4.05 
(m, 3H), 4.57 (s, 2H), 4.61 (d, J = 3.77 Hz, 1H), 5.96 (d, J = 3.76 Hz, 1H), 7.27-7.39 
(m, 5H). 
13
C NMR (CDCl3, 75 MHz) δ ppm 26.15, 26.71, 70.27, 71.09, 81.81, 82.84, 
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105.44, 111.46, 127.59, 127.80, 128.41, 137.32. ESI-HRMS for [C14H18O4 + NH4]
+ 
calcd, 268.1549; found, 268.1565. 
1,2-O-Isopropylidene-3-(p-methoxybenzyl)-β-L-threofuranose (3.3): Compound 
3.1 (1.5 g, 9.4 mmol) was reacted with NaH (60% in mineral oil, 0.45 g, 11.24 mmol) 
and p-methoxybenzyl chloride (1.5 mL, 11.24 mmol) as described for synthesis of 3.2 
to afford compound 3.3 (2.2 g, 84%) as a white low melting solid. 
1
H NMR (CDCl3, 
300 MHz) δ ppm 1.31 (s, 3H), 1.46 (s, 3H), 3.78 (s, 3H), 3.98-4.02 (m, 3H), 4.48 (s, 
3H), 4.58 (d, J = 3.76 Hz, 1H), 5.94 (d, J = 3.76 Hz, 1H), 6.87 (d, J = 8.72 Hz, 2H), 
7.24 (d, J = 8.77 Hz, 2H). 
13
C NMR (CDCl3, 75 MHz) δ ppm 26.15, 26.71, 55.16, 
70.28, 70.78, 81.45, 82.87, 105.42, 111.42, 113.82, 129.27, 129.34, 159, 30. ESI-
HRMS for [C15H20O5 + K]
+
 calcd, 319.0942; found, 319.0937. 
1,2-O-Diacetyl-3-benzyl-α/β-L-threofuranose (3.4): A solution of 3.2 (2.0 g, 8 mmol) 
in 80% aq. acetic acid (40 mL) was stirred at 80 °C for 8h. The reaction mixture was 
evaporated to give the crude intermediate as syrup. This syrup was dissolved in 
pyridine (30 mL) and treated with acetic anhydride (7.5 mL, 80 mmol). The solution 
was stirred at room temperature for 4h. The solvent was removed under vacuum and 
the resulting residue was purified by silica-gel column chromatography (20% EtOAc-
hexanes) to yield 3.4 (1.9 g, 81%) as a low melting solid. α,β anomeric ratio 3:2. 1H 
NMR (CDCl3, 300 MHz) δ ppm 1.98, 2.00, 2.02, 2.03 (s’s, 6H), 3.78-4.29 (m, 3H), 
4.43-4.71 (m, 2H), 5.13-5.19 (m, 1H), 6.06-6.32 (s & d, J = 4.51 Hz, 1H), 7.20-7.32 
(m, 5H). ESI-HRMS for [C15H18O6 + K]
+ 
calcd, 333.0735; found, 333.0738. 
1,2-O-Diacetyl-3-(p-methoxybenzyl)-α/β-L-threofuranose (3.5): Employing the 
procedure described above on 2.2 g of compound 3.3 resulted in 1.6 g (63% yield) of 
compound 3.5 as a white solid. α,β anomeric ratio 1:1. 1H NMR (CDCl3, 300 MHz) δ 
ppm 2.04, 2.07, 2.08, 2.09 (s’s, 6H), 3.79 (s, 3H), 3.82-4.32 (m, 3H), 4.42-4.68 (m, 
2H), 5.17-5.24 (m, 1H), 6.11, 6.37 (2d’s, J = 4.49, 2.39 Hz, 1H), 6.83-6.91 (m, 2H), 
7.20-7.30 (m, 2H). ESI-HRMS for [C16H20O7 + Na]
+
 calcd, 347.1101; found, 
347.1112. 
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General condition for Vorbrüggen coupling reaction: The nucleobase (protected in 
case of adenine and cytosine) (1.2 eq.) was suspended in hexamethyldisilazane (50 eq.) 
containing trimethylsilyl chloride (0.7 eq.) and pyridine (10 eq.). The mixture was 
heated at reflux overnight. After cooling, the reaction mixture was evaporated and 
dried under high vacuum. The silylated nucleobase and the diacetate compound 3.4 or 
3.5 (1 eq.) were dissolved in dry 1,2-dichloroethane (7 mL/mmol), and trimethylsilyl 
triflate (1.2 eq) was added dropwise at 0 °C. The clear solution was stirred for 4h at 
room temperature. The reaction mixture was diluted with CH2Cl2 (50 mL/ mmol) and 
washed with saturated aqueous NaHCO3. The organic layer was dried over anhydrous 
MgSO4 and evaporated. Purification of the residue by silica-gel column 
chromatography (1% MeOH- CH2Cl2) afforded the pure coupling product as white 
foam.  
1ʹ-(Thymin-1-yl)-2ʹ-O-acetyl-3ʹ-O-benzyl-α-L-threofuranose (3.6): Following the 
general reaction conditions a Vorbrüggen coupling between 3.4 and thymine afforded 
the title compound (1.07 g, 87%). 
1
H NMR (CDCl3, 300 MHz) δ ppm 1.72 (d, J = 1.19 
Hz, 3H), 2.12 (s, 3H), 4.00-4.1 (m, 2H), 4.32 (app- dm, J = 8.75 Hz, 1H), 4.63 (app- 
dd, J = 14.68, 11.48 Hz, 2H), 5.22 (s, 1H), 6.08 (d, J = 1.36 Hz, 1H), 7.22-7.34 (m, 
5H), 7.37 (d, J = 1.22 Hz, 1H), 9.42 (br. s, 1H). 
13
C NMR (CDCl3, 75 MHz) δ ppm 
12.57, 21.03, 71.81, 73.74, 79.93, 80.88, 89.41, 110.94, 128.17, 128.47, 128.83, 
136.41, 136.89, 150.69, 164.23, 169.90. ESI-HRMS for [C18H20N2O6 + H]
+
 calcd, 
361.1400; found, 361.1399. 
1ʹ-(Uracil-1-yl)-2ʹ-O-acetyl-3ʹ-O-benzyl-α-L-threofuranose (3.7): Vorbrüggen 
coupling between 3.4 (500 mg, 1.7 mmol) and uracil (230 mg, 2.04 mmol) afforded 
481 mg of the uridine analogue 3.7 (82 % yield). 
1
H NMR (CDCl3, 300 MHz) δ ppm 
2.07 (s, 3H), 3.96 (d, J = 3.78 Hz, 1H), 4.02 (dd, J = 10.25, 3.81 Hz, 1H), 4.24 (d, J = 
10.28 Hz, 1H), 4.56 (app-q, J = 11.76 Hz, 2H), 5.17 (s, 1H), 5.55 (dd, J = 8.19, 1.77 
Hz, 1H), 5.96 (d, J = 1.18 Hz, 1H), 7.17-7.32 (m, 5H), 7.48 (d, J = 8.20 Hz, 1H), 8.93 
(br. s, 1H). 
13
C NMR (CDCl3, 75 MHz) δ ppm 21.03, 71.88, 74.27, 79.72, 80.52, 89.82, 
102.23, 128.28, 128.54, 128.87, 136.80, 140.58, 150.39, 163.39, 169.79. ESI-HRMS 
for [C17H18N2O6 + H]
+
 calcd, 347.1238; found 347.1246. 
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1ʹ-(Thymin-1-yl)-2ʹ-O-acetyl-3ʹ-O-(p-methoxybenzyl)-α-L-threofuranose (3.8): 
Vorbrüggen coupling between 3.5 (600 mg, 1.85 mmol) and thymine yielded 420 mg 
of the title compound (58 %). 
1
H NMR (CDCl3, 300 MHz) δ ppm 1.68 (d, J = 1.21 Hz, 
3H), 2.07 (s, 3H), 3.73 (s, 3H), 3.98 (dd, J = 14.17, 3.72 Hz, 2H), 4.14-4.25 (m, 1H), 
4.50 (app-q, J = 14.14 Hz, 2H), 5.15 (m, 1H), 6.00 (d, J = 1.34 Hz, 1H), 6.80 (d, J = 
8.72 Hz, 2H), 7.14 (d, J = 8.78 Hz, 2H), 7.31 (d, J = 1.24 Hz, 1H), 8.76 (br. s, 1H). 
13
C NMR (CDCl3, 75 MHz): δ ppm 12.60, 21.05, 55.54, 71.48, 73.85, 79.87, 80.53, 
89.45, 110.83, 114.21, 128.95, 129.88, 136.50, 150.48, 159.84, 163.97, 169.87. ESI-
HRMS for [C19H22N2O7 + H]
+
 calcd, 391.1500; found, 391.1521. 
1ʹ-(Uracil-1-yl)-2ʹ-O-acetyl-3ʹ-O-(p-methoxybenzyl)-α-L-threofuranose (3.9): 
Vorbrüggen coupling between 3.5 (325 mg, 1.0 mmol) and uracil yielded compound 
3.9 (180 mg, 47%).
 1
H NMR (CDCl3, 300 MHz) δ ppm 2.12 (s, 3H), 3.79 (s, 3H), 4.00 
(d, J = 3.73 Hz, 1H), 4.07 (dd, J = 10.24, 3.81 Hz, 1H), 4.27 (d, J = 10.23 Hz, 1H), 
4.55 (app-q, J = 12.73 Hz, 2H), 5.23 (s, 1H), 5.62 (dd, J = 8.21, 1.47 Hz, 1H), 6.02 (d, 
J = 1.03 Hz, 1H), 6.86 (d, J = 8.81 Hz, 2H), 7.19 (d, J = 8.79 Hz, 2H), 7.54 (d, J = 
8.21 Hz, 1H), 9.36 (brm, 1H). 
13
C NMR (CDCl3, 75 MHz) δ ppm 21.00, 55.50, 71.42, 
74.32, 79.61, 80.15, 89.76, 102.16, 114.20, 128.91, 129.99, 140.68, 150.71, 159.80, 
164.03, 169.85. ESI-HRMS for [C18H20N2O7 + H]
+
 calcd, 377.1343; found 377.1369. 
1ʹ-(N6-Benzoyladenin-9-yl)-2ʹ-O-acetyl-3ʹ-O-benzyl-α-L-threofuranose (3.10): To 
a suspension of N
6
-benzoyladenine (1.0 g, 4.08 mmol) in hexamethyldisilazane (35 
mL, 0.17 mol) was added trimethylsilyl chloride (0.3 mL, 2.38 mmol) and pyridine 
(2.7 mL, 34 mmol). The mixture was heated at reflux overnight. After cooling it was 
evaporated and dried under high vacuum. The silylated nucleobase and the diacetate 
3.4 (1.0 g, 3.4 mmol) were dissolved in dry 1,2-dichloroethane (20 mL) and 
trimethylsilyl triflate (0.74 mL, 4.08 mmol) was added dropwise at 0 °C. The clear 
solution was stirred at 50 °C for 24h. After dilution with CH2Cl2 (250 mL), the 
reaction mixture was washed with saturated aqueous NaHCO3. The organic layer was 
dried over anhydrous MgSO4 and evaporated. purification of the residue by silica-gel 
flash column chromatography (60 % EtOAc – hexanes) afforded pure 3.10 (0.68 g, 
42%) as white foam.
1
H NMR (CDCl3, 300 MHz) δ ppm 2.08 (s, 3H), 4.04 (d, J = 3.76 
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Hz, 1H), 4.31 (dd, J = 10.34, 3.89 Hz, 1H), 4.4 - 4.52 (m, 3H), 5.48 (s, 1H), 6.71 (s, 
1H), 7.00 - 7.10 (m, 5H), 7.31 – 7.50 (m, 3H), 8.08 (s, 1H), 8.12 – 8.19 (m, 2H), 8.59 
(s, 1H). 
13
C NMR (CDCl3, 75 MHz) δ ppm 21.03, 72.12, 76.07, 79.94, 80.49, 93.07, 
127.81, 128.08, 128.16, 128.22, 128.56, 128.74, 129.89, 132.32, 136.84, 137.81, 
142.01, 143.61, 148.71, 169.68, 175.13. ESI-HRMS for [C25H23N5O5 + H]
+
 calcd, 
474.1772; found, 474.1698. 
1ʹ-(N4-Acetylcytosin-1-yl)-2ʹ-O-acetyl-3ʹ-O-benzyl-α-L-threofuranose (3.11): A 
Vorbrüggen coupling reaction between N
4
-acetylcytosine and compound 3.4 (295 mg, 
1.0 mmol) yielded compound 3.11 (270 mg, 70%). 
1
H NMR (CDCl3, 300 MHz) δ ppm 
2.11 (s, 3H), 2.28 (s, 3H), 4.01 (d, J = 3.77 Hz, 1H), 4.20 (dd, J = 10.31, 3.86 Hz, 1H), 
4.35 (d, J = 10.25 Hz, 1H), 4.97 (app-q, J = 13.94 Hz, 2H), 5.28 (s, 1H), 5.34 (s, 1H), 
6.05 (s, 1H), 7.14 - 7.20 (m, 2H), 7.25 – 7.32 (m, 3H), 7.34 (d, J = 7.61 Hz, 1H), 7.89 
(d, J = 7.57 Hz, 1H), 10.34 (br. s, 1H). 
13
C NMR (CDCl3, 75 MHz) δ ppm 21.10, 
25.10, 71.67, 75.25, 79.15, 80.15, 91.22, 96.48, 128.21, 128.37, 128.77, 136.84, 
145.07, 155.25, 163.53, 169.70, 171.44. ESI-HRMS for [C19H21N3O6 + H]
+
 calcd, 
388.1503; found, 388.1509 
1ʹ-(Thymin-1-yl)-3ʹ-O-benzyl-α-L-threofuranose (3.12): The 2ʹ-O-acetylated 
nucleoside 3.6 (580 mg, 1.6 mmol) was treated with 7N methanolic ammonia solution 
(15 mL) at room temperature overnight. Evaporation yielded a residue which was 
purified by column chromatography (2% MeOH-CH2Cl2) to afford compound 3.12 
(420 mg, 82 %) as a white foam.
1
H NMR (CDCl3, 300 MHz) δ ppm 1.67 (d, J = 0.75 
Hz, 3H), 4.07 (s, 1H), 4.30 (s, 2H), 4.42 (s, 3H), 5.59 (br. s, 1H), 7.78 (s, 1H), 7.06-
7.24 (m, 5H), 7.30 (d, J = 1.14 Hz, 1H), 10.60 (br. s, 1H). 
13
C NMR (CDCl3, 75 MHz) 
δ ppm 12.24, 71.45, 74.97, 78.10, 82.20, 93.54, 109.38, 127.59, 127.96, 128.45, 
136.75, 136.92, 150.96, 164.73. ESI-HRMS for [C16H18N2O5 – H]
-
 calcd, 317.1143; 
found 317.1147. 
1ʹ-(Uracil-1-yl)-3ʹ-O-benzyl-α-L-threofuranose (3.13): Following the procedure 
described for 3.12, compound 3.7 (475 mg, 1.37 mmol) was hydrolysed to afford 3.13 
(340 mg, 81%) as a white foam. 
1
H NMR (CDCl3, 300 MHz) δ ppm 4.05 (s, 1H), 4.28 
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(s, 2H), 4.41 (s, 1H), 4.43 (s, 2H), 5.54 (dd, J = 8.10, 1.81 Hz, 1H), 5.73 (s, 1H), 7.10-
7.30 (m, 5H), 7.48 (d, J = 8.16 Hz, 1H), 10.52 (br. s, 1H). 
13
C NMR (CDCl3, 75 MHz): 
δ ppm 71.85, 75.31, 82.29, 94.00, 101.32, 128.01, 128.37, 128.79, 137.11, 140.94, 
151.30, 164.38. ESI-HRMS for [C15H16N2O5 + H]
+
 calcd, 305.1132; found, 305.1132. 
1ʹ-(Thymin-1-yl)-3ʹ-O-(p-methoxybenzyl)-α-L-threofuranose (3.14): Compound 
3.8 (400 mg, 1.02 mmol) was treated with 1N methanolic ammonia solution (10 mL) 
at room temperature for 6h. Evaporation yielded a residue which was purified by 
column chromatography (2% MeOH-CH2Cl2) to afford compound 3.14 (280 mg, 
78 %) as a white foam.
1
H NMR (CDCl3, 300 MHz): δ 1.69 (d, J = 1.1 Hz, 3H), 3.71 (s, 
3H), 4.03 (m, 1H), 4.27 (d, J = 1.84 Hz, 2H), 4.35 (s, 2H), 4.40 (s, 1H), 5.76 (s, 1H), 
6.76 (d, J = 8.72 Hz, 2H), 7.03 (d, J = 8.70 Hz, 2H), 7.29 (d, J = 1.21 Hz, 1H),10.47 
(br. s, 1H). 
13
C NMR (CDCl3, 75 MHz): δ 12.57, 55.54, 71.41, 75.15, 78.48, 82.24, 
93.77, 109.64, 114.15, 129.30, 129.57, 137.02, 151.20, 159.67, 164.92. ESI-HRMS 
for [C17H20N2O6 + H]
+
 calcd, 349.1394; found, 349.1389. 
1ʹ-(Uracil-1-yl)-3ʹ-O-(p-methoxybenzyl)-α-L-threofuranose (3.15): The ester 
moiety of 3.9 (180 mg, 0.48 mmol) was hydrolysed as described in the preparation of 
3.14 to give compound 3.15 (145 mg, 90%) as white foam. 
1
H NMR (CDCl3, 300 
MHz) δ ppm 3.77 (s, 3H), 4.08-4.12 (m, 1H), 4.26-4.36 (m, 2H), 4.42 (s, 2H), 4.46 (s, 
1H), 5.55 (br. s, 1H), 5.60 (dd, J = 8.14, 1.74 Hz, 1H), 5.79 (s, 1H), 6.83 (d, J = 8.77 
Hz, 2H), 7.11 (d, J = 8.65 Hz, 2H), 7.53 (d, J = 8.19 Hz, 1H), 10.74 (br. s, 1H). 
13
C 
NMR (CDCl3, 75 MHz) δ ppm 55.52, 71.50, 75.44, 78.24, 82.05, 93.93, 101.26, 
114.17, 129.28, 129.69, 141.05, 151.40, 159.71, 164.51. ESI-HRMS for [C16H18N2O6 
+ H]
+
 calcd, 335.1238; found, 335.1255. 
1ʹ-(Adenin-9-yl)-3ʹ-O-benzyl-α-L-threofuranose (3.16): Nucleoside 3.10 (680 mg, 
1.43 mmol) was treated with 7N methanolic ammonia solution (20 mL) at room 
temperature for 2 days. Evaporation yielded a residue which was purified by column 
chromatography (4% MeOH-CH2Cl2) to afford compound 3.16 (450 mg, 95 %) as a 
white foam. 
1
H NMR (DMSO-d6, 300 MHz) δ ppm 4.10 – 4.15 (m, 1H), 4.19 (dd, J = 
9.75, 4.72 Hz, 1H), 4.29 (dd, J = 9.72, 2.61 Hz, 1H), 4.57 (s, 2H), 4.66 – 4.71 (m, 1H), 
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5.95 (d, J = 2.28 Hz, 1H), 6.02 (d, J = 4.52 Hz, 1H), 7.20 – 7.40 (m, 7H), 8.16 (s, 2H). 
13
C NMR (DMSO- d6, 75 MHz) δ ppm 75.82, 78.18, 82.47, 87.32, 95.55, 123.17, 
131.76, 131.96, 132.43, 141.20, 143.53, 152.62, 156.47, 159.74. ESI-HRMS for 
[C16H18N5O3 + H]
+
 calcd, 328.1404; found, 328.1419. 
1ʹ-(Cytosin-1-yl)-3ʹ-O-benzyl-α-L-threofuranose (3.17): The 2ʹ-O-acetylated 
nucleoside 3.11 (210 mg, 0.54 mmol) was treated with 7N methanolic ammonia 
solution (15 mL) at room temperature overnight. Evaporation yielded a residue which 
was purified by column chromatography (2% MeOH-CH2Cl2) to afford 140 mg of 
compound 3.17 (85% yield) as a white foam. 
1
H NMR (DMSO- d6, 300 MHz) δ ppm 
3.94 (app-d, J = 3.98 Hz, 1H), 4.10 (dd, J = 10.08, 4.06 Hz, 1H), 4.18 (d, J = 4.28 Hz, 
1H), 4.28 (d, J = 10.08 Hz, 1H), 4.47 (app-q, J = 11.70 Hz, 2H), 5.60 (d, J = 7.44 Hz, 
1H), 5.68 (d, J = 1.08 Hz, 1H), 5.75 (s, 1H), 5.80 (d, J = 4.35 Hz, 1H), 7.00 (brd, J = 
23.36 Hz, 2H), 7.19 – 7.26 (m, 2H), 7.26 – 7.35 (m, 3H), 7.53 (d, J = 7.41 Hz, 1H). 
13
C NMR (DMSO- d6, 75 MHz) δ ppm 55.60, 70.91, 73.60, 78.12, 83.64, 93.06, 93.53, 
128.18, 128.34, 128.86, 138.44, 142.12, 155.94, 166.44. ESI-HRMS for [C15H17N3O4 
+ H]
+
 calcd, 304.1292; found, 304.1294. 
1ʹ-(N4-Acetylcytosin-1-yl)-3ʹ-O-benzyl-α-L-threofuranose (3.18): To a solution of 
compound 3.17 (180 mg, 0.59 mmol) in dry DMF (1.5 mL) was added acetic 
anhydride (56 µL, 0.59 mmol) and the mixture was stirred at room temperature for 
24h. The residue obtained after distillation of the volatiles under reduced pressure, 
was purified by silica-gel column chromatography to give 3.18 (160 mg, 78%) as a 
white foam. 
1
H NMR (CDCl3, 300 MHz) δ ppm 2.2 (s, 3H), 4.00 – 4.04 (m, 1H), 4.23 
(dd, J = 9.79, 1.48 Hz, 1H), 4.29 (dd, J = 9.93, 3.88 Hz, 1H), 4.39 (s, 1H), 4.42 (s, 1H), 
4.85 (br. s, 1H), 5.73 (d, J = 0.75 Hz, 1H), 7.05 – 7.11 (m, 2H), 7.17 – 7.25 (m, 3H), 
7.31 (d, J = 7.50 Hz, 1H), 7.88 (d, J = 7.50 Hz, 1H), 9.36 (br. s, 1H). 
13
C NMR 
(CDCl3, 75 MHz) δ ppm 25.14, 71.68, 74.99, 78.65, 82.67, 94.89, 96.26, 127.96, 
128.17, 128.69, 137.25, 145.33, 156.17, 163.04, 171.17, 177.08. ESI-HRMS for 
[C17H19N3O5 + H]
+
 calcd, 346.1397; found, 346.1400. 
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Barton – McCombie deoxygenation procedure for the synthesis of compounds 
3.19 – 3.24. To an ice-cold solution of compound 3.12 – 3.18 (1 eq.) and DMAP (2 
eq.) in CH3CN (25 mL/mmol) was gradually added O-p-tolylchlorothionocarbonate 
(1.2 equivalents) at 0 °C and stirring was continued at room temperature. After 2-4h 
the solvent was removed in vacuo and the residue was dissolved in EtOAc. The 
solution was washed twice with water, dried over anhydrous MgSO4, filtered, and 
evaporated in vacuo to give the corresponding xanthate as yellow solid/syrup. The 
xanthate was dissolved in toluene (50 mL/mmol), to which azobisisobutyronitrile 
(AIBN, 2 equivalent) was added. Tri-n-butyltin hydride (2.5 equivalent) was added to 
this mixture at 60-70 °C, which was further stirred for 2-4h at 95-100 °C. The solvent 
was removed in vacuum and the residue was purified by column chromatography (30-
40 % EtOAc - hexanes) to yield the 2ʹ-deoxy compounds 3.19 – 3.24 as a foam. 
1ʹ-(Thymin-1-yl)-2ʹ-deoxy-3ʹ-O-benzyl-α-L-threofuranose (3.19): Deoxygenation 
of 3.12 (420 mg, 1.32 mmol) rendered 330 mg of compound 3.19 in 82% yield. 
1
H 
NMR (CDCl3, 300 MHz) δ ppm 1.69 (d, J = 1.19 Hz, 3H), 2.19 (ddd, J = 15.07, 1.19, 
0.88 Hz, 1H), (ddd, J = 15.11, 7.94, 5.45 Hz, 1H), 3.82 (dd, J = 10.27, 3.60 Hz, 1H), 
4.19 (dd, J = 5.47, 3.66 Hz, 1H), 4.30 (dd, J = 10.33, 1.50 Hz, 1H), 4.42 (app-dd, J = 
15.15, 11.27 Hz, 2H), 6.17 (J = 7.88, 2.17 Hz, 1H), 7.16-7.32 (m, 5H), 7.47 (d, J = 
1.22 Hz, 1H), 8.67 (br. s, 1H). 
13
C NMR (CDCl3, 75 MHz) δ ppm 12.60, 38.49, 71.41, 
74.51, 77.58, 85.48, 110.35, 127.90, 128.32, 128.82, 136.98, 137.28, 150.76, 164.10. 
ESI-HRMS for [C16H18N2O4 + H]
+
 calcd, 303.1339; found, 303.1342.  
1ʹ-(Uracil-1-yl)-2ʹ-deoxy-3ʹ-O-benzyl-α-L-threofuranose (3.20): Deoxygenation of 
3.13 (306 mg, 1.0 mmol) rendered 250 mg of compound 3.20 in 86% yield. 
1
H NMR 
(CDCl3, 300 MHz) δ ppm 2.23 (dm, J = 15.11 Hz, 1H), 2.39 (ddd, J = 15.11, 7.56, 
5.31 Hz, 1H), 3.85 (dd, J = 10.25, 3.67 Hz, 1H), 4.17 (app-t, J = 4.40 Hz, 1H), 4.28 
(dd, J = 10.24, 1.83 Hz, 1H), 4.41 (app-dd, J = 13.75, 11.63 Hz, 2H), 5.55 (dd, J = 
8.16, 1.73 Hz, 1H), 6.12 (dd, J = 7.54, 2.00 Hz, 1H), 7.14-7.34 (m, 5H), 7.61 (d, J = 
8.16 Hz, 1H), 8.86 (br. s, 1H). 
13
C NMR (CDCl3, 75 MHz) δ ppm 38.56, 71.39, 74.99, 
77.28, 86.15, 101.69, 127.96, 128.36, 128,85, 137.20, 141.09, 150.70, 163.63. ESI-
HRMS for [C15H16N2O4 + H]
+
 calcd, 289.1183; found, 289.1183. 
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1ʹ-(Thymin-1-yl)-2ʹ-deoxy-3ʹ-O-(p-methoxybenzyl)-α-L-threofuranose (3.21): 
Deoxygenation reaction of 3.14 (280 mg, 0.81 mmol) rendered 200 mg of compound 
3.21 in 75% yield. 
1
H NMR (CDCl3, 300 MHz) δ ppm 1.70 (d, J = 1.20 Hz, 3H), 2.16 
(ddd, J = 15.09, 2.04, 1.05 Hz, 1H), 2.40 (ddd, J = 15.1, 7.93, 5.52 Hz, 1H), 3.73 (s, 
3H), 3.80 (dd, J = 10.22, 3.66 Hz, 1H), 4.17 (app-t, J = 4.46 Hz, 1H), 4.28 (dd, J = 
10.26, 1.34 Hz, 1H), 4.35 (dd, J = 14.60, 11.00 Hz, 2H), 6.16 (dd, J = 7.90, 2.20 Hz, 
1H), 6.80 (d, J = 8.74 Hz, 2H), 7.12 (d, J = 8.74 Hz, 2H), 7.46 (d, J = 1.23 Hz, 1H), 
8.69 (br. s, 1H). 
13
C NMR (CDCl3, 75 MHz) δ ppm 12.65, 38.44, 55.55, 71.06, 74.57, 
85.50, 110.28, 114.21, 129.37, 129.56, 137.04, 150.79, 159.71, 164.16. ESI-HRMS 
for [C17H20N2O5 + H]
+
 calcd, 333.1445; found, 333.1461. 
1ʹ-(Uracil-1-yl)-2ʹ-deoxy-3ʹ-O-(p-methoxybenzyl)-α-L-threofuranose (3.21): 
Deoxygenation of 3.15 (100 mg, 0.3 mmol) rendered 70 mg of compound 3.22 in 74% 
yield. 
1
H NMR (CDCl3, 300 MHz) δ ppm 2.21 (app-dm, J = 15.15 Hz, 1H), 2.37 (ddd, 
J = 15.03, 7.47, 5.28 Hz, 1H), 3.73 (s, 3H), 3.83 (dd, J = 10.20, 3.66 Hz, 1H), 4.25 (dd, 
J = 10.14, 1.17 Hz, 1H), 4.33 (d, J = 1.40 Hz, 2H), 5.56 (d, J = 8.13 Hz, 1H), 6.11 (dd, 
J = 7.54, 1.96 Hz, 1H), 6.80 (d, J = 8.70 Hz, 2H), 7.09 (d, J = 8.70 Hz, 2H), 7.61 (d, J 
= 8.13 Hz, 1H), 9.21 (br. s, 1H). 
13
C NMR (CDCl3, 75 MHz) δ ppm 38.46, 55.53, 
71.00, 75.06, 76.97, 86.18, 101.67, 114.22, 129.28, 129.63, 141,24, 150.96, 159.70. 
ESI-HRMS for [C16H18N2O5 + H]
+
 calcd, 319.1294; found, 319.1295. 
1ʹ-(Adenin-9-yl)-2ʹ-deoxy-3ʹ-O-benzyl-α-L-threofuranose (3.23): Deoxygenation of 
3.16 (450 mg, 1.38 mmol) rendered 200 mg of compound 3.23 in 47% yield. 
1
H NMR 
(DMSO-d6, 300 MHz) δ ppm 2.59 (dm, J = 14.60 Hz, 1H), 2.70 (ddd, J = 14.60, 7.61, 
5.84 Hz, 1H), 4.00 (dd, J = 9.88, 4.45 Hz, 1H), 4.25 (app-dt, J = 10.05, 1.30 Hz, 1H), 
4.41 (m, 1H), 4.54 (app-d, J = 2.42, 2H), 6.34 (dd, J = 7.55, 2.64 Hz, 1H), 7.24 (br. s, 
2H), 7.26 – 7.38 (m, 5H), 8.24 (s, 1H), 8.22 (s, 1H). 13C NMR (DMSO-d6, 75 MHz) δ 
ppm 37.32, 70.30, 73.21, 77.47, 82.78, 118.52, 127.43, 127.53, 128.18, 137.87, 
138.79, 149. 04, 152. 47, 155.85. ESI-HRMS for [C16H17N5O2 + H]
+
 calcd, 312.1455; 
found, 312.1469. 
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1ʹ-(N
4
-Acetylcytosin-1-yl)-2ʹ-deoxy-3ʹ-O-benzyl-α-L-threofuranose (3.24): 
Deoxygenation of 3.18 (190 mg, 0.55 mmol) rendered 100 mg of compound 3.24 in 
56% yield. 
1
H NMR (CDCl3, 300 MHz) δ ppm 2.20 (s, 3H), 2.35 – 2.44 (m, 2H), 3.98 
(dd, J = 10.12, 3.72 Hz, 1H), 4.13 - 4.18 (m, 1H), 4.31 (s, 2H), 4.34 (dd, J = 10.20, 
0.96 Hz, 1H), 6.09 (dd, J = 6.08, 2.31 Hz, 1H), 7.06 – 7.12 (m, 2H), 7.21 (d, J = 8.44 
Hz, 1H), 7.20 – 7.28 (m, 3H), 7.91 (d, J = 7.50 Hz, 1H), 9.46 (br. s, 1H). 13CNMR 
(CDCl3, 75 MHz) δ ppm 25.06, 38.46, 71.08, 75.89, 77.20, 88.21, 96.20, 127.92, 
128.19, 128.76, 137.23, 145.37, 155.54, 163.35, 171.57. ESI-HRMS for [C17H19N3O4 
+ H]
+
 calcd, 330.1448; found, 330.1463. 
Deprotection method – A. A solution of benzyl protected nucleoside in MeOH (40 
mL/mmol) was hydrogenated at atmospheric pressure for 5-24h in the presence of 10% 
Pd/C (150 mg/mmol). The catalyst was removed by filtration over a Celite path and 
the filtrate was concentrated in vacuo. The residue was purified by column 
chromatography (3% MeOH-CH2Cl2) to isolate the desired product as a white 
amorphous solid. 
Deprotection method – B. To a solution of benzyl protected nucleoside (1 eq.) in an 
acetonitrile-water (5:1) mixture (20 mL/mmol) at 0 °C ceric ammonium nitrate (CAN, 
2.5 equivalents) was added and stirring was continued for 1h. The reaction mixture 
was treated with solid NaHCO3 (2.0 g/mmol) followed by 25% MeOH-CH2Cl2 (50 
mL/mmol). The mixture was filtered over celite and washed with 25% MeOH-CH2Cl2 
(100 mL/mmol). The filtrate was concentrated in vacuum, and the residue was 
purified by column chromatography (3% MeOH-CH2Cl2) to isolate the final product 
as a white amorphous solid. 
1ʹ-(Thymin-1-yl)-2ʹ-deoxy-α-L-threofuranose (3.25): Employing deprotection 
method A, 30 mg of title compound was obtained in 75 % yield from 3.19 (57 mg, 
0.19 mmol), while method B afforded 80 mg of the same compound from 3.21 (150 
mg, 0.45 mmol) in 84 % yield. 
1
H NMR (DMSO-d6, 300 MHz) δ ppm 1.77 (d, J = 
1.16 Hz, 3H), 1.87 (ddd, J = 14.49, 2.89, 1.52 Hz, 1H), 2.46 (ddd, J = 14.05, 8.07, 
5.59 Hz, 1H), 3.77 (dd, J = 9.37, 3.72 Hz, 1H), 3.98 (dt, J = 9.36, 1.41 Hz, 1H), 4.36 
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(brm, 1H), 5.29 (d, J = 2.68 Hz, 1H), 6.05 (dd, J = 8.13, 2.72 Hz, 1H), 7.76 (d, J = 
1.21 Hz, 1H), 11.23 (br. s, 1H). 
13
C NMR (DMSO-d6, 75 MHz) δ ppm 13.06, 40.75, 
69.54, 77.04, 85.32, 109.20, 137.79, 151.21, 164.54. ESI-HRMS for [C9H12N2O4 – H]
- 
calcd, 211.0724; found, 211.0732. 
1ʹ-(Uracil-1-yl)-2ʹ-deoxy-α-L-threofuranose (3.26): Employing deprotection method 
A, 43 mg of the title compound was obtained in 89% yield from 3.20 (70 mg, 0.24 
mmol), while using method B compound 3.22 (70 mg, 0.22 mmol) was converted to 
34 mg of the title compound (78 % yield). 
1
H NMR (DMSO-d6, 300 MHz) δ ppm 1.87 
(ddd, , J = 14.53, 2.91, 1.88 Hz, 1H), 2.43 (ddd, J = 14.45, 8.00, 5.48 Hz, 1H), 3.78 
(dd, J = 9.43, 3.66 Hz, 1H), 3.97 (app-dt, J = 9.46, 1.25 Hz, 1H), 4.34 (t, J = 4.23 Hz, 
1H), 5.27 (br. s, 1H), 5.60 (d, J = 8.05 Hz, 1H), 6.01 (dd, J = 8.00, 2.23 Hz, 1H), 7.85 
(d, J = 8.11 Hz, 1H), 11.19 (br. s, 1H). 
13
C NMR (CDCl3, 75 MHz) δ ppm 41.64, 
70.08, 78.56, 87.97, 100.61, 141.97, 150.95, 165.38. ESI-HRMS for [C8H10N2O4 + 
H]
+
 calcd, 199.0713; found, 199.072. 
1ʹ-(Adenin-9-yl)-2ʹ-deoxy-α-L-threofuranose (3.27): Using method A with catalytic 
amount of acetic acid compound 3.23 (100 mg, 0.32 mmol) was converted to 29 mg of 
compound 3.27 in 40 % yield. 
1
H NMR (DMSO-D6, 300 MHz) δ ppm 2.29 (ddd, J = 
14.44, 2.70, 1.54 Hz, 1H), 2.68 (ddd, J = 14.42, 8.24, 6.10 Hz, 1H), 3.91 (dd, J = 9.30, 
4.10 Hz, 1H), 3.97 (ddd, J = 9.32, 2.10, 1.06 Hz, 1H), 4.48 (m, 1H), 5.79 (d, J = 4.35 
Hz, 1H), 6.28 (dd, J = 8.27, 2.56 Hz, 1H), 7.28 (s, 2H), 8.15 (s, 1H), 8.36 (s, 1H). 
13
C 
NMR (DMSO-d6, 75 MHz) δ ppm 40.86, 69.95, 76.98, 83.83, 119.53, 140.40, 149.53, 
153.06, 156.73. ESI-HRMS for [C9H11N5O2 + H]
+
 calcd, 222.0986; found, 222.0938. 
1ʹ-(N4-Acetylcytosin-1-yl)-2ʹ-deoxy-α-L-threofuranose (3.28): DDQ (770 mg, 3.4 
mmol) was added to a stirring solution of compound 3.24 (112 mg, 0.34 mmol) in dry 
CH2Cl2 (5.0 mL). The mixture was heated to 50 °C for 2 days in a sealed tube. Then it 
was sequentially treated with NaHCO3 (2.0 g), water (0.25 mL) and 20 mL of 1:1 
CH2Cl2-MeOH. After addition of anhydrous MgSO4 the resulting slurry was filtered. 
The filtrate was concentrated and purified by column chromatography (4-6% MeOH-
CH2Cl2) to afford 9 mg of compound 3.28 (11 % yield).
 1
H NMR (CDCl3, 300 MHz) δ 
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ppm 2.14 (s, 3H), 2.37 (ddd, J = 14.90, 7.02, 4.53 Hz, 1H), 2.61 (d, J = 14.90 Hz, 1H), 
4.02 (dd, J = 9.80, 3.46 Hz, 1H), 4.28 (dd, J = 9.78, 1.14 Hz, 1H), 4.52 (t, J = 3.86 Hz, 
1H), 5.94 (d, J = 6.56 Hz, 1H), 7.32 (d, J = 7.50 Hz, 1H), 8.03 (d, J = 7.48 Hz, 1H), 
9.39 (br. s, 1H). 
13
C NMR (CDCl3, 75 MHz) δ ppm 25.12, 41.49, 70.28, 78.87, 89.48, 
95.73, 146.47, 155.43, 162.11, 170.95. ESI-HRMS for [C10H13N3O4 + H]
+
 calcd, 
240.0979; found, 240.0982 & [2M + H]
+
 479.1936. 
1ʹ-(Cytosin-1-yl)-2ʹ-deoxy-α-L-threofuranose (3.28):  
Method – 1. Applying the reaction conditions described for 3.12 on compound 3.28 
(18 mg, 75 µmol) gave 10 mg of compound 3.29 (67% yield) as an amorphous solid. 
Method – 2. To a stirring mixture of 1,2,4-triazole (223 mg, 3.24 mmol) in 5 mL of 
pyridine POCl3 (75 µL, 0.81 mmol) was added dropwise at room temperature. After 
10 minutes compound 3.30 (65 mg, 0.27 mmol) was added and stirring was continued 
for an additional 3h. After that time the reaction was bubbled with ammonia gas for 2h. 
Since TLC indicated that the deacetylation was not completed, the volatiles were 
removed and the residue treated with 7N methanolic ammonia (5 mL) for 5h. After 
evaporation the residue was purified by flash column chromatography (6% MeOH-
CH2Cl2) to give 19 mg of the title compound 3.29 in 36% yield. 
1
H NMR (DMSO-d6, 
300 MHz) δ ppm 1.82 (ddd, J = 14.28, 1.40, 1.10 Hz, 1H), 2.40 (ddd, J = 14.06, 7.87, 
5.59 Hz, 1H), 3.81 (dd, J = 9.35, 3.74Hz, 1H), 3.97 (dt, J = 9.31, 1.28 Hz, 1H), 4.33 
(m, 1H), 5.16 (d, J = 2.76 Hz, 1H), 5.69 (d, J = 7.42 Hz, 1H), 5.99 (dd, J = 7.83, 2.43 
Hz, 1H), 7.08 (brd, J = 15.32 Hz, 2H), 7.75 (d, J = 7.41 Hz, 1H). 
13
C NMR (DMSO-d6, 
75 MHz) δ ppm 41.48, 69.70, 77.26, 86.52, 93.85, 142.46, 155.98, 166.37. ESI-
HRMS for [C8H11N3O3 + H]
+
 calcd, 198.0873; found, 198.0876. 
1ʹ-(Uracil-1-yl)-2ʹ-deoxy-3ʹ-O-acetyl-α-L-threofuranose (3.30): To a stirring 
solution of compound 3.26 (55 mg, 0.277 mmol) and 4-dimethyl aminopyridene 
(DMAP, 50 mg, 0.41 mmol) in 2 mL of DMF acetic anhydride (31 μL, 0.33 mmol) 
was added. After stirring for 24h, the solvent was evaporated under vacuum and the 
residue was purified by column chromatography to isolate compound 3.30 (65 mg, 
97%). 
1
H NMR (CDCl3, 300 MHz) δ ppm 1.96 (s, 3H), 2.22 (ddd, J = 15.48, 2.74, 
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1.76 Hz, 1H), 2.58 (ddd, J = 15.49, 7.24, 5.81 Hz, 1H), 4.04 (dd, J = 10.95, 3.87 Hz, 
1H), 4.21 (ddd, J = 10.95, 1.60, 0.69 Hz, 1H), 5.31 (app-tt, J = 4.80, 0.84 Hz, 1H), 
5.68 (d, J = 8.18 Hz, 1H), 6.07 (dd, J = 7.21, 1.94 Hz, 1H), 7.45 (d, J = 8.18 Hz, 1H), 
9.20 (br. s, 1H). 
13
C NMR (CDCl3, 75 MHz) δ ppm 21.24, 39.13, 72.88, 75.39, 86.61, 
101.63, 139.77, 150.53, 163.72, 170.19. ESI-HRMS for [C10H12N2O5 + H]
+
 calcd, 
241.0819; found, 241.0830. 
Phenyl-(benzoxy-L-alaninyl)-phosphorochloridate (3.33): To a stirred solution of 
phenyldichlorophosphate 3.31 (0.30 mL, 2.00 mmol) and L-alanine benzyl ester 
tosylate 3.32 (0.43 g, 2.00 mmol) in anhydrous CH2Cl2 (15 mL) was added anhydrous 
TEA (0.56 mL, 4.00 mmol) dropwise under an Ar atmosphere at -78 
o
C. Following 
the addition the reaction mixture was stirred at -78 
o
C for 30 min, then at room 
temperature for 2h. Formation of the desired compound was monitored by 
31
P NMR. 
After this period the solvent was removed under reduced pressure and the residue 
triturated with anhydrous diethyl ether. The precipitate was filtered under nitrogen and 
the solution was concentrated to give yellow oil (87%, 0.62 g). 
1
H NMR (CDCl3, 500 
MHz)  ppm 7.33-7.28 (10H, m, PhO, OCH2Ph), 5.15-5.13 (2H, m, OCH2Ph), 4.18-
4.13 (1H, m, CHNH), 1.46-1.44 (3H, m, CH3). 
31
P NMR (CDCl3, 202 MHz)  ppm 
7.86, 7.52. 
α-L-Threofuranosyl-1ʹ-(Thymin-1-yl)-2ʹ-deoxy-3ʹ-O-[phenyl-(benzoxy-L-
alaninyl)]-phosphate (3.34): To a solution of 3.25 (0.093 g, 0.44 mmol) in anhydrous 
THF (10 mL) was added 1.0M solution of tert-butylmagnesium chloride in THF (0.88 
mL, 0.88 mmol) and the reaction mixture was stirred under an Ar atmosphere for 30 
min. After this period, a solution of 3.33 (0.31 g, 0.88 mmol) in anhydrous THF (5 mL) 
was added dropwise and the reaction mixture was stirred at room temperature for 18h. 
Then, 1.0M solution of tert-butyl magnesium chloride in THF (0.44 mL, 0.44 mmol) 
and a solution of 32 (0.15 g, 0.44 mmol) in anhydrous THF (3 mL) was added and the 
stirring was continued for further 5h. After this period, the solvent was removed and 
the residue was purified by column chromatography, gradient elution of 
CH2Cl2/MeOH = 98/2 then 96/4 to give a white solid (33%, 0.077 g).
 1
H NMR 
(CD3OD, 500 MHz)  ppm 7.52 (0.5H, d, J = 1.2 Hz, H-6 of one diastereoisomer), 
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7.47 (0.5H, d, J = 1.2 Hz, H-6 of one diastereoisomer), 7.38-7.30 (7H, m, PhO, 
OCH2Ph), 7.22-7.16 (2H, m, PhO, OCH2Ph), 7.12-7.10 (1H, m, PhO, OCH2Ph), 6.10 
(0.5H, dd, J = 7.8 Hz, 2.3 Hz, H-1ʹ), 6.06 (0.5H, dd, J = 7.5 Hz, 1.8 Hz, H-1ʹ), 5.21-
5.17 (1H, m, H-3ʹ), 5.16, 5.15 (2H, 2s, OCH2Ph), 4.45 (0.5H, dd, J = 10.8 Hz, 1.7 Hz, 
H-4ʹ of one diastereoisomer), 4.37 (0.5H, dd, J = 10.8 Hz, 1.7 Hz, H-4ʹ of one 
diastereoisomer), 4.03-3.92 (2H, m, H-4ʹ, CHCH3), 2.63-2.55 (1H, m, H-2ʹ), 2.32 
(0.5H, d, J = 15.5 Hz, H-2ʹ of one diastereoisomer), 2.24 (0.5H, d, J = 15.5 Hz, H-2ʹ 
of one diastereoisomer), 1.83 (1.5H, d, J = 1.1 Hz, 5-CH3 of one diastereoisomer), 
1.82 (1.5H, d, J = 1.1 Hz, 5-CH3 of one diastereoisomer), 1.36 (1.5H, d, J = 0.9 Hz, 
CHCH3 of one diastereoisomer), 1.34 (1.5H, d, J = 1.0 Hz, CHCH3 of one 
diastereoisomer). 
13
C NMR (CD3OD, 125 MHz)  ppm 12.71 (5-CH3), 20.16 (d, JC–P 
= 7.5 Hz, CHCH3), 20.33 (d, JC–P = 6.5 Hz, CHCH3), 40.51 (d, JC–P = 5.6 Hz, C-2ʹ), 
40.73 (d, JC–P = 3.9 Hz, C-2ʹ), 51.60, 51.84 (2s, CHCH3), 68.00, 68.04 (2s, OCH2Ph), 
76.34 (d, JC–P = 4.0 Hz, C-4ʹ), 76.79 (d, JC–P = 5.5 Hz, C-4ʹ), 77.95 (d, JC–P = 5.2 Hz, 
C-3ʹ), 77.99 (d, JC–P = 4.9 Hz, C-3ʹ), 86.95, 87.47 (2s, C-1ʹ), 110.70, 111.03 (2s, C-5), 
121.09, 121.14, 121.18, 126.26, 126.29, 129.41, 129.43, 129.64, 129.65, 130.82, 
130.92 (PhO, OCH2Ph), 137.29 (‘ipso’ OCH2Ph), 137.77, 137.80 (2s, C-6), 152.03, 
152.07, 152.12, 152.22, 152.31 (C-2, (‘ipso’ OPh), 166.49, 166.55 (2s, C-4), 174.49 
(d, JC–P = 4.6, COOCH2Ph), 174.91 (d, JC–P = 4.1, COOCH2Ph). 
31
P NMR (CD3OD, 
202 MHz)  ppm 2.92, 2.27. ES-MS= 528.16 (M run on negative mode). HPLC = 
H2O/AcCN from 95/5 to 0/100 in 30 min = retention time 13.87, 14.19 min. 
 
3.4.2. Pharmacological assay procedures 
3.4.2.1. Carboxypeptidase Y enzymatic assay 
Compound 3.34 (5.5 mg) was dissolved in d6-acetone (150 L), and Trizma buffer 
(pH 7.6) (300 L) was added. The resulting cloudy solution was placed in a NMR 
tube and a 
31
P NMR experiment at 25 C was recorded as the blank experiment. Then 
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a solution of carboxypeptidase Y (0.1 mg) in Trizma buffer (150 L) was added and a 
31
P NMR experiment was performed recording the experiment every 5 min. 
 
3.4.2.2. Cytostatic activity assay 
The compounds were evaluated for their potential cytostatic activities against murine 
leukemia L1210, human CD4
+
 T-cell lymphocyte CEM and human cervix carcinoma 
HeLa cancer cells. In brief, different concentrations (5-fold dilutions) of the 
compounds were incubated at 37°C for 72h (HeLa and CEM cells) or 48h in the 
L1210 bioassay. After the incubation period, the number of viable cells were counted 
by a Coulter Particle counter and the IC50 were defined as the 50% inhibitory 
concentration or compound concentration required to inhibit tumor cell proliferation 
by 50%. 
 
3.4.2.3. Nucleoside kinase assay 
The activity of recombinant thymidine kinase (TK), TK-2, herpes simplex virus-1 
(HSV-1) TK and varicella-zoster virus (VZV) TK, and the 50% inhibitory 
concentration of the test compounds were assayed in a 50 μL reaction mixture 
containing 50 mM Tris/HCl, pH 8.0, 2.5 mM MgCl2, 10 mM dithiothreitol, 0.5 mM 
CHAPS, 3 mg/mL bovine serum albumin, 2.5 mM ATP, 1 μM [methyl-3H]dThd, and 
enzyme. The samples were incubated at 37 °C for 30 min in the presence or absence 
of different concentrations (5-fold dilutions) of the test compounds. At this time point, 
the enzyme reaction still proceeded linearly. Aliquots of 45 μL of the reaction 
mixtures were spotted on Whatman DE-81 filter paper disks (Whatman, Clifton, NJ). 
The filters were washed three times for 5 min each in 1 mM ammonium formate, once 
for 1 min in water, and once for 5 min in ethanol. The radioactivity was determined by 
scintillation counting. 
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3.4.2.4. Antiviral assays 
The anti-HIV activity was evaluated against the laboratory HIV-1 strain IIIB and 
HIV-2 strain ROD in human T-lymphocyte CEM cell cultures. Briefly, virus stocks 
were titrated in human T-lymphocyte CEM cells and expressed as the 50% cell culture 
infective dose (CCID50, 1 CCID50 being the virus dose required to infect 50% of the 
cell cultures). CEM cells were suspended in culture medium at  3 x 105 cells/ml and 
infected with HIV at  100 CCID50. Immediately after viral exposure, 100 µl of the 
cell suspension was placed in each well of a flat-bottomed microtiter tray containing 
various concentrations of the test compounds. After a 4-day incubation period at 37 
°C, the giant cell formation was microscopically determined. Compounds were tested 
in parallel for their potential cytostatic effects in uninfected CEM cell cultures.  
The other antiviral assays for herpes simplex virus type 1 (HSV-1) (KOS), HSV-2 
(G), VZV (YS) and CMV (Davis and AD-169) were based on inhibition of virus-
induced cytopathicity in HEL cell cultures. Confluent cell cultures in microtiter 96-
well plates were inoculated with 100 CCID50 of virus or 20 plaque forming units 
(VZV) in the presence of varying concentrations of the test compounds. Viral 
cytopathicity was recorded as soon as it reached completion in the control virus-
infected cell cultures that were not treated with the test compounds 
 
3.4.2.5. Spectrophotometric binding assay for TMPKmt 
TMPKmt activities were determined using the coupled spectrophotometric assay 
described by Blondin et al.
167
 using an Eppendorf ECOM 6122 photometer and a 
wavelength of 334 nm. The reaction medium (0.5 mL final volume) contained 50 mM 
Tris-HCl, pH 7.4, 50 mM KCl, 2 mM MgCl2, 0.2 mM NADH, 1 mM phosphoenol 
pyruvate, and 2 units each of lactate dehydrogenase, pyruvate kinase and nucleoside 
diphosphate kinase. The concentrations of ATP and dTMP were kept constant at 0.5 
and 0.05 mM, respectively, whereas the concentrations of analogues varied between 
0.01 and 2 mM. 
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4.1. Objectives 
2ʹ,3ʹ-β-D-Dideoxyapio-D-furanose nucleosides (ddANs, 4.1, Figure 4.1) were 
synthesized in the early 90s for their potential antiviral properties, but were found 
inactive. However, it was recently shown that the 3ʹ-O-phosphonomethylated A and T 
analogues 4.4 exhibit promising anti-HIV properties. Since these phosphonates act as 
bioisosteres of the phosphorylated species 4.5, we decided to reinvestigate the 
biological activity of these ddANs and expand their potential as antiviral agents by 
synthesizing the corresponding phosphoramidate prodrugs 4.6,
168
 which would ideally 
lead to the intracellular release of the parent nucleotide 4.5, thereby by-passing the 
often problematic first phosphorylation step in the conversion to the active 
triphosphate species. We envisioned a synthetic approach that would also give access 
to the known apionucleosides 4.3 and their 3ʹ-deoxy counterparts 4.2.  
 
Figure 4.1. Apionucleosides and their Phosphates 
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4.2. Reported Methods to Synthesize Useful Apiofuranose Intermediates 
Several methods are known for the preparation of apiofuranose intermediates or their 
3-deoxy analogues, suitable for the construction of the corresponding nucleosides. 
Carey et al. described the regioselective hydrolysis of the 3,5-O-isopropylidene 
moiety of 1,2:3,5-di-O-isopropylidene-α-D-apio-D-furanose (4.9) to access 4.10 in a 
single step (Method-1).
169
 Compound 4.9 is synthesized from the expensive 
commercially available material 4.7. An additional drawback of this method is that, 
the sulfuric acid catalyzed equilibration step gives the required product in low yield.  
 
Marquez and coworkers employed the explosive reagent diazomethane to convert 
ketone 4.11 to epoxide intermediate 4.12, which was then treated with sodium 
benzylalkoxide to open the spiro-oxirane to afford intermediate 4.13 (Method-2).
170
  
 
The very first synthesis of D-dideoxyapio-L-furanose nucleoside was realized by 
lipase catalyzed asymmetrization (Method-3).
16
 The method was modified and applied 
to the synthesis of both D-dideoxyapio-D- and L-furano nucleosides by Nair and 
coworkers via intermediate 4.14b. 
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A Barton-McCombie deoxygenation was used by Hammerschmidt et al. to synthesize 
3-deoxyapio sugar 4.18 (Method-4).
24
 Though straightforward, this method provides a 
mixture of D- and L-furanosides, thus lacking selectivity. 
 
Herdewijn et al. reported the formation of 3-deoxy-3-C-branched furanose 4.21a as a 
minor product while synthesizing pyranose nucleosides.
171
 The compound results 
from opening of bicyclic acetal 4.20. Compound 4.19 was accessed in five steps from 
suitably protected L-arabinofuranose. 
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Unlike the previously mentioned chiral pool strategies, Jung et al. used a de novo 
approach starting from allyl alcohol that was converted to (S)-glycidol (4.22), via 
Sharpless asymmetric epoxidation. The latter was converted to the 3-deoxy-apio-
furanose coupling partners 4.27a or 4.27b in good yields (Method-6).
27
 It should be 
noted that the method is not suitable for the simultaneous synthesis of the non-
deoxygenated apionucleosides in which we are also interested. 
 
Jin and coworkers reported a multistep protocol involving the volatile intermediate 
4.28 (Method-7).
26
 In our hands the Wittig reaction on ketone 4.11 turned out to be 
low yielding. The exomethylene compound 4.28 was stereoselectively dihydroxylated 
using osmium tetroxide, followed by dibutyltin oxide mediated selective benzylation. 
The authors claim that Barton-McCombie deoxygenation gave the 3-deoxy-D-apio-D-
furanose intermediate 4.32. Subsequent reactions with this deoxygenated product 
failed to produce the desired nucleosides. We discovered that Jin et al. used D-
galactose as starting material. Hence, they actually synthesized the enantiomer of 3.1, 
i.e. 1,2-O-isopropylidene-α-D-threofuranose (D-3.1). Based on careful analysis of the 
reported 
1H NMR data and their comparison with those of the two possible 3ʹ-epimers, 
we are confident that the stereochemistry of the deoxygenated product obtained by Jin 
et al. was wrongly assigned and actually corresponds to the L-apio isomer L-4.31 
(please refer to Scheme 4.1 & 4.7 for 4.31 and 4.32 respectively).  
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Because all previous methods suffer from limitations, we present an optimized 
procedure to arrive at the desired nucleosides. 
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4.3. Results and Discussion 
4.3.1. Chemistry 
4.3.1.1. Syntheses of α-D-apio-L-furanonucleosides 
 
 
Scheme 4.1. Synthesis of the D-apio D- and L-furanose coupling partners 4.35, 4.36 and 4.37. 
Reagents and conditions: (a) I2, PPh3, imidazole, toluene, 115 °C, 3h, 22%; (b) TEMPO, 
BAIB, CH2Cl2, rt, 3-4h, 90%; (c) BOMSnBu3, n-BuLi, THF, -78 °C, 2h, 68%; (d) (i) 80% aq. 
AcOH, 80 °C, 8h; (ii) Ac2O, DMAP, pyridine, 55 °C, 16h, 75%; (e) (i) NaH, CS2, MeI, THF, 
0 °C → rt, 1h; (ii) Et3B, Bu3SnH, toluene, rt, 3-4h, 68%; (f) (i) 80% aq. AcOH, 80 °C, 8h; (ii) 
Ac2O, DMAP, rt, pyridine, 4h, 57%; (g) (i) p-TSA, MeOH, rt, overnight; (ii) Ac2O, DMAP, 
pyridine, 0 °C → rt, 4h, 77%. 
 
1,2-O-isopropylidene-α-L-threose (3.1, Chapter 3), used as a starting material in this 
new route, was synthesized following a reported procedure. Initially, a synthetic route 
involving the iodo-compound 4.33 was planned, but the low yield in the first step 
rendered this protocol unattractive. Interestingly, screening of different oxidation 
methods to convert 3.1 to ketone 4.11 indicated that TEMPO-BAIB oxidation, which 
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is best known for oxidation of primary hydroxyl groups, was the most effective. 
Several variations of the polarity reversal concept were explored to introduce the 
desired carbon homologation. The reaction of benzyloxymethyl chloride in the 
presence of samarium iodide did not yield the desired product (Table 4.1), while the 
corresponding Grignard reaction gave 4.13 in disappointing yields (25%).
172
 
Nucleophilic attack of the ketone with lithiated benzyloxymethyltributyltin at -78 °C 
afforded 4.13 in a moderate yield (68%),
173
 which may be ascribed to the propensity 
of compound 4.11 to undergo self-condensation to the aldol dimer.
174
  
 
Table 4.1. Conditions for the conversion of compound 4.11 to 4.13 
Entry Reagent Additive Solvent/temp Yield 
1 BOMCl SmI2 (2.2 eq) THF/0 °C 0% 
2 BOM-MgCl HgCl2 (0.2 eq) THF/-78 °C 25% 
3 BOM-Sn(nBu)3, BuLi none THF/-78 °C 68% 
 
The stereochemistry of 4.13 was confirmed by the fact that its NMR spectra were in 
accordance with reported data
170
 as well as by a 2D 
1
H-
1
H NOESY experiment 
(Figure 4.2 and 4.3). The nOe interactions between the anomeric proton (δppm 5.76 
ppm) and 3-CH2 protons (δppm 3.46, 3.56), between 2-H (δppm 4.39) and 3-CH2, 
between 3-OH (δppm 2.85) and 4-Hα (δppm 3.71) and iPr-CH3 (δppm 1.58) are in 
agreement with the stereochemical assignment of 4.13. One-pot acid hydrolysis and 
acetylation of 4.13 gave the tri-acetylated apiose 4.35 in 75% yield in a 2:1 α/β 
anomeric ratio.  
Barton-McCombie deoxygenation of 4.13 afforded the 3-deoxy threo isomer 4.31, 
which is explained by radical quenching from the least hindered face, i.e. opposite to 
the isopropylidene comprising face.
175
 The stereochemistry of 4.31 was deduced by 
the absence of nOe for anomeric proton (δppm 5.83 ppm, Figure 4.2 and 4.4) with 3-
CH2 (δppm 3.69, 3.78) and the presence of relatively intense nOe cross-peaks between 
3-Hα (δppm 2.37-2.52) and 4-Hα (δppm 4.01) as compared to 4-Hβ (δppm 3.69), in 
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addition to intense nOe for 2-H (δppm 4.65) with anomeric proton and 3-H in 2D 
1
H-
1
H 
NOESY experiment. The structure was further confirmed by the synthesis of C3-
epimer (Scheme 4.7). The NMR data of 4.31 match with those reported by Jin et al., 
who incorrectly assigned those to the 3-deoxy erythro intermediate 4.32.  
Compound 4.31 was then hydrolyzed and acetylated to give 4.36 in a 4:1 anomeric 
ratio. The anomeric configuration was inferred from the anomeric proton coupling 
constants, i.e. 0 Hz for the β-isomer and 4.4 Hz for the α-isomer. However, this 
conversion lacked reproducibility, especially on a larger scale. To overcome this 
problem, methyl glycoside 4.37 was synthesized in two steps from 4.31 in 77% yield. 
β-assignment of the methoxy group in 4.37 is based on the coupling constant of the 
anomeric hydrogen (0 Hz).  
 
 
 
Figure 4.2. Observed nOe interactions for compound 4.13 and 4.31 
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Figure 4.3. 2D 
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1
H NOESY spectrum of compound 4.13  
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Figure 4.4. 2D 
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The diisopropylidene derivative of D-apio-D-furanose was purchased from Carbosynth 
(Compton, Berkshire, UK, Figure 4.5). However, in the course of our work we 
discovered that the chemical supplied was the diisopropylidene derivative of D-apio-L-
furanose 4.7 (Scheme 4.2).  
 
 
Figure 4.5. A snapshot of the Carbosynth website  
 
 
Scheme 4.2. Synthesis of D-apio-L-furanose coupling partner 4.38. Reagents and conditions: 
(a) CH3COOH-H2O (2:1), rt, 3 days, 83%; (b) Bu2SnO, toluene, 140 °C, 2h, TBAB, BnBr, 
100 °C, 18h, 94%; (c) (i) 80% aq. AcOH, 80 °C, 8h; (ii) Ac2O, DMAP, pyridine, 55 °C, 16h, 
75%.  
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The 3,5-O-isopropylidene was removed selectively according to the procedure by 
Carey et al. and O-benzyl protection was performed as reported by Marquez et al. The 
1
H NMR spectrum of 4.29 proved identical to that obtained by Jin et al. (Section 4.3, 
method-7). In addition, the relative stereochemistry was confirmed by a 2D 
1
H-
1
H 
NOESY experiment (Figure 4.6 and 4.7). As expected and in contrast to 4.13, the 3-
CH2 protons (δppm 3.54, 3.80) failed to show a nOe interaction with the anomeric (δppm 
5.98) and C-2 (δppm 4.35) protons; on the other hand the 3-OH (δppm 2.76) showed 
interactions with 2-H, 4-H, 3-CH2 but not with the isopropylidene protons (δppm 1.48). 
These nOe peaks fit with an orientation of the 3-CH2 that is opposite to that of the 
anomeric and C-2 protons, i.e. compound 4.29. Hydrolysis and acetylation of 4.29 
gave 4.38 in good overall yield. 
 
 
Figure 4.6. Observed nOe interactions for compound 4.29 
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Figure 4.7. 2D 
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Having 4.35, 4.36, 4.37 and 4.38 in hand, we set out different coupling reactions 
between 4.36 or 4.37 and silylated thymine or N
6
-benzoyladenine under Vorbrüggen 
conditions (Table 4.2). 
 
 
Table 4.2. Vorbrüggen coupling conditions. 
Entry Sugar Silylated 
nucleobase 
Reagent Conditions Product 
(yield)
a
 
1 4.36 T TMSOTf 1,2-(CH2)2Cl2, rt, 4h 4.39 (quant) 
2 4.36 N
6
-BzA TMSOTf 1,2-(CH2)2Cl2, 40 °C, 48h 4.40 (32%)
b
 
3 4.37 T TMSOTf 1,2-(CH2)2Cl2 or CH3CN, rt, 4h 4.42
c
 
4 4.37 T SnCl4 CH3CN, rt, 4h 4.42
c
 
5 4.37 N
6
-BzA SnCl4 CH3CN, rt, 4h - 
6 4.37 T TMSOTf
d
 CH3CN, 150 °C, 5 min. 
microwave 
4.39 
e
 + β-
anomer (78%)
 
 
7 4.37 N
6
-BzA TMSOTf
d
 CH3CN, 150 °C, 5 min. 
microwave 
4.40 (60 %) 
a
 isolated yields, “-“ indicates an unresolvable reaction mixture. 
b
 the 2ʹ-acetyl analogue of 4.41 was isolated in equal amount. 
c
 two diastereomers observed by TLC and HRMS analysis. 
d
 0.2 equivalents of TMSOTf. 
e 
inseparable 1:2 mixture of 4.43 and its α-isomer. 
 
Whereas the acetate anomer 4.36 reacted smoothly at room temperature in 4h with 
silylated thymine in the presence of TMSOTf to give 4.39 in quantitative yield, its 
coupling with N
6
-benzoyladenine proved to be more challenging. The desired 
coupling product 4.40 was obtained in 32% yield by heating the reaction mixture at 
40 °C for 48h. This low yield resulted from the formation of an equal amount of an 
unknown isomer. 
1
H NMR of this isomer suffered from peak broadening and 
indicated the presence of minor impurities. Its UV spectrum (λmax = 331.9 nm) and 
13
C 
chemical shifts are characteristic of an N
1
-isomer.
158
 After treatment with methanolic 
ammonia for two days, a product was formed that was confidently identified as 4.41 
(Figure 4.8). The binding topology of the adenine base to the sugar was determined 
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with NMR as follows. A correlation between H-1ʹ (δppm 6.61) and C-2 (δppm 141.83/ 
A7) in a 2D 
1
H-
13
C HMBC spectrum indicates that the adenine is either bound to N-1 
or N-3 (Figure 4.9). In the 2D 
1
H-
1
H NOESY spectrum (Figure 4.8 and 4.10), strong 
nOe cross-peaks were detected between the ortho protons of benzoyl (δppm 8.22) and 
protons of the sugar moiety, notably H-1ʹ, H-2ʹ (δppm 4.68) and 2ʹ-OH (δppm 4.25). 
These nOe’s are improbable if the base would be attached to N-3, since in this case 
the benzoyl group and the sugar moiety would be positioned para relative to one 
another and be spatially too far apart. 
Coupling reaction between methylglycoside 4.37 and silylated thymine (Table 4.2; 
entries 3 and 4), using either TMSOTf or SnCl4, resulted in the formation of two main 
products that gave spots with comparable intensity on TLC. ESI-HRMS analysis 
allowed identifying these products as the two diastereomers of 4.42. The condensation 
reaction of methylglycoside 4.37 with silylated benzoyladenine in the presence of 
anhydrous SnCl4 gave an unresolvable reaction mixture. 
 
Figure 4.8. Byproducts or deprotected forms of products formed during Vorbrüggen 
coupling and observed nOe interactions confirming structure 4.41. 
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Figure 4.9. Overlay of the HSQC (blue) and HMBC 8 Hz (red) spectra of 4.41 (top) 
and zoom on the A2 and A7 cross-peaks (bottom).
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Figure 4.10. 2D 
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Vorbrüggen coupling of the methyl anomer 4.37 and silylated thymine under 
microwave irradiation resulted in an inseparable mixture of two isomeric products in a 
2:1 ratio.
176
 Unfortunately, removal of the acetyl and benzyl protecting groups did not 
facilitate their separation. The 
1
H NMR spectrum of the minor isomer showed a larger 
splitting of the anomeric hydrogen doublet (3.2 Hz) compared to the major compound 
(2.0 Hz), indicating β-oriented pyrimidine moiety 4.43 (Figure 4.8). The gHMBC 
confirmed the C1ʹ-N1 attachment, while 2D NOESY ratified the relative 
stereochemistry. Conversely, microwave-assisted coupling between 4.37 and silylated 
N
6
-benzoyladenine gave only the desired α-nucleoside 4.40 in 60% isolated yield. 
Clearly, the microwave-assisted coupling with the methyl glycoside is the method of 
choice to prepare the adenine nucleoside. 
 
Scheme 4.3. Syntheses of α-D-apio-L-furanonucleosides 4.53a,b and their 3ʹ-deoxy 
counterparts 4.52a,b. Reagents and conditions: (a) appropriate silylated base, 1,2-(CH2)2Cl2, 
TMSOTf, rt, 4h, 85% for 4.44; (b) appropriate silylated base, CH3CN, 0.2 eq. TMSOTf, MW 
300W, 0 °C → 150 °C (3 min), 150 °C (5 min), 40% for 4.45 and 6% for 4.46; (c) NH3, 
MeOH, rt, 4-48h, 75-96%; (d) H2, Pd/C, MeOH, rt, overnight, 86% for 4.52a from 4.47 and 
71% for 4.53a from 4.49;(e) (i) Pd(OH)2, HCOOH-MeOH (1:1 for 4.51, 4.52b from 4.48 and 
1:9 for 4.53b from 4.50), 55 °C, 5-8h; (ii) NH3, MeOH, rt, 3h, 80% over two steps for 4.51, 
4.52b and 4.53b.  
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Reaction of the triacetyl apiose 4.38 with silylated thymine under classical 
Vorbrüggen conditions provided 4.44 in very good yield (Scheme 4.3). Microwave 
conditions were employed to couple 4.38 with silylated N
6
-benzoyladenine to afford 
4.45 and 2ʹ-OTMS analogue 4.46 in 40% and 6% yield, respectively. The coupling 
products 4.39, 4.40, 4.44 and 4.45 were treated with ammonia in MeOH to provide the 
desired deacetylated products 4.47-50. Debenzylation of thymine nucleosides 4.47 and 
4.49 to give the 3ʹ-deoxyapionucleoside 4.52a and apionucleoside 4.53a was realized 
by palladium-catalyzed hydrogenation. The same reaction condition on adenosines 
4.48 and 4.50 was ineffective, as well as the use of cyclohexene and ammonium 
formate. This result led us to use formic acid as hydrogen source to give 4.52b and 
4.53b. The byproduct 4.51 was converted back to 4.52b after treatment with ammonia 
in MeOH.  
 
Scheme 4.4. Synthesis of 2ʹ,3ʹ-dideoxy-α-D-apio-L-furanosides 4.61a,b and their ProTides 
4.62a,b. Reagents and conditions: (a) TBDMSCl, imidazole, DMF, rt, overnight, 95% for 
4.54 and 82 % for 4.55; (b) (i) O-p-tolylchlorothiono formate, DMAP, CH3CN, 0 °C → rt, 4h; 
(ii) Bu3SnH, AIBN, toluene, reflux, 2-3h, 70-88% over two steps; (c) H2/Pd-C, MeOH, rt, 
overnight, 63% from 4.56 to 4.61a; (d) TBAF, THF, 0 °C → rt, 4h, 89% 4.58 to 4.61a; (e) 
NH4F, MeOH, 50 °C, 2 days, 87% 4.59 to 4.61b; (f) t-butyl magnesium chloride, anh. THF, 
rt, overnight, 22% for 4.62a; anh. NMI, anh. THF, anh. pyridine, rt, 2 days, 15% for 4.62b.  
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Initially, the benzyl protected nucleosides 4.47 and 4.48 were subjected to a standard 
Barton- McCombie protocol to give the 2ʹ-deoxygenated products 4.56 and 4.57 
(Scheme 4.4). Different hydrogen sources were explored for the subsequent Pd-
catalyzed debenzylation, but only the thymine compound 4.56 could be converted to 
the desired product 4.61a with curtailed reproducibility in yield and reaction time. 
This was attributed to catalyst poisoning by remaining sulfur residues. Hence, we 
swapped to TBDMS as a protecting group to give 4.54 and 4.55 from 4.52a and 4.52b, 
respectively, in excellent yields. Compounds 4.54 and 4.55 were submitted to Barton-
McCombie deoxygenation after conversion to the corresponding xanthates with O-p-
tolyl chlorothionoformate in the presence of DMAP. These xanthates were isolated 
after a brief workup and heated in toluene with tributyltin hydride and 
azobisisobutyronitrile to give dideoxycompounds 4.58 and 4.59. The TBDMS group 
of 4.58 and 4.59 was removed using TBAF in THF. However, the removal of 
tetrabutylammonium residue to get pure adenosine derivative 4.61b was not 
satisfactory, hence an alternative method using NH4F in MeOH at 55 °C for 2 days 
gave 4.61b in 87% isolated yield. 
Nucleoside monophosphate prodrugs (ProTides) of compounds 4.61a and 4.61b were 
prepared using two different methods. 4.62a was prepared by coupling 4.61a with the 
phosphorochloridate 3.33, using tert-butyl magnesium chloride as hydroxyl activator 
in anhydrous THF. On the other hand, 4.61b was coupled with 3.33 to provide 4.62b, 
using in this case N-methylimidazole as a base in a mixture of anhydrous THF and 
pyridine as solvents. In both cases, the desired compounds were obtained as a mixture 
of two diasteroisomers resulting from the two possible configurations of the 
phosphorous stereo center, as confirmed by the presence of two equal height peaks in 
the 
31
P NMR spectrum. Moreover, in order to study the effectiveness of 4.61b as a 
potential HIV RT inhibitor, the 2ʹ,3ʹ-dideoxy-α-D-apio-L-furanonucleoside 4.61b was 
also converted to its corresponding triphosphate 4.65 following the method of Caton-
Williams (Scheme 4.5)
177
. 
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Scheme 4.5. Synthesis of 2ʹ,3ʹ-dideoxy-α-D-apio-L-furanoadenosine triphosphate 4.65. 
Reagents and conditions: (a) (i) 4.63, 4.64, Bu3N, anh. DMF, rt, 1.5h; (ii) 4.61b, anh. DMF, 
rt, 1.5h; (iii) I2 (3% in 9:1 Py-H2O), rt, 20 min, H2O, rt, 1.5h, 48% over three steps.  
 
4.3.1.2. Syntheses of β-D-apio-D-furanonucleosides 
Having established that the nucleosides synthesized in section 4.4.1.1 are all L-
furanosides, we envisaged easy access to 2ʹ,3ʹ-dideoxy-β-D-apio-D-furanose 
nucleosides 4.1a,b involving Corey-Winter olefination and stereoselective 
hydrogenation as key steps (Scheme 4.6). During catalytic hydrogenation the syn-
addition of the hydrogen atoms to the double bond is anticipated to occur from the 
face opposite to the one containing the nucleobase.
178
 A combination of classical and 
microwave assisted Vorbrüggen coupling on 4.35, followed by deprotection and 
subsequent thiocarbonyl imidazole treatment provided 4.68 and 4.69 for Corey-Winter 
olefination. Unfortunately, the adenine derivative degraded in trimethylphosphite at 
120 °C. The thymine derivative did gave the desired product 4.70 in excellent yields 
but the hydrogenation reaction resulted in a mixture of diastereomers 4.1a and 4.61a 
that are inseparable by column chromatography. This forced us to find an alternate 
method to prepare the target molecules. 
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Scheme 4.6. Synthesis of β-D-apio-D-furanonucleosides 4.3b and dideoxy congener 4.1a. 
Reagents and conditions: (a) (i) silylated thymine, 1,2-(CH2)2Cl2, TMSOTf, rt, 4h, for 4.66 or 
silylated N
6
-BzA, CH3CN, 0.2 eq. TMSOTf, MW 300W, 0 °C → 150 °C (3 min), 150 °C (5 
min), for 4.67 (ii) 7N NH3-MeOH, rt, 4-48h, 97% for 4.66 and 46% for 4.67 over two steps; 
(b) thiocarbonyl diimidazole, DMF, 80 °C, 90 min, 89% for 4.68 and 78% for 4.69; (c) 
P(OCH3)3, 120 °C, 6h, 90 %; (d) H2, Pd/C, MeOH, rt, 4h, 89%; (e) (i) Pd(OH)2, HCOOH-
MeOH (1:4), 55 °C, 5h (ii) NH3, MeOH, rt, 3h, 89%. 
 
Carey and co-workers found that 1,2-O-isopropylidene-D-apio-L-furanose (4.8) 
equilibrates into the D- and L-furanose form in acidic acetone (section 4.3, Method-1), 
which inspired us to use similar conditions for the epimerization of 4.30. We 
hypothesized that the absence of the 3-hydroxyl group would eliminate the repulsive 
dipole interaction with oxygen at position 2, while the steric interaction of the 
hydroxymethyl group with the 2-oxygen could result in a favorable D-furano isomer 
ratio. Hence compound 4.31 was debenzylated and then treated with acetone-conc. 
H2SO4 to afford the desired epimer 4.71 in 73% yield (Scheme 4.7). It is noteworthy 
that 3 equilibrium cycles were required to convert most of the starting material to the 
desired D-furano epimer. Benzylation of the compound 4.71 gave 4.32 and the 
structure of this was confirmed by 2D 
1
H-
1
H NOESY experiment (Figure 4.11 and 
4.12). The following nOe cross-peaks confirmed the stereochemistry: (a) both the 
anomeric (δppm 5.79) and the C-2 (δppm 4.56) protons give nOe’s with 3-CH2 (δppm 
3.37); (b) 3-H (δppm 2.56) interacts strongly with 4-Hα (δppm 4.09) and only weakly 
Turning Apionucleos(t)ides into Antivirals 
105 
with 4-Hβ (δppm 3.83). Hydrolysis and acetylation of this isomer rendered 3-deoxy-D-
apio-D-furanose derivative 4.72 in good yields. 
 
Scheme 4.7. Synthesis of D-apio-D-furanose coupling partner 4.72 via differential cyclization. 
Reagents and conditions: (a) H2, Pd/C, MeOH, rt, 5h, 90%; (b) acetone, conc. H2SO4, rt, 1.5h, 
Na2CO3, 45 min, 73% (after 3 cycles); (c) DMF, NaH, 0°C, 10 min, BnBr, 0°C → rt, 18h, 
95%; (d) (i) 80% aq. AcOH, 80 °C, 18h; (ii) pyridine, Ac2O, rt, 18h, 79%. 
 
 
Figure 4.11. Notable nOe interactions observed for compound 4.32
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Figure 4.12. 2D 
1
H-
1
H NOESY spectrum of compound 4.32
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Having the glycosyl donor 4.72 at hand, coupling with thymine and benzoyladenine 
towards the intended products 4.2a,b and 4.1a,b was performed as before (Scheme 
4.8). It is noteworthy that, compared to the L- furano series, Vorbrüggen reaction 
generally gave lower yields of the coupling products. Moreover, coupling of 4.72 with 
silylated benzoyladenine produced significant amount of α-isomer (11%) with only 28% 
of desired β-nucleoside. 
 
Scheme 4.8. Syntheses of 3ʹ-deoxy-β-D-apio-D-furanonucleosides 4.2a,b and their 2ʹ,3ʹ-
dideoxy counterparts 4.1a,b. Reagents and conditions: (a) (i) silylated thymine, 1,2-
(CH2)2Cl2, TMSOTf, rt, 4h, or silylated N
6
-BzA, CH3CN, 0.2 eq. TMSOTf, MW 300W, 0 °C 
→ 150 °C (3 min), 150 °C (5 min); (ii) NH3, MeOH, rt, 4-48h, 60% for 4.73, 28% of 4.74 
and 11% of its α-anomer;(b) H2, Pd/C, MeOH, rt, overnight, 86% for 4.2a or (i) Pd(OH)2, 
HCOOH-MeOH (1:4), 18h; (ii) NH3, MeOH, rt, 3h, 88% over two steps for 4.2b; (c) 
TBDMSCl, imidazole, DMF, rt, 18h, 88% for 4.75 and 82% for 4.76; (d) (i) O-p-
tolylchlorothiono formate, DMAP, CH3CN, 0 °C → rt, 4h; (ii) Bu3SnH, AIBN, toluene, 
reflux, 2-3h, 90% for 4.77 and 81% for 4.78 over two steps; (e) NH4F, MeOH, 50 °C, 2 days, 
86% for 4.1a and 94% for 4.1b. 
 
Compounds 4.1 are reported to be inactive against viruses. To examine the HIV 
inhibition potential of a monophosphate prodrug, 4.1b was converted to its 
triphosphate 4.79 (Scheme 4.9). The reaction of Van Boom’s reagent (4.63) and 
pyrophosphate (4.64) resulted in a cyclic diphosphophosphite salicylate, which was 
reacted with 4.1b followed by oxidation and hydrolysis using iodine/H2O gave 
triphsophate 4.79.
177
 The yield of this conversion was lower than observed for the L-
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furano isomer. 
1
H NMR indicated the formation of an internal salt. The 
31
P NMR of 
this compound is uncharacteristic of triphosphate salts, as it showed two broad peaks 
(figure 4.13, red). The addition of 2 equivalents of triethylamine disrupted this internal 
salt leading to the appearance of the characteristic triphosphate peaks (figure 4.13, 
blue). 
 
Scheme 4.9. Synthesis of 2ʹ,3ʹ-dideoxy-β-D-apio-D-furanoadenosine triphosphate 4.79. 
Reagents and conditions: (a) (i) 4.63, 4.64, Bu3N, anh. DMF, rt, 1.5h; (ii) 4.61b, anh. DMF, 
rt, 1.5h; (iii) I2 (3% in 9:1 Py-H2O), rt, 20 min, H2O, rt, 1.5h, 21% over three steps. 
Figure 4.13. 
31
P-NMR of 4.79 before (red) and after triethylamine treatment (blue). 
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The benzyl/isopropyl alaninyl phosphoramidate prodrugs of the 2ʹ,3ʹ-dideoxy-β-D-
apio-D-furanonucleoside 4.1a,b were synthsized by reacting the latter with the 
appropriate phosphochloridate (3.33/4.60) using slightly modified reaction condition 
employed for the synthesis of 4.62b. A prepTLC purification of the reaction mixture 
gave ProTides 4.6a,b and 4.80a,b in low to excellent yields (Scheme 4.10).  
 
Scheme 4.10. Synthesis of 2ʹ,3ʹ-dideoxy-β-D-apio-D-furanonucleoside ProTides 4.6a,b and 
4.80a,b. Reagents and conditions: (a) anh. NMI, anh. THF, anh. pyridine, rt, 2 days, 26-88% . 
 
4.3.2. Pharmacological evaluation 
4.3.2.1. Enzymatic assay using carboxypeptidase Y 
The putative mechanism of activation of ProTides (Figure 4.14, 4.16) involves an 
enzymatic cleavage of the ester (a) mediated by an esterase- or carboxypeptidase-type 
enzyme followed by spontaneous cyclisation to release the aryl moiety (b) and to open 
the unstable mixed anhydride ring by water (c) providing the intermediate metabolite 
4.83. The cleavage of the phosphorous-nitrogen bond (d) requires a phosphoramidase 
type enzyme, perhaps related to human HINT-1, to release the monophosphate form 
(4.84). In order to investigate the bioactivation of L-furano ProTides 4.62a,b and D-
furano ProTide 4.6a, these compounds were incubated with carboxypeptidase Y 
enzyme in acetone-d6 and Trizma buffer (pH = 7.6) recording a 
31
P NMR at specific 
intervals. 
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Figure 4.14. Putative mechanism of bioactivation for L-furano ProTides. 
 
 
Figure 4.15. Bioactivation study for L-furano compounds 4.62a (Panel A) and 4.62b 
(Panel B) using carboxypeptidase Y enzyme. 
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Compound 4.62a (
31
P NMR = 3.3 and 3.5 ppm, Figure 4.15a) showed a fast 
conversion to the intermediate metabolite L-4.81a (
31
P NMR = 4.7 and 4.4 ppm) with 
its formation within 5 minutes after the addition of the enzyme, which is then 
converted to compound L-4.83a (
31
P NMR = 7.0 ppm). Interestingly, one of the 
diastereoisomers (
31
P NMR = 3.3 ppm) seems to be more slowly converted compared 
to the other. In fact, after 18h, it is still present, even after the addition of an extra 
portion of enzyme, while the diastereomer at 3.5 ppm appears fully converted after 
about 10 minutes. In contrast, compound 4.62b (
31
P NMR = 3.2 and 3.4 ppm, Figure 
4.15b) shows a near complete conversion of both diasteroisomers to the metabolite L-
4.83a (
31
P NMR = 7.0 ppm) through the intermediate L-4.81a (31P NMR = 4.5 ppm) 
after 1 hour, although there again exists a clear difference in kinetics. From this study 
it thus appears that both compounds are rapidly converted to the intermediate 
metabolite 4.83, with a slightly better conversion rate for the adenine derivative 
compared to the thymine derivative.  
 
Figure 4.16. Putative mechanism of bioactivation for D-furano ProTides. 
 
Both diastereoisomers of the D-furano ProTide 4.6a were processed to intermediate D-
4.82a within 20 minutes followed by the formation of phosphoramide D-4.83a within 
an hour. From figure 4.17 it is evident that 4.6a lacked pronounced diastereomeric 
discrimination by carboxypeptidase enzyme. Following the trend for adenine analogue 
4.62b, we assume that 4.6b would be processed at the least with the rate of thymine 
analogue 4.6a.  
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Figure 4.17. Bioactivation study for D-furano compound 4.6a using carboxypeptidase 
Y enzyme. 
 
4.3.2.2. DNA chain termination study using HIV Reverse Transcriptase  
Another prerequisite for ProTides to show good anti-HIV activity is that their 
corresponding triphosphates are good alternative substrates for RT. Hence, the ability 
of triphosphates 4.65/79 to act as a substrate of HIV-RT was investigated in a primer-
template assay.43 The template has overhanging T residues to test incorporation of the 
modified A nucleotide. Figure 4.18 clearly shows that both nucleotides 4.65 and 4.79 
function as chain terminators. The D-furano analogue 4.79 is more efficiently 
incorporated than 4.65, but compared to natural substrate dATP, requires a higher 
concentration and longer time for complete incorporation. The characteristics of 4.79 
towards HIV RT render the corresponding ProTides potentially useful HIV inhibitors. 
4.6a 
D-4.81a D-4.83a 
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Figure 4.18. Chain termination through incorporation of 4.65 and 4.79 by HIV RT. The 
DNA polymerization mixtures containing 125 nM annealed (labeled) primer-template 
complex, were treated with 125, 500, or 1000 µM of modified triphosphate (4.65/ 4.79) and 
0.03 U.µl
-1
 HIV RT and incubated at 37°C. Aliquots were taken after 15, 30 and 60 min. In 
the control reaction, 50 µM of natural dATP was used. Samples were separated on a 0.4 mm 
20% denaturing polyacrylamide gel and the bands visualized using phosphorimaging. 
 
4.3.2.3. Antiviral and other data  
2ʹ,3ʹ-Dideoxy-β-D-apio-D-furanoadenosine phosphoramidate ProTides 4.6b and 4.80b 
combine potent anti-HIV activity with reasonable selectivity (Table 4.3). The 
benzylester 4.6b exhibits anti-HIV activity comparable or superior to the acyclic 
nucleoside phosphonate PMPA, but are 10-100 fold less potent than nucleoside 
analogues in therapeutic use. The ProTides 4.6a,b, 4.62a,b and 4.80a,b are weak to 
moderate inhibitors of murine leukemia (L1210), human T-lymphocyte (CEM) and 
human cervix carcinoma (HeLa) cell proliferation (Table 4.4). Compound 4.61a 
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inhibited 1 µM dThd phosphorylation by the following thymidine kinases: TK-2 (IC50: 
150±78 µM), HSV-1 TK (IC50: 117±52 µM) and VZV TK (IC50: 271±59 µM) and 
caused moderate inhibition of M. tuberculosis thymidylate kinase (Ki: 48 µM). 
 
Table 4.3. Anti-HIV property of ProTides 4.6a,b and 4.80a,b 
 EC50 in MT-4 cells (µM)  EC50 in CEM cells (µM) 
 HIV-1 
(NL4.3) 
HIV-2 
(ROD) 
CC50   HIV-1 
(IIIb) 
HIV-2 
(ROD) 
4.6a  >250 - >250 - 196  - - 
4.80a >250 - >250 - >250  - - 
4.6b 0.5 0.5 1 1 93  0.5 1.5 
4.80b 26 2 27 21.5 >250  7.5 38 
PMPA  1.5 2 1 1 >250  3 2.5 
‘-‘ = not performed 
 
Table 4.4. Inhibitory effects of compounds on the proliferation of cancer 
a
 
 L1210  CEM HeLa 
4.6a  113 ± 21 108 ± 11 159 ± 32 
4.6b  110 ± 17 80 ± 4 53 ± 11 
4.62a 167 ± 85 113 ± 3 177 ± 103 
4.62b 79 ± 4 73 ± 5 173 ± 58 
4.80a > 250 > 250 > 250 
4.80b 226 ± 35 204 ± 3 ≥ 250 
a
 IC50 in µM, murine leukemia cells (L1210/0), human T-lymphocyte cells 
(CEM/0) and human cervix carcinoma cells (HeLa)  
 
The L-furano 3ʹ-deoxyapiose nucleosides 4.52a,b and dideoxynucleosides 4.61a,b 
failed to show significant inhibitory activity when tested against HIV-1,2 and panel of 
viruses or cytotoxicity in cell culture. Likewise, the 3ʹ-deoxy-β-D-apio-D-furano 
nucleosides 4.2a,b and dideoxynucleosides 4.1a,b also lacked activity against HIV-
1,2 and cancer proliferation. The inactivity of thymine analogue prodrugs 4.6a and 
4.80a could be due to inefficient metabolism to corresponding monophosphate by 
HINT-1 type phosphoramidase enzyme, or the apioNMP/NDP is a poor substrate for 
the corresponding NMPKs/NDPKs. Alternatively, if efficiently activated to the 
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corresponding 2ʹ,3ʹ-dideoxy-β-D-apio-D-furanothymidine triphosphate, the latter may 
be inefficiently incorporated by HIV RT. 
 
4.4. Conclusions 
A synthetic methodology was developed to create a family of D-apio-D- and L-furano 
nucleosides, their 3ʹ-deoxy- and 2ʹ,3ʹ-dideoxy-analogues. The latter were also 
converted to some representative ProTides. The 2ʹ,3ʹ-dideoxy-β-D-apio-D-
furanoadenosine phosphoramidate prodrugs showed promising activity against HIV-
1,2. These results are in line with the observation that the triphosphate of 2ʹ,3ʹ-
dideoxy-β-D-apio-D-furanoadenosine is readily accepted by HIV RT and acts as a 
DNA chain terminator. The other nucleosides or their prodrugs were neither toxic nor 
active against a panel of viruses and cancer cell lines.  
 
4.5. Experimental Section 
4.5.1. Synthesis  
All reagents were from standard commercial sources and of analytic grade. Dry 
solvents were obtained directly from commercial sources and stored on molecular 
sieves. All reactions were carried out under argon atmosphere using dry solvents, 
unless specified otherwise. Room temperature or rt referes to 25±5 °C. Precoated 
Merck silica-gel F254 plates were used for TLC. The spots were examined under 
ultraviolet light at 254 nm and further visualized by sulphuric acid-anisaldehyde spray 
or CAM spray. Column chromatography was performed on silica gel (40-63 µm, 60 
Å) or on Reveleris flash chromatography system. NMR spectra were recorded on a 
Varian Mercury 300 MHz or a Bruker Avance II 700 MHz spectrometer. Chemical 
shifts are given in ppm (δ), calibrated to the residual solvent signals or TMS. Exact 
mass measurements were performed on aWaters LCT PremierXETMTime of flight 
(TOF) mass spectrometer equipped with a standard electrospray ionization (ESI) and 
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modular LockSpray TM interface. Samples were infused in a CH3CN/H2O (1:1v/v) 
mixture at 10 mL/min. The microwave reactions were carried out in Milestone 
MicroSYNTH Advanced Microwave Synthesis Labstation, equipped with 2 X 800 W 
magnetrons (effective maximum output 1500W pulsed/continuous), an optical fiber 
temperature sensor, a pressure sensor, in continues power mode in a closed PTFE 
vessel. For nucleosides, NMR signals of sugar protons and carbons are indicated with 
a prime, and signals of base protons and carbons are given without a prime.  
3-Iodo-1,2-O-isopropylidene-α-D-erythrofuranose (4.33): Compound 3.1 (500 mg, 
3.1 mmol), triphenylphosphine (1.22 g, 4.65 mmol) and imidazole (316 mg, 4.65 
mmol) was dissolved in anhydrous toluene (25 mL) under inert atmosphere. To this at 
115 °C was added iodine (945 mg, 3.72 mmol) portion-wise and the mixture was 
stirred at this temperature for 3h. After the reaction mixture has cooled, 10% 
aq.Na2S2O3 was added. The products extracted in ethylacetate, dried over anhydrous 
MgSO4, filtered and evaporated. The residue was purified by column chromatography 
using 5-10% ethylacetate in hexanes to afford title compound 4.33 (190 mg, 22%) as a 
white solid. 
1
H NMR (300 MHz, CDCl3) δ ppm 1.31 (s, 3H, CH3), 1.49 (s, 4H, CH3), 
3.74 - 3.92 (m, 2H, 3,4-H), 3.95 - 4.03 (m, 1H, 4-H), 4.52 (t, J = 3.66 Hz, 1H, 2-H), 
5.74 (d, J = 3.51 Hz, 1H, 1-H). 
13
C NMR (75 MHz, CDCl3) δ ppm 17.21 (3-C), 25.34 
(CH3), 25.44 (CH3), 71.35 (4-C), 79.03 (2-C), 102.84 (1-C), 110.78 (C(CH3)2). 
3-Oxo-1,2-O-isopropylidene-α-D-erythrofuranose (4.11): To a solution of 
compound 3.1 (1.0 g, 6.24 mmol) in anhydrous CH2Cl2 (12.5 mL) was added bis-
acetoxyiodobenzene (BAIB, 2.41 g, 7.5 mmol) followed by (2,2,6,6-
tetramethylpiperidin-1-yl)oxyl (TEMPO, 195 mg, 1.25 mmol) at room temperature 
under an argon atmosphere. The mixture was stirred at room temperature for 4h. The 
contents of the reaction was directly loaded on silica-gel and eluted with 30% EtOAc-
hexanes to afford pure product 4.11 (890 mg, 90%) as a white solid. 
1
H NMR (300 
MHz, CDCl3) δ ppm 1.35 (s, 3H, CH3), 1.44 (s, 3H, CH3), 4.03 (dd, J = 4.06, 17.57 
Hz, 1H, 4-H), 4.29 (s, 1H, 2-H), 4.32 (dd, J = 0.59, 17.57 Hz, 1H, 4-H), 6.02 (d, J = 
4.39 Hz, 1H, 1-H). 
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1,2-O-Isopropylidene-5-(O-benzyl)-α-D-apio-D-furanose (4.13): To a stirring 
solution of benzyloxymethyltributlytin (BOMSnBu3, 5.93 g, 14.4 mmol) in dry THF 
(35 mL) at -78 °C under inert condition, was added dropwise n-butyllithium (1.6M in 
hexanes,19.5 mL, 31.3 mmol) and stirred for additional 1h. To this mixture was then 
added dropwise a solution of compound 4.11 (1.9 g, 12.02 mmol) in 10 mL THF and 
stirred at -78 °C for 3h. The reaction was quenched with saturated NH4Cl solution and 
by vigorous stirring. EtOAc (100 mL) was then added to facilitate the layer 
separation. Organic layer was separated and the aqueous layer was extracted twice 
with EtOAc (50 mL). Combined organic layers were dried over anhydrous MgSO4 and 
evaporated under reduced pressure. The residue was purified by column 
chromatography eluting with 17% EtOAc-hexanes to afford 4.13 (2.3 g, 68%) as a 
white solid. 
1
H NMR (300 MHz, CDCl3) δ ppm 1.37 (s, 3H, CH3b), 1.58 (s, 3H, 
CH3a), 2.85 (s, 1H, 3-OH), 3.46 (d, J = 10.25 Hz, 1H, 5-H), 3.56 (d, J = 10.25 Hz, 1H, 
5-H), 3.71 (d, J = 9.08 Hz, 1H, 4-Ha), 3.80 (d, J = 9.08 Hz, 1H, 4-Hb), 4.39 (d, J = 
3.81 Hz, 1H, 2-H), 4.54 - 4.71 (m, 2H, CH2Ph), 5.76 (d, J = 4.10 Hz, 1H, 1-H), 7.27 - 
7.40 (m, 5H, CH2Ph). 
1,2,3-Tri-(O-acetyl)-5-(O-benzyl)-α/β-D-apio-D-furanose (4.35): A solution of 4.13 
(2.5 g, 8.92 mmol) in 80% aq. acetic acid (25 mL) was stirred at 80 °C for 8h. The 
reaction mixture was evaporated to give the crude intermediate as syrup. This syrup 
was dissolved in pyridine (20 mL) and DMAP was added (100 mg) followed by acetic 
anhydride (10 mL, 106 mmol). The solution was stirred at 55 °C for 16h. Then, the 
solvent was removed under vacuum and the resulting residue was partitioned between 
EtOAc and water. Organic layer separated, combined organic layer was washed with 
brine, dried over sodium sulfate, and evaporated. The residue was purified by silica-
gel column chromatography (15-20% EtOAc-hexanes) to yield 4.35 (2.45 g, 75%) as 
a colorless oil as a mixture of α + β isomers (2:1). 1H NMR (300 MHz, CDCl3) δ ppm 
1.96 (s, 3H, major), 2.08 (s, 3H, major), 2.08 (s, 2H, minor), 2.09 (s, 1H, minor), 2.10 
(s, 3H, major), 3.75 (d, J = 9.67 Hz, 0.47H, minor), 3.89 (d, J = 10.54 Hz, 1H, major), 
3.96 (d, J = 9.67 Hz, 0.5H, minor), 4.05 (d, J = 10.54 Hz, 1H, major), 4.22 (d, J = 
10.25 Hz, 1H, major), 4.26 (d, J = 10.54 Hz, 0.52H, minor), 4.32 (d, J = 10.54 Hz, 
0.5H, minor), 4.34 (d, J = 10.25 Hz, 1H, major), 4.51 - 4.62 (m, 3H, major & minor), 
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5.42 (d, J = 4.69 Hz, 0.44H, minor), 5.49 (d, J = 1.17 Hz, 1H, major), 6.08 (d, J = 1.17 
Hz, 1H, major), 6.33 (d, J = 4.69 Hz, 0.43H, minor), 7.27 - 7.41 (m, 7H, major & 
minor). ESI-HRMS [M+Na]
+
 calcd, 389.1212; found, 389.1242. 
1,2-O-Isopropylidene-3-deoxy-5-(O-benzyl)-β-D-apio-L-furanose (4.31): To a 
solution of 4.13 (3.5 g, 12.5 mmol) in dry THF (75 mL) was added NaH (60% in 
mineral oil, 1.5 g, 37.45 mmol) at 0 °C and the reaction mixture was stirred at room 
temperature for 1h. To this mixture was slowly added CS2 (11.2 mL, 188 mmol) and 
MeI (24.0 mL, 375 mmol) and stirred at room temperature for 1h. The reaction 
mixture was evaporated to give crude xanthate. The xanthate was suspended in dry 
toluene (75 mL), triethylborane (19.0 mL, 19.0 mmol, 1.0 M solution in THF) and n-
Bu3SnH (5 mL, 19.0 mmol) were added at room temperature and the mixture was 
stirred for further 3h. The reaction mixture was quenched with water, extracted with 
EtOAc, dried over anhydrous MgSO4, filtered, and evaporated. The residue was 
purified by silica gel column chromatography (10% EtOAc-hexanes) to give 4.31 
(2.26 g, 68 %) as a colorless oil. 
1
H NMR (300 MHz, CDCl3) δ ppm 1.32 (s, 3H, 
CH3a), 1.49 (s, 3H, CH3b), 2.37 - 2.52 (m, 1H, 3-H), 3.52 (dd, J = 9.23, 7.47 Hz, 1H, 
5-H), 3.69 (dd, J = 11.28, 8.35 Hz, 1H, 4-Hb), 3.78 (dd, J = 9.37, 6.74 Hz, 1H, 5-H), 
4.01 (dd, J = 8.35, 7.18 Hz, 1H, 4-Ha), 4.46 - 4.60 (m, 2H, CH2Ph), 4.65 (t, J = 4.10 
Hz, 1H, 2-H), 5.83 (d, J = 3.81 Hz, 1H, 1-H), 7.24 - 7.42 (m, 5H, CH2Ph). 
1,2-Di-O-acetyl-3-deoxy-5-(O-benzyl)-α/β-D-apio-L-furanose (4.36): A solution of 
4.31 (750 mg, 2.84 mmol) in 80% aq. acetic acid (10 mL) was stirred at 80 °C for 8h. 
The reaction mixture was evaporated to give the crude intermediate as a syrup. This 
syrup was dissolved in pyridine (15 mL) and treated with DMAP (50 mg) and acetic 
anhydride (2.0 mL, 21.2 mmol). The solution was stirred at room temperature for 4h. 
The solvent was removed under vacuum and the resulting residue was purified by 
silica-gel column chromatography (20% EtOAc-hexanes) to yield 4.36 (500 mg, 57%) 
as a colorless oil (α:β anomeric ratio 1:4). Major isomer 1H NMR (300 MHz, CDCl3) 
δ ppm 1.94 (s, 3H, Ac) , 1.97 (s, 3H, Ac), 2.83 - 2.96 (m, 1H, 3-H), 3.40 (dd, J = 9.08, 
7.32 Hz, 1H, 5-H), 3.55 (dd, J = 9.08, 7.62 Hz, 1H, 5-H), 3.77 (t, J = 8.79 Hz, 1H, 4-
H), 4.17 (t, J = 8.35 Hz, 1H, 4-H), 4.35 - 4.48 (m, 2H, CH2Ph), 5.20 (d, J = 4.98 Hz, 
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1H, 2H), 6.02 (s, 1H, 1-H), 7.18 - 7.32 (m, 5H, CH2Ph). 
13
C NMR (75 MHz, CDCl3) δ 
ppm 20.54 (CH3CO), 21.01 (CH3CO), 40.11 (3-C), 66.10 (5-C), 70.93 (4-C), 73.27 
(CH2Ph), 76.07 (2-C), 99.67 (1-C), 127.57 (Co Ph), 127.71 (Cp Ph), 128.37 (Cm Ph), 
137.76 (Cipso Ph), 169.36 (CH3CO), 169.71 (CH3CO). ESI-HRMS (M+Na)
+
 calcd: 
331.1158; found: 331.1152. 
1-O-Methyl-2-O-acetyl-3-deoxy-5-(O-benzyl)-β-D-apio-L-furanose (4.37): A 
solution of 4.31 (2.26 g, 8.55 mmol) and p-TsOH (700 mg, 4.06 mmol) in MeOH (60 
mL) was stirred at room temperature for 16h, neutralized with TEA and evaporated. 
The residue was partitioned between EtOAc and water, organic layer separated, dried 
over anhydrous MgSO4 and evaporated. The residue was purified by column 
chromatography. The intermediate was dissolved in pyridine (15 mL), acetic 
anhydride (2.4 mL, 25.2 mmol) and DMAP (200 mg, 1.68 mmol) were added at 0 °C 
and the reaction mixture was stirred at room temperature for 4h. The reaction mixture 
was evaporated, and partitioned between EtOAc and 10% aq. KHSO4. The organic 
layer was dried over anhydrous MgSO4, filtered and evaporated. The residue was 
purified by silica gel column chromatography (15% EtOAc-hexanes) to give 4.37 
(1.85 g, 77%) as a colorless oil. 
1
H NMR (300 MHz, CDCl3) δ ppm 2.00 (s, 3H, 2-
OAc), 2.88-3.02 (m, 1H, 3-H), 3.34 (s, 3H, 1-OMe), 3.46 (dd, J = 9.08, 7.32 Hz, 1H, 
5-H), 3.62 (dd, J = 9.23, 7.18 Hz, 1H, 5-H), 3.78 (t, J = 8.35 Hz, 1H, 4-H), 4.14 (t, J = 
8.49 Hz, 1H, 4-H), 4.46 (d, J = 12.0 Hz, 1H, CH2Ph), 4.52 (d, J = 12.0 Hz, 1H, 
CH2Ph), 4.83 (s, 1H, 1-H), 5.16 (d, J = 5.27 Hz, 1H, 2-H), 7.27 - 7.39 (m, 5H, 
CH2Ph). 
1,2-O-Isopropylidene-β-D-apio-L-furanose (4.8): Compound 4.7 (5.0g, 21.72 mmol) 
was dissolved in 50 mL of 2:1 acetic acid-water mixture and stirred at room 
temperature for 3 days. Solvents were evaporated in vacuo and silica gel column 
chromatography of the residue (50% EtOAc-hexanes) afforded the title compound 4.8 
as white solid (3.4 g, 83%). 
1
H NMR (300 MHz, CDCl3) δ ppm 1.33 (s, 3H, C(CH3)2), 
1.51 (s, 3H, C(CH3)2), 2.12 (t, J = 5.93 Hz, 1H, 5-OH), 2.69 (s, 1H, 3-OH), 3.71 (dd, J 
= 6.28, 11.16 Hz, 1H, 4-H), 3.80 (d, J = 9.77 Hz, 1H, 5-H), 3.94 (d, J = 9.44 Hz, 1H, 
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5-H), 3.96 (dd, J = 5.41, 7.50 Hz, 1H, 4-H), 4.38 (d, J = 3.84 Hz, 1H, 2-H), 5.99 (d, J 
= 3.66 Hz, 1H, 1-H). 
1,2-O-Isopropylidene-5-(O-benzyl)-β-D-apio-L-furanose (4.29): Compound 4.8 (3.1 
g, 16.3 mmol) and dibutyltin oxide (6.7 g, 26.9 mmol) was dissolved in toluene (120 
mL) refluxed at 140 °C for 2h. The reaction mixture was allowed to attain 100 °C then 
added tetrabutylammonium bromide (2.63 g, 8.15 mmol) and benzyl bromide (3.0 
mL, 25.26 mmol). The reaction mixture was stirred at this temperature for 18h. 
Solvent was evaporated under reduced pressure and the residue purified by silica gel 
column chromatography (30% EtOAc-hexanes) to afford 4.29 (4.3 g, 94%) as white 
solid. 
1
H NMR (300 MHz, CDCl3) δ ppm 1.32 (s, 3H, C(CH3)2b), 1.48 (s, 3H, 
C(CH3)2a), 2.76 (d, J = 0.88 Hz, 1H, 3-OH), 3.54 (d, J = 9.67 Hz, 1H, 5-H), 3.80 (d, J 
= 9.67 Hz, 1H, 5-H), 3.82 (dd, J = 9.37, 0.88 Hz, 1H, 4-Ha), 3.88 (dd, J = 9.37 Hz, 1H, 
4-Hb), 4.35 (dd, J = 3.51, 0.88 Hz, 1H, 2-H), 4.57 (d, J = 12.01 Hz, 1H, PhCH2), 4.64 
(d, J = 12.01 Hz, 1H, PhCH2), 5.98 (d, J = 3.51 Hz, 1H, 1-H), 7.27 - 7.42 (m, 5H, 
PhCH2). 
1,2,3-Tri-(O-acetyl)-5-(O-benzyl)-β-D-apio-L-furanose (4.38): Following the similar 
procedure described for the synthesis of 4.35, 2.5g (8.92 mmol) of 4.29 rendered pure 
product 4.38 (2.45 g, 75%). 
1
H NMR (300 MHz, CDCl3) δ ppm 1.96 (s, 3H, COCH3), 
2.07 (s, 3H, COCH3), 2.10 (s, 3H, COCH3), 3.89 (d, J = 10.54 Hz, 1H, 4-H), 4.05 (d, J 
= 10.25 Hz, 1H, 4-H), 4.22 (d, J = 10.25 Hz, 1H, 5-H), 4.34 (d, J = 10.25 Hz, 1H, 5-
H), 4.50 - 4.62 (m, 2H, PhCH2), 5.49 (d, J = 1.17 Hz, 1H, 2-H), 6.08 (d, J = 1.17 Hz, 
1H, 1-H), 7.26 - 7.40 (m, 5H, PhCH2). 
General condition for Vorbrüggen coupling reaction: All operations were carried 
out under an argon protected atmosphere.  
Silylation of nucleobases: The nucleobase (N
6
-benzoyl protected in case of adenine) 
(2 eq.) was suspended in hexamethyldisilazane (50 eq.) containing trimethylsilyl 
chloride (0.7 eq.) and pyridine (10 eq.). The mixture was heated at reflux overnight. 
After cooling, the solvent was evaporated and dried under high vacuum.  
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Coupling at ambient condition (A): To the silylated nucleobase was added 
compound 4.35/36/37/38/72 (1 eq.) dissolved in dry 1,2-dichloroethane (7 mL/mmol), 
and trimethylsilyl triflate or anhydrous SnCl4 (2.5 eq.) was added dropwise at room 
temperature. The clear solution was stirred for stipulated time at same temperature.  
Coupling under microwave condition (B): To the silylated nucleobase was added 
compound 4.35/36/37/38/72 (1 eq.) dissolved in dry acetonitrile (7 mL/mmol), 
followed by the addition of trimethylsilyl triflate (0.2 eq.) at room temperature. The 
clear solution was irradiated to microwave (continuous power-300W, preheating 0 
°C→150 °C in 3 min, at 150 ± 3 °C for 5 min).  
Workup procedure: The reaction mixture was quenched with saturated aqueous 
NaHCO3 and extracted with EtOAc (3 times). The combined organic layers were 
dried over anhydrous Na2SO4 and evaporated. Purification of the residue by silica-gel 
flash column chromatography (MeOH-CH2Cl2) afforded the pure coupled product as 
white foam. 
1ʹ-(Thymin-1-yl)-2ʹ-O-acetyl-3ʹ-deoxy-5ʹ-O-benzyl-α-D-apio-L-furanose (4.39): 
Using condition A, compound 4.36 (320 mg, 1.04 mmol) gave compound 4.39 (420 
mg) in quantitative yield. 
1
H NMR (300 MHz, CDCl3) δ ppm 1.84 (d, J = 0.88 Hz, 
3H, 5-CH3), 1.98 (s, 3H, 2ʹ-OAc), 2.67 - 2.85 (m, 1H, 3ʹ-H), 3.39 (dd, J = 9.08, 7.62 
Hz, 1H, 5ʹ-H), 3.57 (dd, J = 9.23, 6.00 Hz, 1H, 5ʹ-H), 3.89 (t, J = 8.93 Hz, 1H, 4ʹ-H), 
4.36 (t, J = 8.05 Hz, 1H, 4ʹ-H), 4.43 (s, 2H, CH2Ph), 5.39 (dd, J = 6.15, 2.34 Hz, 1H, 
2ʹ-H), 5.74 (d, J = 2.34 Hz, 1H, 1ʹ-H), 6.89 - 7.02 (d, J = 0.88 Hz, 1H, 6-H), 7.21 - 
7.38 (m, 5H, CH2Ph), 8.85 (br s, 1H, NH). 
13
C NMR (75 MHz, CDCl3) δ ppm 12.57 
(5-CH3), 20.57 (2ʹ-OCOCH3), 41.01 (3ʹ-C), 66.31 (5ʹ-C), 71.87 (4ʹ- C), 73.52 
(CH2Ph), 91.20 (1ʹ-C), 110.99 (5-C), 127.71 (CH2Ph), 127.86 (CH2Ph), 128.45 
(CH2Ph), 135.13 (6-C), 137.58 (CH2Ph), 149.97 (2-C), 163.68 (4- C), 169.65 (2ʹ-
OCOCH3). ESI-HRMS (M+H)
+
 calcd: 375.1556; found: 375.1556. 
1ʹ-(N6-Benzoyladenin-9-yl)-2ʹ-O-acetyl-3ʹ-deoxy-5ʹ-O-benzyl-α-D-apio-L-furanose 
(4.40): Using condition B, compound 4.37 (1.0 g, 3.56 mmol) gave compound 4.40 
(1.0 g, 60%). 
1
H NMR (300 MHz, CDCl3) δ ppm 2.00 (s, 3H, 2ʹ-OAc), 3.11 - 3.25 (m, 
Chapter 4 
122 
1H, 3ʹ-H), 3.49 (dd, J = 9.23, 7.18 Hz, 1H, 5ʹ-H), 3.63 (dd, J = 9.37, 6.44 Hz, 1H, 5ʹ-
H), 4.00 (t, J = 8.49 Hz, 1H, 4ʹ-H), 4.45 (s, 2H, PhCH2), 4.50 (t, J = 8.05 Hz, 1H, 4ʹ-
H), 5.79 (dd, J = 5.86, 2.05 Hz, 1H, 2ʹ-H), 6.04 (d, J = 2.34 Hz, 1H, 1ʹ-H), 7.21 - 7.32 
(m, 5H, CH2Ph), 7.37 - 7.47 (m, 2H, Hm Bz), 7.47 - 7.56 (m, 1H, Hp Bz), 7.90 - 7.97 
(m, 2H, Ho Bz), 7.98 (s, 1H, 8-H), 8.72 (s, 1H, 2-H), 9.11 (s, 1H, NH). 
13
C NMR (75 
MHz, CDCl3) δ ppm 20.58 (2ʹ-OCOCH3), 41.01 (3ʹ-C), 66.15 (5ʹ-C), 72.12 (4ʹ-C), 
73.44 (CH2Ph), 76.96 (2ʹ-C), 90.24 (1ʹ- C), 123.57 (5-C), 127.66 (Co, Cp Bn), 127.82 
(Co Bz), 128.44 (Cm Bn), 128.76 (Cm Bz), 132.68 (Cp Bz), 133.58 (Cipso Bz), 137.64 
(Cipso Bn), 141.33 (8-C), 149.54 (6-C), 151.19 (4-C), 152.79 (2-C), 164.59 (N
6
Bz-
CO), 169.90 (2ʹ-OCOCH3). ESI-HRMS (M+H)
+
 calcd: 488.1934; found: 488.1937.  
Spectral data for compound 1ʹ-(N6-Benzoyladenin-1-yl)-3ʹ-deoxy-5ʹ-O-benzyl-α-D-
apio-L-furanose (4.41): 
1
H NMR (300 MHz, CDCl3) δ ppm 2.45 - 2.61 (m, 1H, 3ʹ-
H), 3.68 (dd, J = 9.4, 6.4 Hz, 1H, 5ʹ-H), 3.76 (dd, J = 9.5, 6.3 Hz, 1H, 5ʹ-H), 4.22 (t, J 
= 8.79 Hz, 1H, 4ʹ-H), 4.41 (t, J = 8.20 Hz, 1H, 4ʹ-H), 4.45 - 4.52 (m, 2H, CH2Ph), 4.62 
(d, J = 4.98 Hz, 1H, 2ʹ-H), 6.56 (s, 1H, 1ʹ-H), 7.19 - 7.28 (m, 5H, CH2Ph), 7.29 - 7.37 
(m, 2H, Hm Bz), 7.39 - 7.47 (m, 1H, Hp Bz), 7.97 (s, 1H, 8-H), 8.16 - 8.22 (m, 2H, Ho 
Bz), 8.40 (s, 1H, 2-H), 12.45 (br s, 1H, NH). 
13
C NMR (75 MHz, CDCl3) δ ppm 41.20 
(3ʹ-C), 65.93 (5ʹ-C), 72.06 (4ʹ-C), 73.56 (CH2Ph), 77.60 (2ʹ-C), 96.62 (1ʹ-C), 114.65 
(5-C), 127.90 (Co Bn), 128.17 (Cp Bn), 128.48 (Cm Bz), 128.75 (Cm Bn), 129.94 (Co 
Bz), 132.41 (Cp Bz), 137.51 (Cipso Bz), 137.80 (Cipso Bn), 141.99 (8-C), 142.16 (2-C), 
148.83 (6-C), 157.95 (4-C), 175.46 (Bz CO). ESI-HRMS (M+H)
+
 calcd: 446.1828; 
found: 446.1839. 
1ʹ-(Thymin-1-yl)-3ʹ-deoxy-β-D-apio-L-furanose (4.43): Spectral data for the 
compound mixture 4.43 (minor) + 4.52a: 
1
H NMR (300 MHz, DMSO-d6) δ ppm 1.77 
(d, J = 0.88 Hz, 1.06H, minor 5-CH3), 1.80 (d, J = 1.17 Hz, 2.89H, 5-CH3, major), 
2.22 - 2.36 (m, 1H, 3ʹ-H, major), 2.52-2.60 (m, 0.29H, 3ʹ-H, minor) 3.40 - 3.52 (m, 
1.43H, 5ʹ-H, major & minor), 3.62 - 3.72 (m, 1.43H, 5ʹ-H, major & minor), 3.73 - 3.81 
(m, 1.11H, 4ʹ-H, major), 3.81-3.87 (m, 0.31H, 4ʹ-H, minor), 9.95-4.02 (t, J =7.91 Hz, 
0.39H, 4ʹ-H, minor), 4.11-4.16 (m, 0.36H, 2ʹ-H, minor), 4.19 (td, J = 5.13, 2.05 Hz, 
1.05H, 2ʹ-H, major), 4.33 (t, J = 7.91 Hz, 1H, 4ʹ-H, major), 4.51 (t, J = 5.13 Hz, 
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1.34H, 5ʹ-OH, major & minor), 5.29 (d, J = 4.69 Hz, 0.37H, 2ʹ-OH, minor), 5.51 (d, J 
= 4.98 Hz, 1.02H, 2ʹ-OH, major), 5.61 (d, J = 2.05 Hz, 1H, 1ʹ-H, major), 5.88 (d, J = 
3.22 Hz, 0.36H, 1ʹ-H, minor), 7.30 (d, J = 1.17 Hz, 0.36H, 6-H, minor), 7.38 (d, J = 
1.17 Hz, 1.02H, 6-H, major), 11.21 (s, 0.39H, NH, minor), 11.27 (s, 1.01H, major).
 
13
C NMR (75 MHz, DMSO-d6) δ ppm 12.11 (5-CH3, major), 12.24 (5-CH3, minor), 
43.57 (3ʹ-C, major), 46.06 (3ʹ-C, minor), 57.63 (5ʹ-C, major), 57.74 (5ʹ-C, minor), 
69.31 (2ʹ-C, minor), 69.84 (4ʹ-C, minor), 71.16 (4ʹ-C, major), 74.21 (2ʹ-C, major), 
87.92 (1ʹ-C, minor), 92.24 (1ʹ-C, major), 106.84 (5-C, minor), 108.92 (5-C, major), 
135.74 (6-C, major), 137.99 (6-C, minor), 150.32 (2-C, major), 150.39 (2-C, minor), 
163.93 (4-C, major), 164.07 (4-C, minor). 
1ʹ-(Thymin-1-yl)-2ʹ,3ʹ-di(O-acetyl)-5ʹ-O-benzyl-α-D-apiose-L-furanose (4.44): 
Using condition – A, compound 4.38 (100 mg, 0.27 mmol) gave compound 4.44 (100 
mg, 85%). 
1
H NMR (300 MHz, CDCl3) δ ppm 1.95 (d, J = 1.17 Hz, 3H, 5-CH3), 2.04 
(s, 3H, Ac), 2.08 (s, 3H, Ac), 3.88 (s, 2H, 5ʹ-H), 4.20 (d, J = 10.54 Hz, 1H, 4ʹ-H), 4.55 
(s, 2H, CH2Ph), 4.56 (d, J = 10.54 Hz, 1H, 4ʹ-H), 5.63 (d, J = 4.98 Hz, 1H, 2ʹ-H), 5.96 
(d, J = 4.98 Hz, 1H, 1ʹ-H), 7.28 (d, J = 1.17 Hz , 1H, 6-H), 7.30 - 7.41 (m, 5H, 
CH2Ph), 8.52 (s, 1H, NH).
 13
C NMR (75 MHz, CDCl3) δ ppm 12.69 (5-CH3), 20.51 
(Ac-CH3), 21.58 (Ac-CH3), 66.68 (5ʹ-C), 73.20 (4ʹ-C), 73.80 (CH2Ph), 78.06 (2ʹ-C), 
86.24 (3ʹ-C), 88.23 (1ʹ-C), 111.44 (5-C), 127.81 (Co Bn), 128.04 (Cp Bn), 128.54 (Cm 
Bn), 135.03 (6-C), 137.27 (Cipso Bn),150.19 (2-C), 163.30 (4-C), 169.13 (Ac-CO), 
169.94 (Ac-CO). ESI-HRMS (M+H)
+
 calcd: 433.1611; found: 433.1924. 
1ʹ-(N6-Benzoyladenin-9-yl)-2ʹ,3ʹ-di(O-acetyl)-5ʹ-O-benzyl-α-D-apio-L-furanose 
(4.45): Using condition- B, compound 4.38 (220 mg, 0.6 mmol) gave compound 4.45 
(130 mg, 40%) and 4.46 (20 mg, 6%). 
1
H NMR (300 MHz, CDCl3) δ ppm 2.04 (s, 3H, 
Ac), 2.07 (s, 3H, Ac), 3.94 - 4.04 (2d, J = 9.96 Hz, 2H, 5ʹ-H), 4.37 (d, J = 10.54 Hz, 
1H, 4ʹ-H), 4.59 (s, 2H, CH2Ph), 4.71 (d, J = 10.54 Hz, 1H, 4ʹ-H), 6.13 (d, J = 4.39 Hz, 
1H, 2ʹ-H), 6.17 (d, J = 4.10 Hz, 1H, 1ʹ-H), 7.31 - 7.39 (m, 5H, CH2Ph), 7.51 - 7.56 (m, 
2H, Hm Bz), 7.58 - 7.62 (m, 1H, Hp Bz), 8.00 - 8.05 (m, 2H, Ho Bz) 8.23 (s, 1H, 8-H), 
8.82 (s, 1H, 2-H), 9.01 (s, 1H, NH).
 13
C NMR (75 MHz, CDCl3) δ ppm 20.48 (Ac- 
CH3), 21.53 (Ac-CH3), 66.32 (5ʹ-C) 73.79 (CH2Ph & 4ʹ-C), 78.65 (2ʹ-C), 86.43 (3ʹ-C), 
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87.93 (1ʹ-C), 123.14 (5-C), 127.81 (Co Bn) 127.83 (Co Bz), 128.05 (Cp Bn), 128.54 
(Cm Bn), 128.85 (Cm Bz), 132.77 (Cm Bz), 133.59 (Cipso Bn), 137.28 (Cipso Bz), 141.05 
(8-C), 149.51 (4-C), 151.79 (6-C), 152.94 (2-C), 164.47 (N
6
COPh), 168.89 (COCH3), 
169.94 (COCH3). ESI-HRMS (M+H)
+
 calcd: 546.1989; found: 546.2000. Spectral 
data for compound 1ʹ-(N6-Benzoyladenin-9-yl)-2ʹ-(O-trimethylsilyl)-3ʹ-(O-acetyl)-
5ʹ-O-benzyl-α-D-apio-L-furanose (4.46): 1H NMR (300 MHz, CDCl3) δ ppm 0.14 (s, 
9H, 2ʹ-OSi(CH3)3) 1.89 (s, 3H, 3ʹ-Ac) 3.96 (d, J = 9.96 Hz, 1H, 5ʹ-H) 4.05 (d, J = 9.67 
Hz, 1H, 5ʹ-H) 4.34 (d, J = 10.54 Hz, 1H, 4ʹ-H) 4.49 (d, J = 11.72 Hz, 1H, CH2Ph) 4.57 
(d, J = 12.01 Hz, 1H, CH2Ph) 4.71 (d, J = 10.54 Hz, 1H, 4ʹ-H) 5.05 (d, J = 2.64 Hz, 
1H, 2ʹ-H) 6.04 (d, J = 2.64 Hz, 1H, 1ʹ-H) 7.27 - 7.39 (m, 5H, CH2Ph) 7.50 - 7.56 (m, 
2H, Hm Bz) 7.57 - 7.62 (m, 1H, Hp Bz) 8.00 - 8.06 (m, 2H, Ho Bz) 8.15 (s, 1H, 8-H) 
8.81 (s, 1H, 2-H) 9.08 (s, 1H, NH). 
13
C NMR (75 MHz, CDCl3) δ ppm -0.12 (SiCH3), 
21.55 (Ac-CH3), 65.96 (5ʹ-C), 73.70 (CH2Ph), 74.39 (4ʹ-C), 78.99 (2ʹ-C), 88.13 (3ʹ-C), 
91.74 (1ʹ-C), 123.44 (5-C), 127.69 (Cp Bn), 127.85 (Co Bz), 127.86 (Co Bn), 128.43 
(Cm Bn), 128.86 (Cm Bz), 132.77 (Cp Bz), 133.65 (Cipso Bn), 137.61 (Cipso Bz), 141.27 
(8-C), 149.39 (4-C), 151.33 (6-C), 152.67 (2-C), 164.56 (N
6
Bz-CO), 169.97 (Ac-CO). 
ESI-HRMS (M+H)
+
 calcd: 576.2278; found: 576.2291. 
1ʹ-(Thymin-1-yl)-3ʹ-deoxy-5ʹ-O-benzyl-α-D-apio-L-furanose (4.47): Acetyl 
protected compound 4.39 (400 mg, 1.07 mmol) was dissolved in 7N ammonia in 
MeOH (15 mL). The mixture was stirred at room temoerature until completion (for 
about 3-5h) as indicated by TLC. Solvent was evaporated and the residue was purified 
by flash column chromatography using 0.5-1 % MeOH-CH2Cl2 to afford the title 
compound 4.47 (341 mg, 96%) as a white foam. 
1
H NMR (300 MHz, CDCl3) δ ppm 
1.83 (d, J = 1.17 Hz, 3H, 5-CH3), 2.27 - 2.49 (m, 1H, 3ʹ-H), 3.57 (dd, J = 9.23, 7.76 
Hz, 1H, 5ʹ-H), 3.78 (dd, J = 9.23, 6.00 Hz, 1H, 5ʹ-H), 4.03 (dd, J = 10.54, 8.49 Hz, 
1H, 4ʹ-H), 4.29 - 4.38 (m, 2H, 4ʹ-H & 2ʹ-H), 4.45 (s, 2H, CH2Ph), 5.02 (br s, 1H, 2ʹ-
OH), 5.67 (s, 1H, 1ʹ-H), 7.11 (d, J = 1.17 Hz, 1H, 6-H), 7.19 - 7.30 (m, 5H, CH2Ph), 
10.44 (br s, 1H, NH). 
13
C NMR (75 MHz, CDCl3) δ ppm 12.60 (5-CH3), 41.34 (3ʹ- C), 
66.61 (5ʹ-C), 72.88 (4ʹ-C), 73.55 (CH2Ph), 75.79 (2ʹ-C), 94.33 (1ʹ-C), 110.49 (5-C), 
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127.72 (CH2Ph), 127.74 (CH2Ph), 128.39 (CH2Ph), 134.67 (6- C), 137.88 (CH2Ph), 
150.61 (2-C), 164.47 (4-C). ESI-HRMS (M+H)
+
 calcd: 333.1450; found: 333.1458. 
1ʹ-(Adenin-9-yl)-3ʹ-deoxy-5ʹ-O-benzyl-α-D-apio-L-furanose (4.48): Compound 4.40 
(1.0 g, 2.05 mmol) was dissolved in 7N ammonia in MeOH (30 mL). The mixture was 
stirred at room temperature for 48h. Solvent was evaporated and the residue was 
purified by flash column chromatography using 2% MeOH-CH2Cl2 to afford the title 
compound 4.48 (650 mg, 75%) as a white foam [Procedure to remove acetamide 
residue if any: Suspend the product in water and then collect it by filtration]. 
1
H NMR 
(300 MHz, DMSO-d6) δ ppm 2.75 - 2.89 (m, 1H, 3ʹ-H), 3.53 (t, J = 8.79 Hz, 1H, 5ʹ-
H), 3.73 (dd, J = 9.37, 5.86 Hz, 1H, 5ʹ-H), 3.86 (t, J = 8.20 Hz, 1H, 4ʹ-H), 4.40 (t, J = 
7.76 Hz, 1H, 4ʹ-H), 4.45 - 4.56 (m, 2H, Bn H), 4.63 (td, J = 5.27, 2.05 Hz, 1H, 2ʹ-H), 
5.76 (d, J = 4.69 Hz, 1H, 2ʹ-OH), 5.90 (d, J = 2.34 Hz, 1H, 1ʹ-H), 7.26 (br s, 2H, NH), 
7.27 - 7.39 (m, 5H, CH2Ph), 8.15 (s, 1H, 2-H), 8.23 (s, 1H, 8-H). 
13
C NMR (75 MHz, 
DMSO-d6) δ ppm 41.70 (3ʹ-C), 66.77 (5ʹ-C), 71.09 (4ʹ-C), 72.25 (Bn C), 74.38 (2ʹ-C), 
91.11 (1ʹ-C), 119.16 (5-C), 127.38 (Co Bn), 127.49 (Cp Bn), 128.21 (Cm Bn), 138.46 
(Cipso Bn), 138.98 (8-C), 148.80 (4-C), 152.52 (2-C), 156.00 (6-C). ESI-HRMS 
(M+H)
+
 calcd: 342.1566; found: 342.1565.  
1ʹ-(Thymin-1-yl)-5ʹ-O-benzyl-α-D-apio-L-furanose (4.49): Following a similar 
procedure described for compound 4.47, compound 4.44 (100 mg, 0.23 mmol) gave 
compound 4.49 (81 mg, 86 %) as a white foam. 
1
H NMR (300 MHz, CDCl3) δ ppm 
1.81 (d, J = 0.88 Hz, 3H, 5-CH3), 3.60 (d, J = 9.67 Hz, 1H, 4ʹ-H), 3.85 (d, J = 9.67 Hz, 
1H, 4ʹ-H), 3.90 (d, J = 1.17 Hz, 1H, 3ʹ-OH), 4.06 (dd, J = 9.37, 1.47 Hz, 1H, 5ʹ-H), 
4.17 (d, J = 9.37 Hz, 1H, 5ʹ-H), 4.41 (d, J = 3.51 Hz, 1H, 2ʹ-H), 4.50 - 4.69 (app-q, J = 
12.01 Hz, 2H, CH2Ph), 5.25 (d, J = 3.51 Hz, 1H, 2ʹ-OH), 5.72 (s, 1H, 1ʹ-H), 7.23 - 
7.37 (m, 5H, CH2Ph), 7.52 (d, J = 1.17 Hz, 1H, 6-H), 10.81 (br s, 1H, NH).
 13
C NMR 
(75 MHz, CDCl3) δ ppm 12.41 (5-CH3), 69.57 (4ʹ-C), 73.72 (CH2Ph), 77.01 (5ʹ-C), 
79.96 (2ʹ-C), 80.54 (3ʹ-C), 94.36 (1ʹ-C), 108.63 (5-C), 127.77 (Co Bn), 127.84 (Cp 
Bn), 128.42 (Cm Bn), 137.55 (Cipso Bn), 137.62 (6-C) 151.28 (2-C), 164.83 (4-C). ESI-
HRMS (M+H)
+
 calcd: 349.1400; found: 349.1384. 
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1ʹ-(Adenin-9-yl)-5ʹ-O-benzyl-α-D-apio-L-furanose (4.50): Following a similar 
procedure described for compound 4.48, compound 4.45 (120 mg, 0.22 mmol) gave 
compound 4.50 (73 mg, 93%) as a white foam. The same procedure was employed to 
convert 4.46 to 4.50. 
1
H NMR (300 MHz, DMSO-d6) δ ppm 3.57 - 3.70 (2d, J = 9.67 
Hz, 2H, 5ʹ-H), 4.00 (d, J = 8.79 Hz, 1H, 4ʹ-H), 4.11 (d, J = 9.08 Hz, 1 H4ʹ-H), 4.39 
(dd, J = 5.27, 2.93 Hz, 1H, 2ʹ-H) 4.51 - 4.64 (2d, J = 12.30 Hz, 2H, CH2Ph), 5.59 (s, 
1H, 3ʹ-OH), 5.90 (d, J = 2.93 Hz, 1H, 1ʹ-H), 5.97 (d, J = 5.56 Hz, 1H, 2ʹ-OH), 7.27 (s, 
2H, NH), 7.28 - 7.43 (m, 5H, CH2Ph) 8.15 (s, 1H, 2-H), 8.29 (s, 1H, 8-H). 
13
C NMR 
(75 MHz, DMSO-d6) δ ppm 71.12 (5ʹ-C), 72.70 (CH2Ph), 75.55 (4ʹ-C), 79.84 (3ʹ-C), 
80.28 (2ʹ-C), 90.68 (1ʹ-C), 118.78 (5- C), 127.34 (Cp Bn), 127.44 (Co Bn), 128.19 (Cm 
Bn), 138.50 (Cipso Bn) 139.68 (8-C) 149.03 (4-C) 152.46 (2-C) 155.98 (6-C). ESI-
HRMS (M+H)
+
 calcd: 358.1515; found: 358.1512. 
1ʹ-(Thymin-1-yl)-3ʹ-deoxy-α-D-apio-L-furanose (4.52a): Compound 4.47 (300 mg, 
0.9 mmol) was dissolved in MeOH (10 mL), to this was added Pd-C (300 mg, 10% 
Pd, wet   50%). A stream of hydrogen gas was bubbled through the reaction mixture 
with vigorous stirring for about 1h and the mixture was then stirred under hydrogen 
atmosphere overnight at room temperature. The catalyst was filtered off, the filtrate 
was concentrated and purified by silica-gel flash column chromatography eluting with 
6-8% MeOH-CH2Cl2 to afford compound 4.52a (190 mg, 86%) as a white solid. 
1
H 
NMR (300 MHz, DMSO-d6) δ ppm 1.79 (d, J = 1.17 Hz, 3H, 5-CH3), 2.22 - 2.36 (m, 
1H, 3ʹ-H), 3.46 (ddd, J = 10.76, 7.69, 5.27 Hz, 1H, 5ʹ-H), 3.62 - 3.71 (m, 1H, 5ʹ-H), 
3.76 (t, J = 8.64 Hz, 1H, 4ʹ-H), 4.18 (td, J = 4.98, 2.05 Hz, 1H, 2ʹ-H), 4.33 (t, J = 7.76 
Hz, 1H, 4ʹ-H), 4.51 (t, J = 5.13 Hz, 1H, 5ʹ-OH), 5.51 (d, J = 4.69 Hz, 1H, 2ʹ-OH), 5.61 
(d, J = 2.05 Hz, 1H, 1ʹ-H), 7.38 (d, J = 1.17 Hz, 1H, 6-H), 11.27 (br s, 1H, NH). 13C 
NMR (75 MHz, DMSO-d6) δ ppm 12.09 (5-CH3), 43.55 (3ʹ-C), 57.61 (5ʹ-C), 71.14 
(4ʹ-C), 74.19 (2ʹ-C), 92.22 (1ʹ-C), 108.90 (5-C), 135.73 (6-C), 150.30 (2-C), 163.92 
(4-C). ESI-HRMS (M+H)
+
 calcd: 243.0981; found: 243.0990. 
1ʹ-(Adenin-9-yl)-3ʹ-deoxy-α-D-apio-L-furanose (4.52b): Compound 4.48 (450 mg, 
1.32 mmol) was dissolved in 1:1 v/v mixture of MeOH-formic acid (40 mL), to this 
was added Pd(OH)2-C (300 mg, 10% Pd, wet   50%) and stirred at 55 °C for 5-8h . The 
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catalyst was filtered off and the filtrate was concentrated. The residue contained 
compound 4.52b and 4.51 as mixture. The residue was dissolved in 7N NH3-MeOH 
and stirred at room temperature for 3h. The volatiles were evaporated and the residue 
purified by silica-gel flash column chromatography eluting with 10-12% MeOH-
CH2Cl2 to afford compound 4.52b (265 mg, 80%) as a white solid. Spectral data for 
1ʹ-(adenin-9-yl)-3ʹ-deoxy-5ʹ-O-formyl-α-D-apio-L-furanose (4.51): 1H NMR (300 
MHz, DMSO-d6) δ ppm 2.82 - 3.00 (m, 1H, 3ʹ-H), 3.86 (t, J = 8.20 Hz, 1H, 4ʹ-H), 
4.21 (dd, J = 10.98, 7.76 Hz, 1H, 5ʹ-H), 4.32 - 4.46 (m, 2H, 4ʹ & 5ʹ-H’s), 4.70 (br s, 
1H, 2ʹ-H), 5.93 (d, J = 2.05 Hz, 1H, 1ʹ-H), 7.28 (s, 2H, NH), 8.15 (s, 1H, 2-H), 8.24 (s, 
1H, 5ʹ-OCOH), 8.25 (s, 1H, 8-H). 13C NMR (75 MHz, DMSO-d6) δ ppm 41.34 (3ʹ-C), 
61.27 (5ʹ-C), 71.06 (4ʹ-C), 74.73 (2ʹ-C), 91.80 (1ʹ-C), 119.73 (5-C), 139.85 (8-C), 
149.44 (4-C), 153.29 (2-C), 156.51 (6-C), 162.81 (5ʹ-OCOH). ESI-HRMS (M+H)+ 
calcd: 280.1046; found: 280.1046. Spectral data for 1ʹ-(adenin-9-yl)-3ʹ-deoxy-α-D-
apio-L-furanose (4.52b): 
1
H NMR (300 MHz, DMSO-d6) δ ppm 2.53 - 2.66 (m, 1H, 
3ʹ-H), 3.52 (t, J = 8.79 Hz, 1H, 5ʹ-H), 3.67 - 3.77 (m, 1H, 5ʹ-H), 3.86 (t, J = 8.20 Hz, 
1H, 4ʹ-H), 4.35 (t, J = 7.76 Hz, 1H, 4ʹ-H), 4.54 (br s, 1H, 5ʹ-OH), 4.63 (br s, 1H, 2ʹ-H), 
5.64 (d, J = 4.69 Hz, 1H, 2ʹ-OH), 5.89 (d, J = 2.34 Hz, 1H, 1ʹ-H), 7.25 (br s, 2H, 
NH2), 8.15 (s, 1H, 2-H), 8.22 (s, 1H, 8-H). 
13
C NMR (75 MHz, DMSO-d6) δ ppm 
44.10 (3ʹ-C), 57.64 (5ʹ-C), 70.84 (4ʹ-C), 74.39 (2ʹ-C), 91.11 (1ʹ-C), 119.19 (5- C), 
138.93 (8-C), 148.80 (4-C), 152.51 (2-C), 156.00 (6-C). ESI-HRMS (M+H)
+
 calcd: 
252.1097; found: 252.1090. 
1ʹ-(Thymin-1-yl)-α-D-apio-L-furanose (4.53a): Following a similar procedure 
described for compound 4.52a, compound 4.49 (210 mg, 0.60 mmol) gave compound 
4.53a (110 mg, 71%) as a white foam. 
1
H NMR (300 MHz, DMSO-d6) δ ppm 1.77 (d, 
J = 1.17 Hz, 3H, 5-CH3), 3.54 (s, 2H, 5ʹ-H), 3.88 (d, J = 9.08 Hz, 1H, 4ʹ-H), 3.93 (br 
s, 1H, 2ʹ-H), 3.98 (d, J = 9.08 Hz, 1 H), 4.57 (br s, 1H, 3ʹ-OH), 5.04 (s, 1H, 5ʹ-OH), 
5.67 (d, J = 2.64 Hz, 1H, 1ʹ-H), 5.72 (d, J = 4.69 Hz, 1H, 2ʹ-OH), 7.62 (d, J = 1.17 Hz, 
1H, 6-H), 11.25 (br s, 1H, NH).
13
C NMR (75 MHz, DMSO-d6) δ ppm 12.98 (5-CH3), 
62.95 (5ʹ-C), 76.52 (4ʹ-C), 80.51 (2ʹ-C), 81.00 (3ʹ-C), 92.95 (1ʹ-C), 108.70 (5-C), 
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137.90 (6-C), 151.19 (2-C), 164.62 (4-C). ESI-HRMS (M+H)
+
 calcd: 259.0930; 
found: 259.0927. 
1ʹ-(Adenin-9-yl)-α-D-apio-L-furanose (4.53b): Compound 4.50 (20 mg, 0.056 
mmol) was dissolved in 9:1 v/v mixture MeOH-formic acid (2 mL), to this was added 
Pd(OH)2-C (20 mg, 10% Pd, wet   50%) and stirred at 55 °C for 5-8h . The catalyst 
was filtered off, the filtrate was concentrated and the residue was purified by silica-gel 
flash column chromatography eluting with 10-14% MeOH-CH2Cl2 to afford 
compound 4.53b (12 mg, 80%) as a white solid. 
1
H NMR (300 MHz, DMSO-d6) δ 
ppm 3.62 (d, J = 5.56 Hz, 2H, 5ʹ-H), 3.98 (d, J = 9.08 Hz, 1H, 4ʹ-H), 4.04 (d, J = 9.08 
Hz, 1H, 4ʹ-H), 4.38 (br s, 1H, 2ʹ-H), 4.64 (t, J = 5.71 Hz, 1H, 5ʹ-OH), 5.36 (s, 1H, 3ʹ-
OH), 5.85 (d, J = 4.69 Hz, 1H, 2ʹ-OH), 5.90 (d, J = 2.93 Hz, 1H, 1ʹ-H), 7.26 (s, 2H, 
NH), 8.15 (s, 1H, 2-H), 8.31 (s, 1H, 8-H). 
13
C NMR (75 MHz, DMSO-d6) δ ppm 
62.04 (5ʹ-C), 75.32 (4ʹ-C), 80.13 (2ʹ-C), 80.33 (3ʹ-C), 90.60 (1ʹ-C), 118.70 (5-C), 
139.64 (8-C), 148.95 (4-C), 152.34 (2-C), 155.88 (6-C). ESI-HRMS (M+H)
+
 calcd: 
268.1046; found: 268.1036. 
1ʹ-(Thymin-1-yl)-3ʹ-deoxy-5ʹ-O-(tert-butyldimethylsilyl)-α-D-apio-L-furanose 
(4.54): Compound 4.52a (150 mg, 0.62 mmol) was dissolved in DMF (3.5 mL), to 
this was added imidazole (85 mg, 1.24 mmol) followed by tert-
butyldimethylsilylchloride (TBDMSCl) (112 mg, 0.74 mmol). The mixture was stirred 
at room temperature for 18h. DMF was evaporated under reduced pressure. The 
residue was partitioned between EtOAc and brine. Organic layer separated, dried over 
sodium sulphate, solvent evaporated and the residue purified by silica-gel flash 
column chromatography using 1-2% MeOH-CH2Cl2 to afford compound 4.54 (210 
mg, 95%) as a white solid. 
1
H NMR (300 MHz, CDCl3) δ ppm 0.07 (2s, 6H, 
Si(CH3)2), 0.89 (S, 9H, C(CH3)3), 1.94 (d, J = 0.88 Hz, 3H, 5-CH3), 2.32-2.46 (m, 1H, 
3ʹ-H), 3.84 (d, J = 10.25, 7.32 Hz, 1H, 5ʹ-H), 3.97 (d, J = 10.25, 5.86 Hz, 1H, 5ʹ-H), 
4.10 (t, J = 8.48 Hz, 1H, 4ʹ-H), 4.35 (t, J = 7.91 Hz, 1H, 4ʹ-H), 4.39 (t, J = 4.1 Hz, 1H, 
2ʹ-H), 4.81 (d, J = 3.22 Hz, 1H, 2ʹ-OH), 5.74 (s, 1H, 1ʹ-H), 7.22 (d, J = 1.17 Hz, 1H, 
6-H), 10.19 (br s, 1H, NH). 
13
C NMR (75 MHz, CDCl3) δ ppm -5.51 (Si(CH3)2), -5.47 
(Si(CH3)2), 12.65 (5-CH3), 18.24 (C(CH3)3), 25.85 (C(CH3)3), 43.46 (3ʹ-C), 59.75 (5ʹ- 
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C), 72.48 (4ʹ-C), 76.10 (2ʹ-C), 94.60 (1ʹ-C), 110.54 (5-C), 134.84 (6-C), 150.66 (2-C), 
164.35 (4-C). ESI-HRMS (M+H)
+
 calcd: 357.1846; found: 357.1852. 
1ʹ-(Adenin-9-yl)-3ʹ-deoxy-5ʹ-O-(tert-butyldimethylsilyl)-α-D-apio-L-furanose 
(4.55): Following a similar procedure described for compound 4.54, compound 4.52b 
(260 mg, 1.03 mmol) afforded compound 4.55 (310 mg, 82%) as a white solid. 
1
H 
NMR (300 MHz, CDCl3) δ ppm 0.10 (s, 3H, SiCH3), 0.10 (s, 3H, SiCH3), 0.91 (s, 9H, 
C(CH3)3), 2.65 - 2.78 (m, 1H, 3ʹ-H), 3.97 (dd, J = 6.00, 1.32 Hz, 2H, 5ʹ-H), 4.21 (dd, J 
= 8.35, 7.47 Hz, 1H, 4ʹ-H), 4.39 (dd, J = 8.49, 7.32 Hz, 1H, 4ʹ-H), 4.81 (dt, J = 5.71, 
2.71 Hz, 1H, 2ʹ-H), 5.15 (d, J = 3.22 Hz, 1H, 2ʹ-OH), 5.94 (br s, 2H, NH), 5.97 (d, J = 
2.64 Hz, 1H, 1ʹ-H), 7.94 (s, 1H, 8-H), 8.32 (s, 1H, 2-H). 13C NMR (75 MHz, CDCl3) δ 
ppm -5.52 (SiCH3), -5.50 (SiCH3), 18.19 (C(CH3)3), 25.81 (C(CH3)3), 43.28 (3ʹ-C), 
60.02 (5ʹ-C), 71.17 (4ʹ-C), 77.07 (2ʹ- C), 93.00 (1ʹ-C), 120.31 (5-C), 138.43 (8-C), 
148.96 (4-C), 152.73 (2-C), 155.51 (6-C). ESI-HRMS (M+H)
+
 calcd: 366.1961; 
found: 366.1941. 
1ʹ-(Thymin-1-yl)-2ʹ,3ʹ-dideoxy-5ʹ-O-benzyl-α-D-apio-L-furanose (4.56): To a 
solution of compound 2.47 (250 mg, 0.75 mmol) and DMAP (184 mg, 1.5 mmol) in 
acetonitrile (10 mL) was dropwise added O-p-tolyl chlorothionoformate (138µL, 0.9 
mmol) at room temperature. The mixture was stirred for additional 2h, and then the 
volatile organics were evaporated under reduced pressure. The residue was suspended 
in EtOAc and washed with water and brine. The organic layer was dried over 
anhydrous sodium sulphate and the solvent evaporated to dryness. The residue 
obtained was suspended in toluene (25 mL), tributyltinhydride (0.51 mL, 1.88 mmol) 
was added followed by at 60-70 °C was added azoisobutyronitrile (AIBN, 250 mg, 1.5 
mmol) and heated to 110-120 °C for 3h. Volatile materials were evaporated and the 
residue was purified by silica-gel flash column chromatography using 0.5-2% MeOH-
CH2Cl2 to afford compound 4.56 (167 mg, 70 %) as a white foam. 
1
H NMR (300 
MHz, CDCl3) δ ppm 1.86 (d, J = 1.17 Hz, 3H, 5-CH3), 2.06 (ddd, J = 13.77, 7.91, 
3.81 Hz, 1H, 2ʹ-H), 2.16 (ddd, J = 13.84, 7.54, 6.44 Hz, 1H, 2ʹ-H), 2.52 - 2.68 (m, 1H, 
3ʹ-H), 3.36 (dd, J = 9.08, 7.32 Hz, 1H, 5ʹ-H), 3.45 (dd, J = 9.08, 5.56 Hz, 1H, 5ʹ-H), 
3.74 (dd, J = 8.79, 7.03 Hz, 1H, 4ʹ-H), 4.24 (dd, J = 8.79, 7.32 Hz, 1H, 4ʹ-H), 4.45 (s, 
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2H, CH2Ph), 5.96 (dd, J = 6.44, 4.10 Hz, 1H, 1ʹ-H), 7.07 (d, J = 1.17 Hz, 1H, 6-H), 
7.20 - 7.33 (m, 5H, CH2Ph), 8.56 (br s, 1H, NH). 
13
C NMR (75 MHz, CDCl3) δ ppm 
12.65 (5-CH3), 35.88 (2ʹ-C), 38.06 (3ʹ-C), 70.83 (5ʹ-C), 72.71 (4ʹ-C), 73.39 (CH2Ph), 
86.96 (1ʹ-C), 110.38 (5-C), 127.67 (CH2Ph), 127.85 (CH2Ph), 128.49 (CH2Ph), 
135.04 (6-C), 137.76 (CH2Ph), 150.09 (2-C), 163.72 (4-C). ESI-HRMS (M+H)
+
 
calcd: 317.1501; found: 317.1499. 
1ʹ-(Adenin-9-yl)-2ʹ,3ʹ-dideoxy-5ʹ-O-benzyl-α-D-apio-L-furanose (4.57): Following 
a similar procedure described for compound 4.56, compound 4.48 (45 mg, 0.13 mmol) 
gave compound 4.57 (30 mg, 70 %) as a white foam. 
1
H NMR (300 MHz, CDCl3) δ 
ppm 2.32 (ddd (dt), J = 13.91, 7.10 Hz, 1H, 2ʹ-H), 2.68 (ddd, J = 13.55, 7.83, 2.93 Hz, 
1H, 2ʹ-H), 2.81 - 2.95 (m, 1H, 3ʹ-H), 3.45 - 3.58 (m, 2H, 5ʹ-H), 3.90 (dd, J = 8.79, 6.44 
Hz, 1H, 4ʹ-H), 4.34 (dd, J = 8.64, 7.47 Hz, 1H, 4ʹ-H), 4.53 (s, 2H, CH2Ph), 6.11 (br s, 
2H, NH), 6.29 (dd, J = 6.88, 3.08 Hz, 1H, 1ʹ-H), 7.27 - 7.39 (m, 5H, CH2Ph), 7.90 (s, 
1H, 8-H), 8.32 (s, 1H, 2- H). 
13
C NMR (75 MHz, CDCl3) δ ppm 35.47 (2ʹ-C), 38.19 
(3ʹ-C) 71.02 (5ʹ-C), 72.18 (4ʹ-C), 73.27 (CH2Ph), 85.90 (1ʹ-C), 120.17 (5-C), 127.63 
(CH2Ph), 127.78 (CH2Ph), 128.44 (CH2Ph), 137.85 (CH2Ph), 138.45 (8-C), 149.21 
(4-C) 152.83 (2-C) 155.53 (6-C). ESI-HRMS (M+H)
+
 calcd: 326.1617; found: 
326.1611. 
1ʹ-(Thymin-1-yl)-2ʹ,3ʹ-dideoxy-5ʹ-O-(tert-butyldimethylsilyl)-α-D-apio-L-furanose 
(4.58): Following a similar procedure described for compound 4.56, compound 4.54 
(190 mg, 0.53 mmol) gave compound 4.58 (130 mg, 72 %) as a white foam. 
1
H NMR 
(300 MHz, CDCl3) δ ppm 0.06 (s, 6H, Si(CH3)2), 0.90 (s, 9H, C(CH3)3), 1.94 (d, J = 
1.26 Hz, 3H, 5-CH3), 2.06 (ddd, J = 13.84, 8.18, 3.99 Hz, 1H, 2ʹ-H), 2.25 (dt, J = 
13.84, 6.92 Hz, 1H, 2ʹ-H), 2.48 - 2.63 (m, 1H, 3ʹ-H), 3.58 (dd, J = 9.96, 6.82 Hz, 1H, 
5ʹ-H), 3.66 (dd, J = 10.07, 5.24 Hz, 1H, 5ʹ-H), 3.83 (dd, J = 8.81, 6.92 Hz, 1H, 4ʹ-H), 
4.26 (dd, J = 8.70, 7.24 Hz, 1H, 4ʹ-H), 6.04 (dd, J = 6.61, 3.88 Hz, 1H, 1ʹ-H), 7.16 (q, 
J = 1.26 Hz, 1H, 6-H), 8.88 (br s, 1H, NH). 
13
C NMR (75 MHz, CDCl3) δ ppm -5.51 
(SiCH3), -5.48 (SiCH3), 12.65 (5-CH3), 18.23 (C(CH3)3), 25.81 (C(CH3)3), 35.34 (2ʹ-
C), 40.14 (3ʹ-C), 63.37 (5ʹ-C), 72.17 (4ʹ-C), 87.08 (1ʹ-C), 110.35 (5-C), 135.10 (6-C), 
150.20 (2-C), 163.90 (4-C). ESI-HRMS (M+H)
+
 calcd: 341.1897; found: 341.1884. 
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1ʹ-(Adenin-9-yl)-2ʹ,3ʹ-dideoxy-5ʹ-O-(tert-butyldimethylsilyl)-α-D-apio-L-furanose 
(4.59): Following a similar procedure described for compound 4.56, compound 4.55 
(300 mg, 0.82 mmol) gave compound 4.59 (253 mg, 88 %) as a white foam. 
1
H NMR 
(300 MHz, CDCl3) δ ppm 0.07 (s, 6H, Si(CH3)2), 0.91 (s, 9H, C(CH3)3), 2.34 (ddd 
(dt), J = 13.69, 7.07 Hz, 1H, 2ʹ-H), 2.62 (ddd, J = 13.33, 7.76, 2.93 Hz, 1H, 2ʹ-H), 
2.76 (dq, J = 13.51, 6.87 Hz, 1H, 3ʹ-H), 3.60 - 3.74 (m, 2H, 5ʹ-H), 3.92 (dd, J = 8.79, 
6.44 Hz, 1H, 4ʹ-H), 4.31 (dd, J = 8.49, 7.32 Hz, 1H, 4ʹ-H), 5.70 (br s, 2H, NH), 6.30 
(dd, J = 6.74, 2.93 Hz, 1H, 1ʹ-H), 7.93 (s, 1H, 8-H), 8.36 (s, 1H, 2-H). 13C NMR (75 
MHz, CDCl3) δ ppm -5.45 (Si(CH3)), -5.42 (Si(CH3)), 18.26 (C(CH3)3), 25.84 
(C(CH3)3), 34.94 (2ʹ-C), 40.38 (3ʹ-C), 63.54 (5ʹ-C), 71.80 (4ʹ-C), 86.08 (1ʹ-C), 120.32 
(5-C), 138.57 (8-C), 149.35 (4-C), 152.96 (2-C), 155.36 (6-C). ESI-HRMS (M+H)
+
 
calcd: 350.2012; found: 350.2006. 
1ʹ-(Thymin-1-yl)-2ʹ,3ʹ-dideoxy-α-D-apio-L-furanose (4.61a): Following the 
hydrogenation procedure described for compound 4.52a, compound 4.56 (150 mg, 
0.47 mmol) gave compound 4.61a (80 mg, 63 %) as a white solid. Alternatively, the 
compound 4.58 (110 mg, 0.32 mmol) was dissolved in THF (2 mL) and TBAF (1M, 
0.65 mL, 0.65 mmol) was added at room temperature. The reaction mixture was 
stirred for 3h, solvents evaporated, and the residue was subjected to silica-gel flash 
column chromatography (4-5% MeOH-CH2Cl2) to afford 4.61a (65 mg, 89%) as a 
white solid. 
1
H NMR (300 MHz, DMSO-d6) δ ppm 1.80 (d, J = 0.88 Hz, 3H, 5-CH3), 
1.96 - 2.13 (m, 2H, 2ʹ-H), 2.45-2.60 (m, 1H, 3ʹ-H), 3.33 - 3.48 (m, 2H, 5ʹ-H), 3.63 (dd, 
J = 8.20, 6.15 Hz, 1H, 4ʹ-H), 4.22 (dd, J = 8.20, 7.03 Hz, 1H, 4ʹ-H), 4.76 (t, J = 5.27 
Hz, 1H, 5ʹ-OH), 5.97 (dd, J = 6.44, 4.69 Hz, 1H, 1ʹ-H), 7.43 (d, J = 1.17 Hz, 1H, 6-H), 
11.24 (s, 1H, NH). 
13
C NMR (75 MHz, CD3OD) δ ppm 12.58 (5-CH3), 36.18 (2ʹ-C), 
41.73 (3ʹ-C), 63.92 (5ʹ-C), 73.31 (4ʹ-C), 88.50 (1ʹ-C), 111.36 (5-C), 137.85 (6-C), 
152.42 (2-C), 166.70 (4-C). ESI-HRMS (M+H)
+
 calcd: 227.1032; found: 227.1041. 
1ʹ-(Adenin-9-yl)-2ʹ,3ʹ-dideoxy-α-D-apio-L-furanose (4.61b): Compound 4.59 (350 
mg, 1.0 mmol) was dissolved in MeOH (15 mL) in a polypropylene vessel and NH4F 
(742 mg, 20 mmol) was added at room temperature. The reaction mixture was stirred 
at 50 °C for 48h; CH2Cl2 (20 mL) was added to the reaction vessel and filtered. The 
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filtrate was evaporated, and the residue was subjected to silica-gel flash column 
chromatography (10-12% MeOH-CH2Cl2) to afford 4.61b (205 mg, 87%) as a white 
solid. 
1
H NMR (300 MHz, DMSO-d6) δ ppm 2.21 (app-q, J = 6.74, 13.47 Hz, 1H, 2ʹ-
H), 2.54 (ddd, J = 3.51, 8.20, 12.89 Hz, 1H, 2ʹ-H), 2.76 (sep, J = 6.44 Hz, 1H, 3ʹ-H), 
3.44 (m, 2H, 5ʹ-H), 3.75 (dd, J = 5.27, 8.20 Hz, 1H, 4ʹ-H), 4.18 (t, J = 7.91 Hz, 1H, 4ʹ-
H), 4.82 (t, J = 4.98 Hz, 1H, 5ʹ-OH), 6.27 (dd, J = 3.22, 6.74 Hz, 1H, 1ʹ-H), 7.24 (br s, 
2H, 6-NH2’s), 8.15 (s, 1H, 2-H), 8.26 (s, 1H, 8-H).
 13
C NMR (75 MHz, DMSO-d6) 
33.88 (2ʹ-C), 40.44 (3ʹ-C), 62.18 (5ʹ-C), 70.85 (4ʹ-C), 84.31 (1ʹ-C), 119.15 (5-C), 
139.16 (8-C), 148.93 (4-C), 152.50 (2-C), 155.99 (6-C). ESI-HRMS (M+H)
+
 calcd: 
236.1147; found: 236.1131. 
1ʹ-(Thymin-1-yl)-2ʹ,3ʹ-dideoxy-α-D-apio-L-furanose [phenyl-(benzoxy-L-
alaninyl)] phosphate (4.62a): To a solution of 4.61a (0.095 g, 0.42 mmol) in 
anhydrous THF (10 mL) was added 1.0M solution of tert-butyl magnesium chloride in 
THF (0.84 mL, 0.84 mmol) and the reaction mixture was stirred under an argon 
atmosphere for 30 min. After this period, a solution of 4.60 (0.30 g, 0.84 mmol) in 
anhydrous THF (5 mL) was added dropwise and the reaction mixture was stirred at 
room temperature for 17h. After this period, the solvent was removed and the residue 
was purified by column chromatography, gradient elution of CHCl3/MeOH = 98/2 to 
95/5 to give 4.62a (0.051 g, 22%) as a white solid. 
31
P NMR (CD3OD, 202 MHz):  
3.80, 3.30. 
1
H NMR (CD3OD, 500 MHz):  7.40-7.30 (8H, m, H-6, PhO, OCH2Ph), 
7.23-7.18 (3H, m, PhO, OCH2Ph), 6.01-5.99 (0.5H, m, H-1ʹ), 5.98-5.96 (0.5H, m, H-
1ʹ), 5.17, 5.16 (2H, 2s, OCH2Ph), 4.28-4.21 (1H, m, H-4ʹ of one diastereoisomer), 
4.14-4.00 (3H, m, 3ʹ-CH2, CHCH3), 3.75-3.69 (1H, m, H-4ʹ of one diastereoisomer), 
2.80-2.74 (0.5H, m, H-3ʹ of one diastereoisomer), 2.73-2.66 (0.5H, m, H-3ʹ of one 
diastereoisomer), 2.22-2.07 (2H, m, H-2ʹ), 1.90 (3H, 2s, 5-CH3), 1.38 (1.5H, d, J = 
7.20 Hz, CHCH3 of one diastereoisomer), 1.36 (1.5H, d, J = 7.4 Hz, CHCH3 of one 
diastereoisomer). 
13
C NMR (CD3OD, 125 MHz):  12.56 (5-CH3), 20.38 (d, JC–P = 7.2 
Hz, CH3), 20.44 (d, JC–P = 7.2 Hz, CH3), 35.61, 35.64 (C-2ʹ), 39.73, 39.79 (C-3ʹ), 
51.66, 51.83 (CHCH3), 68.00 (OCH2Ph), 68.49 (d, JC–P = 6.0 Hz, 3ʹ-CH2), 68.53 (d, 
JC–P = 5.8 Hz, 3ʹ-CH2), 72.49, 72.54 (C-4ʹ), 88.36, 88.38 (C-1ʹ), 111.30, 111.33 (C-5), 
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121.50, 121.53, 121.57, 121.61, 126.22, 128.03, 129.33, 129.37, 129.40, 129.42, 
129.65, 129.66, 130.83 (arom H), 137.32 Cipso Bn), 137.74, 137.76 (C-6), 152.16, 
152.19, 152.23 (C-2, Cipso OPh), 166.52 (C-4), 174.75 (d, JC–P = 4.6 Hz, CO), 174.96 
(d, JC–P = 4.6 Hz, CO). ES-MS= 566.17 (M+Na
+
). HPLC = H2O/AcCN from 100/0 to 
0/100 in 30 min = retention time 18.24 min; H2O/MeOH from 100/0 to 0/100 in 30 
min = retention time 25.07 min. 
 1ʹ-(Adenin-9-yl)-2ʹ,3ʹ-dideoxy-α-D-apio-L-furanose [phenyl-(benzoxy-L-
alaninyl)] phosphate (4.62b): To a solution of 4.61b (0.10 g, 0.42 mmol) in 
anhydrous THF (10 mL) and anhydrous pyridine (2 mL) was added a solution of 34 
(0.45g, 1.26 mmol) in anhydrous THF (5 mL), followed by the addition dropwise 
under an argon atmosphere of anhydrous N-methylimidazole (0.10 mL, 1.26 mmol) 
and the reaction mixture was stirred at room temperature for 24h. After this period, a 
solution of 4.60 (0.30 g, 0.84 mmol) in anhydrous THF (3 mL) and anhydrous N-
methylimidazole (0.07 mL, 0.84 mmol) were added and the reaction mixture was 
stirred at room temperature for further 24h. After this period, the solvent was removed 
and the residue was purified by column chromatography, gradient elution of CH2Cl2, 
then CH2Cl2/MeOH = 98/2 then 96/4 then 90/10 to give a white solid which was 
triturated with diethyl ether to give 4.62b (0.035 g, 15%) as a white solid. 
31
P NMR 
(CD3OD, 202 MHz):  3.86, 3.31. 
1
H NMR (CD3OD, 500 MHz):  8.22, 8.21, 8.20, 
8.17 (2H, 4s, H-2, H-8), 7.37-7.16 (10H, m, arom H), 6.31 (0.5H, dd, J = 7.00 Hz, 
3.30 Hz, H-1ʹ of one diastereoisomer), 6.26 (0.5H, dd, J = 7.00 Hz, 3.20 Hz, H-1ʹ of 
one diastereoisomer), 5.16, 5.15 (2H, 2s, CH2Ph), 4.29-4.22 (1H, m, H-4ʹ), 4.18-4.02 
(3H, m, CHCH3, 3ʹ-CH2), 3.86-3.78 (1H, m, H-4ʹ), 3.03-2.89 (1H, m, H-3ʹ), 2.65-2.56 
(1H, m, H-2ʹ), 2.35-2.24 (1H, m, H-2ʹ), 1.39 (1.5H, d, J = 7.00 Hz, CH3 of one 
diastereoisomer), 1.37 (1.5H, d, J = 7.20 Hz, CH3 of one diastereoisomer). 
13
C NMR 
(CD3OD, 125 MHz):  20.35 (d, JC–P = 6.70 Hz, CHCH3), 20.41 (d, JC–P = 6.80 Hz, 
CHCH3), 35.38, 35.39 (C-2ʹ), 40.00 (d, JC–P = 2.70 Hz, C-3ʹ), 40.06 (JC–P = 2.80 Hz, 
C-3ʹ), 51.66, 51.83 (CHCH3), 67.95, 67.97 (CH2Ph), 68.63 (d, JC–P = 5.70 Hz, 3ʹ-
CH2), 68.75 (d, JC–P = 5.8 Hz, 3ʹ-CH2), 72.13, 72.15 (C-4ʹ), 86.98 (C-1ʹ), 120.65, 
121.48, 121.52, 121.57, 121.61, 126.18, 126.21, 129.31, 129.35, 129.37, 129.61, 
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129.72, 130.80 (arom H), 137.31 (Cipso Bn), 140.78 (C-2), 152.19 (d, JC–P = 5.50 Hz, 
Cipso OPh), 152.25 (d, JC–P = 4.70 Hz, Cipso OPh), 153.67, 153.81 (C-8), 157.30 (C-8), 
174.75 (d, JC–P = 4.70 Hz, CO), 174.96 (d, JC–P = 4.50 Hz, CO). ES- MS= 575.1640 
(M+Na
+
). HPLC = H2O/AcCN from 100/0 to 0/100 in 30 min = retention time 17.05 
min. 
1ʹ-(Adenin-9-yl)-2ʹ,3ʹ-dideoxy-α-D-apio-L-furanose triphosphate (4.65): 
Compound 4.61b (25 mg, 0.106 mmol) and tributylammonium pyrophosphate 4.64 
(117 mg, 0.212 mmol) were placed in a 50 mL and a 10 mL RB flask respectively, 
and dried under high vacuum for 1h. 2-chloro-4H-1,3,2-benzodioxaphosphinin-4-one 
4.63 (43 mg, 0.212 mmol) was placed in a separate 10 mL flask and dried briefly (10 
min) under high vacuum. Anhydrous DMF (0.25 mL) was added to each flask under 
argon atmosphere. Tributylamine (dried and stored over 4A molecular sieves, 0.3 mL) 
was added to the flask containing tributylammonium pyrophosphate (4.64) with 
stirring. The contents of this flask were added to the flask containing 2-chloro-4H-
1,3,2-benzodioxaphosphinin-4-one (4.63) and stirring continued for 1.5h. The cyclic 
phosphitodiphosphate formed was added to a flask containing compound 4.61b in 
DMF. After stirred for 1.5h, 3% iodine solution (9:1 pyridine-water, 2.25 mL) was 
added drop wise and stirred for 20 min followed by the addition of water (4 mL) and 
stirred for additional 1.5h. 3M NaCl solution (0.66 mL) was added to the reaction 
mixture. The reaction mixture was transferred to two centrifuge tubes (~4 mL each) 
and absolute ethanol (16 mL) was added to each tube, shaken well and immersed in 
powdered dry ice for 1h. The tubes were centrifuged (20 °C, 3200 rpm, 20 min), and 
the clear solution decanted to afford crude product as white solid. The crude product 
was dissolved in distilled water (3.0 mL) and purified using Source-15Q ion exchange 
HPLC (0.5 mL injection, 0→5 min, 100% H2O; 5→40 min, 100% H2O to 100% 1M 
TEAB buffer, linear gradient @flow rate 6 mL/min). The compound eluting at 33 min 
(or 0.8M TEAB buffer) was collected and lyophilized to afford triethylammonium salt 
of triphosphate 4.65 as white solid (45 mg, 48%). 
1
H NMR (300 MHz, D2O) δ ppm 
1.21 (t, J = 7.32 Hz, 36H, HN(CH2CH3)3), 2.46 (dt, J = 14.42, 7.29 Hz, 1H, 2ʹ-H), 
2.66 (ddd, J = 14.13, 8.13, 3.22 Hz, 1H, 2ʹ-H), 3.10 (q, J = 7.32 Hz, 25H, 3ʹ-H & 
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HN(CH2CH3)3), 3.95 (dd, J = 8.93, 6.30 Hz, 1H, 4ʹ-H), 3.99 - 4.12 (m, 2H, 5ʹ-H), 4.27 
(dd, J = 8.79, 7.62 Hz, 1H, 4ʹ-H), 6.37 (dd, J = 7.03, 3.22 Hz, 1 H), 8.16 (s, 1H, 2-H), 
8.28 (s, 1H, 8-H). 
13
C NMR (75 MHz, D2O) δ ppm 8.44 (HN(CH2CH3)3), 33.86 (2ʹ-
C), 38.35 (d, Jp-c = 8.29 Hz, 3ʹ-C), 46.69 (HN(CH2CH3)3), 66.86 (d, Jp-c = 6.08 Hz, 5ʹ-
C), 71.38 (4ʹ-C), 85.31 (1ʹ-C), 119.09 (5-C), 140.22 (8-C) 148.61 (4-C), 152.73 (2-C), 
155.69 (6-C). 
31
P NMR (121 MHz, D2O) δ ppm -22.64 (dd, J = 21.11, 19.63 Hz, βP), -
11.04 (d, J = 19.63 Hz, αP), -6.34 (d, J = 21.11 Hz, γP). ESI-HRMS (M-H)- calcd: 
473.9981; found: 473.9982. 
1ʹ-(Thymin-1-yl)-5ʹ-O-benzyl-β-D-apio-D-furanose (4.66): Using Vorbrüggen 
coupling condition-A and then following procedure described for 4.47, compound 
4.35 (500 mg, 1.36 mmol) rendered 4.66 (460 mg, 97%) as white foam. 
1
H NMR (300 
MHz, CDCl3) δ ppm 1.89 (d, J = 1.17 Hz, 3H, 5-CH3), 3.49 (d, J = 0.88 Hz, 1H, 3ʹ-
OH), 3.52 (s, 2H, 5ʹ-H), 4.07 (d, J = 9.67 Hz, 1H, 4ʹ-Hb), 4.24 (dd, J = 9.96, 0.88 Hz, 
1H, 4ʹ-Ha), 4.27 (dd, J = 5.57, 3.81 Hz, 1H, 2ʹ-H), 4.38 (d, J = 4.10 Hz, 1H, 2ʹ-OH), 
4.56 (s, 2H, PhCH2), 5.71 (d, J = 5.86 Hz, 1H, 1ʹ-H), 7.22 (d, J = 1.17 Hz, 1H, 6-H), 
7.27 - 7.40 (m, 5H, PhCH2), 9.18 (s, 1H, NH). 
13
C NMR (75 MHz, CDCl3) δ ppm 
12.51 (5-CH3), 70.96 (5ʹ-C), 73.69 (PhCH2), 75.67 (4ʹ-C), 76.91 (2ʹ-C), 78.06 (3ʹ-C), 
92.38 (1ʹ-C), 111.02 (5-C), 127.77, 128.04, 128.55, 137.41 (PhCH2), 135.54 (6-C), 
151.47 (2-C), 163.74 (4-C). ESI-HRMS [M+H]
+
 calcd, 349.1400; found, 349.1414. 
1ʹ-(Adenin-9-yl)-5ʹ-(O-benzyl)-β-D-apio-D-furanose (4.67): Using Vorbrüggen 
coupling condition-B and then following procedure described for 4.48, compound 
4.35 (2.7 g, 7.37 mmol) rendered 4.67 (1.2 g, 46%) as white foam. 
1
H NMR (300 
MHz, DMSO-d6) δ ppm 3.53 (q, J = 9.96 Hz, 2H, 5ʹ-H), 3.83 (d, J = 9.08 Hz, 1H, 4ʹ-
H), 4.36 (d, J = 9.96 Hz, 1H, 4ʹ-H), 4.58 (s, 2H, PhCH2), 4.89 (t, J = 7.18 Hz, 1H, 2ʹ-
H), 5.08 (s, 1H, 3ʹ-OH), 5.53 (d, J = 6.74 Hz, 1H, 2ʹ-OH), 5.88 (d, J = 7.62 Hz, 1H, 1ʹ-
H), 7.19 - 7.29 (br.s, 2H, NH2), 7.29 - 7.45 (m, 5H, PhCH2), 8.14 (s, 1H, 2-H), 8.34 (s, 
1H, 8-H). 
13
C NMR (75 MHz, DMSO-d6) δ ppm 71.28 (5ʹ-C), 72.57 (PhCH2), 73.78 
(2ʹ-C), 74.83 (4ʹ-C), 77.45 (3ʹ-C), 87.78 (1ʹ-C), 119.40 (5-C), 127.29, 127.38, 128.24, 
138.40 (PhCH2), 140.25 (8-C), 149.64 (4-C), 152.56 (2-C), 156.06 (6-C). ESI-HRMS 
[M+H]
+
 calcd, 358.1515; found, 358.1516. 
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1ʹ-(Thymin-1-yl)-2ʹ,3ʹ-(O-thiocarbonyl)-5ʹ-(O-benzyl)-β-D-apio-D-furanose (4.68):
 
To a solution of 4.66 (200 mg, 0.57 mmol) in DMF (4 mL) was added 
thiocarbonyldiimidazole (112 mg, 0.63 mmol) and the mixture heated to 80 °C for 90 
minutes. The volatiles were removed under reduced pressure and the residue was 
purified by silica-gel column chromatography (2% MeOH in CH2Cl2) to afford the 
title thiacarbonate 4.68 (200 mg, 89%) as a pale yellow solid. 
1
H NMR (300 MHz, 
CDCl3) δ ppm 1.94 (d, J = 1.17 Hz, 3H, 5-CH3), 3.89 (d, J = 11.13 Hz, 1H, 5ʹ-H), 4.17 
(d, J = 10.84 Hz, 1H, 5ʹ-H), 4.30 - 4.42 (m, 2H, 4ʹ-H), 4.57 - 4.71 (m, 2H, PhCH2), 
5.47 (d, J = 0.88 Hz, 1H, 1ʹ-H), 5.82 (d, J = 1.17 Hz, 1H, 2ʹ-H), 7.03 (d, J = 1.17 Hz, 
1H, 6-H), 7.27 - 7.38 (m, 5H, PhCH2), 9.35 (s, 1H, NH). 
13
C NMR (75 MHz, CDCl3) 
δ ppm 12.29 (5-CH3), 67.73 (5ʹ-C), 73.74 (PhCH2), 77.44 (4ʹ-C), 88.71 (2ʹ-C), 97.49 
(1ʹ-C), 100.15 (3ʹ-C), 112.22 (5-C), 127.63, 127.99, 128.52, 137.05 (PhCH2), 139.36 
(6-C), 151.18 (2-C), 163.57 (4-C), 189.42 (CS). ESI-HRMS [M+H]
+
 calcd, 391.0964; 
found, 391.0544. 
1ʹ-(Adenin-9-yl)-2ʹ,3ʹ-(O-thiocarbonyl)-5ʹ-(O-benzyl)-β-D-apio-D-furanose (4.69): 
Following the procedure described for the synthesis of 4.68, compound 4.67 (300 mg, 
0.84 mmol) rendered title compound 4.69 (260 mg, 78%) as a pale yellow solid. 
1
H 
NMR (300 MHz, CDCl3) δ ppm 4.03 (d, J = 10.84 Hz, 1H, 5ʹ-H), 4.33 (d, J = 11.13 
Hz, 1H, 4ʹ-H), 4.42 (d, J = 11.13 Hz, 1H, 4ʹ-H), 4.45 (d, J = 10.54 Hz, 1H, 5ʹ-H), 4.61, 
4.75 (d, J = 12.30 Hz, 2H, PhCH2), 5.74 (br. s, 2H, NH2), 6.14 (s, 1H, 2ʹ-H), 6.20 (s, 
1H, 1ʹ-H), 7.29 - 7.40 (m, 5H, PhCH2), 7.87 (s, 1H, 8-H) 7.95 (s, 1H, 2-H). 
13
C NMR 
(75 MHz, CDCl3) δ ppm 66.95 (5ʹ-C), 73.86 (PhCH2), 75.00 (4ʹ-C), 88.29 (2ʹ-C), 
90.33 (1ʹ-C), 99.62 (3ʹ-C), 119.90 (5-C), 127.98, 128.22, 128.63, 136.93 (PhCH2), 
140.28 (8-C), 149.13 (4-C), 153.04 (2-C), 155.59 (6-C), 189.43 (CS). ESI-HRMS 
[M+H]
+
 calcd, 400.1079; found, 400.1060. 
1ʹ-(Thymin-1-yl)-2ʹ,3ʹ-(dideoxydidehydro)-5ʹ-(O-benzyl)-β-D-apio-D-furanose 
(4.70): A solution of compound 4.67 (180 mg, 0.46 mmol) in trimethyphosphite 
(P(OCH3)3, 8.0 mL) was heated to 120 °C for 6h. The volatiles materials were 
removed under reduced pressure and then co-evoporated 2-3 times with toluene. the 
residue was purified by silica-gel column chromatography (0-2% MeOH in CH2Cl2) 
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to afford 4.70 (130 mg, 90%) as a foam. 
1
H NMR (300 MHz, CDCl3) δ ppm 1.91 (d, J 
= 1.17 Hz, 3H, 5-CH3), 4.25 (s, 2H, 5ʹ-H), 4.58 (s, 2H, PhCH2), 4.63 - 4.74 (m, 1H, 4ʹ-
H), 4.77 - 4.90 (m, 1H, 4ʹ-H), 5.67 - 5.76 (m, 1H, 2ʹ-H) 6.91 (q, J=1.17 Hz, 1H, 6-H), 
7.00 (m, 1H, 1ʹ-H), 7.29 - 7.44 (m, 5H, PhCH2), 8.47 (br. s, 1H, NH). 
13
C NMR (75 
MHz, CDCl3) δ ppm 12.60 (5-CH3), 65.08 (5ʹ-CH2), 73.18 (PhCH2), 75.57 (4ʹ-C), 
90.91 (1ʹ-C), 111.26 (5-C), 119.90 (2ʹ-C), 127.77, 128.11, 128.61, 137.28 (PhCH2), 
135.33 (6-C), 145.44 (3ʹ-C), 150.47 (2-C), 163.63 (4-C). ESI-HRMS [M+Na]+ calcd, 
337.1159; found, 337.1168.  
1ʹ-(Thymin-1-yl)-2ʹ,3ʹ-(dideoxy)-β/α-D-apio-D/L-furanose (4.1a + 4.61a): 
Following the procedure described for the synthesis of 4.52a, compound 4.70 (120 mg, 
0.38 mmol) rendered 4.1a and 4.61a as inseparable mixtures in 4: 1 ratio respectively 
(77 mg, 89%) as a white solid.  
1ʹ-(Adenin-9-yl)-β-D-apio-D-furanose (4.3b): Following the procedure described for 
the synthesis of 4.53b, compound 4.67 (1.2g, 3.37 mmol) rendered title compound 
4.3b (800 mg, 89%) as a white solid. 
1
H NMR (300 MHz, DMSO-d6) δ ppm 3.46 (q, J 
= 11.13 Hz, 1H, 5ʹ-H), 3.76 (d, J = 9.08 Hz, 1H, 4ʹ-H), 4.31 (d, J = 9.37 Hz, 1H, 4ʹ-H), 
4.80 (t, J = 6.44 Hz, 1H, 2ʹ-H), 4.85 (s, 1H, 3ʹ-OH), 4.91 (br. s, 1H, 5ʹ-OH), 5.42 (d, J 
= 6.44 Hz, 1H, 2ʹ-OH), 5.88 (d, J = 7.62 Hz, 1H, 1ʹ-H), 7.26 (s, 2H, NH2), 8.15 (s, 1H, 
2-H), 8.33 (s, 1H, 8-H). 
13
C NMR (75 MHz, DMSO-d6) δ ppm 62.42 (5ʹ-C), 73.37 (2ʹ-
C), 74.53 (4ʹ-C), 78.23 (3ʹ-C), 87.65 (1ʹ-C), 119.27 (5-C), 139.93 (8-C), 149.72 (4-C), 
152.62 (2-C), 156.04 (6-C). ESI-HRMS for [M+H]
+
 calcd, 268.1046; found, 268.1107. 
1,2-O-Isopropylidene-3-deoxy-β-D-apio-L-furanose (4.30): Following the procedure 
described for the synthesis of 4.52a, compound 4.31 (3.7 g, 14 mmol) rendered 4.30 
(2.2 g, 90%) as colorless oil. 
1
H NMR (300 MHz, CDCl3) δ ppm 1.34 (d, J = 0.59 Hz, 
3H, C(CH3)2), 1.53 (s, 3H, C(CH3)2), 2.21 (br. s, 1H, 5-OH), 2.34 (ddtd, J = 11.44, 
6.94, 5.97, 5.97, 4.83 Hz, 1H, 3-H), 3.82 - 3.91 (m, 3H, 4-H & 5-H’s), 3.97 (dd, J = 
8.49, 7.32 Hz, 1H, 4-H), 4.73 (t, d, J = 4.39 Hz,1H, 2-H), 5.86 (d, J = 3.81 Hz, 1H, 1-
H). 
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1,2-O-Isopropylidene-3-deoxy-α-D-apio-D-furanose (4.71): To a solution of 
compound 4.30 (2.2 g, 12.63 mmol) in 400 mL of acetone was added concentrated 
sulfuric acid (2.2 mL) and the mixture was stirred at room temperature for 1.5h. Then 
sodium carbonate (14 g) was added and stirred at room temperature for 45 minutes. 
Inorganic salts were removed by filtration and the filtrate concentrated under reduced 
pressure to afford oil. TLC indicated the conversion in favour of required isomer 
(roughly 2:1). The title compound is slightly more polar than the starting material (Rf 
after two runs: 0.35 for 4.71 and 0.4 for 4.30; eluent, 2.5% MeOH in CH2Cl2). Silica-
gel flash column chromatography (0.5-1.5% MeOH in CH2Cl2) afforded title 
compound and starting material. After three cycles 1.6 g (73%) of 4.71 was procured 
as colorless oil. 
1
H NMR (300 MHz, CDCl3) δ ppm 1.31 (d, J = 0.59 Hz, 3H, 
C(CH3)b), 1.50 (s, 3H, C(CH3)a), 1.89 (br. s, 1H, 5-OH), 2.36 - 2.46 (m, 1H, 3-H), 
3.58 (dd, J = 6.59, 3.37 Hz, 2H, 5-CH2), 3.83 (d, J = 9.08 Hz, 1H, 4-Hb), 4.10 (dd, J = 
8.93, 5.13 Hz, 1H, 4-Ha), 4.60 (d, J = 3.51 Hz, 1H, 2-H), 5.81 (d, J = 3.81 Hz, 1H, 1-
H). 
13
C NMR (75 MHz, CDCl3) δ ppm 26.20 (C(CH3)b), 26.81 (C(CH3)a), 48.07 (3-
C), 62.00 (5-C), 68.74 (4-C), 82.28 (2-C), 105.61 (1-C), 111.25 (C(CH3)2). 
1,2-O-Isopropylidene-3-deoxy-5-(O-benzyl)-α-D-apio-D-furanose (4.32): To an ice 
cold solution of compound 4.71 (1.6 g, 9.2 mmol) in DMF (30 mL) was added NaH 
(60% in mineral oil, 0.55g, 13.8 mmol) and then benzyl bromide (1.64 mL, 13.8 
mmol) drop wise. The reaction mixture was stirred at room temperature overnight. 
Methanol (5 mL) was added and stirred further for 30 minutes. The volatile materials 
were removed under vacuo and the residue was partitioned between ethylacetate and 
water. The organic layer was separated, dried, evaporated and the residue purified by 
column chromatography (5-15% EtOAc in hexanes) to afford 4.32 (2.3 g, 95%) as 
colorless oil. 
1
H NMR (300 MHz, CDCl3) δ ppm 1.31 (d, J = 0.59 Hz, 3H, C(CH3)b), 
1.51 (s, 3H, C(CH3)a), 2.56 (td, J = 7.54, 5.13 Hz, 1H, 3-H), 3.37 (d, J = 7.62 Hz, 2H, 
5-CH2), 3.83 (d, J = 8.79 Hz, 1H, 4-Hb) 4.09 (dd, J = 8.93, 5.13 Hz, 1H, 4-Ha) 4.51 (d, 
J = 3.22 Hz, 2H, PhCH2), 4.56 (d, J = 3.51 Hz, 1H, 2-H), 5.79 (d, J = 3.51 Hz, 1H, 1-
H), 7.27 - 7.41 (m, 5H, PhCH2). 
13
C NMR (75 MHz, CDCl3) δ ppm 26.30 (C(CH3)b), 
26.90 (C(CH3)a), 46.07 (3-C), 68.78 (4&5-C), 73.34 (PhCH2), 82.39 (2-C), 105.55 (1-
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C), 111.24 (C(CH3)2) 127.77, 127.90, 128.59, 138.06 (PhCH2). ESI-HRMS for 
[M+K]
+
 calcd, 303.0999; found, 303.1078. 
1,2-Di-O-acetyl-3-deoxy-5-(O-benzyl)-α/β-D-apio-D-furanose (4.72): Following the 
procedure described for the synthesis of 4.36, compound 4.32 (1.3 g, 4.92 mmol) 
rendered 4.72 (1.2 g, 79%) as colorless oil. Mixture of α+β (3:2). 1H NMR (300 MHz, 
CDCl3) δ ppm 2.00 (s, major, C(CH3)2) 2.04 (s, minor, C(CH3)2) 2.07 (s, minor, 
C(CH3)2) 2.08 (s, major, C(CH3)2), 2.56 - 2.69 (m, major, 3-H) 2.69 - 2.83 (m, minor, 
3-H) 3.46 - 3.74 (m, major & minor, 5-H) 3.80 - 3.94 (m, major & minor, 4-H) 4.20 – 
4.34 (m, major & minor, 4-H) 4.51 (s, minor, PhCH2), 4.54 (s, major, PhCH2), 5.05 (t, 
J = 4.10 Hz, minor, 2-H), 5.08 (d, J = 2.64 Hz, major, 2-H), 6.13 (s, major, 1-H), 6.33 
(d, J = 4.39 Hz, minor, 1-H), 7.27 - 7.40 (m, major & minor, PhCH2). ESI-HRMS for 
[M+K]
+
 calcd, 347.0897; found, 347.0898. 
1ʹ-(Thymin-1-yl)-3ʹ-deoxy-5ʹ-O-benzyl-β-D-apio-D-furanose (4.73): Using 
Vorbrüggen coupling condition-A and then following procedure described for 4.47, 
compound 4.72 (550 mg, 1.78 mmol) gave 4.73 (360 mg, 60%) as white foam. 
1
H 
NMR (300 MHz, CDCl3) δ ppm 1.84 (d, J = 0.7 Hz, 3H, 5-CH3), 2.68 (ddt, J = 12.72, 
7.65, 6.41, 6.41 Hz, 1H, 3ʹ-H), 3.51 (dd, J = 9.51, 6.64 Hz, 1H, 5ʹ-H), 3.59 (dd, J = 
9.51, 5.02 Hz, 1H, 5ʹ-H), 4.01 (dd, J = 8.79, 7.89 Hz, 1H, 4ʹ-H), 4.22 (dd, J = 6.19, 
3.86 Hz, 1H, 2ʹ-H), 4.32 (dd, J = 8.79, 7.89 Hz, 1H, 4ʹ-H), 4.50 (s, 2H, PhCH2), 5.60 
(d, J = 3.77 Hz, 1H, 1ʹ-H), 7.24 (d, J = 1.26 Hz, 1H, 6-H), 7.26 - 7.38 (m, 5H, PhCH2), 
9.77 (s, 1H, NH). 
13
C NMR (75 MHz, CDCl3) δ ppm 12.53 (5-CH3), 46.38 (3ʹ-C), 
68.58 (5ʹ-C), 71.44 (4ʹ-C), 73.31 (PhCH2), 79.23 (2ʹ-C), 94.34 (1ʹ-C), 110.43 (5-C), 
127.66, 127.88, 128.48 (PhCH2) 134.98 (6-C) 137.78 (PhCH2), 151.58 (2-C), 164.11 
(4-C). ESI-HRMS for [M+H]
+
 calcd, 333.1445; found, 333.1452. 
1ʹ-(Adenin-9-yl)-3ʹ-deoxy-5ʹ-O-benzyl-β-D-apio-D-furanose (4.74): Using 
Vorbrüggen coupling condition-B and then following procedure described for 4.48, 
compound 4.72 (1.55 g, 5 mmol) gave 4.74 (480 mg, 28%) and its α-anomer (200 mg, 
11%) as white solid. 
1
H NMR (300 MHz, DMSO-d6) δ ppm 2.60 (quind, J = 8.13, 
4.98 Hz, 1H, 3ʹ-H), 3.61 (t, J = 8.49 Hz, 1H, 5ʹ-H), 3.70 (dd, J = 9.67, 4.98 Hz, 1H, 5ʹ-
Chapter 4 
140 
H), 4.05 (t, J = 8.79 Hz, 1H, 4ʹ-Hb), 4.17 (t, J = 8.20 Hz, 1H, 4ʹ-Ha), 4.51 (s, 2H, 
PhCH2), 4.70 (dt, J = 7.62, 5.71 Hz, 1H, 2ʹ-H), 5.69 (d, J = 5.86 Hz, 1H, 2ʹ-OH), 5.79 
(d, J = 5.56 Hz, 1H, 1ʹ-H), 7.26 (s, 2H, NH2), 7.29 - 7.40 (m, 5H, PhCH2), 8.13 (s, 1H, 
2-H), 8.31 (s, 1H, 8-H). 
13
C NMR (75 MHz, DMSO-d6) δ ppm 46.65 (3ʹ-C), 69.19 (5ʹ-
C), 70.45 (4ʹ-C), 72.16 (PhCH2), 75.12 (2ʹ-C), 89.96 (1ʹ-C), 119.23 (5-C), 127.44, 
127.46, 128.27, 138.34 (PhCH2), 139.79 (8-C), 149.42 (4-C), 152.57 (2-C), 156.05 (6-
C). ESI-HRMS for [M+H]
+
 calcd, 342.1566; found, 342.1553. Spectral data for 1ʹ-
(Adenin-9-yl)-3ʹ-deoxy-5ʹ-O-benzyl-α-D-apio-D-furanose. 1H NMR (300 MHz, 
DMSO-d6) δ ppm 2.69 - 2.83 (m, 1H, 3ʹ-H), 3.55 (dd, J = 9.52, 7.18 Hz, 1H, 5ʹ-H), 
3.66 (dd, J = 9.52, 5.13 Hz, 1H, 5ʹ-H), 3.73 (dd, J = 8.49, 7.03 Hz, 1H, 4ʹ-Hb), 4.29 (q, 
J = 5.56 Hz, 1H, 2ʹ-H), 4.36 (t, J = 8.20 Hz, 1H, 4ʹ-Ha), 4.54 (s, 2H, PhCH2), 5.53 (d, 
J = 5.27 Hz, 1H, 2ʹ-OH), 6.19 (d, J = 5.27 Hz, 1H, 1ʹ-H), 7.22 (s, 2H, NH2), 7.26 - 
7.43 (m, 5H, PhCH2), 8.14 (s, 1H, 2-H), 8.16 (s, 1H, 8-H). 
13
C NMR (75 MHz, 
DMSO-d6) δ ppm 45.32 (3ʹ-C), 69.17 (4ʹ-C), 69.42 (5ʹ-C), 71.98 (2ʹ-C) 72.22 (PhCH2), 
84.36 (1ʹ-C), 118.23 (5-C), 127.48, 127.54, 128.30, 138.33 (PhCH2), 140.21 (8-C), 
149.55 (4-C), 152.35 (2-C), 155.84 (6-C). 
1ʹ-(Thymin-1-yl)-3ʹ-deoxy-β-D-apio-D-furanose (4.2a): Following the procedure 
described for the synthesis of 4.52a, compound 4.73 (350 mg, 1.05 mmol) gave 4.2a 
(220 mg, 86%) as white solid.
 1
H NMR (300 MHz, CD3OD) δ ppm 1.89 (d, J = 1.17 
Hz, 3H, 5-CH3) 2.39 - 2.55 (m, 1H, 3ʹ-H), 3.65 (dd, J = 10.84, 6.74 Hz, 1H, 5ʹ-H), 
3.73 (dd, J = 10.98, 4.83 Hz, 1H, 5ʹ-H), 4.02 - 4.10 (t, J = 8.20 Hz, 1H, 4ʹ-H), 4.17 - 
4.26 (m, 2H, 2ʹ & 4ʹ-H’s), 5.72 (d, J = 5.56 Hz, 1H, 1ʹ-H), 7.46 (d, J = 1.17 Hz, 1H, 6-
H).
 13
C NMR (75 MHz, CD3OD) δ ppm 11.16 (5-CH3), 48.29 (3ʹ-C), 60.46 (5ʹ-C), 
70.25 (4ʹ-C), 75.70 (2ʹ-C), 92.29 (1ʹ-C), 110.42 (5-C), 137.14 (6-C), 151.56 (2-C), 
165.23 (4-C). ESI-HRMS for [M+H]
+
 calcd, 243.0981; found, 243.0975. 
1ʹ-(Adenin-9-yl)-3ʹ-deoxy-β-D-apio-D-furanose (4.2b): Following the procedure 
described for the synthesis of 4.52b, compound 4.74 (600 mg, 1.76 mmol) gave 4.2b 
(390 mg, 88%) as white solid.
 1
H NMR (300 MHz, DMSO-d6) δ ppm 2.34 - 2.48 (m, 
1H, 3ʹ-H), 3.56 (dd, J = 10.69, 7.76 Hz, 1H, 5ʹ-H), 3.68 (dd, J = 10.69, 4.54 Hz, 1H, 
5ʹ-H), 4.04 (t, J = 8.79 Hz, 1H, 4ʹ-H), 4.13 (t, J = 8.20 Hz, 1H, 4ʹ-H), 4.62 (t, J = 6.44 
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Hz, 1H, 2ʹ-H), 4.79 (br.s, 1H, 5ʹ-OH), 5.61 (br.s, 1H, 2ʹ-OH), 5.79 (d, J = 5.56 Hz, 1H, 
1ʹ-H), 7.26 (s, 2H, NH2), 8.15 (s, 1H, 2-H), 8.31 (s, 1H, 8-H).
 13
C NMR (75 MHz, 
DMSO-d6) δ ppm 48.98 (3ʹ-C), 60.18 (5ʹ-C), 70.29 (4ʹ-C), 75.12 (2ʹ-C), 89.98 (1ʹ-C), 
119.15 (5-C), 139.61 (8-C), 149.46 (4-C), 152.59 (2-C), 156.04 (6-C). ESI-HRMS for 
[M+H]
+
 calcd, 252.1097; found, 252.1081. 
1ʹ-(Thymin-1-yl)-3ʹ-deoxy-5ʹ-O-(tert-butyldimethylsilyl)-β-D-apio-D-furanose 
(4.75): Following a similar procedure described for compound 4.54, compound 4.2a 
(200 mg, 0.83 mmol) afforded compound 4.75 (260 mg, 88%) as a foam. 
1
H NMR 
(300 MHz, CDCl3) δ ppm 0.05 (s, 6H, Si(CH3)2), 0.87 (s, 9H, C(CH3)3), 1.92 (d, J = 
1.17 Hz, 3H, 5-CH3), 2.51 - 2.66 (m, 1H, 3ʹ-H), 3.69 (dd, J = 10.54, 6.15 Hz, 1H, 5ʹ-
H), 3.75 (dd, J = 10.25, 4.69 Hz, 1H, 5ʹ-H), 3.94 - 4.07 (m, 2H, 4ʹ-H & 2ʹ-OH), 4.18 
(ddd, J = 6.96, 4.03, 2.78 Hz, 1H, 2ʹ-H), 4.28 (t, J = 8.35 Hz, 1H, 4ʹ-H), 5.61 (d, J = 
4.10 Hz, 1H, 1ʹ-H), 7.27 (d, J = 1.17 Hz, 1H, 6-H), 9.42 (s, 1H, NH). 13C NMR (75 
MHz, CDCl3) δ ppm -5.40, -5.35 (SiCH3), 12.71 (5-CH3), 18.34 (C(CH3)3), 25.92 
(C(CH3)3), 48.36 (3ʹ-C), 60.80 (5ʹ-C), 70.95 (4ʹ-C), 78.74 (2ʹ-C), 94.35 (1ʹ-C), 110.69 
(5-C), 134.88 (6-C), 151.72 (2-C), 164.07 (4-C). ESI-HRMS for [M+H]
+
 calcd, 
357.1846; found, 357.1855. 
1ʹ-(Adenin-9-yl)-3ʹ-deoxy-5ʹ-O-(tert-butyldimethylsilyl)-β-D-apio-D-furanose 
(4.76): Following a similar procedure described for compound 4.54, compound 4.2b 
(350 mg, 1.39 mmol) afforded compound 4.76 (415 mg, 82%) as a white solid. 
1
H 
NMR (300 MHz, CDCl3) δ ppm 0.03, 0.04 (s’s, 2 x 3H, Si(CH3)3), 0.85 (s, 9H, 
C(CH3)3), 2.64 - 2.79 (m, 1H, 3ʹ-H), 3.76 (dd, J = 10.40, 6.30 Hz, 1H, 5ʹ-H), 3.85 (dd, 
J = 10.40, 4.54 Hz, 1H, 5ʹ-H), 4.15 (t, J = 9.08 Hz, 1H, 4ʹ-H), 4.30 - 4.40 (t, J = 8.49 
Hz, 1H, 4ʹ-H), 4.52 (dd, J = 8.64, 5.71 Hz, 1H, 2ʹ-H), 5.69 (br.s, 1H, 2ʹ-OH), 5.79 (d, J 
= 5.86 Hz, 1H, 1ʹ-H), 5.95 (s, 2H, NH2), 7.97 (s, 1H, 8-H), 8.27 (s, 1H, 2-H). 
13
C 
NMR (75 MHz, CDCl3) δ ppm -5.53, -5.49 (SiCH3), 18.24 (C(CH3)3), 25.80 
(C(CH3)3), 47.70 (3ʹ-C), 61.06 (5ʹ-C), 71.08 (4ʹ-C), 77.36 (2ʹ-C), 92.83 (1ʹ-C), 120.08 
(5-C), 138.38 (8-C), 149.18 (4-C), 152.51 (2-C), 155.53 (6-C). ESI-HRMS for 
[M+H]
+
 calcd, 366.1961; found, 366.1962. 
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1ʹ-(Thymin-1-yl)-2ʹ,3ʹ-dideoxy-5ʹ-(tert-butyldimethylsilyl)-β-D-apio-D-furanose 
(4.77): Following a similar procedure described for compound 4.56, compound 4.75 
(250 mg, 0.70 mmol) gave compound 4.77 (215 mg, 90 %) as a white foam. 
1
H NMR 
(300 MHz, CDCl3) δ ppm 0.06 (s, 6H, SiCH3), 0.89 (s, 9H, C(CH3)3), 1.77 (ddd, J = 
13.25, 8.86, 7.18 Hz, 1H, 2ʹ-H), 1.94 (d, J = 1.17 Hz, 3H, 5-CH3), 2.43 - 2.55 (m, 1H, 
2ʹ-H), 2.55 - 2.72 (m, 1H, 3ʹ-H), 3.60 (dd, J = 10.25, 5.86 Hz, 1H, 5ʹ-H), 3.67 (dd, J = 
10.25, 4.98 Hz, 1H, 5ʹ-H), 3.94 (t, J = 7.80 Hz, 1H, 4ʹ-H), 4.07 (t, J = 8.05 Hz, 1H, 4ʹ-
H), 6.06 (dd, J = 7.03, 6.44 Hz, 1H, 1ʹ-H), 7.21 (q, J = 1.18 Hz,1H, 6-H), 8.31 (br.s, 
1H, NH). 
13
C NMR (75 MHz, CDCl3) δ ppm -5.47, -5.44 (SiCH3), 12.62 (5-CH3), 
18.25 (C(CH3)3), 25.82 (C(CH3)3), 34.57 (2ʹ-C), 40.88 (3ʹ-C), 62.64 (5ʹ-C), 71.02 (4ʹ-
C), 86.63 (1ʹ-C), 110.87 (5-C), 134.93 (6-C), 150.34 (2-C), 163.79 (4-C). ESI-HRMS 
for [M+H]
+
 calcd, 341.1897; found, 341.1891. 
1ʹ-(Adenin-9-yl)-2ʹ,3ʹ-dideoxy-5ʹ-(tert-butyldimethylsilyl)-β-D-apio-D-furanose 
(4.78): Following a similar procedure described for compound 4.56, compound 4.76 
(400 mg, 1.10 mmol) gave compound 4.78 (310 mg, 81 %) as a white foam.
 1
H NMR 
(300 MHz, CDCl3) δ ppm 0.05 (s, 6H, SiCH3), 0.88 (s, 9H, C(CH3)3), 2.33 - 2.50 (m, 
1H, 2ʹ-H), 2.57 - 2.81 (m, 2H, 2ʹ & 3ʹ-H’s), 3.71 (d, J = 5.27 Hz, 2H, 5ʹ-H), 4.04 (t, J 
= 8.20 Hz,1H, 4ʹ-H), 4.14 (t, J = 7.59 Hz, 1H, 4ʹ-H), 5.82 (br.s, 2H, NH2), 6.29 (t, J = 
5.86 Hz,1H, 1ʹ-H), 8.05 (s, 1H, 8-H), 8.36 (s, 1H, 2-H). 13C NMR (75 MHz, CDCl3) δ 
ppm -5.44 (SiCH3), 18.29 (C(CH3)3), 25.85 (C(CH3)3)’ 34.56 (2ʹ-C), 41.59 (3ʹ-C), 
63.00 (5ʹ-C), 71.09 (4ʹ-C), 85.50 (1ʹ-C), 120.22 (5-C), 138.43 (8-C), 149.71 (4-C), 
153.00 (2-C), 155.46 (6-C). ESI-HRMS for [M+H]
+
 calcd, 350.2012; found, 350.2009. 
1ʹ-(Thymin-1-yl)-2ʹ,3ʹ-dideoxy-β-D-apio-D-furanose (4.1a): Following a similar 
procedure described for the synthesis of compound 4.61b, compound 4.77 (200 mg, 
0.59 mmol) gave compound 4.1a (115 mg, 86 %) as a white solid. 
1
H NMR (300 MHz, 
CDCl3) δ ppm 1.71 (t, J = 4.69 Hz, 1H, 5ʹ-OH), 1.74 - 1.86 (m, 1H, 2ʹ-H), 1.94 (d, J = 
1.46 Hz, 3H, 5-CH3), 2.51 - 2.75 (m, 2H, 2ʹ & 3ʹ-H’s), 3.64 - 3.81 (m, 2H, 5ʹ-H), 3.98 
(dd, J = 8.79, 7.03 Hz, 1H, 4ʹ-H), 4.07 - 4.16 (m, 1H, 4ʹ-H), 6.02 (t, J = 6.59 Hz, 1H, 
1ʹ-H), 7.27 - 7.30 (q, J = 1.44 Hz, 1H, 6-H), 8.43 (br.s, 1H, NH). 13C NMR (75 MHz, 
CDCl3) δ ppm 12.64 (5-CH3), 34.70 (2ʹ-C), 40.65 (3ʹ-C), 63.23 (5ʹ-C), 71.16 (4ʹ-C), 
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86.92 (1ʹ-C), 110.78 (5-C), 135.28 (6-C), 150.26 (2-C), 163.63 (4-C). ESI-HRMS for 
[M-H]
-
 calcd, 225.0881; found, 225.0875. 
1ʹ-(Adenin-9-yl)-2ʹ,3ʹ-dideoxy-α-D-apio-L-furanose (4.1b): Following a similar 
procedure described for the synthesis of compound 4.61b, compound 4.78 (300 mg, 
0.86 mmol) gave compound 4.1b (190 mg, 94 %) as a white solid.
 1
H NMR (300 MHz, 
DMSO-d6) δ ppm 2.25 - 2.39 (m, 1H, 2ʹ-H), 2.52 - 2.67 (m, 2H, 2ʹ & 3ʹ-H’s), 3.48 - 
3.65 (m, 2H, 5ʹ-H), 3.89 (t, J = 8.20 Hz, 1H, 4ʹ-H), 4.00 (t, J = 7.91 Hz, 1H, 4ʹ-H), 
4.82 (t, J = 5.13 Hz, 1H, 5ʹ-OH), 6.23 (t, J = 6.74 Hz, 1H, 1ʹ-H), 7.26 (s, 2H, NH2), 
8.15 (s, 1H, 2-H), 8.32 (s, 1H, 8-H).
 13
C NMR (75 MHz, DMSO-d6) δ ppm 33.73 (2ʹ-
C), 41.70 (3ʹ-C), 61.67 (5ʹ-C), 70.77 (4’-C), 84.28 (1ʹ-C), 119.17 (5-C), 139.05 (8-C), 
149.17 (4-C), 152.52 (2-C). 156.02 (6-C). ESI-HRMS for [M+H]
+
 calcd, 236.1147; 
found, 236.1137. 
1ʹ-(Adenin-9-yl)-2ʹ,3ʹ-dideoxy-β-D-apio-D-furanose triphosphate (4.79): following 
the synthetic protocol described for 4.65, compound 4.1b (25 mg, 0.106 mmol) gave 
triphosphate derivative 4.79 (17 mg, 21%) as highly hygroscopic colorless solid.
 1
H 
NMR (300 MHz, D2O) δ ppm 1.27 (t, J = 7.32 Hz, 24H, NCH2CH3), 1.33 (t, J = 7.32 
Hz, 3H, NCH2CH3), 2.42 (ddd, J = 13.62, 8.64, 6.74 Hz, 1H, 2ʹ-H), 2.74 - 2.89 (m, 1H, 
2ʹ-H), 2.89 - 3.12 (m, 3H, 3ʹ-H & NCH2CH3), 3.19 (q, J = 7.32 Hz, 14H, NCH2CH3), 
3.54 (q, J = 7.13 Hz, 2H, NCH2CH3), 4.05 (t, J = 8.64 Hz, 1H, 4ʹ-H), 4.14 (app-t, J = 
6.15 Hz, 2H, 5ʹ-H), 4.28 (t, J = 8.49 Hz, 1H, 4ʹ-H), 6.35 (t, J = 6.74 Hz, 1H, 1ʹ-H), 
8.26 (s, 1H), 8.47 (s, 1H). 
13
C NMR (75 MHz, D2O) δ ppm 7.34, 8.38, 10.68 
(NCH2CH3), 33.59 (2ʹ-C), 39.30 (d, Jp-c = 8.10 Hz, 3ʹ-C), 42.36, 46.79 (NCH2CH3), 
66.32 (d, Jp-c = 5.92 Hz, 5ʹ-C), 70.79 (4ʹ-C), 85.05 (1ʹ-C), 150.79, 154.26.
 31
P NMR 
(121 MHz, D2O) δ ppm -23.28 (br. s, 1P, β-P) -11.20, -11.04 (br. d, 2P, α & γ-P). ESI-
HRMS for [M-H]
-
 calcd, 473.9981; found, 473.9987. 
Phenyl(isopropoxy-L-alaninyl)phosphorochloridate (4.60): To a stirred solution of 
phenyldichlorophosphate (0.30 mL, 2.00 mmol), L-alanine isopropyl ester 
hydrochloride (0.34 g, 2.00 mmol) in anhydrous CH2Cl2 (15 mL), anhydrous TEA 
(0.56 mL, 4.00 mmol) was added dropwise under an argon atmosphere at -78 
o
C. 
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Following the addition the reaction mixture was stirred at -78 
o
C for 30 min, then at 
room temperature for 2h. Formation of the desired compound was monitored by 
31
P 
NMR. After this period the solvent was removed under reduced pressure and the 
residue triturated with anhydrous diethyl ether. The precipitate was filtered under 
nitrogen and the solution was concentrated to give 4.60 (0.58 g, 96%) as a yellow oil. 
31
P NMR (CDCl3, 202 MHz): δ 8.13, 7.75. 
1
H NMR (CDCl3, 500 MHz): δppm 7.47-
7.16 (m, 5H, PhO), 5.18-4.98 (m, 1H, COOCH), 4.41, 4.33 (2bs, 1H, NHCH), 4.21-
4.09 (m, 1H, NHCH), 1.53, 1.51 (2d, 3H, J = 2.30, CHCH3), 1.35-1.27 (m, 6H, 
COOCH(CH3)2). 
1ʹ-(Thymin-1-yl)-2ʹ,3ʹ-dideoxy-α-D-apio-D-furanose [phenyl-(isopropoxy-L-
alaninyl)] phosphate (4.80a): To a solution of 4.1a (0.050 g, 0.22 mmol) in 
anhydrous THF (4 mL) was added a solution of phosphorochloridate 4.60 (0.203g, 
0.66 mmol) in anhydrous THF (2 mL), followed by drop wise addition, under an 
argon atmosphere, of anhydrous N-methylimidazole (0.88 mL, 1.11 mmol) and the 
reaction mixture was stirred at room temperature for 48h. After this period, the solvent 
was removed and the residue taken up in dichloromethane and washed with 0.5 M 
HCl (2 x 15 mL). The combined organics were dried over MgSO4 filtered and 
evaporated. The residue was purified by preparative thin layer chromatography (2000 
micron, Aldrich) using a mixture DCM/MeOH 95:5 v/v as eluent to give a 4.80a 
(0.096 g, 88%) as a pale yellow foamy solid. 
1
H NMR (500 MHz, CD3OD) δ ppm 
7.58, 7.57 (2s, 2H, H-6), 7.45 (d, J = 8.0 Hz, 2H, Ph), 7.44 (d, J = 7.5 Hz, 2H, Ph), 
7.33-7.28 (m, 6H, Ph), 6.10 (t, J = 7.0 Hz, 1H, H-1ʹ), 6.08 (t, J = 7.0 Hz, 1H, H-1ʹ), 
5.10-5.03 (m, 2H, CH(CH3)2), 4.33-4.21 (m, 4H, CH2OP), 4.16-4.10 (m, 2H, CH2O), 
4.01-3.96 (m, 2H,CH2O), 3.94-3.89 (m, 2H, CHCH3), 2.95-2.86 (m, 2H, H-3ʹ), 2.64-
2.56 (m, 2H, H-2ʹa), 1.97 (s, 6H, CH3), 1.95-1.88 (m, 2H, H-2ʹb), 1.43 (d, J = 7.5 Hz, 
3H, CHCH3), 1.40 (d, J = 6.5 Hz, 3H, CHCH3), 1.34-1.30 (m, 12H, CH(CH3)2). 
13
C 
NMR (125 MHz, CD3OD) δ ppm (d, JCP = 5.4 Hz, CO2iPr), 174.54 (d, JCP = 4.5 Hz, 
CO2iPr), 166.46, 166.44 (CO), 152.30 (d, JCP = 3.6 Hz, CipsoOPh), 152.28 (CO), 
152.25 (d, JCP = 3.6 Hz, CipsoOPh), 137.57 (C-6), 130.84, 130.81, 126.25, 126.23 (Ph), 
121.54 (d, JCP = 4.5 Hz, Ph), 121.47 (d, JCP = 5.3 Hz, Ph), 111.69 (C-5), 88.15, 88.12, 
(C-1ʹ), 71.73, 71.58 (CH2O), 70.19, 70.16 (CH(CH3)2), 68.42 (d, JCP = 5.4 Hz, 
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CH2OP), 68.32 (d, JCP = 5.4 Hz, CH2OP), 51.89, 51.88 (CHCH3), 40.55 (d, JCP = 3.5 
Hz, C-3ʹ), 40.49 (d, JCP = 3.6 Hz, C-3ʹ), 35.27, 35.18 (CH2), 22.05, 22.03, 21.98, 
(CH(CH3)2), 20.55 (d, JCP = 7.2 Hz, CHCH3), 20.43 (d, JCP = 7.2 Hz, CHCH3), 12.54, 
12.52 (CH3). 
31
P NMR (202 MHz, CD3OD) δ ppm 3.89, 3.49. ESI-MS; 518 [M+Na]
+
. 
HPLC; ACN/H2O 10:90 v/v to 100:0 in 30 min.; λ = 280 nm, flow 1 mL/min, tR = 
13.79, 13.81 min. 
1ʹ-(Adenin-9-yl)-2ʹ,3ʹ-dideoxy-α-D-apio-D-furanose [phenyl-(isopropoxy-L-
alaninyl)] phosphate (4.80b): Following the reaction protocol mentioned for the 
synthesis of compound 4.80a, 4.1b (0.050 g, 0.21 mmol) was reacted with 
phosphorochloridate 4.60 (0.201g, 0.66 mmol) to give 4.80b (0.054 g, 51%) as a 
white foamy solid. 
1
H NMR (500 MHz, CD3OD) δ ppm 8.27, 8.25 (2s, 2H, H-8), 8.23, 
8.22 (2s, 2H, H-2), 7.35 (d, J = 8.0 Hz, 2H, Ph), 7.34 (d, J = 7.8 Hz, 2H, Ph), 7.26-
7.16 (m, 6H, Ph), 6.29 (t, J = 7.0 Hz, 1H, H-1ʹ), 6.28 (t, J = 7.0 Hz, 1H, H-1ʹ), 5.02-
4.94 (m, 2H, CH(CH3)2), 4.33 (m, 4H, CH2OP), 4.16-4.05 (m, 4H, CH2O), 3.93-3.88 
(m, 2H, CHCH3), 2.96-2.89 (m, 2H, H-3ʹ), 2.75- 2.66 (m, 2H, H2ʹa), 2.49-2.43 (m, 2H, 
H2ʹb), 1.35 (d, J = 7.0 Hz, 3H, CH3), 1.33 (d, J = 7.0 Hz, 3H, CH3), 1.23-1.21 (m, 
12H, CH(CH3)2). 
13
C NMR (125 MHz, CD3OD) δ ppm (d, JCP = 4.5 Hz, CO2iPr), 
174.51 (d, JCP = 4.5 Hz, CO2iPr), 157.35 (C-6), 153.89 (C-2), 152.27 (d, JCP = 3.4 Hz, 
CipsoOPh), 152.22 (d, JCP = 2.6 Hz, CipsoOPh), 150.38 (C-4), 140.82, 140.79 (C-8), 
130.81, 126.19, 126.16 (Ph), 121.53 (d, JCP = 5.5Hz, Ph), 121.45 (d, JCP = 5.5Hz,CH 
Ph), 120.73, 120.70 (C-5), 87.04, 87.04, (C-1ʹ), 71.89, 71.83 (CH2O), 70.15 
(CH(CH3)3), 68.32 (d, JCP = 6.4 Hz, CH2OP), 68.23 (d, JCP = 6.4 Hz, CH2OP), 51.88, 
51.72 (CHCH3), 41.19 (d, JCP = 7.2 Hz, C-3ʹ), 41.13 (d, JCP = 7.2 Hz, C-3ʹ), 35.24, 
35.11 (CH2), 22.00, 21.95, 21.94, (CH(CH3)3), 20.55 (d, JCP = 6.4 Hz, CHCH3), 20.43 
(d, JCP = 6.4 Hz, CHCH3). 
31
P NMR (202 MHz, CD3OD) δ ppm 3.81, 3.46. ESI-MS; 
505 [M+H]
+ 
, 527 [M+Na]
+
. HPLC; ACN/H2O 10/90 v/v to 100/0 in 30 min, λ = 280 
nm, flow 1 mL/min, tR = 12.61 min. 
1ʹ-(Thymin-1-yl)-2ʹ,3ʹ-dideoxy-α-D-apio-D-furanose [phenyl-(benzoxy-L-
alaninyl)] phosphate (4.6a): Following the reaction protocol mentioned for the 
synthesis of compound 4.80a, 1a (0.048 g, 0.21 mmol) was reacted with 
Chapter 4 
146 
phosphorochloridate 3.33 (0.22g, 0.64 mmol) to give 4.6a (0.040 g, 35%) as a pale 
white foamy solid. 
1
H NMR (500 MHz, CD3OD) δ ppm 7.47, 7.46 (d, J = 2.5Hz, 2H, 
H-6), 7.37-7.32 (m, 14H, Ph and CH2Ph), 7.23-7.18 (m, 6H, Ph), 5.99 (t, J = 6.0 Hz, 
1H, H-1ʹ), 5.98 (t, J = 6.0 Hz, 1H, H-1ʹ), 5.17-5.15 (m, 4H, CH2Ph), 4.17-4.05 (m, 
4H,CH2OP), 4.04-4.01 (m, 2H, CHCH3), 4.00-3.87 (m, 4H, CH2O), 2.79-2.73 (m, 1H, 
H-3ʹ), 2.72-2.66 (m, 1H, H-3ʹ), 2.05-2.39 (m, 2H, H-2ʹa), 1.89, 1.88 (d, J = 1.5 Hz, 6H, 
CH3), 1.81-1.72 (m, 2H, H-2ʹb), 1.38 (d, J = 7.5 Hz, 3H, CHCH3), 1.35 (d, J = 7.5 Hz, 
3H, CHCH3). 
13
C NMR (125 MHz, CD3OD) δ ppm 174.93 (d, JCP = 5.0 Hz, CO2Bn), 
174.74 (d, JCP = 5.0 Hz, CO2Bn), 166.44, 166.42 (CO), 152.30, 152.29 (CO), 152.21 
(d, JCP = 2.75 Hz, CipsoOPh), 152.16 (d, JCP = 2.75 Hz, CipsoOPh), 137.54, 137.52 (C-6), 
137.32, 137.31 (CipsoOCH2Ph), 130.82, 130.80 (Ph), 129.66, 129.64, 129.43, 129.40, 
129.36, 129.31 (CH2Ph), 126.25, 126.23 (Ph), 121.53 (d, JCP = 4.6 Hz, Ph), 121.44 (d, 
JCP = 5.3 Hz, Ph), 111.65 (C-5), 88.07, 88.03, (C-1ʹ), 71.65, 71.46 (CH2O), 68.37 (d, 
JCP = 5.0 Hz, CH2OP), 68.25 (d, JCP = 5.0 Hz, CH2OP), 67.98 (CH2Ph), 51.83, 51.65 
(CHCH3), 40.45 (d, JCP = 3.75 Hz, C-3ʹ), 40.39 (d, JCP = 3.75 Hz, C-3ʹ), 35.20, 35.12 
(CH2), 20.35 (d, JCP = 7.5 Hz, CHCH3), 20.29 (d, JCP = 7.5 Hz, CHCH3), 12.51 (CH3). 
31
P NMR (202 MHz, CD3OD) δ ppm 3.88, 3.33. MS (ESI); 566 [M+Na]
+
. HPLC; 
ACN/H2O 10/90 v/v to 100/0 in 30 min, λ = 280 nm, flow 1 mL/min, tR = 15.42 min. 
1ʹ-(Adenin-9-yl)-2ʹ,3ʹ-dideoxy-α-D-apio-D-furanose [phenyl-(benzoxy-L-alaninyl)] 
phosphate (4.6b): Following the reaction protocol mentioned for the synthesis of 
compound 4.80a, 4.1b (0.050 g, 0.21 mmol) was reacted with phosphorochloridate 
3.33 (0.23 g, 0.66 mmol) to give 4.6b (0.030 g, 26%) as a white foamy solid. 
1
H NMR 
(500 MHz, CD3OD) δ ppm 8.24, 8.23 (2s, 1H, H-8), 8.22, 8.21 (2s, 1H, H-2), 7.40-
7.26 (m, 16H, Ph), 7.22-7.15 (m, 4H, Ph), 6.27 (t, J = 7.0 Hz, 1H, H-1ʹ), 6.24 (t, J = 
6.5 Hz, 1H, H-1ʹ), 5.14 (s, 4H, CH2Ph), 4.26-4.19 (m, 4H CH2OP), 4.10-3.96 (m, 6H, 
CH2O and CHCH3), 2.91-2.75 (m, 2H, H-3ʹ), 2.69- 2.57 (m, 2H, H2ʹa), 2.41-2.34 (m, 
2H, H2ʹb), 1.37 (d, J = 6.5 Hz, 3H, CH3), 1.35 (d, J = 7.0 Hz, 3H, CH3). 
13
C NMR 
(125 MHz, CD3OD) δppm 174.96 (d, JCP = 4.2 Hz, CO2Bn), 174.74 (d, JCP = 4.6 Hz, 
CO2Bn), 157.32 (C-6), 153.84, 153.83 (C-2), 152.22 (d, JCP = 2.5 Hz, CipsoOPh), 
152.17 (d, JCP = 2.5 Hz, CipsoOPh), 150.36 (C-4), 140.78, 140.74 (C-8), 137.29, 137.28 
(CipsoOCH2Ph), 130.80 (d, JCP = 0.7 Hz, Ph), 130.78 (d, JCP = 0.9 Hz, Ph), 129.60, 
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129.38, 129.36, 129.35, 129.30 (CH2Ph), 126.20 (d, JCP = 1.25 Hz, Ph), 126.17 (d, JCP 
= 1.25 Hz, Ph), 121.52 (d, JCP = 4.6 Hz, Ph), 121.42 (d, JCP = 4.6 Hz, Ph), 120.70, 
120.68 (C-5), 87.00, 86.98, (C-1ʹ), 71.82, 71.70 (CH2O), 68.22 (d, JCP = 5.5 Hz, 
CH2OP), 68.15 (d, JCP = 5.5 Hz, CH2OP), 67.99, 67.97 (CH2Ph), 51.83 (d, JCP = 1.4 
Hz, CHCH3), 51.65 (CHCH3), 41.10 (d, JCP = 7.8 Hz, C-3ʹ), 41.05 (d, JCP = 7.8 Hz, C-
3ʹ), 35.23, 35.10 (CH2), 20.39 (d, JCP = 7.0 Hz, CHCH3), 20.33 (d, JCP =7.0 Hz, 
CHCH3). 
31
P NMR (202 MHz, CD3OD) δppm 3.80, 3.28. ESI-MS; 553 [M+H]
+
, 575 
[M+Na]
+
. HPLC; ACN/H2O 10/90 v/v to 100/0 in 30 min, λ = 280 nm, flow 1 
mL/min, tR = 14.36 min. 
 
4.5.2. Pharmacological assay procedures 
For other biological assays please refer to Chapter 3, Section 3.4.2 
HIV-RT primer-template assay 
Primer oligonucleotides 5ʹ CAGGAAACAGCTATGAC 3ʹ (Sigma Genosys) were 
labeled with 5ʹ [γ-33P]-ATP (Perkin Elmer) using T4 polynucleotide kinase (New 
England Biolabs) according to the manufacturer’s protocol. The labeled primers were 
further purified using illustra MicroSpin G-25 Column (GE Healthcare) and then 
annealed with template oligonucleotides 5ʹ TTTTTTTGTCATAGCTGTTTCCTG 3ʹ 
(Eurogentec) in a 1:2 molar ratio by heating the mixture at 75°C for 5 min, followed 
by slowly cooling to room temperature. The DNA polymerization mixtures containing 
125 nM primer-template complex, reaction buffer (supplied with the HIV RT), 125, 
500, or 1000 µM of modified triphosphate (4.65, 79) and 0.03 U.µL
-1
 HIV RT 
(Ambion) were incubated at 37°C and aliquots were taken after 15, 30 and 60 min. In 
the control reaction, 50µM of natural dATP was used. All polymerase reactions were 
then stopped by adding a double volume of gel loading buffer (90% formamide, 
50mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol). Samples were 
heated at 70°C for 5 min prior to separation on a 0.4mm 20% denaturing 
polyacrylamide gel. The bands were then visualized using phosphorimaging.  
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5.1. Objectives 
Besides adenosine itself, which is used clinically for the treatment of supraventricular 
tachycardia and in myocardial perfusion imaging, only one adenosine receptor-
specific agent, the A2A AR agonist regedenoson, has so far been approved by the FDA. 
However, a relatively large group of AR ligands are currently under clinical 
evaluation (see Chapter 1, Section 1.4). 
With the exception of compound 5.1, which was reported in the mid 1980s as being 
inactive at A1 and A2ARs,
179
 the recently reported carbocyclic analogue 5.2,
180
 a weak 
A3AR agonist, 4ʹ-hydroxymethyl transposed nucleosides have not been investigated as 
adenosine receptor ligands.  
This led us to employ a new and convenient method for the synthesis of 
apioadenosines from 1,2-O-isopropylidene-α-L-threose (see Chapter 4) for the 
construction of suitably modified 9-(3-C-hydroxymethyl-β-D-
erythrofuranosyl)adenines as potential A3AR modulators (Figure 1). 
 
Figure 5.1. Known A3AR modulators and target analogues in the present study. 
 
On the one hand, we envisaged to substitute the N
6
 position of apioadenosine 4.3b 
with substituted benzyl groups known to enhance A3AR affinity (5.24-26, See Chapter 
1, Section 1.4), on the other hand we planned to substitute the well-known 
ethylcarboxamide moiety for the 3ʹ-CH2OH group. However, synthetic problems in 
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introducing the ethylcarboxamide moiety motivated us to introduce an N-methyl (5.30) 
or N-ethylcarbamoyloxymethyl group instead. 
 
5.2. Results and Discussion 
5.2.1. Chemistry 
5.2.1.1. Syntheses of α-D-apio-L-furanoadenosine derivatives 
 
 
Scheme 5.1. Synthesis of N
6
-substituted α-D-apio-L-furanoadenosines. Reagents and 
conditions: (a) (i) appropriate benzyl bromide, DMF, 50 °C, 48h; (ii) 25% NH4OH, 50 °C, 
24h or 90 °C, 3h, 20-56% over two steps; (b) TBDMSCl, imidazole, DMF, 100 °C, 3 days, 
80%; (c) 7N NH3 in MeOH, rt, 18h, 73%; (d) HF.pyridine, pyridine, THF, rt or TCA-H2O, 
THF, rt, 20-30%. 
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The α-D-apio-L-furanoadenosines 4.53b and its 3ʹ-deoxy counterpart 4.52b were 
prepared by microwave assisted synthesis as described in Chapter 4. Treatment of the 
former with the appropriate benzyl bromide first afforded the N
1
-benzyl derivative, 
which was isolated in the case of the 3-chlorobenzyl derivative 5.3 (Scheme 5.1). 
Upon prolonged heating with aquous ammonia, the N
1
-benzyl intermediate was 
converted to the desired N
6
-benzylated compounds 5.5-5.7 via Dimroth rearrangement 
(Figure 5.2).
181
 Although in many cases this method suffered from low yields, it 
allowed fast access to target molecules. 
 
Figure 5.2. Mechanism of Dimroth rearrengment.  
 
Selective modification of the 5ʹ-position requires a suitable protecting strategy. First 
attempts were made to per-silylate the hydroxyl groups of compound 4.53b (Scheme 
5.1). Under mild conditions the tertiary hydroxyl group failed to react, while raising 
the temperature to 100 °C in DMF led to exclusive formation of the N
6
-imide 5.8. 
Since exploration of different solvents and scavenging bases did not allow the 
preparation of compound 5.9, the latter was obtained by treatment of 5.8 with 
ammonia in MeOH.
182
 Two different methods to selectively remove the TBDMS 
group from the primary hydroxyl of 5.9 resulted in complex reaction mixtures,
183,184
 
from which isomers 5.10 and 5.11 proved inseparable on TLC and by flash 
chromatography. 
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Scheme 5.2. Synthesis of sugar modified α-D-apio-L-furanoadenosines. Reagents and 
conditions: (a) TBDMSCl, imidazole, DMF, rt, 18h, 75-83%; (b) 5.14, HF.pyridine, pyridine, 
THF, 0°C, 1h, rt, 1h, 82%; 5.15, TCA-H2O, THF, 0°C, 1h, rt, 1h, 87%; (c) (i) CDI, THF, rt, 
3h; (ii) EtNH2, rt, 16h, 55-95%; (d) (i) RuCl3, NaIO4, CH3CN-CCl4-H2O, rt, 7h; (ii) CDI, 
THF, rt, 3h; (iii) EtNH2, rt, 18h, 9% over three steps; (e) NH4F, MeOH, 50 °C, 48h, 70-94%. 
 
The aforementioned problems led us to synthesize the bis-silylated products 5.14 and 
5.15, which could be selectively deprotected to provide 5.16 and 5.17 in excellent 
yields (Scheme 5.2). Introduction of the desired 3ʹ-carboxamide was tested on 
intermediate 5.16. Conversion of the primary hydroxyl group of 5.16 to the 
corresponding carboxylic acid via a TEMPO-BAIB oxidation gave the corresponding 
TEMPO ester (Entry 1, Table 5.1).
185
 This may be due to the high catalyst loading in 
the reaction, since slow conversion of the aldehyde intermediate forced us to add an 
extra amount of reagents. Efforts to convert the TEMPO-ester to the ethylamide failed. 
Under conditions of Jones oxidation (CrO3 + dil. H2SO4) the starting material 
degraded. Oxidation using RuCl3-NaIO4,
186
 followed by amide coupling, provided 
5.20 and 5.18, albeit in very low yields (Scheme 5.2). Removal of the TBDMS group 
in 5.20 gave the desired 3ʹ-ethylcarboxamide 5.21. Attempted ruthenium chloride 
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oxidation of 5.17 resulted in decarboxylation and further oxidation to the ketone as the 
only product (Entry 2, table 5.1). On the other hand, oxidation of 5.11 (as a mixture 
with 5.12) did not proceed beyond the aldehyde stage, thus weakening the prospects 
of synthesizing the corresponding ethylcarboxamide via the carboxylic acid route. 
Sequential treatment of 5.16 and 5.17 with carbonyldiimidazole (CDI) and ethylamine 
produced 5ʹ-O-ethylcarbamate derivatives 5.18 and 5.19,187 which were deprotected 
upon treatment with NH4F in warm MeOH to give the desired 5ʹ-O-ethylcarbamate 
apionucleosides 5.22 and 5.23 in excellent yields. 
 
 
5.2.1.2. Syntheses of β-D-apio-D-furanoadenosine derivatives 
Given the problems encountered for the oxidation of α-D-apio-L-furanoadenosine 5.17 
and its conversion to carboxamide 5.21 and oxidation of 5.15, the corresponding D-
furano epimer was only converted to carbamate 5.30. The synthesis of 4.3b is 
described in chapter 4. The β-D-apio-D-furanoadenosine 4.3b was benzylated at N6 
using similar reaction conditions as described for the L-furano counterpart (Scheme 
5.3). RP-HPLC or PTLC was required to purify the target compounds, which were 
isolated in low yields. In the case of 5.26, using excess of the benzyl bromide led to 
Table 5.1. Products from oxidation reactions 
Entry Reactant Condition Product HRMS (Obs) 
 
1 
 
5.16 
 
TEMPO-BAIB, 
CH3CN-H2O, rt, 16h 
 
 
[M+H]
+
 - 
519.3119 
2 5.17 RuCl3-NaIO4, 
CH3CN-CCl4-H2O, 
rt, 7h  
[M+H]
+
 - 
350.1656 
[M+H3O]
+
 - 
368.1762 
3 5.11 RuCl3-NaIO4, 
CH3CN-CCl4-H2O, 
50 °C, 2days 
 
[M+H]
+
 - 
494.2609 
[M+H3O]
+
 - 
512.2742 
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degradation of the starting material and afforded bis-(2-methoxy-5-
chlorobenzyl)adenine as observed by HRMS. By limiting the amount of this benzyl 
bromide to one equivalent, 5.26 could be obtained in 21% yield. The silylation and 
desilylation of 4.3b rendered 2ʹ-O-monosilylated species 5.28, which upon treatment 
with carbonyldiimidazole and liq. methylamine gave 5.29. The deprotection of 
TBDMS group furnished 5ʹ-O-methylcarbamoyl -D-apio-D-furanoadenosine 5.30.  
 
Scheme 5.3. Synthesis of N
6
-substituted and 5ʹ-O-methylcarbamoyl β-D-apio-D-
furanoadenosines. Reagents and conditions: (a) (i) appropriate benzyl bromide, DMF, rt, 48h; 
(ii) 25% NH4OH, 50 °C, 24h, 8-21% over two steps; (b) TBDMSCl, imidazole, DMF, rt, 18h, 
74%; (c) TCA-H2O, THF, 0°C, 1h, rt, 3h, 35%; (c) (i) CDI, THF, rt, 3h; (ii) MeNH2, rt, 16h, 
72%; (e) NH4F, MeOH, 50 °C, 48h, 90%.  
 
5.2.2. Pharmacological evaluation 
For the apio-type adenosine derivatives prepared in this study (5.3, 5.5-7, 5.21-26 and 
5.30) we measured the binding affinities at the hA1, hA2A and hA3AR. The results are 
reported in Table 5.2. The ability of each of these adenosine derivatives to compete 
for radioligand binding at each of these hARs was evaluated at a fixed concentration 
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of 10 µM and a full inhibition curve was determined for compound 5.7 and 5.26 at the 
A3AR (Figure 5.3). Most compounds only caused marginal displacement of the 
radioligands from all AR subtypes tested. The N
6
-benzyl derivatives 5.5-7, 5.24-26 
and 5.30 showed weak affinity at A3AR. However, N
6
-(5-chloro-2-methoxybenzyl)-α-
D-apio-L-furanoadenosine 5.7 showed a binding affinity to the A3AR in the low 
micromolar range (Ki: 3 ± 0.75 µM) and behaved as a partial agonist. Surprisingly, the 
D-furano counterpart 5.26 displayed similar binding affinity and a functional data 
suggest that it behaves as an antagonist. Comparison with the A3AR binding affinity 
of N
6
-(5-chloro-2-ethoxy)benzyladenosine (Ki: 1.31 nM), the structural isomer from 
which 5.7 was derived, indicates that substitution of the apiofuranose for a 
ribofuranose moiety is detrimental for binding to the ARs. 
 
Table 5.2. Affinities of apioadenosine derivatives.
a
 
Compound 
number 
% inhibition or Ki (nM) 
hA1 hA2A hA3 
5.3 6 ± 5% 12 ± 7% 3 ± 2% 
5.5 19 ± 1% 15 ± 5% 44 ± 1% 
5.6 35 ± 5% 22 ± 2% 45 ± 1% 
5.7 13 ± 5% 14 ± 5% 3070 ± 750 
5.21 8 ± 7% 9 ± 5% 10 ± 2% 
5.22 9 ± 5% 12 ± 4% 6 ± 2% 
5.23 7 ± 2% 2 ± 2% 8 ± 1% 
5.24 10 ± 6% 10 ± 8% 43 ± 5% 
5.25 27 ± 9% 17 ± 11% 48 ± 6% 
5.26 12 ± 3% 17 ± 6% 978 ± 150 
5.30 12 ± 4% 10 ± 8% 26 ± 6 % 
a 
Binding in membranes of CHO or HEK293 (A2A only) cells stably expressing 
one of three hAR subtypes. Percent refers to inhibition of binding at 10 μM. 
The binding affinity for hA1, A2A, and A3ARs was expressed as Ki values using 
agonists [
3
H]N
6
-R-phenylisopropyladenosine, [
3
H]2-[p-(2-
carboxyethyl)phenyl-ethylamino]-5′-N-ethylcarboxamidoadenosine, or 
[
125
I]N
6
-(4-amino-3-iodobenzyl)adenosine-5′-N-methyluronamide, 
respectively.  
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Figure 5.3. Efficacy curve for compound 5.7 and 5.26. 
 
5.2.3. Homology modelling studies 
Both compounds 5.7 and 5.26 show docking poses at the hA3AR well superimposable 
to the binding mode of Cl-IB-MECA (for structure of Cl-IB-MECA, see Figure 5.3). 
For all nucleosides featuring N
6
-benzyl adenosine type structure, the interactions are 
predictably similar. The side chain of Asn250 (6.55, using Ballesteros-Weinstein 
notation
188
) in the hA3AR homology model strongly interacts through two H-bonds 
involving the 6-amino group and the N
7
 atom of the adenine ring (Figure 5.4). 
Moreover, the adenine ring is anchored inside the binding site by a π−π stacking 
interaction with Phe168 (EL2) and strong hydrophobic contacts with Leu246 (6.51) 
and Ile268 (7.39). The N
6
-3-iodobenzyl ring is accommodated in a hydrophobic 
pocket delimited by TM5, TM6 and EL2 to form strong hydrophobic interactions with 
Val169 (EL2), Met174 (5.35) and Ile253 (6.58). Finally, the 3′- and 2′-hydroxyl 
groups of the ribose ring form H-bonds with Ser271 (7.42) and His272 (7.43), 
respectively, while the 5'-N-methyluronamido moiety forms a H-bond with Thr94 
(3.36). These latter interactions involving the ribose moiety are particular to agonist 
binding, as shown by the comparison of the reported crystallographic structures of the 
hA2AAR in complex with agonists and antagonists,
132 and are supposed to be 
important for the activation process in the AR family. 
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Figure 5.4. Binding mode of Cl-IB-MECA with A3 AR. 
 
It has been previously shown that the 4'-truncation of nucleoside derivatives that are 
potent A3AR ligands leads to compounds with good affinity for the A3 receptor but 
with decreased efficacy, i.e. behaving as partial agonist or antagonist of this subtype. 
Docking of nucleoside analogues in the hA3AR homology model
 
indicated that the 
absence of a hydroxymethyl or uronamide substituent at the 4'-position prevented 
these compounds from interacting with Thr94 (3.36). This residue is a conserved 
recognition point in agonist binding, and therefore the lack of this interaction was 
considered as a reason for the low efficacy profile of 4'-truncated nucleosides.
189
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Figure 5.5. Important interactions for compound 5.7 with A3 AR. 
 
For compounds 5.7 and 5.26 conserved interactions stabilizing the adenine core and 
the N
6
 substituent are similar to Cl-IB-MECA at the hA3AR. Differences can be 
observed in the interactions formed by the sugar moiety; in fact, both compounds form 
only two of the three H-bonds predicted for binding of the full agonist Cl-IB-MECA. 
In particular, compound 5.7 forms H-bonds with Thr94 (3.36) and Ser271 (7.42) and 
not with His272 (7.43) (Figure 5.5), while compound 5.26 forms two H-bonds with 
Ser271 (7.42) and His272 (7.43), but it cannot reach Thr94 in TM3 (Figure 5.6). 
Therefore, compound 5.26 show a binding mode similar to the one observed for other 
4'-truncated nucleosides and the missing interaction with Thr94 (3.36) is consistent 
with its lack of receptor activation, indicative of antagonist behavior. However, the 
ability of partial agonist 5.7 to bridging between TM3 and TM7 likely correlates with 
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the ability to induce the conformational changes required for receptor activation, such 
as an inward movement of TM7. Thus, the preferred modeled binding modes of 5.7 
and 5.26 differ in the crucial interaction with Thr94, which seems to be associated 
with residual efficacy at the hA3AR in apionucleosides. 
 
 
Figure 5.6. Important interactions for compound 5.26 with A3 AR. 
 
5.3. Conclusions 
In summary, we have synthesized a small number of modified apioadenosines as 
potential A3AR ligands. Generally, substituting an apiofuranose for a ribofuranose 
moiety is detrimental for binding to the ARs. Nevertheless, selected N
6
-substituted 9-
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(3-C-hydroxymethyl-β-D-erythrofuranosyl)adenines showed weak but selective 
binding affinity for the A3AR. Remarkably, this was also the case for their 3ʹ-epimers 
(D-apio-L-furanosyl analogues), which are capable of partially activating the A3AR. 
 
5.4. Experimental Section 
5.4.1. Synthesis 
All reagents were from standard commercial sources and of analytic grade. Dry 
solvents were obtained directly from commercial sources and stored on molecular 
sieves. Moisture sensitive reactions were carried out under argon atmosphere. A 
temperature of 25±5 °C is referred to as ‘room temperature/ rt’. Precoated Merck 
silica gel F254 plates were used for TLC, spots were examined under ultraviolet light 
at 254 nm and further visualized by sulphuric acid-anisaldehyde spray. Column 
chromatography was performed on silica gel (200-400 mesh, 60 Å, Biosolve, 
Valkenswaard, The Netherlands). RP-HPLC was performed using Waters XBridge 
OBD
TM
 Prep C18 5µm column @ 17.5 mL/min flow rate. NMR spectra were 
determined using a Varian Mercury 300 MHz spectrometer. Chemical shifts are given 
in ppm (δ) relative to the residual solvent signals or TMS as internal standard. Exact 
mass measurements were performed on a Waters LCT PremierXETMTime of flight 
(TOF) mass spectrometer equipped with a standard electrospray ionization (ESI) and 
modular LockSpray TM interface. Samples were infused in a CH3CN/water (1:1) 
mixture at 10 μL/min. For nucleosides, NMR signals of sugar protons and carbons are 
indicated with a prime, and signals of base protons and carbons are given without a 
prime. 
1ʹ-[N1-(3-Chlorobenzyl)-adenin-9-yl]-α-D-apio-L-furanose bromide (5.3): To a 
solution of apioadenosine 4.53b (25 mg, 0.094mmol) in anh. DMF (1 mL) was added 
3-chlorobenzyl bromide (50µL, 0.374 mmol) and the mixture was stirred at 50 °C for 
48h. The solvent was evaporated under reduced pressure and the residue was purified 
first by column chromatography (8-12% MeOH in CH2Cl2) and then with preparative 
thin layer chromatography (15% MeOH in CH2Cl2, Rf: 0.2) to afford the title 
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compound 5.3 as a white solid (16 mg, 44%). 
1
H NMR (300 MHz, CD3OD) δ ppm 
3.75 (d, J = 11.72 Hz, 1H, 5ʹ-H), 3.85 (d, J = 11.72 Hz, 1H, 5ʹ-H), 4.18 (d, J = 9.67 Hz, 
1H, 4ʹ-H), 4.25 (d, J = 9.37 Hz, 1H, 4ʹ-H), 4.42 (d, J = 0.88 Hz,1H, 2ʹ-H), 5.63 (s, 2H, 
ArCH2), 6.15 (d, J = 1.46 Hz, 1H, 1ʹ-H), 7.14 - 7.24 (m, 1H, Ar-H), 7.33 - 7.46 (m, 3H, 
Ar-H), 8.55 (s, 1H, 8-H), 8.68 (s, 1H, 2-H). 
13
C NMR (75 MHz, CD3OD) δ ppm 53.40 
(ArCH2), 63.43 (5ʹ-C), 78.14 (4ʹ-C), 81.97 (2ʹ-C), 82.77 (3ʹ-C), 94.30 (1ʹ-C), 120.91 
(5-C), 126.28, 128.22 (Ar 2,6-Cs), 130.06, 131.98 (Ar 3,4-Cs), 136.26 (Ar 5-C), 
136.52 (Ar 1-C), 144.79 (8-C), 148.09 (4-C), 148.42 (2-C), 152.29 (6-C). ESI-HRMS 
for [C17H18ClN5O4 + H]
+
 calcd, 392.1126; found, 392.1139. 
1ʹ-[N6-(3-Chlorobenzyl)-adenin-9-yl]-α-D-apio-L-furanose (5.5): To a solution of 
apioadenosine 4.53b (25 mg, 0.094mmol) in anh. DMF (1 mL) was added 3-
chlorobenzyl bromide (50µL, 0.374 mmol) and the mixture was stirred at 50 °C for 
48h. Ammonium hydroxide (25%, 3.0 mL) was added and stirred at 50 °C for 24h 
(alternatively, at 90 °C for 3h was used only for 5.5). The volatiles were evaporated 
under reduced pressure and the residue purified by column chromatography (3-6% 
MeOH in CH2Cl2) to afford desired product 5.5 (20 mg, 56%) as a white solid. 
1
H 
NMR (300 MHz, DMSO-d6) δ ppm 3.62 (d, J = 5.56 Hz, 2H, 5ʹ-H), 3.99 (d, J = 9.08 
Hz, 1H, 4ʹ-H), 4.05 (d, J = 9.08 Hz, 1H, 4ʹ-H), 4.40 (dd, J = 4.98, 2.93 Hz, 1H, 2ʹ-H), 
4.64 (t, J = 5.56 Hz, 1H, 5ʹ-OH), 4.71 (br.s, 2H, Ar-CH2), 5.32 (s, 1H, 3ʹ-OH), 5.86 (d, 
J = 5.27 Hz, 1H, 2ʹ-OH), 5.92 (d, J = 2.93 Hz, 1H, 1ʹ-H), 7.23 - 7.37 (m, 3H, Ar-H’s), 
7.39 (s, 1H, Ar-H), 8.23 (s, 1H, 2-H), 8.35 (s, 1H, 8-H), 8.44 (br.s, 1H, NH). 
13
C NMR 
(75 MHz, CD3OD) δ ppm 44.68 (ArCH2), 63.74 (5ʹ-C), 77.69 (4ʹ-C), 82.33 (2ʹ-C), 
82.73 (3ʹ-C), 94.27 (1ʹ-C), 120.82 (5-C), 126.96, 128.34, 128.56, 131.16 (Ar 2,3,4,6-
C’s), 135.50 (Ar 5-C), 141.44 (8-C), 143.08 (Ar 1-C), 149.50 (4-C), 153.79 (2-C), 
156.08 (6-C).ESI-HRMS for [C17H18ClN5O4 + H]
+
 calcd, 392.1126; found, 392.1105. 
1ʹ-[N6-(3-Iodobenzyl)-adenin-9-yl]-α-D-apio-L-furanose (5.6): Following the 
protocol for the synthesis of compound 5.5, the title compound (33 mg, 36%) was 
obtained from apioadenosine 4.53b (50 mg, 0.19 mmol) as a white solid. 
1
H NMR 
(300 MHz, CD3OD) δ ppm 3.76 (d, J = 11.57 Hz, 1H, 5ʹ-H), 3.84 (d, J = 11.57 Hz, 1H, 
5ʹ-H), 4.12 (d, J = 9.45 Hz, 1H, 4ʹ-H), 4.18 (d, J = 9.45 Hz, 1H, 4ʹ-H), 4.37 (d, J = 
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1.46 Hz, 1H, 2ʹ-H), 4.78 (br.s, 2H, ArCH2), 6.02 (d, J = 1.75 Hz, 1H, 1ʹ-H), 7.07 (t, J 
= 7.79 Hz, 1H, Ar 5-H), 7.37 (d, J = 7.66 Hz, 1H, Ar 2-H), 7.58 (d, J = 7.87 Hz, 1H, 
Ar 4-H), 7.74 (s, 1H, Ar 6-H), 8.26 (s, 1H, 2-H), 8.29 (s, 1H, 8-H). 
13
C NMR (75 
MHz, CD3OD) δ ppm 44.45 (ArCH2), 63.60 (5ʹ-C), 77.54 (4ʹ-C), 82.19 (2ʹ-C), 82.59 
(3ʹ-C), 94.13 (1ʹ-C), 94.96 (Ar 5-C), 120.68 (5-C), 127.84(Ar 2-C), 131.37 (Ar 3-C), 
137.33 (Ar 4-C), 137.51 (Ar 6-C), 141.30 (8-C), 143.11 (Ar 1-C), 149.46 (4-C), 
153.66 (2-C), 155.91 (6-C).ESI-HRMS for [C17H18IN5O4 + H]
+
 calcd, 484.0482; 
found, 484.0470. 
1ʹ-[N6-(2-Methoxy-5-chlorobenzyl)-adenin-9-yl]-α-D-apio-L-furanose (5.7): 
Following the protocol used for the synthesis of compound 5.5, apioadenosine 4.53b 
(50 mg, 0.19 mmol) was converted to the title compound 5.7 (15 mg, 20%), which 
was obtained as a white solid. 
1
H NMR (300 MHz, CD3OD) δ ppm 3.75 (d, J = 11.4 
Hz, 1H, 5ʹ-H), 3.84 (d, J = 11.7 Hz, 1H, 5ʹ-H), 3.87 (s, 3H, Ar-OCH3), 4.12 (d, J = 9.3 
Hz, 1H, 4ʹ-H), 4.18 (d, J = 9.9 Hz, 1H, 4ʹ-H), 4.37 (d, J = 1.2 Hz, 1H, 2ʹ-H), 4.77 (br.s, 
2H, ArCH2), 6.02 (d, J = 1.5 Hz, 1H, 1ʹ-H), 6.94 (d, J = 8.7 Hz, 1H, Ar 5-H), 7.21 (dd, 
J = 8.7, 2.7 Hz, 1H, Ar 4-H), 7.25 (d, J = 2.4 Hz, 1H, Ar 6-H), 8.26 (s, 1H, 2-H), 8.29 
(s, 1H, 8-H). 
13
C NMR (75 MHz, CD3OD) δ ppm 40.30 (Ar-CH2), 56.27 (ArOCH3), 
63.60 (5ʹ-C), 77.56 (4ʹ-C), 82.17 (3ʹ-C), 82.60 (2ʹ-C), 94.15 (1ʹ-H), 112.83 (Ar 3-C), 
120.66 (5-C), 126.30 (Ar 5-C), 129.07 (Ar 6-C), 129.09 (Ar 4-C), 130.00 (Ar 1-C), 
141.24 (8-C), 149.20 (4-C), 153.68 (2-C), 155.99 (6-C), 157.57 (Ar 2-C). ESI-HRMS 
for [C18H20ClN5O5 + H]
+
 calcd, 422.1231; found, 422.1236.  
1ʹ-[N
6
-(N,N-Dimethylformamidine)-adenin-9-yl]-2ʹ,3ʹ,5ʹ-O-tris(tert-
butyldimethylsilyl)-α-D-apio-L-furanose (5.8): To a solution of apioadenosine 4.53b 
(150 mg, 0.56 mmol) in anh. DMF (5 mL) was added imidazole (458 mg, 6.73 mmol) 
and TBDMSCl (845 mg, 5.6 mmol). The mixture was heated to 100 °C for 3 days, 
cooled and a saturated aqueous NH4Cl solution was added. The product was extracted 
with EtOAc (3 X 20 mL) and the combined organic layers were dried over anh. 
Na2SO4. The residue obtained after evaporation of the organic layers was subjected to 
column chromatography (15-30% EtOAc in hexanes) to afford 5.8 (300 mg, 80 %) as 
a colorless glassy solid. 
1
H NMR (300 MHz, CDCl3) δ ppm -0.38 (s, 3H, SiCH3), -
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0.07 (s, 3H, SiCH3), 0.00 (s, 3H, SiCH3), 0.11 (s, 3H, SiCH3), 0.14 (s, 3H, SiCH3), 
0.15 (s, 3H, SiCH3), 0.18 (s, 3H, SiCH3), 0.78 (s, 9H, C(CH3)3), 0.93 (s, 9H, C(CH3)3), 
0.96 (s, 9H, C(CH3)3), 3.21 (s, 3H, NCH3), 3.27 (s, 3H, NCH3), 3.71 (d, J = 10.54 Hz, 
1H, 4ʹ-H), 3.95 (d, J = 10.54 Hz, 1H, 4ʹ-H), 4.25 (d, J = 8.49 Hz, 1H, 5ʹ-H), 4.34 (d, J 
= 8.79 Hz, 1H, 5ʹ-H), 5.16 (d, J = 6.15 Hz, 1H, 2ʹ-H), 5.75 (d, J = 6.15 Hz, 1H, 1ʹ-H), 
7.94 (s, 1H, 8-H), 8.54 (s, 1H, 2-H), 8.97 (s, 1H, N
6
CH). ESI-HRMS for 
[C31H60N6O4Si3 + H]
+
 calcd, 665.4062; found, 665.4075. 
1ʹ-(Adenin-9-yl)-2ʹ,3ʹ,5ʹ-O-tri(tert-butyldimethylsilyl)-α-D-apio-L-furanose (5.9): 
The N
6
-dimethyformamidine derivative 5.8 (300 mg, 0.45 mmol) was dissolved in a 
7N solution of ammonia in MeOH and stirred at room temperature for 18h. The 
mixture was evaporated and the residue purified by column chromatography (20-40% 
EtOAc in hexanes) to afford 5.9 (200 mg, 73%) as a white foam. 
1
H NMR (300 MHz, 
CDCl3) δ ppm -0.34, -0.04, 0.09, 0.14, 0.15, 0.17 (s, 6x3H, SiCH3), 0.79 (s, 9H, 
C(CH3)3), 0.92 (s, 9H, C(CH3)3), 0.97 (s, 9H, C(CH3)3), 3.71 (d, J = 10.54 Hz, 1H, 4ʹ-
H), 3.96 (d, J = 10.84 Hz, 1H, 4ʹ-H), 4.25 (d, J = 8.79 Hz, 1H, 5ʹ-H), 4.32 (d, J = 8.49 
Hz, 1H, 5ʹ-H), 5.13 (d, J = 6.15 Hz, 1H, 2ʹ-H), 5.61 (s, 2H, NH2), 5.73 (d, J = 6.15 Hz, 
1H, 1ʹ-H), 7.87 (s, 1H, 8-H) 8.35 (s, 1H, 2-H). 13C NMR (75 MHz, CDCl3) δ ppm -
5.29, -5.27, -5.19, -4.65, -2.85, -2.70 (SiCH3), 17.97, 18.41, 18.75 (C(CH3)3), 25.66, 
26.04, 26.19 (C(CH3)3), 64.94 (5ʹ-C), 74.45 (4ʹ-C), 83.16 (2ʹ & 3ʹ-C), 90.42 (1ʹ-C), 
120.57 (5-C), 140.12 (8-C), 150.07 (4-C), 153.22 (2-C), 155.55 (6-C). ESI-HRMS for 
[C28H55N5O4Si3 + H]
+
 calcd, 610.3640; found, 610.3651. 
Method A: A solution of compound 5.9 (180 mg, 0.3 mmol) in anh. THF (4.25 mL) 
was placed in a Teflon flask under inert atmosphere and cooled to 0 °C. In a separate 
polypropylene flask, anh. THF (1.25 mL) and anh. pyridine (0.5 mL) were placed 
under inert atmosphere and cooled to 0 °C. A solution of 70% HF in pyridine (0.5 mL) 
was added dropwise to the latter mixture. 1.7 mL of the resulting chilled THF-
pyridine–HF.pyridine (2.5:1:1) mixture was added dropwise to the solution of 5.9 and 
the mixture was stirred at 0 °C for 1h. The ice-bath was removed and reaction 
continued at room temperature for 24h. The reaction mixture was poured to an ice-
cold solution of NaHCO3 (1.5 g in 8 mL) with vigorous stirring. The product was 
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extracted with EtOAc (3 X 20 mL), washed with brine and dried over anh. Na2SO4. 
The residue obtained after evaporation was subjected to flash column chromatography 
(2–5% MeOH in CH2Cl2) to obtain following compounds as white foam. Starting 
material 5.9 (70 mg, 39%), compound 5.10 (33 mg, 29%) and mixture of compounds 
5.11 and 5.12 (~2:1, 37 mg, 25%). 
Method B: To a cooled (0 °C) solution of compound 5.9 (70 mg, 0.12 mmol) in anh. 
THF (1 mL) was added a solution of trichloroacetic acid (507 mg, 3.1 mmol) in water 
(0.27 mL) and the mixture was stirred for 20 min at 0 °C, and for 24h at room 
temperature. The reaction mixture was cooled and neutralized with a cold sat. 
NaHCO3 solution. The products were extracted with EtOAc (3 X 30 mL), the 
combined organic phase was dried over anh.Na2SO4, filtered, and evaporated under 
reduced pressure. The residue was purified by column chromatography to afford 
following compounds: Starting material 5.9 (20 mg, 29%), compound 5.10 (10 mg, 
23%) and a mixture of compounds 5.11 and 5.12 (~2:1, 17 mg, 30%). 
1ʹ-(Adenin-9-yl)-3ʹ-O-(tert-butyldimethylsilyl)-α-D-apio-L-furanose (5.10): 1H 
NMR (300 MHz, DMSO-d6) δ ppm 0.08 (s, 6H, (SiCH3)2), 0.90 (s, 9H, C(CH3)3), 
3.74 (d, J = 10.54 Hz, 1H, 4ʹ-H), 3.84 (d, J = 10.25 Hz, 1H, 4ʹ-H), 3.99 (d, J = 9.08 Hz, 
1H, 5ʹ-H), 4.06 (d, J = 8.79 Hz, 1H, 5ʹ-H), 4.41 (dd, J = 5.27, 3.22 Hz, 1H, 2ʹ-H), 5.32 
(s, 1H, 5ʹ-OH), 5.88 (d, J = 5.56 Hz, 1H, 2ʹ-OH), 5.90 (d, J = 3.22 Hz, 1H, 1ʹ-H), 7.26 
(br. s, 2H, NH2), 8.15 (s, 1H, 2-H), 8.30 (s, 1H, 8-H). 
1
H NMR (75 MHz, DMSO-d6) δ 
ppm -5.48, -5.37 (SiCH3), 18.05 (C(CH3)3), 25.79 (C(CH3)3), 64.25 (5ʹ-C), 75.07 (4ʹ-
C), 79.93 (2ʹ-C), 80.13 (3ʹ-C), 90.57 (1ʹ-C), 118.76 (5-C), 139.62 (8-C), 148.99 (4-C), 
152.39 (2-C), 155.90 (6-C). ESI-HRMS for [C16H27N5O4Si +H]
+
 calcd, 382.1911; 
found, 382.1903. 
1ʹ-(Adenin-9-yl)-2ʹ,3ʹ-O-di(tert-butyldimethylsilyl)-α-D-apio-L-furanose (5.11): 1H 
NMR (300 MHz, DMSO-d6) δ ppm -0.18, -0.05, 0.08 (s, 4X3H, SiCH3), 0.78, 0.90 (s, 
2X9H, C(CH3)3), 3.67 (d, J = 10.25 Hz, 1H, 5ʹ-H), 3.82 (d, J = 10.25 Hz, 1H, 5ʹ-H), 
4.01 (d, J = 8.79 Hz, 1H, 4ʹ-H), 4.11 (d, J = 8.79 Hz, 1H, 4ʹ-H), 4.68 (d, J = 4.39 Hz, 
1H, 2ʹ-H), 5.33 (s, 1H, 5ʹ-OH), 5.89 (d, J = 4.39 Hz, 1H, 1ʹ-H), 7.27 (br. s, 2H, NH2), 
Apioadenosines as A3 Adenosine Receptor Modulators 
167 
8.15 (s, 1H, 2-H), 8.29 (s, 1H, 8-H). ESI-HRMS for [C22H41N5O4Si2 + H]
+
 calcd, 
496.2775; found, 496.2775. 
1ʹ-(Adenin-9-yl)-3ʹ,5ʹ-O-di(tert-butyldimethylsilyl)-α-D-apio-L-furanose (5.12): 1H 
NMR (300 MHz, DMSO-d6) δ ppm 0.10, 0.10, 0.12, 0.13 (s, 4X3H, SiCH3), 0.87, 
0.92 (s, 2X6H, C(CH3)3), 3.75 (d, J = 10.84 Hz, 1H, 5ʹ-H), 3.87 (d, J = 11.13 Hz, 1H, 
5ʹ-H), 4.06 (d, J = 8.20 Hz, 1H, 4ʹ-H), 4.19 (d, J = 8.20 Hz, 1H, 4ʹ-H), 5.00 (t, J = 5.13 
Hz, 1H, 2ʹ-H), 5.76 (d, J = 5.86 Hz, 1H, 1ʹ-H), 5.84 (d, J = 4.98 Hz, 1H, 2ʹ-OH), 7.27 
(br. s, 2H, NH2), 8.12 (s, 1H, 2-H), 8.24 (s, 1H, 8-H). ESI-HRMS for [C22H41N5O4Si2 
+ H]
+
 calcd, 496.2775; found, 496.2775. 
1ʹ-(Adenin-9-yl)-2ʹ,5ʹ-O-di(tert-butyldimethylsilyl)-3ʹ-deoxy-α-D-apio-L-furanose 
(5.14): To a solution of 3ʹ-deoxyapioadenosine 4.52b (170 mg, 0.67 mmol) in anh. 
DMF (2 mL) was added imidazole (230 mg, 3.38 mmol), followed by TBDMSCl (305 
mg, 2.03 mmol) and the mixture was stirred at room temperature for 18h. The reaction 
mixture was diluted with water (10 mL) and extracted with EtOAc (3 X 20 mL). The 
combined organic layer was dried over anh. Na2SO4, filtered and evaporated. The 
residue was purified by column chromatography using 3-5% MeOH in CH2Cl2 to 
afford 5.14 (242 mg, 75%) as a white foam. 
1
H NMR (300 MHz, CDCl3) δ ppm 0.05 
(s, 6H, Si(CH3)2), 0.07 (s, 3H, SiCH3), 0.11 (s, 3H, SiCH3), 0.88 (s, 9H, C(CH3)3), 
0.90 (s, 9H, C(CH3)3), 2.56 (qt, J = 7.81, 5.71 Hz, 1H, 3ʹ-H), 3.75 (dd, J = 9.96, 7.91 
Hz, 1H, 5ʹ-H), 3.87 (dd, J = 10.10, 6.00 Hz, 1H, 5ʹ-H), 4.08 (t, J = 8.35 Hz, 1H, 4ʹ-H), 
4.45 (dd, J = 8.20, 7.62 Hz, 1H, 4ʹ-H), 4.85 (dd, J = 4.98, 2.05 Hz, 1H, 2ʹ-H), 5.55 
(br.s, 2H, NH2), 5.90 (d, J = 2.05 Hz, 1H, 1ʹ-H), 7.87 (s, 1H, 8-H), 8.35 (s, 1H, 2-H). 
13
C NMR (75 MHz, CDCl3) δ ppm -5.47, -5.39, -5.28, -4.70 (SiCH3), 17.99, 18.26 
(C(CH3)3), 25.69, 25.87 (C(CH3)3), 44.77 (3ʹ-C), 60.02 (5ʹ-C), 71.91 (4ʹ-C), 76.02 (2ʹ-
C), 92.47 (1ʹ-C), 120.45 (5-C), 138.77 (8-C), 149.35 (4-C), 152.95 (2-C), 155.24 (6-C). 
ESI-HRMS for [C22H41N5O3Si2] calcd, 480.2826; found, 480.2828. 
1ʹ-(Adenin-9-yl)-2ʹ,5ʹ-O-di(tert-butyldimethylsilyl)-α-D-apio-L-furanose (5.15): To 
a solution of Apioadenosine 4.53b (150 mg, 0.56 mmol) in anh. DMF (2 mL) was 
added imidazole (155 mg, 2.28 mmol), followed by TBDMSCl (253 mg, 1.68 mmol) 
and the mixture was stirred at room temperature for 18h. The reaction mixture was 
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diluted with water (10 mL) and extracted with EtOAc (3 X 20 mL). The combined 
organic layer was dried over anh. Na2SO4, filtered and evaporated. The residue was 
purified by column chromatography using 3-5% MeOH in CH2Cl2 to afford 5.15 (230 
mg, 83%) as a white foam. 
1
H NMR (300 MHz, CDCl3) δ ppm 0.08 (s, 3H, SiCH3), 
0.10 (s, 6H, SiCH3), 0.12 (s, 3H, SiCH3), 0.91 (s, 18H, C(CH3)3), 3.75 (d, J = 9.96 Hz, 
1H, 4ʹ-H), 3.92 (d, J = 10.25 Hz, 1H, 4ʹ-H), 4.08 (d, J = 9.08 Hz, 1H, 5ʹ-H), 4.21 (d, J 
= 9.37 Hz, 1H, 5ʹ-H), 4.45 (d, J = 1.46 Hz, 1H, 2ʹ-H), 5.80 (br.s, 2H, NH), 5.95 (d, J = 
1.76 Hz, 1H, 1ʹ-H), 8.13 (s, 1H, 8-H) 8.32 (s, 1H, 2-H). 13C NMR (75 MHz, CDCl3) δ 
ppm -5.51, -5.31, -5.22, -4.55 (SiCH3), 17.87, 18.37 (C(CH3)3), 25.66, 25.91 
(C(CH3)3), 63.15 (4ʹ-C), 76.68 (5ʹ-C), 81.43 (3ʹ-C), 81.53 (2ʹ-C), 92.75 (1ʹ-C), 119.81 
(5-C), 140.04 (8-C), 149.27 (4-C), 152.68 (2-C), 155.31 (6-C). ESI-HRMS for 
[C22H41N5O4Si2 + H]
+
 calcd, 496.2775; found, 496.2783. 
 1ʹ-(Adenin-9-yl)-2ʹ-O-(tert-butyldimethylsilyl)-3ʹ-deoxy-α-D-apio-L-furanose 
(5.16): Following the desilylation method A (which was slightly modified in that the 
reaction mixture was stirred for 1h at room temperature) starting material 5.14 (240 
mg, 0.5 mmol) was converted to 5.16 (150 mg, 82%), obtained as a white foam. 
1
H 
NMR (300 MHz, CDCl3) δ ppm 0.08 (s, 3H, SiCH3), 0.11 (s, 3H, SiCH3), 0.91 (s, 9H, 
C(CH3)3), 2.14 (br. s, 1H, 5ʹ-OH), 2.66 (tq, J = 7.94, 5.74 Hz, 1H, 3ʹ-H), 3.89 (d, J = 
5.57 Hz, 2H, 5ʹ-H), 4.19 (t, J = 8.35 Hz, 1H, 4ʹ-H), 4.46 (dd, J = 8.49, 7.91 Hz, 1H, 4ʹ-
H), 5.07 (dd, J = 5.71, 2.49 Hz, 1H, 2ʹ-H), 5.56 (br. s, 2H, NH2), 5.89 (d, J = 2.34 Hz, 
1H, 1ʹ-H), 7.87 (s, 1H, 8-H), 8.35 (s, 1H, 2-H). 13C NMR (75 MHz, CDCl3) δ ppm -
5.22, -4.72 (SiCH3), 17.94 (C(CH3)3), 25.70 (C(CH3)3), 43.69 (3ʹ-C), 59.79 (5ʹ-C), 
70.79 (4ʹ-C), 77.09 (2ʹ-C), 92.38 (1ʹ-C), 120.45 (5-C), 138.92 (8-C), 149.38 (4-C), 
153.04 (2-C), 155.29 (6-C). ESI-HRMS for [C16H27N5O3Si + H]
+
 calcd, 366.1961; 
found, 366.1956. 
1ʹ-(Adenin-9-yl)-2ʹ-O-(tert-butyldimethylsilyl)-α-D-apio-L-furanose (5.17): 
Following the desilylation method B (which was slightly modified in that the reaction 
mixture was stirred for 2h at room temperature) 5.15 (210 mg, 0.42 mmol) was 
converted to 5.17 (140 mg, 87%), which was obtained as a white foam. 
1
H NMR (300 
MHz, DMSO-d6) δ ppm -0.17 (s, 3H, SiCH3), -0.04 (s, 3H, SiCH3), 0.79 (s, 9H, 
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C(CH3)3), 3.55 (dd, J = 11.13, 4.98 Hz, 1H, 5ʹ-H), 3.64 (dd, J = 11.13, 5.27 Hz, 1H, 
5ʹ-H), 4.02 (d, J = 8.79 Hz, 1H, 4ʹ-H), 4.08 (d, J = 8.79 Hz, 1H, 4ʹ-H), 4.66 (d, J = 
4.10 Hz, 1H, 2ʹ-H), 4.74 (t, J = 5.27 Hz, 1H, 5ʹ-OH), 5.35 (s, 1H, 3ʹ-OH), 5.87 (d, J = 
4.10 Hz, 1H, 1ʹ-H), 7.27 (br. s, 2H, NH2), 8.15 (s, 1H, 2-H), 8.32 (s, 1H, 8-H). 
13
C 
NMR (75 MHz, DMSO-d6) δ ppm -5.30 (Si(CH3)2), 17.49 (C(CH3)3), 25.37 (C(CH3)3), 
61.85 (5ʹ-C), 74.59 (4ʹ-C), 79.92 (3ʹ-C) 81.13 (2ʹ-C) 89.86 (1ʹ-C), 118.84 (5-C), 
139.70 (8-C), 149.00 (4-C), 152.42 (2-C), 155.90 (6-C). ESI-HRMS for 
[C16H27N5O4Si +H]
+
 calcd, 382.1911; found, 382.1908. 
1ʹ-(Adenin-9-yl)-2ʹ-O-(tert-butyldimethylsilyl)-3ʹ-deoxy-5ʹ-O-(N-ethylcarbamoyl)-
α-D-apio-L-furanose (5.18): To a solution of compound 5.16 (30 mg, 0.082 mmol) in 
anh. THF (2 mL) was added CDI (27 mg, 0.164 mmol) and the mixture was stirred at 
room temperature for 3h. Cold ethylamine (0.3 mL) was added to the reaction mixture 
and stirring continued at room temperature for 16h. Volatiles were evaporated and the 
residue suspended in CH2Cl2, washed with sat. NH4Cl, water and brine. The organic 
layer was dried over anh. Na2SO4, filtered, evaporated. The residue was purified by 
column chromatography (1-3% MeOH in CH2Cl2) to afford the title compound (35 
mg, 98%) as a white foam. 
1
H NMR (300 MHz, CDCl3) δ ppm 0.12 (s, 3H, SiCH3), 
0.18 (s, 3H, SiCH3), 0.92 (s, 9H, C(CH3)3), 1.12 (t, J = 7.18 Hz, 3H, NCH2CH3) 2.61 - 
2.80 (m, 1H, 3ʹ-H), 3.20 (quin, J = 6.59 Hz, 2H, NCH2CH3), 4.05 (t, J = 8.79 Hz, 1H, 
4ʹ-H), 4.14 - 4.34 (m, 2H, 5ʹ-H), 4.44 (t, J = 8.05 Hz, 1H, 4ʹ-H), 4.62 (t, J = 4.83 Hz, 
1H, NH), 4.87 (d, J = 4.10 Hz, 1H, 2ʹ-H), 5.65 (br.s, 2H, NH2), 5.87 - 5.96 (d, J = 1.17 
Hz, 1H, 1ʹ-H), 7.87 (s, 1H, 8-H), 8.35 (s, 1H, 2-H). 13C NMR (75 MHz, CDCl3) δ ppm 
-5.29, -4.59 (Si(CH3)2), 15.25 (NCH2CH3), 18.00 (C(CH3)3), 25.72 (C(CH3)3), 35.89 
(NCH2CH3), 41.75 (3ʹ-C), 61.03 (5ʹ-C), 71.26 (4ʹ-C), 75.99 (2ʹ-C), 92.67 (1ʹ-C), 
120.44 (5-C), 138.51 (8-C), 149.24 (4-C), 153.00 (2-C), 155.30 (6-C), 155.97 (CO). 
ESI-HRMS for [C19H32N6O4Si] calcd, 437.2333; found, 437.2338. 
1ʹ-(Adenin-9-yl)-2ʹ-O-(tert-butyldimethylsilyl)-5ʹ-O-(N-ethylcarbamoyl)-α-D-apio-
L-furanose (5.19): Following the same protocol as described for 5.18, 30 mg (0.078 
mmol) of 5.17 was converted to 5.19 (17 mg, 52%), obtained as a white foam. 
1
H 
NMR (300 MHz, CDCl3) δ ppm 0.01 (s, 3H, SiCH3), 0.06 (s, 3H, SiCH3), 0.91 (s, 9H, 
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C(CH3)3), 1.14 (t, J = 7.18 Hz, 3H, NCH2CH3), 3.24 (qd, J = 7.32, 1.17 Hz, 2H, 
NCH2CH3) 4.06 (d, J = 9.37 Hz, 1H, 4ʹ-H), 4.17 (d, J = 9.37 Hz, 1H, 4ʹ-H), 4.32 (d, J 
= 11.42 Hz, 1H, 5ʹ-H), 4.41 (d, J = 11.42 Hz, 1H, 5ʹ-H), 4.56 (s, 1H, 2ʹ-H), 4.84 (t, J = 
5.13 Hz, 1H, CONH), 5.75 (s, 1H, 1ʹ-H), 5.83 (br. s, 2H, NH2), 7.95 (s, 1H, 8-H), 8.32 
(s, 1H, 2-H). 
13
C NMR (75 MHz, CDCl3) δ ppm -5.22 (SiCH3), -4.44 (SiCH3), 15.17 
(NCH2CH3), 17.81 (C(CH3)3), 25.61 (C(CH3)3), 35.99 (NCH2CH3), 65.30 (5ʹ-C), 
76.41 (4ʹ-C), 80.48 (3ʹ-C), 82.81 (1ʹ-C), 94.41 (1ʹ-C), 120.43 (5-C), 140.41 (8-C), 
148.43 (4-C), 152.50 (2-C), 155.70 (6-C), 156.44 (CO). ESI-HRMS for 
[C19H32N6O5Si + H]
+
 calcd, 453.2282; found, 453.2220. 
1ʹ-(Adenin-9-yl)-2ʹ-O-(tert-butyldimethylsilyl)-3ʹ-deoxy-5ʹ-(N-ethyl)-
carboxamido-α-D-apio-L-furanose (5.20): To a suspension of compound 5.16 (30 
mg, 0.082 mmol) in a 1:1:1.5 mixture of acetonitrile-CCl4-water (2 mL) was added 
NaIO4 (75 mg, 0.33 mmol), followed by RuCl3 (12 mg). The reaction mixture was 
stirred at room temperature for 7h and the solvents evaporated under vacuum. The 
residue was suspended in MeOH (5 mL), subjected to centrifugation and the clear 
supernatant liquid was decanted and evaporated. The residue was dried under high 
vacuum, and suspended in anh. THF (1.5 mL). To this suspension was added DMAP 
(23 mg, 0.19 mmol) and CDI (27 mg, 0.17 mmol) and the mixture was stirred at room 
temperature for 2-3h. Cold ethylamine (0.3 mL) was added, stirring was continued at 
room temperature for 18h, after which the reaction mixture was evaporated and the 
residue purified by column chromatography. The products were further purified by 
preparative thin layer chromatography (10% MeOH in CH2Cl2) to afford the title 
compound 5.20 (Rf: 0.4, 3 mg, 9%), as well as the carbamate 5.18 (Rf: 0.55, 3 mg, 
8%). 
1
H NMR (300 MHz, CDCl3) δ ppm -0.01 (s, 3H, SiCH3), 0.06 (s, 3H, SiCH3), 
0.87 (s, 9H, C(CH3)3), 1.18 (t, J = 7.32 Hz, 3H, NCH2CH3), 3.14 - 3.23 (m, 1H, 3ʹ-H), 
3.27 - 3.44 (m, 2H, NCH2CH3), 4.51 (dd, J = 8.79, 6.74 Hz, 1H, 4ʹ-H), 4.57 (dd, J = 
8.64, 7.18 Hz, 1H, 4ʹ-H), 5.33 (dd, J = 5.86, 3.22 Hz, 1H, 2ʹ-H), 5.64 (br. s, 2H, 6-
NH2), 5.91 (d, J = 3.51 Hz, 1H, 1ʹ-H), 6.09 (t, J = 4.54 Hz, 1H, 5ʹ-NH), 7.86 (s, 1H, 8-
H), 8.35 (s, 1H, 2-H). ESI-HRMS for [C18H30N6O3Si + H]
+
 calcd, 407.2227; found, 
407.2222.  
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1ʹ-(Adenin-9-yl)-3ʹ-deoxy-5ʹ-(N-ethyl)-carboxamido-α-D-apio-L-furanose (5.21): 
To a solution of compound 5.20 (3 mg, 0.007 mmol) in MeOH (0.5 mL) in a 
polypropylene vessel was added NH4F (6 mg, 0.14 mmol) and the reaction mixture 
was stirred at 50 °C for 48h. After addition of CH2Cl2 (1.5 mL) and the reaction 
mixture was filtered through celite pad. The filtrate was concentrated and the residue 
purified by column chromatography (5-7 % MeOH in CH2Cl2) to afford the title 
compound 5.21 (1.5 mg, 70 %) as a white solid after lyophylization. 
1
H NMR (300 
MHz, DMSO-d6) δ ppm 1.02 (t, J = 7.18 Hz, 3H, NCH2CH3), 3.04 - 3.15 (m, 2H, 
NCH2CH3), 4.23 (t, J = 8.20 Hz, 1H, 4ʹ-H), 4.35 (t, J = 8.05 Hz, 1H, 4ʹ-H), 4.77 (br. s, 
1H, 2ʹ-H), 5.88 (d, J = 3.51 Hz, 1H, 2ʹ-OH), 5.95 (d, J = 2.64 Hz, 1H, 1ʹ-H), 7.26 (s, 
2H, 6-NH2), 7.89 (t, J = 5.42 Hz, 1H, 5ʹ-NH), 8.15 (s, 1H, 2-H), 8.23 (s, 1H, 8-H). 
13
C 
NMR (75 MHz, DMSO-d6) δ ppm 14.64 (NCH2CH3), 33.43 (NCH2CH3), 47.11 (3ʹ-C), 
69.12 (4ʹ-C), 75.17 (2ʹ-C), 90.38 (1ʹ-C), 119.19 (5-C), 138.83 (8-C), 148.91 (4-C), 
152.56 (2-C), 156.01 (6-C), 168.19 (CO). ESI-HRMS [C12H16N6O3 + H]
+
 calcd, 
293.1362; found, 293.1360. 
1ʹ-(Adenin-9-yl)-3ʹ-deoxy-5ʹ-O-(N-ethylcarbamoyl)-α-D-apio-L-furanose (5.22): 
To a solution of compound 5.20 (35 mg, 0.08 mmol) in MeOH (1.5 mL) in a 
polypropylene vessel was added NH4F (60 mg, 1.6 mmol) and the reaction mixture 
was stirred at 50 °C for 48h. After addition of CH2Cl2 (5 mL) and the reaction mixture 
was filtered through celite pad. The filtrate was concentrated and the residue purified 
by column chromatography (5-7 % MeOH in CH2Cl2) to afford the title compound 
5.22 (23 mg, 90%) as a white solid. 
1
H NMR (300 MHz, DMSO-d6) δ ppm 1.00 (t, J = 
7.20 Hz, 3H, NCH2CH3), 2.73 - 2.87 (m, 1H, 3ʹ-H), 2.93 - 3.05 (m, 2H, NCH2CH3), 
3.85 (t, J = 8.35 Hz, 1H, 4ʹ-H), 4.03 (dd, J = 10.56, 8.25 Hz, 1H, 5ʹ-H), 4.23 (dd, J = 
10.85, 6.24 Hz, 1H, 5ʹ-H), 4.37 (t, J = 7.77 Hz, 1H, 4ʹ-H), 4.66 (t, J = 3.55 Hz, 1H, 2ʹ-
H), 5.86 (d, J = 4.80 Hz, 1H, 2ʹ-OH), 5.92 (d, J = 2.11 Hz, 1H, 1ʹ-H), 7.10 (t, J = 5.37 
Hz, 1H, NH), 7.27 (br.s, 2H, NH2), 8.15 (s, 1H, 2-H), 8.23 (s, 1H, 8-H). 
13
C NMR (75 
MHz, DMSO-d6) δ ppm 15.01 (NCH2CH3), 35.00 (NCH2CH3), 41.19 (3ʹ-C), 60.76 
(5ʹ-C), 70.59 (4ʹ-C), 74.24 (2ʹ-C), 91.29 (1ʹ-C), 119.24 (5-C), 139.05 (8-C), 148.73 (4-
C), 152.55 (2-C), 155.99 (CO), 156.02 (6-C). ESI-HRMS for [C13H18N6O4 + H]
+
 calcd, 
323.1468; found, 323.1472. 
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1ʹ-(Adenin-9-yl)-5ʹ-O-(N-ethylcarbamoyl)-α-D-apio-L-furanose (5.23): Following 
the protocol used for the synthesis of 5.22, compound 5.21 (20 mg, 0.044 mmol) was 
converted to the title compound 5.23 (14 mg, 94%), obtained as a white solid. 
1
H 
NMR (300 MHz, CD3OD) δ ppm 1.11 (t, J = 7.18 Hz, 3H, NCH2CH3), 3.14 (q, J = 
7.03 Hz, 2H, NCH2CH3), 4.13 (d, J = 9.37 Hz, 1H, 4ʹ-H), 4.20 (d, J = 9.37 Hz, 1H, 4ʹ-
H), 4.26 (d, J = 11.42 Hz, 1H, 5ʹ-H), 4.33 (d, J = 11.13 Hz, 1H, 5ʹ-H), 4.37 (d, J = 
1.17 Hz, 1H, 2ʹ-H), 6.04 (d, J = 1.76 Hz, 1H, 1ʹ-H), 8.21 (s, 1H, 2-H), 8.31 (s, 1H, 8-
H). 
13
C NMR (75 MHz, CD3OD) δ ppm 15.33 (NCH2CH3), 36.70 (NCH2CH3), 66.37 
(5ʹ-C), 77.43 (4ʹ-C), 81.34 (3ʹ-C), 81.93 (2ʹ-C), 93.89 (1ʹ-C), 120.30 (5-C), 141.53 (8-
C), 150.00 (4-C) 153.69 (2-C), 157.35 (6-C), 158.83 (CO). ESI-HRMS for 
[C13H18N6O5 + H]
+
 calcd, 339.1417; found, 339.1409. 
1ʹ-[N6-(3-Chlorobenzyl)-adenin-9-yl]-β-D-apio-D-furanose (5.24): Following the 
protocol used for the synthesis of compound 5.5, β-D-apio-D-furanoadenosine 4.3b 
(100 mg, 0.38 mmol) was converted to the title compound, which was first purified by 
silica-gel coumn chromatography and then by RP-HPLC (H2O/AcCN, 90/10→70/30 
in 18 min, Rt = 12.5 min) to obtain 5.24 as white solid (16 mg, 11%). 
1
H NMR (300 
MHz, DMSO-d6) δ ppm 3.46 (q, J = 11.02 Hz, 2H, 5ʹ-H), 3.77 (d, J = 9.25 Hz, 1H, 4ʹ-
H), 4.32 (d, J = 9.05 Hz, 1H, 4ʹ-H), 4.72 (br. s, 2H, PhCH2), 4.82 (d, J = 7.48 Hz, 1H, 
2ʹ-H), 4.87 (br.s, 1H, 3ʹ-OH), 5.43 (br.s, 1H, 2ʹ-OH), 5.90 (d, J = 7.67 Hz, 1H, 1ʹ-H), 
7.23 - 7.43 (m, 4H, PhCH2), 8.23 (s, 1H, 2-H), 8.38 (s, 1H, 8-H), 8.44 (br.s, 1H, NH).
 
13
C NMR (75 MHz, DMSO-d6) δ ppm 42.41 (PhCH2), 62.38 (5ʹ-C), 73.42 (2ʹ-C), 
74.59 (4ʹ-C), 78.28 (3ʹ-C), 87.81 (1ʹ-C), 119.70 (5-C) 125.80, 126.58, 126.88, 130.14, 
132.87 (PhCH2), 140.21 (8-C), 142.78 (PhCH2), 149.18 (4-C), 152.56 (2-C), 154.33 
(6-C). ESI-HRMS for [C17H18ClN5O4 + H]
+
 calcd, 392.1120; found, 392.1127. 
1ʹ-[N6-(3-Iodobenzyl)-adenin-9-yl]-β-D-apio-D-furanose (5.25): Following the 
protocol used for the synthesis of compound 5.5, β-D-apio-D-furanoadenosine 4.3b 
(100 mg, 0.38 mmol) was converted to the title compound 5.25, which was first 
purified by silica-gel coumn chromatography and then by trituration with methanol to 
obtain as white solid (15 mg, 8%).
1
H NMR (300 MHz, DMSO-d6) δ ppm 3.37 - 3.57 
(m, 2H, 5ʹ-CH2), 3.76 (d, J = 9.21 Hz, 1H, 4ʹ-H), 4.32 (d, J = 9.21 Hz, 1H, 4ʹ-H), 4.67 
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(br. s, 2H, PhCH2), 4.76 - 4.82 (m, 1H, 2ʹ-H), 4.84 (s, 1H, 3ʹ-OH), 4.90 (t, J = 5.49 Hz, 
1H, 5ʹ-OH), 5.40 (d, J = 6.86 Hz, 1H, 2ʹ-H), 5.89 (d, J = 7.45 Hz, 1H, 1ʹ-H), 7.11(t, J 
= 7.64 Hz, 1H, Ph 5-H), 7.36 (d, J = 7.64 Hz, 1H, Ph) 7.58 (d, J = 7.84 Hz, 1H, Ph) 
7.72 (s, 1H, Ph 2-H), 8.22 (s, 1H, 2-H), 8.38 (s, 1H, 8-H), 8.41 (br.s, 1H, NH). 
13
C 
NMR (75 MHz, DMSO-d6) δ ppm 42.24 (PhCH2), 62.37 (5ʹ-C), 73.39 (2ʹ-C), 74.57 
(4ʹ-C), 78.26 (3ʹ-C), 87.80 (1ʹ-C), 94.71 (Ph), 119.72 (5-C), 126.59, 130.47, 135.32, 
135.68 (Ph), 140.17 (8-C) 142.88 (Ph), 149.13 (4-C), 152.54 (2-C), 154.31 (6-C). 
ESI-HRMS for [C17H18IN5O4 + H]
+
 calcd, 484.0476; found, 484.0490. 
1ʹ-[N6-(2-Methoxy-5-chlorobenzyl)-adenin-9-yl]-β-D-apio-D-furanose (5.26): To a 
solution of apioadenosine 4.53b (60 mg, 0.23 mmol) in anh. DMF (2 mL) was added 
2-methoxy-5-chlorobenzyl bromide (58 mg, 0.25 mmol) and the mixture was stirred at 
room temperature for 24h. Solvent was evaporated in vacuo. The residue was trated 
with ammonium hydroxide (25%, 3.0 mL) and stirred at 55 °C for 24h. The volatiles 
were evaporated under reduced pressure and the residue purified by silica-gel column 
chromatography (3-6% MeOH in CH2Cl2) and the products were further purified by 
preperative thin layer chromatography to afford desired product 5.26 (20 mg, 21%) as 
white solid.
 1
H NMR (300 MHz, CD3OD) δ ppm 3.59 - 3.74 (q, J = 11.37 Hz, 2H, 5ʹ-
H), 3.87 (s, 3H, OCH3), 3.98 (d, J = 9.63 Hz, 1H, 4ʹ-H), 4.49 (d, J = 9.63 Hz, 1H, 4ʹ-
H), 4.77 (br.s, 2H, PhCH2), 4.85 (d, J = 7.13 Hz, 1H, 2ʹ-H), 6.01 (d, J = 7.13 Hz, 1H, 
1ʹ-H), 6.93 (d, J = 8.67 Hz, 1H, Ph 5-H), 7.20 (dd, J = 8.67, 2.70 Hz, 1H, Ph 4-H), 
7.25 (d, J = 2.50 Hz, 1H, Ph 2-H), 8.25 (s, 2H, 2-H & 8-H).
 13
C NMR (75 MHz, 
CD3OD) δ ppm 40.25 (PhCH2), 56.25 (OCH3), 64.42 (5ʹ-C), 75.99 (2ʹ-C), 76.42 (4ʹ-C), 
79.85 (3ʹ-C), 90.47 (1ʹ-C), 112.79 (Ph) 120.99 (5-C), 126.27, 129.03, 129.05, 129.96 
(Ph), 141.13 (8-C), 150.25 (4-C), 153.97 (2-C), 156.01 (6-C), 157.52 (Ph). ESI-
HRMS for [C18H20ClN5O5 + H]
+
 calcd, 422.1226; found, 422.1235. 
1ʹ-(Adenin-9-yl)-2ʹ,5ʹ-O-di(tert-butyldimethylsilyl)-β-D-apio-D-furanose (5.27): 
Following the reaction protocol used for the synthesis of compound 5.14, β-D-apio-D-
furanoadenosine 4.3b (150 mg, 0.56 mmol) was converted to the title compound 5.27 
(207 mg, 74%) as white foam.
 1
H NMR (300 MHz, CDCl3) δ ppm -0.47, -0.07, 0.10, 
0.12 (s’s, 4 x 3H, SiCH3), 0.81, 0.97 (s’s, 9H, C(CH3)3), 3.01 (s, 1H, 3ʹ-OH), 3.50 (d, 
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J = 10.26 Hz, 1H, 5ʹ-H), 3.59 (d, J = 10.26 Hz, 1H, 5ʹ-H), 4.02 (d, J = 9.43 Hz, 1H, 4ʹ-
H), 4.50 (dd, J = 9.43, 1.03 Hz, 1H, 4ʹ-H), 5.41 (d, J = 6.56 Hz, 1H, 2ʹ-H), 5.65 (br.s, 
2H, NH2), 5.89 (d, J = 6.77 Hz, 1H, 1ʹ-H), 7.86 (s, 1H, 2-H), 8.34 (s, 1H, 8-H).
 13
C 
NMR (75 MHz, CDCl3) δ ppm -5.68, -5.47, -5.22, -5.02 (SiCH3), 17.76, 18.13 
(C(CH3)3) 25.54, 25.73 (C(CH3)3), 62.13 (5ʹ-C), 73.95 (2ʹ-C), 74.11 (4ʹ-C), 78.79 (3ʹ-
C), 89.89 (1ʹ-C), 120.43 (5-C), 140.03 (8-C), 150.11 (4-C), 153.23 (2-C), 155.46 (6-C). 
ESI-HRMS for [C22H41N5O4Si2 + H]
+
 calcd, 496.2775; found, 496.2781. 
1ʹ-(Adenin-9-yl)-2ʹ-O-(tert-butyldimethylsilyl)-β-D-apio-D-furanose (5.28): 
Following the desilylation method B (which was slightly modified in that the reaction 
mixture was stirred for 3h at room temperature) 5.27 (200 mg, 0.4 mmol) was 
converted to 5.28 (90 mg, 35%), which was obtained as a white solid.
 1
H NMR (300 
MHz, CDCl3) δ ppm -0.33, -0.03 (s’s, 2 x 3H, SiCH3), 0.84 (s, 9H, C(CH3)3), 3.28 (s, 
1H, 3ʹ-OH), 3.78 (s, 2H, 5ʹ-H), 4.04 (d, J = 9.71 Hz, 1H, 4ʹ-H), 4.45 (d, J = 9.71 Hz, 
1H, 4ʹ-H), 5.25 (d, J = 5.26 Hz, 1H, 2ʹ-H), 5.71 (br.s, 2H, NH2), 5.78 (d, J = 5.26 Hz, 
1H, 1ʹ-H), 7.87 (s, 1H, 8-H), 8.36 (s, 1H, 2-H). 13C NMR (75 MHz, CDCl3) δ ppm -
4.91, 0.15 (SiCH3), 17.96 (C(CH3)3), 25.69 (C(CH3)3), 65.64 (5ʹ-C), 75.56 (2ʹ-C), 
75.74 (4ʹ-C), 78.33 (3ʹ-C), 91.67 (1ʹ-C), 120.72 (5-C), 140.57 (8-C), 149.76 (4-C), 
153.35 (2-C), 155.78 (6-C). ESI-HRMS for [C16H27N5O4Si + H]
+
 calcd, 382.1911; 
found, 382.1910. 
1ʹ-(Adenin-9-yl)-2ʹ-O-(tert-butyldimethylsilyl)-5ʹ-O-(N-methylcarbamoyl)-β-D-
apio-D-furanose (5.29): Following the same protocol as described for 5.18, 85 mg 
(0.22 mmol) of 5.28 was converted to 5.29 (70 mg, 72%), obtained as a white foam.
 
1
H NMR (300 MHz, CDCl3) δ ppm -0.42, -0.05 (s’s, 3H, SiCH3), 0.83 (s, 9H, 
C(CH3)3), 2.85 (d, J = 4.90 Hz, 3H, NCH3), 3.26 (br.s, 1H, 3ʹ-OH), 4.09 (d, J = 9.81 
Hz, 1H, 4ʹ-H), 4.18 (d, J = 11.44 Hz, 1H, 5ʹ-H), 4.28 (d, J = 11.44 Hz, 1H, 5ʹ-H), 4.46 
(d, J = 9.81 Hz, 1H, 4ʹ-H), 4.90 (br.s, 1H, NH), 5.32 (d, J = 6.13 Hz, 1H, 2ʹ-H), 5.81 
(d, J = 6.13 Hz, 1H, 1ʹ-H), 5.89 (br.m, 2H, NH2), 7.86 (s, 1H, 8-H), 8.35 (s, 1H, 2-H).
 
13
C NMR (75 MHz, CDCl3) δ ppm -5.14, -5.09 (SiCH3), 17.76 (C(CH3)3), 25.52 
(C(CH3)3), 27.71 (NCH3), 65.43 (5ʹ-C), 74.99 (2ʹ-C), 75.13 (4ʹ-C), 90.60 (1ʹ-C), 
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120.60 (5-C), 140.49 (8-C), 149.86 (4-C), 153.17 (2-C), 155.65 (6-C), 156.60 (C=O). 
ESI-HRMS for [C18H30N6O5Si + H]
+
 calcd, 439.2125; found, 439.2128. 
1ʹ-(Adenin-9-yl)-5ʹ-O-(N-methylcarbamoyl)-β-D-apio-D-furanose (5.30): 
Following the protocol used for the synthesis of 5.22, compound 5.29 (60 mg, 0.13 
mmol) was converted to the title compound 5.30 (40 mg, 90%), obtained as a white 
solid. 
1
H NMR (300 MHz, CD3OD) δ ppm 2.73 (s, 3H, NCH3), 3.99 (d, J = 9.63 Hz, 
1H, 4ʹ-H), 4.15 - 4.31 (q, J = 11.18 Hz, 2H, 5ʹ-H), 4.46 (d, J = 9.83 Hz, 1H, 4ʹ-H), 
4.91 (d, J = 7.13 Hz, 1H, 2ʹ-H), 5.99 (d, J = 7.13 Hz, 1H, 1ʹ-H), 8.21 (s, 1H, 2-H), 
8.28 (s, 1H, 8-H).
 13
C NMR (75 MHz, CD3OD) δ ppm 27.53 (NCH3), 66.69 (5ʹ-C), 
76.15 (2ʹ-C), 76.43 (4ʹ-C), 78.55 (3ʹ-C), 90.40 (1ʹ-C), 120.72 (5-C), 141.79 (8-C), 
150.86 (4-C), 153.92 (2-C), 157.33 (6-C), 159.21 (C=O). RSI-HRMS for [C12H16N6O5 
+ H]
+
 calcd, 325.1255; found, 325.1260. 
 
5.4.2. Pharmacological assay procedures 
Receptor binding and functional assays 
[
3
H]R-N
6
-Phenylisopropyladenosine ([
3
H]R-PIA, 63 Ci/mmol), [
125
I]N
6
-(4-Amino-3-
iodobenzyl)adenosine-5ʹ-N-methyluronamide ([125I]I-AB-MECA, 2200 Ci/mmol), and 
[
3
H](2-[p-(2-carboxyethyl)phenyl-ethylamino]-5-N-ethylcarboxamido-adenosine) 
([
3
H]CGS21680, 40.5 Ci/mmol) were purchased from Perkin–Elmer Life and 
Analytical Science (Boston, MA). Test compounds were prepared as 5 mM stock 
solutions in DMSO and stored frozen.  
Cell Culture and Membrane Preparation - CHO cells stably expressing the 
recombinant hA1, hA3, and rA3Rs, and HEK-293 cells stably expressing the hA2AAR 
were cultured in Dulbecco’s modified Eagle medium (DMEM) and F12 (1:1) 
supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 100 μg/mL 
streptomycin, and 2 μmol/mL glutamine. In addition, 800 μg/mL geneticin was added 
to the A2A media, while 500 μg/mL hygromycin was added to the A1 and A3 media. 
After harvesting, cells were homogenized and suspended in PBS. Cells were then 
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centrifuged at 240 g for 5 min, and the pellet was resuspended in 50 mM Tris-HCl 
buffer (pH 7.5) containing 10 mM MgCl2. The suspension was homogenized and was 
then ultra-centrifuged at 14,330 g for 30 min at 4 °C. The resultant pellets were 
resuspended in Tris buffer, incubated with adenosine deaminase (3 units/mL) for 30 
min at 37 
o
C. The suspension was homogenized with an electric homogenizer for 10 
sec, pipetted into 1 mL vials and then stored at -80 °C until the binding experiments. 
The protein concentration was measured using the BCA Protein Assay Kit from Pierce 
Biotechnology, Inc. (Rockford, IL).  
Binding assays: Into each tube in the binding assay was added 50 μL of increasing 
concentrations of the test ligand in Tris-HCl buffer (50 mM, pH 7.5) containing 10 
mM MgCl2, 50 μL of the appropriate agonist radioligand, and finally 100 μL of 
membrane suspension. For the A1AR (22 μg of protein/tube) the radioligand used was 
[
3
H]R-PIA (final concentration of 3.5 nM). For the A2AAR (20 μg/tube) the 
radioligand used was [
3
H]CGS21680 (10 nM). For the A3AR (21 μg/tube) the 
radioligand used was [
125
I]I-AB-MECA (0.34 nM). Nonspecific binding was 
determined using a final concentration of 10 μM adenosine-5ʹ-N-ethylcarboxamide 
(NECA) diluted with the buffer. The mixtures were incubated at 25 °C for 60 min in a 
shaking water bath. Binding reactions were terminated by filtration through Brandel 
GF/B filters under a reduced pressure using a M-24 cell harvester (Brandel, 
Gaithersburg, MD). Filters were washed three times with 3 mL of 50 mM ice-cold 
Tris-HCl buffer (pH 7.5). Filters for A1 and A2AAR binding were placed in 
scintillation vials containing 5 mL of Hydrofluor scintillation buffer and counted 
using a Perkin Elmer Liquid Scintillation Analyzer (Tri-Carb 2810TR). Filters for 
A3AR binding were counted using a Packard Cobra II γ-counter. The Ki values were 
determined using GraphPad Prism for all assays.  
cAMP accumulation assay: Intracellular cAMP levels were measured with a 
competitive protein binding method. CHO cells that expressed the recombinant 
hA3AR were harvested by trypsinization. After centrifugation and resuspended in 
medium, cells were planted in 96-well plates in 0.1 mL medium. After 24h, the 
medium was removed and cells were washed three times with 0.2 mL DMEM, 
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containing 50 mM HEPES, pH 7.4. Cells were then treated with the agonist NECA or 
test compound in the presence of rolipram (10 M) and adenosine deaminase (3 
units/mL). After 30 min forskolin (10 M) was added to the medium, and incubation 
was continued for an additional 15 min. The reaction was terminated by removing the 
supernatant, and cells were lysed upon the addition of 100 L of 0.1 M ice-cold HCl. 
The cell lysate was resuspended and stored at -20C. For determination of cAMP 
production, 50 µL of the HCl solution was used in the Amersham cAMP Enzyme 
Immunoassay following the instructions provided with the kit. The results were 
interpreted using a SpectroMax M5 Microplate reader at 450 nm. 
 
  
 
 
 
  
  
 
 
 
 
 
 
 
 
CHAPTER – 6 
5,5ʹ-MODIFIED 2ʹ-DEOXYURIDINES AS 
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Part of this Chapter was published as 
 
Synthesis and evaluation of 5ʹ-modified thymidines and 5-hydroxymethyl-2ʹ-
deoxyuridines as M. tuberculosis thymidylate kinase inhibitors.  
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6.1. Objectives 
Frecer et al. recently reported on the combinatorial design and structure-based in 
silico screening of a virtual focused library of bicyclic thymidine analogs.
154
 In their 
study they used the three-dimensional structure of TMPKmt complexed with 5-
hydroxymethyl-dUMP (6.1) to develop a QSAR model, to parameterize a target-
specific scoring function for TMPKmt and to select virtual hits which display the 
highest predicted binding to the target. Compound 6.3 emerged as one of the best 
analogues. The binding of 6.3 to TMPKmt is predicted to be similar to that of 6.2. 
Beside the fact that it is a carba-nucleoside contains a sulfondiamide group replacing 
the thiourethane moiety of the condensed ring of 6.2, 6.3 differs from 6.2 by the 
presence of a 5-CH2OH group, known to possibly make an extra hydrogen bond with 
a water molecule (W12) or with the side chain of Ser99, and a 5ʹ-(N-
methylsulfamoyl)methyl moiety. The latter fragment, which replaces the phosphate 
moiety present in dTMP, was anticipated to favorably interact Arg95, Arg153 and 
especially with the magnesium ion. Alternative phosphate isosteres suggested in the 
Frecer publication are a 5-tetrazolylmethyl and methylsulfonylmethyl group. In this 
pilot study we decided to explore the importance of the proposed 5-CH2OH and 5ʹ-
modifications for TMPKmt inhibition. 
 
Figure 5.1. TMPKmt inhibitors designed previously in our laboratory (6.1 and 6.2) or 
predicted by QSAR model (6.3). Ki
exp
 and Ki
pre
 indicate experimental and predicted Ki 
values, respectively.  
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6.2. Results and Discussion 
6.2.1. Chemistry 
We envisioned synthesizing the target molecules using a Wittig-Horner reaction to 
introduce the desired 5ʹ-modifications as a key step. For this purpose two non-
commercial Horner reagents were self-made (Scheme 6.1). Diethyl 
((methylsulfonyl)methyl)phosphonate 6.5
190
 was prepared according to known 
procedures, while Horner reagent 6.8
191
 was obtained by reacting half an equivalent of 
chlorodiethylphosphate with bis-lithiated 6.7.
192
 3ʹ-Silylated thymidine 6.11 was 
produced by a selective cleavage of the primary TBDMS
183
 group of 6.10.
193
 
 
Scheme 6.1. Synthesis of Horner reagents 6.5 and 6.8, and intermediate 6.11. Reagents and 
conditions:(a) CH2Cl2, m-CPBA, rt, 48h, 99%; (b) aq.methylamine, H2O, 0 °C → rt, 18h, 
92%; (c) THF, BuLi, -78 °C, 1h, diethylchlorophosphate (0.5 eq), -78 °C → 0 °C, 1h, 65 %; 
(d) DMF, TBDMSCl, imidazole, rt, 18h, quant. yield; (e) THF, pyridine, HF-pyridine, 0 °C, 
1h, 0 °C → rt, 1h, 36 %. 
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Scheme 6.2. Synthesis of the 5ʹ-modified thymidines. Reagents and conditions: (a) CH2Cl2, 
Dess-Martin periodinane, rt, 4h; (b) THF, 6.5, BuLi, -78 °C, 15 min, -78 °C, 1h, rt, 18h, 20%; 
(c) H2, Pd-C, MeOH, 4h, rt; (d) THF, TBAF, 40 °C, 15h, 20% over two steps; (e) THF, 6.8, 
BuLi, -78 °C, 1h, -78 °C, 1h, rt, 18h, 48%; (f) (i) MeOH-THF (5:1), NiCl2, NaBH4, 0 °C, 1h; 
(ii) THF, TBAF, 40 °C, 1h, 12% over two steps; (g)THF, cyanomethyltriphenylphosphonium 
chloride, BuLi, 0 °C, 30 min, 0 °C → rt, 18h; (h) pyridine-MeOH (3:1), NaBH4, 120 °C, 4h, 
53%; (i) THF, TBAF, rt, 4h, 76%; (j) toluene, TMSN3, Bu2SnO, 110 °C, 4h, 32%; (k) THF, 
TBAF, rt, 4h, 34%. (l) 50% aq.NH2OH, ethanol, rt, 48h, 83%. 
 
To synthesize the 5ʹ-modified thymidines 6.15, 6.17, 6.20, 6.22 and 6.23 (Scheme 6.2), 
the 5ʹ-OH group of 6.11 was oxidized using Dess-Martin periodinane and the resulting 
aldehyde 6.12 was reacted with the proper Wittig-Horner reagents to give 6.13, 6.16 
and 6.18 in moderate yields. Methylsulfone 6.15 was obtained by Pd catalyzed 
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hydrogenation of 6.13, followed by the removal of TBDMS group. The conjugated 
double bond in 6.16 was reduced using NaBH4/NiCl2 
194
 and the product was 
desilylated using TBAF affording 6.17. Conjugate reduction of nitrile 6.18 was 
achieved with NaBH4 in a pyridine-MeOH mixture at elevated temperature.
195
 
Deprotection of 6.19 afforded the 6ʹ-nitrile analogue 6.20 in 76% yield. A 
cycloaddition between nitrile 6.19 and TMSN3 in the presence of dibutyltinoxide gave 
6.21 in moderate yield.
196
 Even though the conversion of 6.21 to 6.22 was complete 
(by LCMS), the isolated yield is lowered by the elaborate purification necessary to 
isolate the product.
197
 Compound 6.20 on treatment with hydroxylamine gave N-
hydroxyamidine 6.23 in good yield. 
 
Scheme 6.3. Attempted hydroxymethylation route to 6.30. Reagents and conditions: (a) 
TBDMSCl, DMF, imidazole, rt, 18h, quant. Yield; (b) THF, pyridine, HF-Pyridine, 0 °C, 1h, 
0 °C → rt, 1h, 53 %; (c) (i) CH2Cl2, Dess-Martin periodinane, rt, 4h; (ii) THF, 
cyanomethyltriphenylphosphonium chloride, BuLi, 0 °C, 30 min, 0 °C → rt, 18h, 51% over 
two steps; (d) H2, Pd-C, MeOH, 4h, rt; (e) THF, TBAF, rt, 4h, 73%; (f) paraformaldehyde, 
H2O, TEA, 100 °C, 3 days or paraformaldehyde, H2O, TEA, continuous irradiation of 
microwave from  rt → 150 °C in 3 min, 10 min at 150 °C. 
 
Hydroxymethylation at position 5 of dU (Scheme 6.3; 6.24) of pyrimidine is reported. 
However, selective protection of this hydroxyl group appears difficult.
198
 An attempt 
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to hydroxymethylate the 5-position of 6.25 failed, possibly due to the low solubility of 
the substrate in formalin-TEA system and the lability of the TBDMS groups under the 
harsh reaction conditions. Hence, we decided to introduce the 5-CH2OH group after 
modifying the 5ʹ-position in 2ʹ-deoxyuridine. As a model substrate for this strategy, 
compound 6.29 was synthesized smoothly using similar transformations as before. 
Unfortunately, reaction of 6.29 with formaldehyde at elevated temperature was very 
slow with only traces of the desired product formed after several days, while under 
microwave conditions, the starting material degraded. 
Because of this setback, we decided to start from compound 6.31, obtained via the 
benzylic oxidation as reported by Grover et al. 
193
 (Scheme 6.4). Selective primary 
desilylation of 6.31 gave 6.32. Attempted successive Dess-Martin and Wittig-Horner 
reactions involving two different Horner reagents failed to give the desired products.  
 
Scheme 6.4. Attempted 5ʹ-derivatization of acetyl protected 2ʹ-deoxy-5-
hydroxymethyluridine. Reagents and conditions: (a) (i) benzene, NBS, AIBN, 90 °C, 1h; (ii) 
DMF, CsOAc, rt, 1h, 26% over two steps; (b) THF, pyridine, HF-pyridine, 0 °C, 1h, 0 °C → 
rt, 1h, 33 %; (c) (i) CH2Cl2, Dess-Martin periodinane, rt, 4h; (ii) THF, 6.5, BuLi, -78 °C, 15 
min, -78 °C, 1h, rt; (d) (i) CH2Cl2, Dess-Martin periodinane, rt, 4h; (ii) THF, 
cyanomethyltriphenylphosphonium chloride, BuLi, 0 °C, 30 min, 0 °C → rt. (e) K2CO3, 
MeOH, rt, 6h, 72%. 
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At this point we chose to look for a suitable protecting group for the 5-hydroxymethyl 
moiety that is compatible with the reaction conditions used to modify the 5ʹ-position 
and can also be removed under mild conditions. Towards this end 5-hydroxymethyl 
derivative 6.33 was synthesized according to a literature procedure.
199
 
 
Scheme 6.5. Screening viable protecting group for 5-hydroxymethyl-2ʹ-deoxyuridine. 
Reagents and conditions: (a) DMF, DIPEA, BOM-Cl, 0 °C → rt, 16h, 37 %; (b) MeOH, H2, 
Pd-C; (c) CH2Cl2, DIPEA, SEM-Cl, 40 °C, 6h, 50%; (d) THF, pyridine, HF-pyridine, 0 °C, 
1h, 0 °C → rt, 1h, 38%; (e) (i) CH2Cl2, Dess-Martin periodinane, rt, 4h; (ii) THF, 6.5, BuLi, -
78 °C, 15 min, -78 °C, 1h, rt, 16h, 29% over two steps; (f) THF, TBAF, ∆; (g) THF, DEAD, 
triphenylphosphine, PMP, 0 °C → rt; (h) DMF, PMB-Cl, NaH, 0 °C → rt, 4h, 13%. 
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BOM derivatization of 6.33 to 6.34 proceeded in 37% yield (Scheme 6.5). Since the 
desired product also features a benzylic hydroxyl group, we ran a model 
hydrogenation reaction on 6.34 with palladium as catalyst. Unsurprisingly, the 
reaction mainly afforded thymidine 6.10, besides minor amounts (24 %) of 6.11. Next, 
the use of a 2-(trimethylsilyl)ethoxymethyl (SEM) protecting group, known to be 
cleavable under mild conditions, was investigated. Compound 6.33 was converted to 
6.35 in moderate yield. Selective removal of the primary TBDMS gave 6.36, which on 
DMP oxidation followed by Horner reaction gave 6.37. Unfortunately, attempts to 
remove both SEM groups with TBAF in anhydrous THF at elevated temperature 
failed. Attempts to protect 6.33 as 4-methoxyphenol (PMP) ether under the Mitsunobu 
conditions led to degradation of the starting material. Conditions used to protect 6.33 
with two 4-methoxybenzyl (PMB) groups afforded 6.38 only in low yields (13%), 
mainly because of simultaneous formation of compounds with three PMB & one 
TBDMS group and four PMB groups, leaving these protection methods unattractive.  
These problems finally led us to protect the 5-CH2OH group of 6.33 as pivaloate ester 
in good yield (Scheme 6.6). A series of routine transformations was used to convert 
6.39 into the acrylonitrile 6.41 in acceptable yields. Several conditions were evaluated 
to reduce the double bond in 6.41, including H2-Pd-C, NaBH4 in pyridine and NaBH4-
NiCl2 in MeOH-THF. Unfortunately, all these methods led to deoxygenation of the 5-
CH2OH group and formation of a thymine base as a predominant side product. 
Attempts to remove the pivaloyl prior from 6.41 with tetrabutylammmonium 
hydroxide gave undesired product 6.42. Hydrogenation using platinum on carbon 
afforded 6.43 in 70 % yield. Subsequent removal of the TBDMS group with TBAF 
and the pivaloyl group with sodium methoxide gave 6.30 in excellent yield. 
Azidotrimethylsilane mediated cycloaddition of nitrile 6.43 gave 6.45 in 74% yield. 
Removal of the remaining protecting groups with NaOMe in MeOH and NH4F in 
MeOH allowed obtaining 6.47 in excellent yield. For the desilylation NH4F proved to 
be superior to TBAF with regard to purification of the final product.  
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Scheme 6.6. Synthesis of the 5ʹ-modified 2ʹ-deoxy-5-hydroxymethyluridine analogs 30 and 
47. Reagents and conditions: (a) pyridine, DMAP, Piv-Cl, rt, 18h,74%; (b) THF, pyridine, 
HF-pyridine, 0 °C, 1h, 0 °C → rt, 1h, 59%; (c) (i) CH2Cl2, Dess-Martin periodinane, rt, 4h; (ii) 
anh. THF, cyanomethyltriphenyl phosphonium chloride, -78 °C, BuLi, 30 min, -78 °C → rt, 
18h, 82% over two steps; (d) THF, Bu4NOH, rt, 5h, 40%; (e) MeOH, H2, Pt-C, rt, 4h, 70%; (f) 
THF, TBAF, rt, 4h, 90%; (g) 0.5M NaOMe in MeOH, rt, 3h, 95%; (h) toluene, TMSN3, 
Bu2SnO, 110 °C, 4h, 74%; (i) 0.5M NaOMe in MeOH, rt, 3h, 92%; (j) NH4F, MeOH, 50 °C, 
2 days, 87%.  
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6.2.2. Pharmacological and modelling results 
The capacity of compounds 6.15, 6.17, 6.20, 6.22, 6.23, 6.30 and 6.47 to inhibit 
TMPKmt was assessed via a spectrophotometric binding assay (Ki).
150
 Compound 
6.20 (Ki: 48 µM) and 6.22 (Ki: 70 µM) showed the highest activity, while compounds 
6.15 (340 µM), 6.17 (240 µM) and 6.23 (140 µM) were comparatively less active. 
Surprisingly, compounds 6.30 and 6.47, in which the favorable 5ʹ-modifications were 
combined with a 5-CH2OH modification of the nucleobase, failed to inhibit the 
enzyme at the highest concentration tested (2.6 and 2.4 mM, respectively). Clearly, 
introduction of the 5-hydroxymethyl group jeopardized the binding of 5ʹ-modified 
analogues to TMPKmt. 
 
Figure 6.2. Comparison of structure and interactions of models of 6.22 and 6.47 
superimposed at the active site of TMPKmt (color codes: Mg - purple, H - white/gray, C - 
green, O - red, N - blue). Side chains of selected active site residues are shown in stick 
representations. Majority of hydrogen atoms were omitted for better clarity. Structures of the 
enzyme-inhibitor complexes were obtained by (semi)flexible docking and refinement of the 
model ligands into the crystal structure of TMPKmt co-crystallyzed with 5-CH2OH dUMP 
(PDB entry code 1MRS). 
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It is rather unfortunate that enzyme assays indicated that combination of both 
modifications did not reinforce the TMPKmt binding affinity and led to very weak 
inhibitors. A possible explanation of the observed drop in the inhibitory potencies of 
the 5-CH2OH substituted compounds may be related to an elevated steric strain in the 
bisubstituted analogs. A superposition of the models of inhibitors 6.22 and 6.47 at the 
active site of TMPKmt (Figure 6.2) shows that the 5ʹ-tetrazolylmethyl moiety is firmly 
anchored in a polar cavity formed by the charged residues Asp9, Arg160, Asp163, and 
Glu166 and coordinated by the Mg
2+
 ion and a structural water molecule. However, 
the thymidine ring shows a higher degree of deviation between the two inhibitors, 
while the 5-CH2OH group of 6.47 does not seem to reach up to an ideal stabilizing 
position.  
As shown on Figure 6.2, the oxygen of the 5-CH2OH group is oriented mainly by the 
interactions with the Arg74 and Phe70 residues into a position where it directs its H 
atom towards the hydrogen of C of Phe36 with a relatively short distance of only 
1.85 Å (red line in Fig. 6.2). This leads to an electrostatic repulsion, which may be 
responsible for the observed weak inhibitory potency of 6.47. In the crystal structure 
of TMPKmt co-crystallyzed with 5-CH2OH dUMP the 5-hydroxymethyl group of 
dUMP is stabilized by hydrogen bonding interactions with the guanidine group of 
Arg74 and nitrogen atom of Pro37. Still, this does not exclude that a 2ʹ,3ʹ-α- fused 
cyclic sulfuryldiamide substituent may show synergistic inhibitory effects with a 5-
CH2OH group, since conformational restriction by a fused ring may very well change 
the topology of the molecular interactions with the enzyme.  
 
6.3. Conclusions 
In short, a small series of 5ʹ-modified thymidine analogues was synthesized and 
evaluated as TMPKmt inhibitors. The analogues in which the 5ʹ-hydroxyl group was 
replaced by an acetonitrile or a 5ʹ-tetrazolylmethyl moiety proved capable of 
inhibiting the target enzyme with substantial affinity. Hence we developed a synthetic 
route that allowed combining these 5ʹ-modifications with a hydroxymethyl moiety at 
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position 5 of the pyrimidine base. Given the recent interest in the phenomenon of 
hydroxymethylation of pyrimidine bases in mammalian genomes, the successful 
synthetic strategy, featuring pivaloyl protection of the 5-CH2OH group prior to 5ʹ-
modification, may find future application in the synthesis of other 5-hydroxymethyl-
2ʹ-deoxyuridine tool compounds.  
 
6.4. Experimental Section 
6.4.1. Chemistry 
All reagents were from standard commercial sources and of analytical grade. Dry 
solvents were obtained directly from commercial sources and stored on molecular 
sieves. All reactions were carried out under argon atmosphere unless specified 
otherwise. A temperature of 25±5 °C is referred to as ‘room temperature/ rt’. 
Precoated Merck silica-gel F254 plates were used for TLC; spots were examined 
under ultraviolet light at 254 nm and further visualized by sulphuric acid-anisaldehyde 
spray. Column chromatography was performed on silica gel (40-60 µm, 60 Å). NMR 
spectra were recorded on a Varian Mercury 300 MHz spectrometer. Chemical shifts 
are given in ppm (δ), calibrated to the residual solvent signals or TMS. Exact mass 
measurements were performed on aWaters LCT PremierXETMTime of flight (TOF) 
mass spectrometer equipped with a standard electrospray ionization (ESI) and 
modular LockSpray TM interface. Samples were infused in a CH3CN/water (1:1 v/v) 
mixture at 10 mL/min. The microwave reactions were carried out in Milestone 
MicroSYNTH Advanced Microwave Synthesis Labstation, equipped with 2 X 800 W 
magnetrons (effective maximum output 1500W pulsed/continuous), an optical fiber 
temperature sensor, a pressure sensor, under continues power mode in a closed PTFE 
vessel. NMR signals of sugar protons and carbons are indicated with a prime, and 
signals of base protons and carbons are given without a prime. 
Diethyl ((N-methylsulfamoyl)methyl)phosphonate (6.8): To a solution of 6.7 (1.0 g, 
9.1 mmol) in anhydrous THF (40.0 mL) at – 78 °C was added n-BuLi (1.6M, 11.5 mL, 
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18.3 mmol) dropwise under argon atmosphere. The mixture was stirred for an hour at 
– 78 °C and diethyl clorophosphate (0.67 mL, 4.6 mmol) was added slowly. The 
reaction mixture was stirred at 0 °C for an hour. The reaction was stopped by adding 
sat. NH4Cl solution (10 mL) followed by extraction with CH2Cl2 (3 X 50 mL). The 
combined organic layers were dried over anhyd. Na2SO4. The desiccant was filtered 
off and the filtrate was concentrated. The residue was purified by flash column 
chromatography (50-80% EtOAc in hexanes) to afford unreacted starting material 
(450 mg) and product 6.8 as colourless oil (800 mg, 65 % based on recovered starting 
material). 
1
H NMR (300 MHz, CDCl3) δ ppm 1.36 (td, J = 7.2, 0.9 Hz, 6H, 
OCH2CH3), 2.37 (d, J = 5.4 Hz, 3H, NCH3), 3.60 (d, J = 16.2 Hz, 2H, SCH2P), 4.22 
(qt, J = 6.9 Hz, 0.9 Hz, 4H, OCH2CH3), 5.26 (q, J = 5.1 Hz, NH). 
13
C NMR (75 MHz, 
CDCl3) δppm 16.14 (d, J = 6 Hz, OCH2CH3), 29.59 (NCH3), 46.90 (d, J = 138.5 Hz, 
PCH2S), 63.53 (d, J = 6.1 Hz, OCH2CH3). 
31
P NMR (121 MHz, CDCl3) δ ppm 13.52. 
ESI-HRMS for [C6H16NO5PS + H]
+
 calcd, 246.0565; found, 246.0548. 
1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)tetrahydrofuran 
-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (6.11): Compound 6.10 (9.71 g, 20.64 
mmoles) and anhydrous THF (106.4 mL) was placed in a Teflon flask under inert 
condition and cooled to 0 °C. In a separate polypropylene flask, anhydrous THF (79.8 
mL) and anhydrous pyridine (31.9 mL) were placed under inert atomsphere; to this at 
0 °C ~70%HF in pyridine (28.7 mL) was added drop wise. The chilled THF-Pyridine-
HF.pyridine mixture was added dropwise to a flask containing compound 6.10 also at 
0 °C and stirred at this temperature for 1 hour. The cold bath was removed and 
reaction continued at room temperature for 45 minutes. The reaction mixture was 
poured to an ice-cold solution of NaHCO3 (100g in 500 mL) with vigorous stirring. 
The compound was extracted in EtOAc (3 X 150 mL), washed with brine and dried 
over anhyd.Na2SO4. The residue after evaporation was subjected to flash column 
chromatography (20 to 50% EtOAc in hexanes) to obtain compound 6.11 as white 
foam (2.615 g, 36 %). 
1
H NMR (300 MHz, CDCl3) δ ppm 0.07 (s, 6H, Si(CH3)2), 0.88 
(s, 9H, C(CH3)3), 1.88 (s, 3H, 5-CH3), 2.20 (ddd, J = 13.25, 6.37, 3.81 Hz, 1H, 2ʹ-H), 
2.32 (dt, J = 13.40, 6.63 Hz, 1H, 2ʹ-H), 2.98 - 3.13 (m, 1H, 5ʹ-OH), 3.68 - 3.80 (m, 1H, 
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5ʹ-H), 3.85 - 3.96 (m, 2H, 5ʹ & 4ʹ-H), 4.48 (dt, J = 6.44, 3.51 Hz, 1H, 3ʹ-H), 6.16 (t, J 
= 6.74 Hz, 1H, 1ʹ-H), 7.35 - 7.48 (m, 1H, 6-H), 9.31 (br. s, 1H, NH). 13C NMR (75 
MHz, CDCl3) δ ppm -4.66 (SiCH3), -4.50 (SiCH3), 12.69 (5-CH3), 18.15 (C(CH3)3), 
25.92 (C(CH3)3), 40.76 (2ʹ-C), 62.11 (5ʹ-C), 71.81 (3ʹ-C), 86.87 (1ʹ-C), 87.84 (4ʹ-C), 
111.13 (5-C), 137.25 (6-C), 150.67 (2-C), 164.26 (4-C). ESI-HRMS for 
[C16H28N2O5Si + H]
+
 calcd, 357.1846; found, 357.1847. 
1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-((E)-2-(methylsulfonyl)vinyl) 
tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (6.13): To a solution 
of Dess-Martin reagent (1.28 g, 3 mmol) in anhydrous CH2Cl2 (5 mL) at 0 °C under 
argon atmosphere was added compound 6.11 (713 mg, 2 mmol) in CH2Cl2 (5 mL) and 
the reaction continued at room temperature. After 4 hours saturated NaHCO3 solution 
(10 mL) was added and the product extracted in CH2Cl2 (3 X 20 mL). The organic 
layers were combined, washed with brine, dried over anhyd.Na2SO4, filtered. The 
filtrate was evaporated and dried under high vacuum to give aldehyde 6.12 as white 
foamy residue which was used without purification for Horner-Wittig reaction. 
In a separate flask, Diethyl ((methylsulfonyl)methyl)phosphonate 6.5 (553 mg, 2.4 
mmol) was dissolved in anhydrous THF (20 mL) under argon atmosphere. The 
mixture was brought to – 78 °C and n-BuLi (1.6M in hexanes, 1.38 mL, 2.2 mmol) 
was added slowly and stirred for 15 minutes. The solution of the above aldehyde 6.12 
(2 mmol) in anhydrous THF (15 mL) was added dropwise. The flask was kept at – 
78 °C for 1h and at room temperature overnight (18h). Water (10 mL) was added and 
the product extracted in EtOAc (3 X 50 mL). The combined organic layers were 
washed with brine, dried over anhyd.Na2SO4, filtered and filtrate was evaporated. The 
residue was purified by flash column chromatography (20-50 % EtOAc in hexanes) to 
afford 6.13 as white solid (175 mg, 20 %). 
1
H NMR (300 MHz, CDCl3) δ ppm 0.03 (s, 
3H, SiCH3), 0.04 (s, 3H, SiCH3), 0.84 (s, 9H, C(CH3)3), 1.89 (d, J = 1.17 Hz, 3H, 5-
CH3), 2.16 - 2.24 (m, 2H, 2ʹ-H), 2.91 (s, 3H, SO2CH3), 4.25 (dt, J = 6.37, 4.87 Hz, 1H, 
3ʹ-H), 4.33 - 4.43 (m, 1H, 4ʹ-H), 6.22 (t, J = 6.74 Hz, 1H, 1ʹ-H) 6.62 (dd, J = 15.08, 
1.90 Hz, 1H, 6ʹ-H), 6.93 (dd, J = 14.94, 4.10 Hz, 1H, 5ʹ-H), 6.96 (d, J = 1.17 Hz, 1H, 
6-H), 8.39 (s, 1H, NH). 
13
C NMR (75 MHz, CDCl3) δ ppm -4.78 (SiCH3), -4.66 
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(SiCH3), 12.64 (5-CH3), 17.90 (C(CH3)3), 25.63 (C(CH3)3), 39.46 (2ʹ-C), 42.68 
(SO2CH3), 74.66 (3ʹ-C), 84.05 (4ʹ-C), 85.56 (1ʹ-C), 111.93 (5-C), 130.75 (6ʹ-C), 
135.28 (6-C), 142.90 (5ʹ-C), 150.00 (2-C), 163.14 (4-C). ESI-HRMS for 
[C18H30N2O6SSi +H]
+
 calcd, 431.1672; found, 431.1519. 
1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(2-(methylsulfonyl)ethyl)tetra 
hydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (6.14): To a solution of 
6.13 (175 mg, 0.41 mmol) in EtOAc (10.0 mL) was added Pd-C (10% Pd, ~50% H2O, 
100 mg) and stirred with purging H2 gas through the reaction mixture at room 
temperature for 4 hours. The catalyst was filtered over celite and filtrate was 
evaporated. The residue was dried under high vacuum to afford practically pure 
compound 6.14 (175 mg) which was used as such for the next step. 
1
H NMR (300 
MHz, CDCl3) δ ppm 0.02 (s, 3H, SiCH3), 0.03 (s, 3H, SiCH3), 0.83 (s, 9H, C(CH3)3), 
1.89 (d, J = 1.17 Hz, 3H, 5-CH3), 1.92 - 2.07 (m, 2H, 5ʹ-H), 2.14 - 2.30 (m, 2H, 2ʹ-H), 
2.88 (s, 3H, SO2CH3), 3.04 (ddd, J = 13.7, 11.1, 5.7 Hz, 1H, 6ʹ-H), 3.13 - 3.25 (m, 1H, 
6ʹ-H), 3.75 (dt, J = 10.40, 3.88 Hz, 1H, 4ʹ-H), 4.08 - 4.12 (m, 1H, 3ʹ-H), 6.09 (t, J = 
6.88 Hz, 1H, 1ʹ-H), 6.99 (d, J = 1.46 Hz, 1H, 6-H), 8.08 (br. s, 1H, NH). ESI-HRMS 
for [C18H32N2O6SSi + H]
+
 calcd, 433.1829; found, 433.0574. 
1-((2R,4S,5R)-4-hydroxy-5-(2-(methylsulfonyl)ethyl)tetrahydrofuran-2-yl)-5-
methylpyrimidine-2,4(1H,3H)-dione (6.15): To a solution of compound 6.14 (175 
mg, 0.41 mmol) in anhydrous THF (3.0 mL) was added tetrabutylammonium fluoride 
(TBAF, 0.14 mL, 0.49 mmol) dropwise. The flask was heated to 40 °C overnight. The 
volatile materials were evaporated under high vacuum and the residue was purified by 
flash column chromatography (3% MeOH in CH2Cl2). The product was purified 
further by crystallization/ triturating in MeOH to afford compound 6.15 as a colorless 
needles (25 mg, 20 %). 
1
H NMR (300 MHz, DMSO-d6) δ ppm 1.80 (d, J = 1.17 Hz, 
3H, 5-CH3), 1.87 - 2.00 (m, 1H, 5ʹ-H), 2.00 - 2.15 (m, 2H, 2ʹ & 5ʹ-H), 2.25 (dt, J = 
13.84, 6.99 Hz, 1H, 2ʹ-H), 3.00 (s, 3H, SO2CH3), 3.19 (t, J = 8.05 Hz, 2H, 6ʹ-H), 3.72 
(dt, J = 8.57, 4.36 Hz, 1H, 4ʹ-H), 4.08 - 4.18 (m, 1H, 3ʹ-H), 5.34 (d, J = 4.39 Hz, 1H, 
3ʹ-OH), 6.15 (t, J = 7.03 Hz, 1H, 1ʹ-H), 7.44 (d, J = 1.17 Hz, 1H, 6-H), 11.30 (s, 1H, 
NH). 
13
C NMR (75 MHz, DMSO-d6) δ ppm 12.06 (5- CH3), 25.78 (5ʹ-C), 38.05 (2ʹ-C), 
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40.15 (SO2CH3), 50.39 (6ʹ-C), 72.84 (3ʹ-C), 83.46 (1ʹ-C), 83.83 (4ʹ-C), 109.97 (5-C), 
136.17 (6-C), 150.47 (2-C), 163.68 (4-C). ESI-HRMS for [C12H18N2O6S + H]
+
 calcd, 
319.0964; found 319.0963. 
(E)-2-((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)-N-methylethenesulfonamide 
(6.16): Compound 6.11 (100 mg, 0.28 mmol)was reacted in similar fashion as 
described for 6.13 to get the aldehyde 6.12. In a separate flask, to the solution of 
diethyl ((N-methylsulfamoyl)methyl)phosphonate 6.8 (83 mg, 0.36 mmol) in 
anhydrous THF (3 mL) at -78 °C under inert atmosphere was added n-BuLi (1.6M in 
hexanes, 0.39 mL, 0.62 mmol) drop wise and stirred for 1h. A solution of above 
aldehyde 6.12 (0.28 mmol) in THF (3 mL) was added and the mixture was kept at -
78 °C for 1h then allowed to stir at room temperature overnight (18h). Water (5 mL) 
was added and the reaction mixture was extracted with EtOAc (3 X 25 mL). The 
combined organic layer was washed with brine, dried over anhyd.Na2SO4, filtered, 
and evaporated. The residue was purified by preperative TLC (50% EtOAc in toluene) 
to obtain 6.16 as a white foam (60 mg, 48 %). 
1
H NMR (300 MHz, CDCl3): δ 0.10 (s, 
3H, SiCH3), 0.11 (s, 3H, SiCH3), 0.91 (s, 9H, C(CH3)3), 1.96 (d, J = 1.2 Hz, 3H, 5-
CH3), 2.23-2.29 (m, 2H, 2ʹ-H), 2.76 (s, 3H, NHCH3), 4.28-4.33 (m, 1H, 4ʹ-H), 4.41 (td, 
J = 4.8, 1.2 Hz, 1H, 3ʹ-H), 6.30 (t, J = 6.9Hz, 1H, 1ʹ-H), 6.47 (dd, J = 15.3, 1.5 Hz, 1H, 
6ʹ-H), 6.82 (dd, J = 15.3, 4.5 Hz, 1H, 5ʹ-H), 7.04 (d, J = 1.2 Hz, 1H, 6-H) ESI-HRMS 
for [C18H31N3O6SSi
 
+ H]
+
 calcd, 446.1781; found, 446.1773. 
2-((2R,3S,5R)-3-(hydroxy)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)tetrahydrofuran-2-yl)-N-methylethanesulfonamide (6.17): To a solution of 6.16 
(60 mg, 0.135 mmol) in 5:1 MeOH-THF (1.5 mL) at 0 °C was added NiCl.6H2O (16 
mg, 0.075 mmol) and NaBH4 (10.2 mg, 0.27 mmol). The reaction mixture was stirred 
for 1h at 0 °C and the solvent was evaporated. The residue suspended in EtOAc, 
filtrated over celite, the filtrate was evaporated. The residue obtained was dissolved in 
THF (1.5 mL) and was added TBAF (80 µL, 0.268 mmol). The reaction mixture was 
stirred at 40 °C for 1h. The solvent was evaporated to dryness and the residue was 
purified by flash column chromatography (3-7% MeOH in CH2Cl2) to afford 6.17 (5 
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mg, 12 %) as white solid. 
1
H NMR (300 MHz, DMSO-d6) δ ppm 1.80 (d, J = 0.88 Hz, 
3H, 5-CH3), 1.91 (td, J = 9.15, 4.54 Hz, 1H, 5ʹ-H), 1.96 - 2.10 (m, 2H, 2ʹ-H and 5ʹ-H), 
2.24 (dt, J = 13.84, 6.99 Hz, 1H, 2ʹ-H), 2.57 (d, J = 4.98 Hz, 3H, N-CH3), 3.07 (dt, J = 
9.81, 5.64 Hz, 2H, 6ʹ-H), 3.73 (dt, J = 8.42, 4.43 Hz, 1H, 4ʹ-H), 4.11 (dd, J = 6.74, 
4.10 Hz, 1H, 3ʹ-H), 5.34 (d, J = 4.39 Hz, 1H, 3ʹ-OH), 6.14 (t, J = 6.88 Hz, 1H, 1ʹ-H), 
6.92 (q, J = 4.98 Hz, 1H, CH3NH) 7.42 (d, J = 1.17 Hz, 1H, 6-H), 11.30 (br. s, 1H, 
NH). 
13
C NMR (75 MHz, DMSO-d6) δ ppm 11.96 (5-CH3), 27.01 (5ʹ-C), 28.47 
(NCH3), 38.04 (2ʹ-C), 46.01 (6ʹ-C), 72.73 (3ʹ-C), 83.29 (1ʹ-C), 83.62 (4ʹ-C), 109.84 (5-
C), 136.00 (6-C), 150.33 (2-C), 163. 55 (4-C). ESI-HRMS for [C12H19N3O6S + H]
+
 
calcd, 334.1073; found, 334.1085. 
(E)-3-((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)acrylonitrile (6.18): Compound 
6.11 (1.22 g, 3.43 mmol) was reacted in similar fashion as described for 6.13 to get 
the aldehyde 6.12. In a separate flask, to a solution of 
cyanomethyltriphenylphosphonium chloride (3.48 g, 10.3 mmol) in anhydrous THF 
(35 mL) at 0 °C under argon atmosphere was added drop wise n-BuLi (1.6M in 
hexanes, 6.4 mL, 10.3 mmol) and stirred for 30 minutes. To this ylide at 0 °C was 
added slowly a solution of above aldehyde 6.12 (3.43 mmol) in anhydrous THF (15 
mL) and stirred at room temperature overnight. The reaction was quenched with water 
(30 mL) and extracted with EtOAc (3 X 100 mL). Combined organic layer was 
washed with brine, dried over anhyd.Na2SO4, filtered and evaporated. The residue 
obtained was purified by flash column chromatography (15-30% EtOAc in hexanes) 
to afford 6.18 as a light yellow foam (740.4 mg, 57 %). 
1
H NMR (300 MHz, CDCl3) δ 
ppm 0.09 (s, 3H, SiCH3), 0.10 (s, 3H, SiCH3), 0.90 (s, 9H, C(CH3)3), 1.96 (d, J = 1.17 
Hz, 3H, 5-CH3), 2.27 - 2.36 (m, 2H, 2ʹ-H), 4.27 - 4.35 (m, 2H, 3ʹ-H and 4ʹ-H), 5.67 
(dd, J = 16.26, 1.61 Hz, 1H, 6ʹ-H), 6.19 (t, J = 6.59 Hz, 1H, 1ʹ-H), 6.80 (dd, J = 16.11, 
4.69 Hz, 1H, 5ʹ-H), 7.01 (d, J = 1.17 Hz, 1H, 6-H), 9.46 (s, 1H, NH). 13C NMR (75 
MHz, CDCl3) δ ppm -4.82 (SiCH3), -4.63 (SiCH3), 12.65 (5-CH3), 17.89 (C(CH3)3), 
25.63 (C(CH3)3), 39.79 (2ʹ-C) 74.69 (3ʹ-C), 84.96 (4ʹ-C), 86.14 (1ʹ-C), 101.00 (6ʹ-C), 
111.74 (5-C), 116.56 (7ʹ-C), 135.74 (6-C) 149.95 (5ʹ-C), 150.25 (2-C), 163.80 (4-C). 
ESI-HRMS for [C18H27N3O4Si + H]
+
 calcd, 378.1849; found, 378.1852. 
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3-((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)propanenitrile (6.19): To a 
solution of 6.18 (443 mg, 1.18 mmol) in 3:1 anhydrous pyridine-MeOH (2 mL) was 
added NaBH4 (45 mg, 1.18 mmol) and the reaction mixture was stirred at 120 °C 
under inert atmosphere for 4h. The reaction mixture was evaporated and the residue 
was purified by flash column chromatography (30-50% EtOAc in hexanes) to afford 
6.19 as white foam (240 mg, 54%). 
1
H NMR (300 MHz, CDCl3) δ ppm 0.09 (s, 3H, 
SiCH3), 0.10 (s, 3H, SiCH3), 0.90 (s, 9H, C(CH3)3), 1.84 - 1.93 (m, 1H, 5ʹ-H), 1.95 (d, 
J = 1.46 Hz, 3H, 5-CH3), 2.02 - 2.16 (m, 1H, 5ʹ-H), 2.27 (t, J = 6.44 Hz, 2H, 2ʹ-H), 
2.41 - 2.62 (m, 2H, 6ʹ-H), 3.80 (ddd, J = 9.30, 5.35, 3.81 Hz, 1H, 4ʹ-H), 4.12 - 4.20 (m, 
1H, 3ʹ-H), 6.08 (t, J = 6.59 Hz, 1H, 1ʹ-H), 7.05 (d, J = 1.17 Hz, 1H, 6-H), 8.44 (br. s, 
1H, NH).
 13
C NMR (75 MHz, CDCl3) δ ppm -4.81 (SiCH3), -4.53 (SiCH3), 12.62 (5-
CH3), 14.22 (6ʹ-C), 17.91 (C(CH3)3), 25.68 (C(CH3)3), 28.94 (5ʹ-C), 40.15 (2ʹ-C), 
74.43 (3ʹ-C), 84.04 (4ʹ-C), 85.60 (1ʹ-C), 111.35 (5-C), 119.11 (7ʹ-C), 135.87 (6-C), 
149.86 (2-C), 163.32 (6-C). ESI-HRMS for [C18H29N3O4Si + H]
+
 calcd, 380.2006; 
found, 380.2015. 
3-((2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)tetrahydrofuran-2-yl)propanenitrile (6.20): To the stirring solution of compound 
6.19 (100 mg, 0.26 mmol) in anhydrous THF (2 mL) was added tetrabutylammonium 
fluoride (TBAF, 1M in THF, 0.5 mL, 0.5 mmol) under inert atmosphere and stirred at 
room temperature for 4h. The reaction mixture was evaporated under vacuum and the 
residue was purified by flash column chromatography (EtOAc) to afford product 6.20 
as a white solid (53 mg, 76%). 
1
H NMR (300 MHz, DMSO-d6) δ ppm 1.80 (d, J = 
1.17 Hz, 3H, 5-CH3), 1.83 - 1.98 (m, 2H, 5ʹ-H), 2.05 (ddd, J = 13.55, 6.52, 3.95 Hz, 
1H, 2ʹ-H), 2.22 (dt, J = 13.77, 6.88 Hz, 1H, 2ʹ-H), 2.52 - 2.62 (m, 2H, 6ʹ-H), 3.63 - 
3.74 (m, 1H, 4ʹ-H), 4.04 - 4.17 (m, 1H, 5ʹ-H), 5.34 (d, J = 4.39 Hz, 1H, 3ʹ-OH), 6.15 (t, 
J = 6.88 Hz, 1H, 1ʹ-H), 7.44 (d, J = 1.17 Hz, 1H, 6-H), 11.30 (br. s, 1H, NH). 13C 
NMR (75 MHz, DMSO-d6) δ ppm 11.96 (5-CH3), 13.20 (6ʹ-C), 28.37 (5ʹ-C), 38.01 
(2ʹ-C), 72.50 (3ʹ-C), 83.42 (1ʹ-C), 83.92 (4ʹ-C), 109.75 (5-C), 120.30 (7ʹ-C), 136.13 
(6-C), 150.33 (2-C), 163.56 (4-C). ESI-HRMS for [C12H15N3O4 - H]
- 
calcd, 264.099; 
found, 264.0617. 
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1-((2R,4S,5R)-5-(2-(1H-tetrazol-5-yl)ethyl)-4-((tert-butyldimethylsilyl)oxy)tetra 
hydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (6.21): Compound 6.19 
(120 mg, 0.32 mmol) was dessolved in anhydrous toluene (5 mL), to this was added 
dibutyltin oxide (Bu2SnO, 16 mg) and azidotrimethylsilane (TMSN3, 158 µL, 1.6 
mmol) under argon atmosphere. The reaction vessel was sealed with septum and 
stirred at 110 °C for 4h. The volatiles were evaporated under reduced pressure and the 
residue was purified by flash column chromatography (2% AcOH/ EtOAc) to afford 
6.21 as a white foam (43 mg, 32%). 
1
H NMR (300 MHz, DMSO-d6) δ ppm 0.00 (s, 
6H, Si(CH3)2), 0.78 (s, 9H, C(CH3)3), 1.73 (d, J = 0.88 Hz, 3H, 5-CH3), 1.86 - 2.07 (m, 
3H, 2ʹ-H and 5ʹ-H), 2.21 (dt, J = 13.62, 6.96 Hz, 1H, 2ʹ-H), 2.80 - 2.96 (m, 2H, 6ʹ-H), 
3.61 (dt, J = 8.42, 4.43 Hz, 1H, 4ʹ-H), 4.20 (dt, J = 6.59, 4.03 Hz, 1H, 3ʹ-H), 6.04 (t, J 
= 6.88 Hz, 1H, 1ʹ-H), 7.33 (d, J = 1.17 Hz, 1H, 6-H), 11.23 (br. s, 1H, NH). 13C NMR 
(75 MHz, DMSO-d6) δ ppm -4.89 (SiCH3), -4.72 (SiCH3), 12.10 (5-CH3), 17.61 
(C(CH3)3), 19.63 (6ʹ-C), 25.65 (C(CH3)3), 30.42 (5ʹ-C), 38.60 (2ʹ-C), 74.35 (3ʹ-C), 
83.46 (1ʹ-C), 84.44 (4ʹ-C), 109.89 (5-C), 136.21 (6-C), 150.39 (2-C), 155.69 (7ʹ-C) 
163.66 (4-C). ESI-HRMS for [C18H30N6O4Si - H]
-
 calcd, 421.2020; found, 421.1249. 
1-((2R,4S,5R)-5-(2-(1H-tetrazol-5-yl)ethyl)-4-hydroxytetrahydrofuran-2-yl)-5-
methylpyrimidine-2,4(1H,3H)-dione (6.22): Compound 6.21 (40 mg, 0.1 mmol) was 
dissolved in anhydrous THF (2 mL) and added TBAF (0.5 mL, 0.5 mmol) at room 
temperature. After 4h, MeOH (2 mL) was added, followed by CaCO3 (1g) with 
vigorous stirring. After 10 minutes was added Dowex resin (H
+
 form, 1g) portion wise. 
The mixture was stirred for 30 minutes and filtered over a pad of celite. The filtrate 
was concentrated and purified by flash column chromatography (5-8 % MeOH + 2% 
AcOH in CH2Cl2) to afford title compound 6.22 as a white solid (10 mg, 34%). 
1
H 
NMR (300 MHz, DMSO-d6) δ ppm 1.80 (d, J = 1.17 Hz, 3H, 5-CH3), 1.89 - 2.14 (m, 
3H, 2ʹ-H and 5ʹ-H), 2.14 - 2.33 (m, 1H, 2ʹ-H), 2.87 - 3.06 (m, 2H, 6ʹ-H), 3.66 (dt, J = 
8.57, 4.36 Hz, 1H, 4ʹ-H), 4.05 - 4.17 (m, 1H, 3ʹ-H), 5.30 (br. s, 1H, 3ʹ-OH), 6.14 (t, J 
= 6.88 Hz, 1H, 1ʹ-H), 7.39 (d, J = 0.88 Hz, 1H, 6-H), 11.30 (s, 1H, NH). 13C NMR (75 
MHz, DMSO-d6) δ ppm 11.99 (5-CH3), 19.39 (6ʹ-C), 30.56 (5ʹ-C), 38.20 (2ʹ-C), 72.73 
(3ʹ-C), 83.18 (1ʹ-C), 84.30 (4ʹ-C), 109.79 (5-C), 135.94 (6-C), 150.33 (2-C), 155.07 
5,5ʹ-Modified 2ʹ-Deoxyuridines as TMPKmt Inhibitors 
199 
(7ʹ-C), 163.56 (4-C). ESI-HRMS for [C12H16N6O4 - H]
-
 calcd, 307.1155; found, 
307.0597. 
6ʹ-(N-hydroxyformamidine)-β-D-thymidine (6.23): Compound 6.20 (30 mg, 0.11 
mmol) was dissolved in ethanol (2 mL) to this was added hydroxylamine solution (83 
µL) and stirred at room temperature for 2 days. The volatiles were evaporated under 
high vacuum and the residue purified by column chromatography using 5-10% MeOH 
in CH2CL2 with 0.1% TEA to afford title compound 6.23 (28 mg, 83%) as a white 
solid. 
1
H NMR (300 MHz, DMSO-d6) δ ppm 1.64 - 1.75 (m, 1H, 5ʹ-H), 1.78 (d, J = 
1.17 Hz, 3H, 5-CH3), 1.81 - 1.89 (m, 1H, 5ʹ-H), 1.91 - 2.09 (m, 3H, 2X6ʹ-H, 1X2ʹ-H), 
2.10-2.22 (m, 1H, 2ʹ-H), 3.56 - 3.72 (m, 1H, 4ʹ-H), 3.95 - 4.14 (m, 1H, 3ʹ-H), 5.24 
(br.s, 1H, 3ʹ-OH), 5.34 (s, 2H, NH2) 6.10 (t, J = 6.88 Hz, 1H, 1ʹ-H), 7.37 (d, J = 1.17 
Hz, 1H, 6-H), 8.71 (br.s, 1H, NOH), 11.26 (br.s, 1H, NH). 
13
C NMR (75 MHz, 
DMSO-d6) δ ppm 12.05 (5-CH3), 27.30 (6ʹ-C), 30.19 (5ʹ-C), 38.37 (2ʹ-C), 72.84 (3ʹ-C), 
83.11 (1ʹ-C), 85.17 (4ʹ-C), 109.70 (5-C), 135.85 (6-C), 150.35 (2-C), 152.22 (7ʹ-C), 
163.57 (4-C). ESI-HRMS [C12H18N4O5 + H]
+
, calcd, 299.1355; found, 299.1350. 
1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)tetrahydrofuran 
-2-yl)pyrimidine-2,4(1H,3H)-dione (6.26): Removal of primary TBDMS group 
using the procedure described for compound 6.11, compound 6.25 (1.8 g, 4 mmol) 
rendered 6.26 (600 mg, 53%) as a white solid. 
1
H NMR (300 MHz, CDCl3) δ ppm 
0.09 (s, 6H, Si(CH3)2), 0.90 (s, 9H, C(CH3)3), 2.24 - 2.32 (m, 2H, 2ʹ-H) 2.50 (br. s, 1H, 
5ʹ-OH), 3.69 - 3.82 (m, 1H, 5ʹ-H), 3.87 - 4.00 (m, 2H, 4ʹ-H and 5ʹ-H), 4.43 - 4.55 (m, 
1H, 3ʹ-H), 5.74 (dd, J = 8.20, 2.05 Hz, 1H, 5-H), 6.18 (t, J = 6.59 Hz, 1H, 1ʹ-H), 7.65 
(d, J = 8.20 Hz, 1H, 6-H), 8.89 (br. s, 1H, NH). 
13
C NMR (75 MHz, CDCl3) δ ppm -
4.64 (SiCH3), -4.47 (SiCH3), 18.18 (C(CH3)3), 25.93 (C(CH3)3), 41.09 (2ʹ-C), 62.09 
(5ʹ-C), 71.64 (3ʹ-C), 87.02 (1ʹ-C), 87.82 (4ʹ-C), 102.71 (5-C), 141.31 (6-C), 150.42 (2-
C), 163.40 (4-C). ESI-HRMS for [C15H26N2O5Si + H]
+
 calcd, 343.1689; found, 
343.1682. 
(E)-3-((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)acrylonitrile (6.27): Following 
Chapter 6 
200 
the oxidation and Wittig reaction procedure described for compound 6.18, compound 
6.26 (600 mg, 1.75 mmol) rendered 6.27 (325 mg, 51%) as a white solid. 
1
H NMR 
(300 MHz, CDCl3) δ ppm 0.10 (s, 6H, Si(CH3)2), 0.90 (s, 9H, C(CH3)3), 2.19 - 2.43 
(m, 2H, 2ʹ-H), 4.24 - 4.30 (m, 1H, 3ʹ-H), 4.30 - 4.37 (m, 1H, 4ʹ-H), 5.67 (dd, J = 16.40, 
1.76 Hz, 1H, 6ʹ-H), 5.81 (dd, J = 8.20, 2.34 Hz, 1H, 5-H), 6.19 (t, J = 6.44 Hz, 1H, 1ʹ-
H), 6.77 (dd, J = 16.11, 4.69 Hz, 1H, 5ʹ-H), 7.21 (d, J = 8.20 Hz, 1H, 6-H), 8.65 (br. s, 
1H, NH). 
13
C NMR (75 MHz, CDCl3) δ ppm -4.82 (SiCH3), -4.63 (SiCH3), 17.90 
(C(CH3)3), 25.63 (C(CH3)3), 40.06 (2ʹ-C), 74.59 (3ʹ-C), 85.04 (4ʹ-C), 86.30 (1ʹ-C), 
101.19 (6ʹ-C), 103.21 (5-C), 116.42 (7ʹ-C), 139.83 (6-C), 149.61 (5ʹ-C), 149.82 (2-C), 
162.71 (4-C). ESI-HRMS for [C17H25N3O4Si + CH3CN + H]
+
 calcd, 405.1958; found, 
405.1955.
 
3-((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(2,4-dioxo-3,4-dihydropyrimidin-
1(2H)-yl)tetrahydrofuran-2-yl)propanenitrile (6.28): Following the reaction 
procedure described for compound 6.14 but using MeOH as solvent, compound 6.27 
(55 mg, 0.15 mmol) gave 6.28 as a white solid (50 mg, 89%). 
1
H NMR (300 MHz, 
CDCl3) δ ppm 0.09 (d, 6H, Si(CH3)2), 0.90 (s, 9H, C(CH3)3), 1.89 (dddd, J = 13.84, 
9.45, 7.47, 6.15 Hz, 1H, 5ʹ-H), 2.03 - 2.15 (m, 1H, 5ʹ-H), 2.19 - 2.38 (m, 2H, 2ʹ-H), 
2.42 - 2.62 (m, 2H, 6ʹ-H), 3.82 (ddd, J = 9.37, 5.42, 3.66 Hz, 1H, 4ʹ-H), 4.14 (dt, J = 
7.03, 5.42 Hz, 1H, 3ʹ-H), 5.77 (d, J = 7.91 Hz, 1H, 5-H), 6.08 (t, J = 6.59 Hz, 1H, 1ʹ-
H), 7.26 (d, J = 8.20 Hz, 1H, 6-H), 8.40 (br. s, 1H, NH). 
13
C NMR (75 MHz, CDCl3) δ 
ppm -4.83 (SiCH3), -4.54 (SiCH3), 14.25 (6ʹ-C), 17.90 (C(CH3)3), 25.67 (C(CH3)3), 
28.98 (5ʹ-C), 40.40 (2ʹ-C), 74.37 (3ʹ-C), 84.20 (4ʹ-C), 85.95 (1ʹ-C), 102.83 (5-C), 
119.01 (7ʹ-C), 140.08 (6-C), 149.84 (2-C), 162.84 (4-C). ESI-HRMS for 
[C17H27N3O4Si + H]
+
 calcd, 366.1849; found, 366.1842.
 
3-((2R,3S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydro 
furan-2-yl)propanenitrile (6.29): Following the reaction procedure described for 
compound 6.20, compound 6.28 (50 mg, 0.14 mmol) rendered 6.29 (25 mg, 73%) as a 
white solid. 
1
H NMR (300 MHz, CD3OD) δ ppm 1.89 - 2.14 (m, 2H, 5ʹ-H), 2.20 - 
2.37 (m, 2H, 2ʹ-H), 2.48 - 2.69 (m, 2H, 6ʹ-H), 3.85 (dt, J = 9.23, 4.47 Hz, 1H, 4ʹ-H), 
4.13 - 4.25 (m, 1H, 3ʹ-H), 5.71 (d, J = 7.91 Hz, 1H, 5-H), 6.18 (t, J = 6.74 Hz, 1H, 1ʹ-
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H), 7.62 (d, J = 8.20 Hz, 1H, 6-H). 
13
C NMR (75 MHz, CD3OD) δ ppm 14.48 (6ʹ-C), 
30.32 (5ʹ-C), 40.21 (2ʹ-C), 74.68 (3ʹ-C), 85.87 (4ʹ-C), 86.71 (1ʹ-C), 103.04 (5-C), 
120.79 (7ʹ-C), 142.57 (6-C), 152.07 (2-C), 166.15 (4-C). ESI-HRMS for [C11H13N3O4 
- H]
-
 calcd, 250.0828; found, 250.0833.
 
(1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)tetrahydro 
furan-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl acetate (6.32): 
Following the procedure described for the synthesis of 6.11, compound 6.31 (1 g, 1.94 
mmol) rendered 6.32 (265 mg, 33%) as a white foam. 
1
H NMR (300 MHz, CDCl3) δ 
ppm 0.09 (s, 6H, Si(CH3)2), 0.90 (s, 9H, C(CH3)3), 2.06 (s, 3H, OAc), 2.18 - 2.40 (m, 
2H, 2ʹ-H), 3.77 (dd, J = 12.7, 3.2 Hz,1H, 5ʹ-H), 3.88 - 4.04 (m, 2H, 5ʹ & 4ʹ-H), 4.52 
(dt, J = 5.80, 3.70 Hz, 1H, 3ʹ-H), 4.79 - 4.97 (m, 2H, 5-CH2OH), 6.24 (t, J = 6.49 Hz, 
1H, 1ʹ-H), 8.11 (s, 1H, 6-H), 9.02 (s, 1H, NH). 13C NMR (75 MHz, CDCl3) δ ppm -
4.90, -4.74 (SiCH3), 17.94 (C(CH3)3), 21.14 (Ac-C), 25.69 (C(CH3)3), 41.36 (1ʹ-C), 
58.82 (5-CH2OH), 61.82 (5ʹ-C), 71.66 (3ʹ-C), 86.49 (1ʹ-C), 88.12 (4ʹ-C), 109.02 (5-C), 
142.86 (6-C), 149.94 (2-C), 162.58 (4-C), 171.96 (Ac-C= O). ESI-HRMS for 
[C18H30N2O7Si + H]
+
 calcd, 415.1901; found, 415.1904. 
5-(((benzyloxy)methoxy)methyl)-3-((benzyloxy)methyl)-1-((2R,4S,5R)-4-((tert-
butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-
2-yl)pyrimidine-2,4(1H,3H)-dione (6.34): To a mixture of compound 6.33 (150 mg, 
0.31 mmol) and anhydrous diisopropylethylamine (DIPEA, 160 µL, 0.92 mmol) in 
anhydrous DMF (2.5 mL) at 0 °C under inert atmosphere was added drop wise 
benzyloxymethyl chloride (~75 % BOMCl, 94 µL, 0.68 mmol) and stirred at room 
temperature overnight. Saturated aq.NH4Cl (5 mL) was added to quench the reaction. 
The products were extracted in EtOAc (50 mL), organic layer washed with water, 
brine, dried over anhyd.Na2SO4 and evaporated. The residue was purified by flash 
column chromatography (5-10 % EtOAc in hexanes) to yield 6.34 (80 mg, 36 %). 
1
H 
NMR (300 MHz, CDCl3) δ ppm 0.08 - 0.12 (m, 12H, 2XSi(CH3)2), 0.88 - 0.94 (m, 
18H, 2XC(CH3)3), 1.97 (ddd, J = 13.34, 7.64, 5.97 Hz, 1H, 2ʹ-H), 2.30 (ddd, J = 13.16, 
5.74, 2.44 Hz, 1H, 2ʹ-H), 3.76 (dd, J = 11.40, 3.08 Hz, 1H, 5ʹ-H), 3.82 (dd, J = 11.22, 
3.26 Hz, 1H, 5ʹ-H), 3.96 (q, J = 3.08 Hz, 1H, 4ʹ-H), 4.34 - 4.47 (m, 3H, 3ʹ-H & 5-CH2), 
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4.65 (s, 2H, OCH2Ph), 4.71 (s, 2H, OCH2Ph), 4.80 - 4.87 (m, 2H, OCH2O), 5.50 (s, 
2H, NCH2O), 6.31 (dd, J = 7.87, 5.70 Hz, 1H, 1ʹ-H), 7.22 - 7.41 (m, 10H, CH2Ph), 
7.65 (s, 1H, 6-H). 
13
C NMR (75 MHz, CDCl3) δ ppm -5.50, -5.40, -4.84, -4.65 
(SiCH3), 17.98, 18.39 (C(CH3)3), 25.73, 25.93 (C(CH3)3), 41.35 (1ʹ-C), 62.99 (5-CH2), 
63.07 (5ʹ-C), 69.39 (CH2Ph), 70.45 (NCH2O), 72.24 (3ʹ-C), 72.28 (CH2Ph), 85.95 (1ʹ-
C), 87.94 (4ʹ-C), 94.36 (OCH2O), 110.72 (5-C) 126.97, 127.61, 127.69, 127.92, 
128.26, 128.39, 128.56 (CH2Ph), 136.92 (6-C), 137.70, 137.93 (CH2Ph), 150.80 (2-C), 
162.24 (4-C). ESI-HRMS for [C38H58N2O8Si2 + H]
+
 calcd, 727.381; found, 727.3805. 
1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy) 
methyl)tetrahydrofuran-2-yl)-5-(((2-(trimethylsilyl)ethoxy)methoxy)methyl)-3-
((2-(trimethylsilyl)ethoxy)methyl)pyrimidine-2,4(1H,3H)-dione (6.35): Under an 
inert condition compound 6.33 (486 mg, 1 mmol) was dissolved in anhydrous CH2Cl2 
(3 mL) and anhydrous DIPEA (0.5 mL, 3 mmol) and added 
ethyltrimethysilylchloromethyl ether (SEMCl, 0.44 ml, 2.5 mmol). The reaction was 
continued at 40 °C for 6h. The reaction mixture was partitioned between brine (5 mL) 
and EtOAc (20 mL). The organic layer was separated and dried over anhyd.Na2SO4. 
The residue after evaporation of organic phase was purified by flash column 
chromatography (5% EtOAc in hexanes) to afford compound 6.35 (370 mg, 50 %) as 
a glass. 
1
H NMR (300 MHz, CDCl3) δ ppm 0.00 (s, 9H, Si(CH3)3), 0.03 (s, 9H, 
Si(CH3)3), 0.08 (s, 3H, Si(CH3)2), 0.09 (s, 3H, Si(CH3)2), 0.11 (s, 6H, Si(CH3)2), 0.90 
(s, 9H, C(CH3)3), 0.92 (s, 9H, C(CH3)3), 0.94-1.02 (m, 4H, (CH3)3SiCH2), 2.00 (ddd, J 
= 15.3 Hz,7.8 Hz, 1.8 Hz, 1H, 2ʹ-H), 2.31 (ddd, J = 13.2 Hz, 5.7 Hz, 2.4 Hz, 1H, 2ʹ-H), 
3.60-3.73 (m, 4H, OCH2CH2 (SiCH3)3), 3.76 (dd, J = 11.10, 3.15 Hz, 1H, 5ʹ-H), 3.82 
(dd, J = 11.29, 3.33 Hz, 1H, 5ʹ-H), 3.96 (q, J = 2.96 Hz, 1H, 4ʹ-H), 4.31 (d, J = 12.24 
Hz, 1H, 5-CH2), 4.37 (d, J = 12.0 Hz, 1H, 5-CH2), 4.37-4.42 (m, 1H, 3ʹ-H), 4.74 (s, 
2H, OCH2O), 5.40 (s, 2H, NCH2O), 6.32 (1H, dd, J = 7.8 Hz, 5.7 Hz, 1ʹ-H), 7.65 (s, 
1H, 6-H). 
13
C NMR (75 MHz, CDCl3): δ ppm -5.50, -5.38, -4.84, -4.67 (Si(CH3)2), -
1.44, -1.38 (Si(CH3)3), 17.97 (t-Bu-tC), 18.07, 18.11 (SEM SiCH2); 18.40 (C(CH3)3), 
25.72, 25.95 (C(CH3)3), 41.34 (2ʹ-C), 62.96 (5-CH2O), 62.99 (5ʹ-C), 65.28, 67.49 
(SEM CH2O), 70.22 (NCH2O), 72.43 (3ʹ-C), 86.11 (1ʹ-C), 88.06 (4ʹ-C), 94.94 
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(OCH2O), 111.08 (5-C), 136.71 (6-C), 150.99 (2-C), 162.34 (4-C). ESI-HRMS for 
[C34H70N2O8Si4
 
+ H]
+ 
calcd, 747.4287; found, 747.4144. 
1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)tetrahydrofuran 
-2-yl)-5-(((2-(trimethylsilyl)ethoxy)methoxy)methyl)-3-((2-(trimethylsilyl)ethoxy) 
methyl)pyrimidine-2,4(1H,3H)-dione (6.36): Following the procedure described for 
the synthesis of 6.11, compound 6.35 (350 mg, 0.48 mmol) gave compound 6.36 as a 
glassy wax (114 mg, 38 %). 
1
H NMR (300 MHz, CDCl3) δ ppm 0.00 (s, 9H, 
Si(CH3)3), 0.03 (s, 9H, Si(CH3)3), 0.09 (s, 6H, Si(CH3)2), 0.90 (s, 9H, C(CH3)3); 0.92-
1.00 (m, 4H, SEM SiCH2), 2.22-2.41 (m, 2H, 2ʹ-H), 2.58 (t, J = 4.8 Hz, 1H, 5ʹ-OH), 
3.60-3.72 (m, 4H, SEM CH2O), 3.72-3.80 (m, 1H, 5ʹ-H), 3.87-3.93 (m, 1H, 5ʹ-H), 
3.93-3.98 (m, 1H, 4ʹ-H), 4.39 (s, 2H, 5-CH2O), 4.51 (1H, dt, J = 6.6, 3.81 Hz, 3ʹ-H), 
4.73 (s, 2H, OCH2O), 5.39 (s, 2H, NCH2O), 6.20 (t, J = 6.44 Hz, 1H, 1ʹ-H), 7.75 (s, 
1H, 6-H). 
13
C NMR (75 MHz, CDCl3) δ ppm –4.86, -4.69 (Si(CH3)2), -1.43, -1.42 
(Si(CH3)3), 17.95 (C(CH3)3), 18.12 (SEM SiCH2), 25.71 (C(CH3)3), 40.91 (2ʹ-C), 
62.04 (5ʹ-C), 62.27 (5-CH2O), 65.56, 67.58 (SEM CH2O), 70.03 (NCH2O-C), 71.68 
(3ʹ-C), 87.80 (1ʹ-C), 87.88 (4ʹ-C), 93.96 (OCH2O-C), 110.24 (5-C), 138.05 (6-C), 
150.86 (2-C), 162.03 (4-C). ESI-HRMS for [C28H56N2O8Si3 + H]
+
 calcd, 633.3423; 
found, 633.3451. 
1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-((E)-2-(methylsulfonyl)vinyl) 
tetrahydrofuran-2-yl)-5-(((2-(trimethylsilyl)ethoxy)methoxy)methyl)-3-((2-
(trimethylsilyl)ethoxy) methyl)pyrimidine-2,4(1H,3H)-dione (6.37): Following the 
procedure described for the synthesis of 6.13, compound 6.36 (113 mg, 0.18 mmol) 
rendered 6.37 as white solid (33 mg, 29 %). 
1
H NMR (300 MHz, CDCl3) δ ppm 0.00 
(s, 9H, Si(CH3)3), 0.02 (s, 9H, Si(CH3)3), 0.10 (s, 3H, Si(CH3)2), 0.10 (s, 3H, 
Si(CH3)2), 0.90 (s, 9H, C(CH3)3), 0.92-1.02 (s, 4H, SEM SiCH2), 2.15-2.40 (m, 2H, 2ʹ-
C), 2.97 (s, 3H, SO2CH3), 3.58-3.75 (m, 4H, SEM CH2O), 4.33 (dt, J = 6.4, 4.7 Hz, 
1H, 4ʹ-H), 4.40 (s, 2H, 5-CH2O), 4.47 (td, J = 4.7, 1.8 Hz, 1H, 3ʹ-H), 4.73 (s, 2H, 
OCH2O), 5.39 (s, 2H, NCH2O), 6.33 (t, J = 6.6 Hz, 1H, 1ʹ-H), 6.69 (dd, J = 15.3 Hz, 
1.8 Hz, 1H, 6ʹ-H), 7.00 (1H, dd, J = 15 Hz, 4.2 Hz, 5ʹ-H), 7.34 (s, 1H, 6-H). ESI-
HRMS for [C30H58N2O9SSi3 + Na]
+ 
calcd, 729.3069; found, 729.1077. 
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1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy) 
methyl)tetrahydrofuran-2-yl)-3-(4-methoxybenzyl)-5-(((4-methoxybenzyl)oxy) 
methyl)pyrimidine-2,4(1H,3H)-dione (6.38): To a stirring solution of 6.33 (200 mg, 
0.41 mmol) in anhydrous DMF (2 mL) at 0 °C under argon atmosphere was added 4-
methoxybenzyl chloride (PMBCl, 167 µL, 1.23 mmol) followed by NaH (60% in 
mineral oil, 50 mg, 1.23 mmol) portion wise and stirred at room temperature for 4h. 
EtOAc (20 mL) and saturated aq.NH4Cl (10 mL) was added. The aqueous layer was 
extracted with EtOAc (3 X 20 mL) and the combined organic layers were dried over 
anhyd.Na2SO4, filtered, evaporated. The residue was purified by flash column 
chromatography (10% EtOAc in hexanes) to afford the title compound 6.38 as a white 
foam (40 mg, 13%). 
1
H NMR (300 MHz, CDCl3) δ ppm 0.05 (s, 3H, SiCH3), 0.06 (s, 
6H, Si(CH3)3), 0.07 (s, 3H, SiCH3), 0.88 (s, 9H, C(CH3)3), 0.89 (s, 9H, C(CH3)3), 1.97 
(ddd, J = 13.40, 7.69, 6.15 Hz, 1H, 2ʹ-H), 2.26 (ddd, J = 13.18, 5.71, 2.49 Hz, 1H, 2ʹ-
H), 3.72 - 3.76 (m, 1H, 5ʹ-H), 3.77 (s, 3H, PMB OCH3), 3.79 (s, 2H, PMB OCH3), 
3.92 (q, J = 3.22 Hz, 1H, 5ʹ-H), 4.18 - 4.33 (m, 2H, 5-CH2O,) 4.37 (dt, J = 5.64, 2.60 
Hz, 1H, 3ʹ-H), 4.52 (s, 2H, PMB OCH2), 4.95 - 5.13 (m, 2H, PMB NCH2), 6.32 (dd, J 
= 7.91, 5.56 Hz, 1H, 1ʹ-H), 6.82 (d, J = 8.79 Hz, 2H, Ar), 6.86 (d, J = 8.49 Hz, 2H, 
Ar), 7.26 (d, J = 8.49 Hz, 2H, Ar), 7.44 (d, J = 8.79 Hz, 2H, Ar), 7.59 (s, 1H, 6-H). 
13
C NMR (75 MHz, CDCl3) δ ppm -5.51, -5.43, -4.84, -4.66 (SiCH3), 17.98, 18.39 
(C(CH3)3), 25.74, 25.94 (C(CH3)3), 41.17 (2ʹ-C), 43.88 (NCH2-C), 55.23, 55.25 
(OCH3), 63.01 (5ʹ-C), 65.06 (5-CH2O), 72.30 (3ʹ-C), 72.81 (PMB CH2O), 85.83 (1ʹ-C), 
87.80 (4ʹ-C), 111.19 (5-C), 113.69, 113.80, 129.05, 129.51, 130.06, 130.73 (Ar-C) 
135.99 (6-C), 150.80 (2-C), 159.04, 159.27 (Ar-C), 162.23 (2-C). ESI-HRMS for 
[C38H58N2O8Si2 + H]
+
 calcd, 727.3810; found, 727.3797. 
(1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy) 
methyl)tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl 
pivalate (6.39): To a solution of 6.33 (2.0 g, 4.1 mmol) in anhydrous pyridine (20 mL) 
and DMAP (100 mg) under inert atmosphere was added pivaloyl chloride (0.76 mL, 
6.16 mmol) and the reaction mixture was stirred at room temperature overnight (18h). 
Pyridine was evaporated under reduced pressure and the residue was purified by flash 
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column chromatography (10-25 % EtOAc in hexanes) to afford 6.39 as a white solid 
(2.0g, 74 %). 
1
H NMR (300 MHz, CDCl3) δ ppm 0.09 (s, 3H, SiCH3), 0.09 (s, 3H, 
SiCH3), 0.10 (s, 6H, Si(CH3)2), 0.90 (d, 9H, C(CH3)3), 0.91 (d, 9H, C(CH3)3), 1.19 (s, 
9H, Piv C(CH3)3), 2.01 (ddd, J = 13.40, 7.69, 5.86 Hz, 1H, 2ʹ-H), 2.32 (ddd, J = 13.18, 
5.86, 2.64 Hz, 1H, 2ʹ-H), 3.73 - 3.85 (m, 2H, 5ʹ-H), 3.96 (q, J = 3.22 Hz, 1H, 4ʹ-H), 
4.40 (dt, J = 5.49, 2.67 Hz, 1H, 3ʹ-H), 4.80 (s, 2H, 5-CH2), 6.28 (dd, J = 7.91, 5.86 Hz, 
1H, 1ʹ-H), 7.78 (s, 1H, 6-H), 8.28 (s, 1H, NH). 13C NMR (75 MHz, CDCl3) δ ppm -
5.42 (SiCH3), -5.38 (SiCH3), -4.83 (SiCH3), -4.65 (SiCH3), 18.01 (C(CH3)3), 18.42 
(C(CH3)3), 25.74 (C(CH3)3), 25.93 (C(CH3)3), 27.15 (Piv C(CH3)3), 38.79 (Piv 
C(CH3)3), 41.39 (2ʹ-C), 59.07 (5-CH2-C), 63.11 (5ʹ-C), 72.36 (3ʹ-C), 85.51 (1ʹ-C), 
88.09 (4ʹ-C), 109.62 (5-C), 140.25 (6-C), 149.76 (2-C), 161.86 (4-C), 178.23 (Piv CO). 
ESI-HRMS for [C27H50N2O7Si2 + H]
+
 calcd, 571.3235; found, 471.3242. 
(1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)tetrahydro 
furan-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl pivalate (6.40): 
Following the procedure described for the synthesis of 6.11, compound 6.39 (2.0 g, 
3.05 mmol) gave compound 6.40 as a white solid (822 mg, 59 %). 
1
H NMR (300 MHz, 
CDCl3) δ ppm 0.09 (s, 6H, Si(CH3)2), 0.90 (s, 9H, C(CH3)3), 1.18 (s, 9H, Piv C(CH3)3), 
2.19 - 2.38 (m, 2H, 2ʹ-H), 2.94 (t, J = 5.32 Hz, 1H, 5ʹ-OH), 3.70 - 3.81 (m, 1H, 5ʹ-H), 
3.90 - 3.99 (m, 2H, 5ʹ & 4ʹ-H), 4.52 (dt, J = 6.25, 3.54 Hz, 1H, 3ʹ-H), 4.83 - 4.94 (m, 
2H, 5-CH2O), 6.23 (t, J = 6.67 Hz, 1H, 1ʹ-H), 8.08 (s, 1H, 6-H), 8.78 (s, 1H, NH). 
13
C 
NMR (75 MHz, CDCl3) δ ppm -4.86, -4.70 (SiCH3), 17.98 (C(CH3)3), 25.73 
(C(CH3)3), 27.04 (C(CH3)3), 38.97 (piv C(CH3)3), 41.42 (2ʹ-C), 58.63 (5-CH2O-C), 
62.06 (5ʹ-C), 71.91 (3ʹ-C), 86.60 (1ʹ-C), 88.29 (4ʹ-C), 109.26 (5-C), 142.71 (6-C), 
149.70 (2-C), 161.95 (4-C), 179.70 (Piv CO). ESI-HRMS for [C21H36N2O7Si + H]
+
 
calcd, 457.2370; found, 457.2414. 
(1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(2-cyanovinyl)tetrahydrofuran-
2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl pivalate (6.41): Following 
the similar procedure to synthesize 6.12, the reaction of compound 6.40 (0.8 g, 1.75 
mmol), Dess-Martin reagent (0.48 M in CH2Cl2, 4.4 mL, 2.1 mmol) at room 
temperature for 7h gave aldehyde as white foamy residue.  
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In a separate flask, to a solution of cyanomethyltriphenylphosphonium chloride (1.78 
g, 5.25 mmol) in anhydrous THF (30 mL) at -78 °C under argon condition was added 
drop wise n-BuLi (1.6M in hexanes, 3.3 mL, 5.25 mmol) and stirred for 30 minutes. 
To this ylide at -78 °C was added slowly a solution of above aldehyde in anhydrous 
THF (5 mL) and stirred at room temperature overnight. Following the similar workup 
procedure described for compound 6.19, afforded 6.41 as a white solid (E-isomer - 
450 mg and E+Z mixture - 240 mg, 82%). Data for E-isomer: 
1
H NMR (300 MHz, 
CDCl3) δ ppm 0.10 (s, 3H, SiCH3), 0.11 (s, 3H, SiCH3), 0.90 (s, 9H, C(CH3)3), 1.20 (s, 
9H, Piv C(CH3)3), 2.21 - 2.42 (m, 2H, 2ʹ-H), 4.25 - 4.38 (m, 2H, 3ʹ & 4ʹ-H), 4.81 - 
4.95 (m, 2H, 5-CH2O), 5.72 (dd, J = 16.40, 1.76 Hz, 1H, 6ʹ-H), 6.24 (t, J = 6.44 Hz, 
1H, 1ʹ-H), 6.79 (dd, J = 16.26, 4.54 Hz, 1H, 5ʹ-H), 7.54 (s, 1H, 6-H), 9.34 (br. s, 1H, 
NH). 
13
C NMR (75 MHz, CDCl3) δ ppm -4.84, -4.66 (SiCH3), 17.89 (C(CH3)3), 25.63 
(C(CH3)3), 27.12 (C(CH3)3), 38.91 (Piv C(CH3)3), 40.10 (2ʹ-C), 58.36 (5-CH2O-C), 
74.53 (3ʹ-C), 85.12 (4ʹ-C), 86.07 (1ʹ-C), 101.41 (6ʹ-C), 110.38 (7ʹ-C), 116.49 (5-C), 
140.93 (6-C), 149.39 (5ʹ-C), 149.70 (2-C), 162.32 (4-C), 178.84 (Piv CO). ESI-HRMS 
for [C23H35N3O6Si + H]
+
 calcd, 478.2373; found, 478.2383. 
(1-((2R,4S)-5-(2-cyanoethylidene)-4-hydroxytetrahydrofuran-2-yl)-2,4-dioxo-
1,2,3,4-tetrahydropyrimidin-5-yl)methyl pivalate (6.42): To a solution of 
compound 6.41 (65 mg, 0.136 mmol) in THF (1 mL) was added tetrabutylammonium 
hydroxide (Bu4N
+
OH
-
, 40% in H2O, 186 mg, 0.286 mmol) and stirred at room 
temperature for 5h. Volatiles were evaporated under reduced pressure and the residue 
was purified by flash column chromatography (40-70% EtOAc in hexanes) to afford 
6.42 as a white powder (20 mg, 40%). 
1
H NMR (300 MHz, CDCl3) δ ppm 1.19 (s, 9H, 
C(CH3)3), 2.20 (d, J = 3.51 Hz, 1H, 3ʹ-OH), 2.31 (dt, J = 13.84, 6.70 Hz, 1H, 2ʹ-H), 
2.56 (ddd, J = 14.06, 6.44, 2.64 Hz, 1H, 2ʹ-H), 3.17 (dd, J = 7.03, 1.17 Hz, 2H, 6ʹ-H), 
4.77 (t, J = 7.03 Hz, 1H, 5ʹ-H), 4.83 - 4.92 (m, 3H, 3ʹ-H & 5-CH2O-H), 6.62 (t, J = 
6.74 Hz, 1H, 1ʹ-H), 7.38 (s, 1H, 6-H), 8.46 (s, 1H, NH). 13C NMR (75 MHz, CDCl3) δ 
ppm 13.70 (6-C), 27.10 (C(CH3)3) 38.90 (C(CH3)3), 39.22 (2ʹ-C), 58.48 (5-CH2O-C), 
70.25 (3ʹ-C), 87.13 (1ʹ-C), 89.96 (5ʹ-C), 111.06 (5-C), 117.77 (7ʹ-C), 139.55 (6-C), 
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149.40 (2-C), 159.39 (4-C), 161.42 (4ʹ-C), 178.68 (Piv CO). ESI-HRMS for 
[C17H21N3O6 + H]
+
 calcd, 364.1509; found, 364.1455. 
(1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(2-cyanoethyl)tetrahydrofuran-
2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl pivalate (6.43): To a 
solution of 6.41 (240 mg, 0.5 mmol) in ethylacetate (10 mL) was added 5%Pt-C (250 
mg) and stream of hydrogen gas was bubbled through the reaction mixture for 4h. The 
catalyst was filtered off and the filtrate was concentrated. The residue was purified by 
flash column chromatography (20-40% EtOAc in hexanes) to afford 6.43 as a white 
solid (170 mg, 70%). 
1
H NMR (300 MHz, CDCl3) δ ppm 0.09 (s, 3H, SiCH3), 0.10 (s, 
3H, SiCH3), 0.90 (s, 9H, C(CH3)3), 1.20 (s, 9H, Piv C(CH3)3), 1.94 (dddd, J = 13.88, 
9.63, 7.54, 6.15 Hz, 1H, 5ʹ-H), 2.02 - 2.17 (m, 1H, 5ʹ-H), 2.23 (ddd, J = 13.40, 7.25, 
5.71 Hz, 1H, 2ʹ-H), 2.34 (ddd, J = 13.77, 7.03, 5.86 Hz, 1H, 2ʹ-H), 2.43 - 2.65 (m, 2H, 
6ʹ-H), 3.85 (ddd, J = 9.37, 5.42, 3.66 Hz, 1H, 4ʹ-H), 4.16 (dt, J = 11.13, 5.57 Hz, 1H, 
3ʹ-H), 4.88 (s, 2H, 5-CH2O), 6.12 (dd, J = 6.74, 5.86 Hz, 1H, 1ʹ-H), 7.55 (s, 1H, 6ʹ-H), 
9.13 (br. s, 1H, NH). 
13
C NMR (75 MHz, CDCl3) δ ppm -4.88, -4.61 (SiCH3), 14.22 
(6ʹ-C), 17.86 (C(CH3)3), 25.64 (C(CH3)3), 27.09 (C(CH3)3), 28.96 (5ʹ-C), 38.86 (Piv 
C(CH3)3), 40.48 (2ʹ-C), 58.38 (5-CH2O), 74.27 (3ʹ-C), 84.26 (4ʹ-C), 85.84 (1ʹ-C), 
109.99 (5-C), 118.95 (7ʹ-C), 141.07 (6-C), 149.64 (2-C), 162.27 (4-C), 178.77 (Piv 
CO). ESI-HRMS for [C23H37N3O6Si + H]
+
 calcd, 480.2530; found, 480.2535. 
(1-((2R,4S,5R)-5-(2-cyanoethyl)-4-hydroxytetrahydrofuran-2-yl)-2,4-dioxo-
1,2,3,4-tetrahydropyrimidin-5-yl)methyl pivalate (6.44): Following the synthetic 
procedure described for compound 6.20, compound 6.43 (80 mg, 0.17 mmol) afforded 
product 6.44 as a white solid (55 mg, 90%). 
1
H NMR (300 MHz, CD3OD) δ ppm 1.18 
(s, 9H, C(CH3)3), 1.92 - 2.06 (m, 1H, 5ʹ-H) 2.06 - 2.16 (m, 1H, 5ʹ-H), 2.29 (dd, J = 
6.59, 5.71 Hz, 2H, 2ʹ-H), 2.52 - 2.71 (m, 2H, 6ʹ-H), 3.87 (dt, J = 9.01, 4.43 Hz, 1H, 4ʹ-
H), 4.17 - 4.24 (m, 1H, 3ʹ-H), 4.84 (s, 2H, 5-CH2O), 6.20 (t, J = 6.59 Hz, 1H, 1ʹ-H), 
7.78 (s,1H, 6-H). 
13
C NMR (75 MHz, CD3OD) δ ppm 14.51 (6ʹ-C), 27.53 (C(CH3)3), 
30.37(5ʹ-C), 39.90 (C(CH3)3), 40.30 (2ʹ-C), 60.22 (5-CH2O), 74.70 (3ʹ-C), 86.05 (4ʹ-
C), 86.85 (1ʹ-C), 110.70 (5-C), 120.82 (7ʹ-C), 143.01 (6-C), 151.87 (2-C), 164.85 (4-
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C), 180.09 (Piv CO). ESI-HRMS for [C17H23N3O6 + H]
+
 calcd, 366.1665; found, 
366.1631. 
3-((2R,3S,5R)-3-hydroxy-5-(5-(hydroxymethyl)-2,4-dioxo-3,4-dihydropyrimidin-
1(2H)-yl)tetrahydrofuran-2-yl)propanenitrile (6.30): A solution of 0.5M NaOMe 
in MeOH (0.7 mL, 0.342 mmol) was added to compound 6.44 (25 mg, 0.068 mmol) 
and stirred at room temperature for 3h. Acetic acid (30 µL, 0.5 mmol) was added and 
the solvents were evaporated. The residue was purified by flash column 
chromatography (4-8% MeOH in CH2Cl2) to afford 6.30 as a white solid (19 mg, 
95%). 
1
H NMR (300 MHz, DMSO-d6) δ ppm 1.76 - 1.90 (m, 1H, 5ʹ-H), 1.90 - 2.03 
(m, 1H, 5ʹ-H), 2.06 - 2.25 (m, 2H, 2ʹ-H), 2.53 - 2.68 (m, 2H, 6ʹ-H), 3.72 (dt, J = 8.49, 
4.54 Hz, 1H, 4ʹ-H), 4.05 - 4.13 (m, 1H, 3ʹ-H), 4.16 (s, 2H, 5-CH2OH), 4.97 (br. s, 1H, 
5-CH2OH), 5.39 (br. s, 1H, 3ʹ-OH), 6.16 (t, J = 6.74 Hz, 1H, 1ʹ-H), 7.42 (s, 1H, 6-H), 
11.34 (br. s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6) δ ppm 13.21 (6ʹ-C), 28.53 (5ʹ-
C), 38.36 (2ʹ-C), 55.70 (5-CH2OH), 72.53 (3ʹ-C), 83.87 (1ʹ-C), 83.97 (4ʹ-C), 114.46 
(5-C), 120.17 (7ʹ-C), 136.38 (6-C), 150.13 (2-C), 162.42 (4-C). ESI-HRMS for 
[C12H15N3O5 + HCOO
-
]
-
 calcd, 326.0988; found, 326.0985. 
(1-((2R,4S,5R)-5-(2-(1H-tetrazol-5-yl)ethyl)-4-((tert-butyldimethylsilyl)oxy) 
tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl pivalate 
(6.45): Following the procedure described for the synthesis of 6.21, compound 6.43 
(80 mg, 0.17 mmol) rendered 6.45 as white solid (74 mg, 74 %). 
1
H NMR (300 MHz, 
CDCl3) δ ppm 0.08 (s, 6H, SiCH3), 0.89 (s, 9H, C(CH3)3), 1.24 (s, 9H, Piv C(CH3)3), 
1.74 - 1.91 (m, 1H, 5ʹ-H), 2.04 - 2.17 (m, 1H, 2ʹ-H), 2.19 - 2.33 (m, 1H, 5ʹ-H), 2.39 
(ddd, J = 13.55, 5.93, 3.95 Hz, 1H, 2ʹ-H), 3.13 - 3.28 (m, 2H, 6ʹ-H), 4.03 (dt, J = 
10.69, 3.00 Hz, 1H, 4ʹ-H), 4.10 - 4.18 (m, 1H, 3ʹ-H), 4.93 - 5.08 (m, 2H, 5-CH2O), 
6.21 (t, J = 6.30 Hz, 1H, 1ʹ-H), 7.79 (s, 1H, 6-H), 8.99 (br. s, 1H, NH). 13C NMR (75 
MHz, CDCl3) δ ppm -4.83, -4.66 (SiCH3), 17.95 (C(CH3)3), 20.40 (6ʹ-C), 25.68 
(C(CH3)3), 27.12 (C(CH3)3), 33.34 (5ʹ-C), 39.38 (Piv C(CH3)3), 40.56 (2ʹ-C), 59.14 (5-
CH2O), 75.13 (3ʹ-C), 86.66 (4ʹ-C), 87.00 (1ʹ-C), 109.27 (5-C), 142.20 (6-C), 149.73 
(2-C), 155.28 (7ʹ-C), 162.27 (4-C), 182.48 (Piv CO). ESI-HRMS for [C23H38N6O6Si - 
H]
-
 calcd, 521.2544; found, 521.2551. 
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1-((2R,4S,5R)-5-(2-(1H-tetrazol-5-yl)ethyl)-4-((tert-butyldimethylsilyl)oxy) 
tetrahydrofuran-2-yl)-5-(hydroxymethyl)pyrimidine-2,4(1H,3H)-dione (6.46): 
Following the procedure described for the synthesis of 6.30, compound 6.45 (90 mg, 
0.17 mmol) after chromatography (5-7 % MeOH + 0.5 % HCOOH in CH2Cl2) 
rendered 6.46 as white solid (70 mg, 92 %). 
1
H NMR (300 MHz, CD3OD) δ ppm 0.11 
(s, 6H, Si(CH3)2), 0.91 (s, 9H, C(CH3)3), 2.00 - 2.12 (m, 1H, 5ʹ-H), 2.12 - 2.38 (m, 3H, 
2ʹ & 5ʹ-H), 2.99 - 3.19 (m, 2H, 6ʹ-H), 3.82 (dt, J = 9.37, 4.10 Hz, 1H, 4ʹ-H), 4.31 (dt, J 
= 6.00, 4.32 Hz, 1H, 3ʹ-H), 4.35 (d, J = 1.17 Hz, 2H, 5-CH2OH), 6.20 (t, J = 6.74 Hz, 
1H, 1ʹ-H), 7.53 (s, 1H, 6-H). 13C NMR (75 MHz, CD3OD) δ ppm -4.70, -4.50 (SiCH3), 
18.80 (C(CH3)3), 21.38 (6ʹ-C), 26.25 (C(CH3)3), 32.52 (5ʹ-C), 40.87 (2ʹ-C), 57.80 (5-
CH2OH), 76.34 (3ʹ-C), 86.61 (1ʹ-C), 87.00 (4ʹ-C), 115.70 (5-C), 138.70 (6-C), 152.12 
(2-C), 158.26 (7ʹ-C), 165.00 (4-C). ESI-HRMS for [C18H30N6O5Si - H]
-
 calcd, 
437.1969; found, 437.1982.  
1-((2R,4S,5R)-5-(2-(1H-tetrazol-5-yl)ethyl)-4-hydroxytetrahydrofuran-2-yl)-5-
(hydroxymethyl)pyrimidine-2,4(1H,3H)-dione (6.47): In a polypropylene vessel, to 
a solution of compound 6.46 (70 mg, 0.16 mmol) in MeOH (10 mL) was added NH4F 
(120 mg, 3.2 mmol) and stirred at 50 °C for 2 days. CH2Cl2 (10 mL) was added and 
filtered. The filtrate was concentrated and the residue purified by flash column 
chromatography (8-12 % MeOH + 0.5% HCOOH in CH2Cl2) to afford 6.47 as a white 
solid (45 mg, 87%).
1
H NMR (300 MHz, DMSO-d6) δ ppm 1.88 - 2.01 (m, 1H, 5ʹ-H), 
2.01 - 2.24 (m, 3H, 5ʹ & 2ʹ-H), 2.86 - 3.05 (m, 2H, 6ʹ-H), 3.65 - 3.75 (m, 1H, 4ʹ-H), 
4.05 - 4.13 (m, 1H, 3ʹ-H), 4.16 (d, J = 0.88 Hz, 2H, 5-CH2OH), 6.15 (t, J = 6.74 Hz, 
1H, 1ʹ-H), 7.44 (s, 1H, 6-H), 11.35 (br. s, 1H, NH). 13C NMR (75 MHz, DMSO-d6) δ 
ppm 19.65 (6ʹ-C), 30.89 (5ʹ-C), 38.63 (2ʹ-C), 55.69 (5-CH2OH), 72.77 (3ʹ-C), 83.60 
(1ʹ-C), 84.50 (4ʹ-C), 114.48 (5-C), 136.18 (6-C), 150.14 (2-C), 155.96 (7ʹ-C), 162.42 
(4-C). ESI-HRMS for [C12H16N6O5 - H]
-
 calcd, 323.1104; found, 323.1234. 
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6.4.2. Pharmacological assay procedures 
Please refer to Chapter 3, Section 3.4.2.5 for spectrophotometric binding assay 
procedure 
 
  
  
  
  
  
 
 
 
 
 
 
 
 
CHAPTER – 7 
GENERAL CONCLUSIONS AND FUTURE 
PERSPECTIVES 
  
  
 
General Conclusions 
215 
General Conclusions 
A series of previously undisclosed 2ʹ-deoxy--L-threofuranosylnucleosides (3.25-27 
and 3.29), synthesized from 1,2-O-isopropylidene--L-threofuranose in seven steps, 
failed to show antiviral activity. Assuming that the incapability of cellular kinases to 
execute the first phosphorylation step (unprecedented on a secondary hydroxyl of a 
nucleoside substrate) was responsible for the lack of activity, we decided to synthesize 
prodrug 3.34, which, however, also lacked antiviral activity. Hindering factors may be 
the inefficient processing to the corresponding monophosphate (although we 
demonstrated fluent conversion to the alanylmonophosphate precursor upon 
carboxypeptidase treatment of the thymine analogue), inefficient conversion of the 
mono- to the triphosphate form or the incapacity of the triphosphate to act as RT 
substrate/inhibitor. 
 
Therefore, we decided to revisit the corresponding 2ʹ,3ʹ-dideoxy-β-D-apio-D-furanose 
nucleosides, which may be considered as homologues of the aforementioned 2ʹ-
deoxy--L-threofuranosylnucleosides. We envisaged a synthetic approach that would 
also give access to the corresponding 3ʹ-deoxy-D-apio-D-furano nucleosides and D-
apio-D-furanonucleosides (Chapter 4). In the course of our attempts to synthesize this 
family of apionucleosides, we discovered anomalies in the structural assignments of 
related compounds reported by Jin et al. and also experienced that a compound 
purchased from the chemical supplier Carbosynth Ltd as 1,2:3,5-di-O-isopropylidene-
-D-apio-D-furanose proved to be the D-apio-L-furanose epimer, which demonstrates 
the importance of using a nomenclature that unambiguously denotes the 
stereochemistry at carbons 2 and 3 of this unusual sugar. Clues in the synthesis of the 
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desired apionucleosides were a single carbon homologation, a tandem acid catalyzed 
ring opening followed by differential ring closing and an optimized microwave 
assisted glycosylation protocol. 
In accordance with earlier reports the target D-apio-D-furanose nucleosides failed to 
show antiviral activity and so did their D-apio-L-furanose epimers. However, the 
triphosphate of 2ʹ,3ʹ-dideoxy-β-D-apio-D-furanoadenosine (4.1b) (in contrast to its D-
apio-L-furanose epimer) was readily accepted by viral DNA polymerase to act as 
chain terminator. This led us to convert 4.1b into the phosphoramidate prodrug 4.6b, 
which indeed showed considerable anti-HIV activity. This indicates that the lack of 
activity of these 2ʹ,3ʹ-dideoxy-β-D-apio-D-furanose nucleosides must be sought in the 
inefficient conversion to the monophosphate. 
 
The synthetic methodology developed to synthesize the family of apionucleosides was 
applied for the preparation of N
6
-aralkyl-β-D-apio-D/L-furanoadenosines, as well as 
their 5ʹ-carboxamide or ethyl/methyl carbamoyl derivatives (Chapter 5). Some 
analogues showed moderate affinity for adenosine A3 receptors. Surprisingly, D-apio-
D-furanoadenosine analogue 5.26 behaved as an antagonist for this receptor, while its 
D-apio-L-furanoadenosine counterpart 5.7 showed partial agonist activities. This 
stereochemical preference to activate this target receptor is in striking contrast with 
that earlier observed for HIV RT. The relatively low affinity of these apionucleosides 
(compared to the natural ribonucleosides) for this purinergic receptor may be 
explained by the fact that they adopt an inapt conformation for receptor recognition. 
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Selected 5ʹ-modified thymidine congeners are moderate inhibitors of TMPKmt 
(Chapter 6). Unfortunately, combining the most favorable 5ʹ-modification (6.20, 6.22) 
with a 5-CH2OH was detrimental for inhibitory activity, which may indicate the 
QSAR from which this combination emerged, is only valuable in the presence of a 
fused 2ʹ,3ʹ-sulfuryldiamide ring. The protecting group strategy employed for the 5-
CH2OH group may prove practical for the synthesis of analogues of 5-hydroxymethyl-
2ʹ-deoxycytidine, believed to have an important role in embryo development and in 
the epigenetic control of neuronal function. 
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Future Perspectives 
In general, inhibition of HIV viruses by thymine nucleoside analogues is poor 
compared to their adenine counterparts. In the case of 2ʹ,3ʹ-dideoxy-β-D-apio-D-
furanose nucleosides, the prodrugs of adenine analogues were found to have potent 
anti-HIV properties (4.6b and 4.80b), while their thymine congeners  were only 
weakly active. Hence, it would be interesting to investigate whether the triphosphate 
of 2ʹ-deoxythreoadenosine (7.1) could terminate growing DNA/ inhibit HIV RT 
enzyme. If affirmative, the synthesis and screening of 7.2 may be rewarding. 
 
As exemplified for 2ʹ,3ʹ-dideoxy-β-D-apio-D-furanoadenosine (4.1b) the inactivity of 
many nucleoside analogues is largely due to inefficient phosphorylation(s). testing 
final metabolites (triphosphates in these cases) is perhaps more prudent. To uncover 
promising RT or polymerase inhibitors it might therefore be worthwhile to 
systematically screen the triphosphate metabolites of nucleosides that were previously 
found inactive. Ready availability of these data could create opportunities to convert 
(old) nucleosides analogues to promising (pro)drugs. 
Obviously, the antiviral activity of ProTides is critically dependent on the ester type of 
the amino acid. The benzyl ester 4.6b for instance is at least 15 times more active than 
the isopropyl ester in vitro, against HIV 1,2. Therefore, a more systematic screening 
of a library of ProTides 7.3 with various ‘R’ groups is warranted. 
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Oxetanocin and their ring expanded analogues are potent antiviral compounds. Still, 
synthesis and activity of their phosphonate equivalents 7.4 are not reported. Similarly, 
the hydroxyl compound 7.5 and α-difluorophosphonate analogues of 7.4 and 7.5 are 
worth investigation.  
 
Based on the observation that the oxidation of 3ʹ-CH2OH of the α-D-apio-L-
furanoadenosine to carboxylic acid resulted in decarboxylation, synthesis of 3ʹ-
carboxamide 7.6 as adenosine A3 receptor modulator was not attempted, but access to 
7.6 may be feasible using a different protecting/ synthetic strategies like, a 2ʹ,3ʹ-O-
isopropylidene group followed by a screen of various oxidation methods.  
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We attributed the inactivity of the D-apio-L-furano and D-furanoadenosines to its inapt 
conformations, moreover, 2ʹ,4ʹ-locked adenosines are reported as potent antagonists, 
hence efforts to determine affinity profiles of the north-locked congeners 7.7-7.9 may 
be rewarding. 
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SUMMARY 
Nucleoside analogues with different modes of action have proven useful for treating 
various diseases, particularly for viral infections. To act as antivirals nucleosides 
generally require metabolic activation to their triphosphate form by nucleoside kinases. 
The triphosphates then act as inhibitors of viral DNA or RNA polymerases or as DNA 
or RNA chain terminators. Nucleos(t)ide prodrugs have been developed to increase 
bioavailability or to bypass the first phosphorylation step.  
In Chapter 1 we tried to give the relevant chemical and biological background for the 
research work performed in this thesis, i.e. nucleosides as antivirals, A3 adenosine 
receptor ligands and M. tuberculosis TMPK inhibitors. We provide quite an elaborate 
overview of nucleosides in which either the base or the 5ʹ-CH2OH has been 
transposed and the effects of such modifications on the biological activity.  
Chapter 2 summarizes the goals of this thesis. 
In Chapter 3 and 4 of this thesis we describe the synthesis of sugar-modified 
nucleosides as potential antivirals. Chapter 3 is dedicated to the synthesis of a series of 
α-L-2ʹ-deoxythreofuranosyl nucleosides featuring the nucleobases A, T, C and U. The 
target molecules were synthesized from 1,2-O-isopropylidene-α-L-threose, involving a 
Vorbrüggen coupling and a Barton-McCombie deoxygenation protocol as the key 
steps. All target nucleosides failed to show significant activity against a broad panel of 
viruses and also lacked notable cellular toxicity. Therefore, we decided to convert the 
thymidine analogue to a phosphoramidate prodrug, which, however, failed to restore 
the antiviral activity. Evaluation against a number of thymidine kinases learned that 
1ʹ-(thymin-1-yl)-2ʹ-deoxy-α-L-threofuranose causes moderate inhibition of 
mitochondrial thymidine kinase-2 (TK-2; IC50: 429 µM), herpes simplex virus type 1 
TK (IC50: 66 µM, Ki: 20 µM), varicella-zoster virus TK (IC50: 123 µM) and M. 
tuberculosis thymidylate kinase (Ki: 18 µM).  
In Chapter 4 we describe a new and convenient synthesis towards thymine and 
adenine congener of D-apio- L- and D-furanonucleosides, their 3ʹ-deoxy-, as well as 
 232 
their 2ʹ,3ʹ-dideoxy-analogues. In the course of this work, we rectified some anomalies 
in the structure assignments reported by other groups. Single carbon homologation of 
the carbohydrate moiety and optimized glycosylation conditions involving microwave 
irradiation allowed the successful synthesis of the target compounds.  
Initially, following a reported method we arrived at a family of unintended D-apio-L-
furanonucleosides. These nucleosides and prodrugs of their 2ʹ,3ʹ-dideoxy counterparts 
were devoid of antiviral activity. The 1ʹ-(Thymin-1-yl)-2ʹ,3ʹ-dideoxy-α-D-apio-L-
furanose was poorly active as inhibitor of several viral thymidine kinases (IC50s in the 
150-270 µM range), moderately active as inhibitor of thymidylate kinase of M. 
tuberculosis (Ki: 48 µM) and the triphosphate of 1ʹ-(adenin-9-yl)-2ʹ,3ʹ-dideoxy-α-D-
apio-L-furanose proved a poor substrate of HIV RT. After overcoming some synthetic 
challenges, a group of β-D-apio-D-furano target nucleosides and relevant ProTides 
were prepared. Although the nucleosides themselves are neither active nor cytotoxic, 
the ProTides of 1ʹ-(adenin-9-yl)-2ʹ,3ʹ-dideoxy-β-D-apio-D-furanose are moderately 
potent anti-HIV-1,2 (EC50: 0.5-38 µM) agents, showing weak cytotoxicity (IC50: 53-
110 µM). Accordingly, 2ʹ,3ʹ-dideoxy-β-D-apio-D-furanoadenosine triphosphate is 
readily accepted by HIV RT and acts as viral DNA chain terminator. 
Adenosine receptors are GPCRs that are activated by extracellular adenosine to 
modulate signal transduction pathways inside the cell. Selective A3 adenosine receptor 
modulators are being investigated in the clinic for controlling inflammatory disorders 
(rheumetoid arthritis), immune diseases (psoriasis), dry eye syndrome, glaucoma and 
colorectal cancer. In search of new modulators of this receptor, we synthesized a small 
series of N
6
-benzyl substituted 9-(3-C-hydroxymethyl-β-D-
erythrofuranosyl)adenosines (Chapter 5). Because the starting material supplied had 
the undesired stereochemistry at C-3 of apiofuranose (see also Chapter 4), early work 
in this study resulted in 9-(3-C-hydroxymethyl-α-L-threofuranosyl)adenosines and its 
3ʹ-deoxy congeners. After evaluation of all compounds, N6-(5-chloro-2-
methoxybenzyl) derivative of D-apio- L- and D-furanoadenosines showed appreciable 
binding affinity to the A3AR, but with affinity 100-fold lower than the parent N
6
-(5-
chloro-2-methoxy)benzyladenosine. All together it may be concluded that substitution 
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of the apiofuranose for a ribofuranose moiety is detrimental for binding to the 
adenosine receptors.  
TMPK of M. tuberculosis is responsible for converting deoxythymidine 
monophophate to deoxythymidine diphosphate, a crucial step in the biosynthesis of 
bacterial DNA. Since TMPKmt lies at the junction of de novo and salvage pathways 
for DNA biosynthesis and significantly differs from its human counterpart, it is 
deemed an attractive target for designing new TB drugs. In Chapter 6 we describe the 
synthesis of 5ʹ-modified thymidines and 5,5ʹ-bis-substituted 2ʹ-deoxyuridine 
analogues as potential inhibitors of TMPKmt. A lot of efforts were made to find a 
protecting group for the 5-CH2OH moiety of 2ʹ-deoxyuridines, that enables to 
introduce the desired 5ʹ-modifications. The 5ʹ and 5,5ʹ-modified analogues were 
evaluated for their capacity to inhibit TMPKmt. Solely the 5ʹ-cyanomethyl (Ki: 48 µM) 
and 5ʹ-tetrazolylmethyl (Ki: 70 µM) modified thymidines were found to possess 
moderate TMPKmt inhibitory activity. Remarkably, compounds in which these 
favorable 5ʹ-modifications were combined with a 5-CH2OH modification of the 
nucleobase, failed to inhibit the enzyme. 
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Samenvatting in het Nederlands 
Nucleoside analogen met uiteenlopende werkingsmechanismen hebben bewezen 
buitengewoon effectief te zijn bij de behandeling van een scala aan ziekten, in het 
bijzonder virale infecties. Voor het verkrijgen van deze antivirale activiteit, dienen 
nucleosiden, in de regel, door middel van nucleoside kinasen te worden omgezet in 
hun corresponderende trifosfaat vorm. Deze trifosfaten kunnen vervolgens optreden 
als inhibitor van virale DNA- of RNA-polymerasen en/of als DNA- of RNA-keten 
terminatoren.  
In Hoofdstuk 1 is ernaar gestreefd een relevant chemische en biologische achtergrond 
te schetsen voor het werk uiteengezet in dit proefschrift, te weten: antivirale 
nucleosiden, A3 adenosine receptor liganden en inhibitoren van TMPK in M. 
tuberculosis. Wij bieden een gedetailleerd overzicht van tal van nucleosiden waarin de 
base en/of de 5ʹ-CH2OH is verplaatst en het effect hiervan op de biologische activiteit.  
In Hoofdstuk 2 staan de doelstellingen van dit proefschrift uiteengezet.  
De Hoofdstukken 3 en 4 beschrijven de synthese van suiker-gemodificeerde 
nucleosiden als mogelijk antivirale agentia. Hoofdstuk 3 beschrijft de synthese van 
een reeks α-L-2ʹ-desoxythreofuranosylnucleosiden uitgerust met de nucleobasen A, T, 
C and U. De doelmoleculen werden verkregen uit 1,2-O-isopropylideen-α-L-threose, 
met, onder meer, een Vorbrüggen koppeling en een Barton-McCombie deoxygenering 
als voornaamste omzettingen. Geen van de verkregen nucleosiden vertoonde een 
significante activiteit tegen een breed scala aan virussen. De nucleosiden vertoonden 
bovendien een (zeer) lage celtoxiciteit. Dit zette er ons toe aan het thymidine analoog 
om te zetten in een fosforamidaat prodrug, wat echter geen aanleiding gaf tot een 
verhoogde antivirale activiteit.  
Enzym inhibitiestudies toonden aan het 1ʹ-(thymin-1-yl)-2ʹ-deoxy-α-L-threofuranose 
een zwakke inhibitor is van: mitochondriaal thymidine kinase-2 (TK-2; IC50: 429 µM), 
herpes simplex virus type 1 TK (IC50: 66 µM, Ki: 20 µM), varicella-zoster virus TK 
(IC50: 123 µM) en thymidylaat kinase van M. tuberculosis (Ki: 18 µM).  
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Hoofdstuk 4 beschrijft een nieuwe en efficiënte synthese van zowel de D- als de D-
apio-L-furanonucleosiden van thymine en adenine, alsook hun corresponderende 3ʹ-
deoxy-, en 2ʹ,3ʹ-dideoxyanalogen. Gedurende het verloop van dit onderzoek werd een 
onjuistheid in de stereochemische toekenning van een eerder door een andere 
onderzoeksgroep beschreven, intermediar vastgesteld en gecorrigeerd. Homologatie 
van het glycon met één koolstofatoom en glycosylering in een microgolfoven 
speelden een sleutelrol in de synthese van deze derivaten.  
Aanvankelijk werd gebaseerd op een gepubliceerde methode een reeks van 
(onbedoelde) D-apio-L-furanonucleosiden verkregen. Deze nucleosiden en de 
prodrugs van hun respectieve 2ʹ,3ʹ-dideoxy analogen vertoonden geen 
noemenswaardige antivirale activiteit. 1ʹ-(Thymin-1-yl)-2ʹ,3ʹ-dideoxy-β-D-apiose 
blijkt een zwakke inhibitor te zijn van virale thymidine kinasen (IC50s circa 150-270 
µM) en een matig potente inhibitor van thymidylaat kinase van M. tuberculosis (Ki: 48 
µM). Het trifosfaat van 1ʹ-(adenin-9-yl)-2ʹ,3ʹ-dideoxy-α-D-apio-L-furanose bleek een 
pover substraat van HIV RT. Na het nemen van enkele synthetische horden werd de 
initieel voorgenomen groep D-apio-D-furanonucleosiden (inclusief de relevante 
ProTides) verkregen. Hoewel de nucleosiden op zichzelf actief noch cytotoxisch zijn, 
blijken de ProTides van 1ʹ-(adenin-9-yl)-2ʹ,3ʹ-dideoxy-β-D-apio-D-furanose relatief 
potente anti-HIV-1,2 (EC50: 0.5-38 µM) agentia, met een lage cytotoxiciteit (IC50: 53-
110 µM). Overeenkomstig blijkt het corresponderende 2ʹ,3ʹ-dideoxy-β-D-apio-D-
furanoadenosine trifosfaat een goed substraat van HIV RT en treedt daarbij op als 
virale DNA ketenterminator. 
Adenosine receptoren behoren tot de GPCRs en zijn, na activatie door extracellulair 
adenosine, betrokken bij signaaltransductie in de cel. De waarde van selectieve A3 
adenosine receptor modulatoren in de behandeling van ontstekingen (reumatoïde 
artritis), immuunziekten (psoriasis), droge ogen syndroom, glaucoom en darmkanker 
wordt thans klinisch onderzocht. 
In de zoektocht naar nieuwe modulatoren van deze receptor werd een kleine reeks N
6
-
gesubstitueerde 9-(3-C-hydroxymethyl-β-D-erythrofuranosyl)adeninen 
gesynthetiseerd (Hoofdstuk 5). Aangezien bij aanvang van deze studie werd 
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vertrokken van een startmateriaal met de verkeerde configuratie op C-3 van 
apiofuranose (zie Hoofdstuk 4), werden initieel 9-(3-C-hydroxymethyl-α-L-
threofuranosyl)adenosinen en hun 3ʹ-deoxy analogen verkregen. 
Bij de biologische evaluatie van alle verbindingen bleken de N
6
-(5-chloro-2-
methoxybenzyl) derivaten van D-apio-L- en D-furanoadenosine een behoorlijke 
bindingsaffiniteit te vertonen voor de A3 adenosine receptor, maar toch een factor 100 
lager dan die van de oorspronkelijke verbinding N
6
-(5-chloro-2-
methoxy)benzyladenosine. Dit alles in ogenschouw nemend, kan worden 
geconcludeerd dat het vervangen van een ribofuranose door een apiofuranose 
structuur nadelig is voor de binding aan de adenosine receptor. 
TMPK van M. tuberculosis katalyseert de omzetting van deoxythymidinemonofosfaat 
in deoxythymidinedifosfaat, een sleutelstap in de bacteriële biosynthese van DNA. 
TMPKmt wordt beschouwd als een aantrekkelijk aangrijpingspunt voor het ontwerp 
van nieuwe TB medicatie aangezien het werkzaam is op het punt waar de de novo en 
salvage paden voor DNA biosynthese samenvloeien en het bovendien significant 
verschillend is van het analoge enzym in de mens. 
Hoofdstuk 6 behandelt de synthese van 5ʹ-gemodificeerde thymidinen en 5,5ʹ-
bisgesubstitueerde 2ʹ-deoxyuridine analogen. Veel aandacht ging hierbij uit naar de 
zoektocht naar een geschikte beschermgroep voor de 5-CH2OH groep van 2ʹ-
deoxyuridinen die verenigbaar is met de transformaties noodzakelijk voor de 
invoering van de 5ʹ-modificaties. De 5ʹ en 5,5ʹ-gemodificeerde analogen werden getest 
op de inhibitie van TMPKmt. Het 5ʹ-cyanomethylderivaat (Ki: 48 µM) en het 5ʹ-
tetrazolylmethylderivaat (Ki: 70 µM) van thymidine vertoonden bescheiden TMPKmt 
inhibitie. Vreemd genoeg vertoonden de verbindingen waarin deze 5ʹ-modificaties 
werden gecombineerd met een 5-CH2OH groep op de nucleobase, geen significante 
remming van TMPKmt. 
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